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Note 
 
This deliverable is divided in two main parts. Part A provides a general overview of the 
research undertaken and cross-countries’ comparisons. Part B includes in depth analyses 
and descriptions of each country study.  
 
Glossary 
 
In order to ensure the delivery of a harmonised effort some terms will be clarified regarding 
how and why they are used in this deliverable. 
The term ICT literacy which is a separate section in the questionnaire administered to the 
participants reflects their familiarity rather their competence in operating a PC.  
Health professionals in this study are: a) physicians, b) pharmacists, and c) nurses.  
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Executive Summary 
 
PART A 
 
Introduction: Research has shown that certain diseases and disorders may affect driving 
performance. However, the medicines prescribed for many diseases and disorders can make 
us just as dangerous being behind the wheel. Current research focuses primarily on the 
Central Nervous System impairment brought even by some over-the-counter medicines. The 
realisation of the need for alterations in existing guidelines on the way physicians and 
pharmacists prescribe and dispense medicines is a general goal of WP7. Experts have 
formulated new guidelines and protocols within the framework of the European DRUID 
project. 
Professional guidelines provide the foundation for better and cost-effective practice. The 
rising of comparability in medical practice ensures the development of collaboration between 
research findings and evidence-based medicine. Increased application of methodological 
frameworks and criteria has increased the capacity of research-based evidence to derive 
information from relevant research outcomes. In other words, similar clinical practices allows 
for translation of their findings into applicable ideas.  
Extensive reviews on guidelines implementation have half-heartedly reported limited and non-
consistent effect of guidelines in changing physicians’ behaviour (Cabana et al, 1999). The 
processes and factors involved in health care professionals’ adherence to guidelines have not 
been investigated in depth and little is known with regards how it could successfully be 
succeeded (Cabana et al., 1999). The adopted theoretical model was the one proposed by 
Cabana and colleagues (1999) and advocates that guidelines adherence should follow 
change in behaviour, knowledge and attitudes.  
Prescribing and dispensing guidelines developed within the DRUID project were evaluated in 
clinical practice settings as one of the tasks in Work Package 7. The primary goals of this task 
were to evaluate the effectiveness of the implementation of developed protocols and 
guidelines on healthcare professionals’ (physicians, pharmacists, nurses) attitude, knowledge 
and reported behaviour via two different approaches: i) by using an integrated (ICT) tool 
(additional software integrated into the ICT software used by the professional in his daily 
practice; country specific development) and ii) by using a non-integrated tool for presenting  
the protocols and guidelines (ICT tool developed within the framework of the project). 
 
Materials and Methods:  
 
The target populations were health care professionals in the primary care setting: i) 
physicians (Belgium, Spain), ii) pharmacists (Belgium, the Netherlands, Spain) and iii) Nurses 
(Spain).  
In addition, a “pure” control group was added to evaluate the effectiveness of current 
practices with no DRUID-relevant information.   
Participants were introduced to the tools/software(s) used through a training scheme. Some 
of the participants did not receive training (e.g. the integrated group of physicians 
(SoSoeMe)). In addition, participants were informed about the DRUID guidelines regarding 
driving and medicines intake. The time sequence involved a standard procedure of 
recruitment, briefing, and consent. Participants filled in the pre-questionnaire at the start of 
their training and a post-questionnaire after six months of using the DRUID guidelines in their 
practice).  
They used the software during their daily practice for either prescribing or dispensing 
medicines depending on the professional groups they belonged to and after the testing period 
ended they filled in a post-questionnaire investigating the same artefacts more or less as the 
initial one in order to enhance and allow comparability and evaluate the effectiveness of the 
tool and the applied guidelines.  
Procedural differences exist and were discussed in depth in the respective reports; however, 
the framework was not significantly violated allowing for similar up to a certain extent data 
analysis. 
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A step further in analysis (Part A) was the creation of composite scores to facilitate between 
countries potential comparisons and present the opportunity of an overall evaluation of the 
effect of guidelines. Overall composite scores were based on commonalities’ analysis across 
national studies with clustering of questionnaire items taken into account. Composite scores 
were created for three behavioural clusters: a) Reported Behaviour, b) Attitudes/Awareness, 
c) Actual Knowledge. The Reported Behaviour cluster included question items about how 
much health professionals take into account the impairing effect of medicines in their daily 
practice. The Attitudes/Awareness cluster included items about health professionals’ attitudes 
towards prescribing/dispensing drugs that may have an impairing effect on driving fitness. 
The Actual Knowledge cluster included items about health professional’s knowledge of 
specific effects of certain medicines on driving fitness. These clusters correspond to 
questionnaire items that were common for all studies.  
 
Results: 
 
Physicians 
Almost 74% of participants received no education regarding medicines and driving during 
their academic studies and their professional participation in post-graduate education. 
The knowledge received during the training did change their knowledge about the potentially 
detrimental effects of medicines on driving fitness for more than half the participants (55%). 
After the implementation of DRUID guidelines, a 10% increase difference in the positive 
change in Reported Behaviour was observed in the overall physicians’ samples across the 
country studies. Changes only in Reported behaviour for the physicians have been detected 
mainly for the following reasons. Reported behaviour questionnaires are straightforward, 
therefore easier to detect change. Usually, question items related to knowledge and 
attitudes/awareness have more associations with other personality characteristics such as 
target characteristics (e.g. self-esteem, intelligence) and other source (e.g. atracttiveness) 
and message characteristics (e.g. nature), therefore it is more difficult to be studied and 
isolated, especially in a cross-country study with limited time available to extrapolate findings 
of certain magnitude. The same outcome with regard to Reported Behaviour holds true for 
pharmacists as well. 
 
Perhaps pharmacists are more used to focus on medicines side effects and instructing 
patients on how to use their medicines safely, physicians might be more focussed on disease 
issues, anamnesis and treatment decisions, and less involved in deciding on medicines' 
behavioural side effects, such as impairing effects on driving fitness. 
 
Pharmacists 
The majority of pharmacists (67%) had not received any type of (post-graduate) education on 
medicines and driving with the exception of the participants in the Spanish study where half 
the participants had received relevant education (51%).  
Pharmacists showed an overall positive change in all behavioural clusters under study.  
Pharmacists incorporated driving related information in their daily dispensing practice. The 
DRUID guidelines were well received and viewed as an addition to existing guidelines.  
 
Conclusions: 
Part A 
Positive change has been found for both professional groups but for pharmacists this was 
revealed for all clusters of behavioural items under investigation.  
The application of DRUID guidelines was successful and pinpoints the readiness of health 
care professionals to adopt them. The findings should be treated with caution as 
extrapolations and generalisations are limited mainly because of design variations in the 
separate country studies. Moreover, these findings support the statement that guidelines are 
important and can improve the quality of health care. Physicians and pharmacists have 
shown a change in behaviour after the implementation of DRUID guidelines, therefore these 
guidelines could be successfully incorporated in existing decision support systems. These 
guidelines fill in an important “gap” linking prescribing and dispensing of medicine with both 
patient and road safety. Physicians are affected by the DRUID material training but this 
should not be a short-term endeavour but be flexible, adaptable, and personalized to local 
settings. 
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Overall 
Overall, the country studies showed that decision support tools are welcome and usable, 
DRUID materials fulfilled a need and most participants anticipated the ultimate integration of 
these materials to their own software packages.  
Based on the comments made by the health professionals within the country reports, the 
implementation of computerised guidelines and DRUID categorisation was highly accepted as 
practical information by both physicians and pharmacists and participants were willing to 
continue using the DRUID information if integrated in their prescribing and dispensing 
computer systems for easier incorporation in their daily practices. Participants offered ideas 
for future developments such as inclusion of other medicines in the categorisation scheme 
and the information should be adjusted to the native language. Future recommendations 
should also include specialized and elderly directed advices incorporated in the system and 
adaptation to other target groups and not only drivers (e.g. heavy machinery usage and 
senior people information). 
A long term goal would be to evaluate the impact to the health care system, to various 
stakeholder groups associated with the implementation of health care professionals’ 
guidelines and compare it with other related studies’ findings. In addition, further research 
could facilitate its adaptation and customisation for different groups of health care 
professionals and national settings. A set of DRUID recommendations has been derived from 
the main conclusions of both composite cross comparisons and country studies. The key 
message is clear about the necessity of diffusion of DRUID information to physicians, 
pharmacists, and nurses in all clinical settings. 
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PART B 
 
Belgium 
 
Physicians study 
Objective: To measure the effectiveness of physicians’ training on the guidelines for 
prescribing medicines with an influence on driving abilities, as well as the use and user 
acceptance of the developed prescribing support tools in which medicinal risk classification 
system was integrated.  
Method: The effectiveness was measured through the actual use rates of the integrated and 
stand-alone ICT support tool and in a questionnaire survey (compared to baseline 
measurement), after 6 months as a change in attitudes/awareness, knowledge and (reported) 
behaviour due to the implementation of the training. The study has a controlled experimental 
design, including pre- and post-conditions and includes two experimental (training + 
intervention) and one control group. (1) Integrated software group, SoSoeMe group: a group 
of physicians using the SoSoeme prescribing system in their daily practice. The DRUID WP4 
and WP7 information was integrated into the SoSoeMe software. (2) Stand-alone software 
group, USB group: a group of physicians from East Flanders.The DRUID WP4 and WP7 
information was delivered through an USB stick to be installed on the physician’s computer, 
together with a paper tool or compendium including the same information. (3) Control group, a 
group of physicians in East Flanders. This group did not receive the DRUID information. 
Results 
Except for years practicing as a physician the three groups (SoSoeMe, USB and Control 
group) did not differ significantly regarding personal or practice related background variables. 
The three groups were similar with regard to information sources for medicinal driving risk, 
pre-level attitudes and awareness, knowledge, willingness to use a prescribing support tool 
that takes driving risks into account). Two significant differences were found though with 
regard to reported behaviour (1) and knowledge (1): the SoSoeMe group at baseline 
significantly indicated to provide less detailed information when prescribing as compared to 
the USB and Control group. On the knowledge question on Amitriptyline the participants from 
the control group gave significantly less correct answers than the other two groups. The 
participants in the present study (in all groups) had a high ICT familiarity. Despite the high use 
of the Internet and use of medical software only half of the physicians stated to have easy 
access to data and information on the topic ‘medicines and driving’. Overall the physicians 
had a positive attitude towards the importance of being well informed on the topic drugged 
driving and the potential role they can play in providing information on the potential risk of 
medicines to the patient. Remarkably, half of the physicians in all groups felt not being well 
aware of the effects of medicines on driving skills. In general a low knowledge on the topic 
‘medicines and driving’ was measured. The physicians were more informed about legal 
obligations and responsibilities of physicians/pharmacists and patients. 
Little pre-post questionnaire change was found on attitudinal level. a significant pre-post 
change was found Only for the SoSoeMe group with regard to reported behaviour. The 
SoSoeMe participants provided the patient significantly more with written information 
materials after the trial period. Two positive pre post change trends were found for the USB 
group on the questions if the physicians provided a patient with written information materials 
and if the discussed medicinal drug consumption and driving related responsibility issues with 
the patient. However not significant, it can be said that a positive change in reported 
behaviour was measured after the training/ trial period. No significant pre-post changes were 
found with regard to the knowledge questions in the SoSoeMe group and the USB group. For 
the control group a significant negative pre post change was found for both composite scored 
and the question on Amitripthyline. The physicians in the control group gave significant less 
correct answers in the post questionnaire.  
Conclusions. we observed few significant pre-post changes in attitude & awareness, 
reported behaviour and knowledge. We did expect, conform with the results from the 
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pharmacist study, to find more (significant) positive changes for the SoSoeMe group. A 
possible explanation could be the lack of contact between the research team and the 
participants. This group had no training and received no newsletters during the trial period. 
Also no follow up (e.g. when some problems raised when updating the software) could be 
foreseen. At the start of the study this group was not very eager to fill in questionnaires but 
they did want to use the information integrated in SoSoeme. About 90% of the physicians that 
used SoSoeMe had used the information on a quite regular base. Their feedback was very 
positive and all physicians wanted a continuation of the DRUID information into their daily 
used software. Therefore the lack of positive change found in attitude, behaviour and 
knowledge should be nuanced and it is very plausible that the found results are an 
underestimation of the real impact of the study. 
The lack of (significant) pre post changes in the USB group could be explained by the low use 
of the USB tool. Few physicians used the tool, not even on a sporadic base, but several 
physicians used the manual very often. Most physicians did prefer a manual above the tool.  
In the control group significant pre-post changes were found on the knowledge questions. A 
possible explanation could be that the physicians were, after filling in the pre-questionnaires, 
confronted with their low knowledge on the topic ‘medicines and driving’, and paid more 
attention to the potential risk of medicines on driving. 
The physicians are willing to use a prescribing support tool when this tool is integrated in their 
daily used software, asks no extra efforts or time to update, is easy to use and contains 
practical information. The physicians underlined the need for more information on the topic 
‘medicines and driving’. This information should not only be made available to physicians but 
also be integrated in the patient leaflet or on the medicine box. 
Pharmacists study 
Objective: To measure the effectiveness of pharmacists’ training on the developed 
dispensing guidelines for delivering medicines with an influence on driving abilities, as well as 
the use and user acceptance of the developed dispensing support tools in which the 
medicinal risk classification system was integrated.  
Method: The effectiveness was measured through the actual use rates of the integrated and 
stand-alone ICT support tool and in a questionnaire survey (compared to baseline 
measurement), after 6 months as a change in attitudes/awareness, knowledge and (reported) 
behaviour due to the implementation of the training. The study has a pre- and post-design 
and includes 2 intervention groups (training + implementation support tool) and one control 
group: (1) An integrated software group, the ViaNova group: a group of pharmacists using the 
ViaNova dispensing system in their daily practice. (2) Stand-alone software group (USB 
group): a group of pharmacists in East Flanders. The DRUID information was delivered 
through an USB stick to be installed on the pharmacists’ computer. (3) Control group: a group 
of pharmacists in East Flanders. This group did not receive the DRUID information. 
Results 
The three groups (ViaNova, USB and Control group) did not differ significantly regarding 
personal or practice related background variables except for the number of inhabitants in the 
practice area (a measure of more rural versus more urban practice area).. 
The three groups were quite similar with regard to pre-level ICT familiarity, attitudes, 
awareness, reported behaviour and knowledge. The participants in the present study (in all 
groups) had a high general ICT familiarity and indicated a high access to information (on the 
potential effect of medicines on driving). Despite the high access to information the 
participants did report a lack and need for information, and there seemed to be a low 
knowledge on medicinal driving risk specifics. The pharmacists had positive attitudes towards 
the importance of being well informed on the topic and on the potential role they can play. 
Contrary to the positive attitudes, low frequencies of reported behaviour that considers 
medicinal driving risks’ were found prior to the training/intervention in all groups. With regard 
to user acceptance of possible dispensing support tools, more than 90% of the ViaNova 
respondents and over 70% of the respondents from the USB and Control group stated that 
they would be willing to use a dispensing support tool to easily find information regarding 
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medicinal drugs and driving. Their first choice was software integrated in the daily used 
software, second choice was a website, and third a manual; a stand-alone software (like cd-
rom or USB stick) was generally not preferred. 
Significant pre-post changes at composite score level were only found in the ViaNova group: 
reported behaviour and medicinal risk specific knowledge increased significantly. 
Furthermore, taking a look at the number of significant pre-post changes on individual 
statements or questions, the ViaNova group had in total 10 significant positive changes (on a 
total of 20 statements/questions), compared to just 2 in the USB group and none in the 
Control group. Little pre-post questionnaire change were generally found on pharmacists’ 
attitudinal and awareness level. Very good results were found on the pre-post reported 
behaviour comparison of the integrated software group. Rather limited pre-post change was 
generally found on knowledge of individual medicinal risks on driving; this knowledge 
remained generally at a low level. 
Conclusions. Most changes were found in the integrated ViaNova software group, as 
compared to far less in the stand-alone USB group and none in the Control group, after the 
DRUID training and intervention phase. Most positive changes were found on specific 
reported behaviour, on which the pharmacists were specifically trained. Almost no change on 
attitudinal level for none of the three groups was observed, which can be related to an already 
rather a priori good attitude towards the topic medicinal driving risks of the participating 
pharmacists. One could say that the pharmacists who participated in this study firmly 
underline the importance of being well informed and aware of the possible risks of medicines 
on driving. In other words their positive attitude was a motivation to take part in the present 
study. Although the training and 6 months trial increased some awareness for risks of 
medicines for driving (also related to fine-tuned knowledge about specific medicines’ risks), 
more effort still seems to be required in order to further help pharmacists increase their 
awareness and knowledge.   
The DRUID dispensing guidelines were well accepted and liked. What stands out most 
strikingly from all results (questionnaire changes, tools’ observed use data and user 
friendliness rates, and mentioned requirements/wishes for dispensing support tools), is the 
importance of having a support system integrated in the daily dispensing software in order to 
be effectively used. The majority is willing to use a tool in their daily practice, as long as it is 
integrated into their daily software, updated automatically, easy to use, focus on first 
deliveries, cost- and time-efficient, contain concrete & detailed information and if possible 
safer alternatives. 
The Netherlands 
 
Background: The present study refers to the development, and consequent evaluation, of a 
training session that was carried out with the intention of informing Dutch pharmacists, who 
are not actively using their Pharmacom® computer system, about the influence of medicines 
on driving fitness. The materials provided during the training were developed within DRUID 
WP7 (task 7.4) and aim to assist pharmacists with more background information to be 
provided to patients while dispensing medicines that are known to influence driving fitness.  
Objectives:  i) to determine the effectiveness of pharmacists’ training activities related with 
dispensing driving impairing medication as well as the use of ICT tools; ii) to determine the 
effect of the pharmacists intervention at the patient level by investigating a change in patients’ 
knowledge, attitudes/awareness and (reported) behavior; and iii) to determine, the dispensing 
patterns of medicines that might impair driving fitness.  
Methods: This study was conducted in the Netherlands and consisted of the training of 
community pharmacists who do not actively use the Pharmacom® system for the first-time 
dispensing counselling (EUB) and the second-time dispensing counselling (TUB), with 
respect to anxiolytic (ATC code: N05B), hypnotic (ATC code: N05C), and antidepressant 
(ATC code: N06A) medicines, known to impair driving fitness. Those pharmacists were 
randomly and equally distributed in the intervention group (pharmacists were given the 
training) and in the control group. The training was evaluated by means of a questionnaire 
that was presented to pharmacists before (T0) and 6 months after (T1) the training had been 
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carried out. The information that was provided to pharmacists regarding the information about 
the influence of medicines in driving fitness, which should be provided to patients while 
dispensing driving impairing medicines, was evaluated at the patient level. This was done by 
means of a patient questionnaire, sent to patients visiting the participating pharmacies and 
who were taking any anxiolytic, hypnotic or antidepressant medicine(s) for the first time before 
(T0) and 6 months after (T1) the training. 
Results: A total of 277 pharmacists (26.9% response rate) responded to the invitation and 
agreed to participate in this DRUID study. Drop-outs were verified and the final number of 
participants was as follows: 49 in the intervention group and 42 in the control group, which 
means a total of 91 pharmacists enrolled in the study. Pharmacists’ awareness about the side 
effects of medicines on driving skills significantly increased after the training (p-value < 
0.001). Pharmacists’ reported behaviour and actual knowledge significantly improved after the 
training. Pharmacists’ user acceptance of the materials and usability of the tool was very 
positive. Pharmacists used the materials to train and inform their assistants but failed to share 
that information with general practitioners.  
A total of 930 patients (15.2% average response rate) participated in the study (421 at T0 and 
509 at T1). Regarding patients’ knowledge about causes of road accidents, no significant 
differences were found between time measurements, despite a general improvement had 
been observed in the follow-up measurement.  After the training, patients visiting pharmacists 
belonging to the intervention group were significantly more spontaneously informed about the 
influence of medicines on driving fitness than patients visiting pharmacists belonging to the 
control group (p-value 0.007). After receiving information about the possible impairing effects 
of the medicines, patients decided not to change their driving behaviour and no statistically 
differences were found between time of the measurement or between pharmacy group.  
For the dispensing data analysis, only the data of 77 pharmacies (43 from the intervention 
and 34 from the reference group) was used. The mean number of patients registered in both 
groups of pharmacies was similar. The number of new users of N05B, N05C and N06A 
medicines was always higher during the follow-up period, but the difference was never 
statistically significant. Regarding the dispensing pattern of these groups of medicines, no 
changes in the follow-up period were verified. Considering the 3 categories on the different 
levels of impairment, it was not possible to see a decrease in the dispensing of higher 
categories medicines and a consequent increase in the safer alternatives. 
Conclusion:  It can be concluded that the training positively changed pharmacists’ reported 
behavior and knowledge. The positive outcome related to these two variables was expected 
as the training aimed at improving pharmacists’ knowledge and behaviour. Pharmacists’ 
awareness, however, did not significantly change after the training which could be explained 
by pharmacists’ positive attitudes already at the baseline measurement (T0). In fact, 
pharmacists’ awareness towards the use of driving impairing medicines might have 
contributed to pharmacists’ willingness to participate in the study. The training and the 
information materials developed helped pharmacists to improve some daily routines and 
contributed greatly to improve the information provided to patients, which became more 
adequate. According to patients, pharmacists are considered to be the main source of 
information about medicines and the message was spontaneous and successfully transmitted 
to patients. Patients did not change their driving behavior, despite all the efforts from the 
pharmacist to transmit adequate information to patients. The training did not have any 
influence in the dispensing of safer alternatives of driving impairing medicines to new users.  
Patient study: The majority of patients knew that some medicines can influence fitness to 
drive, and most patients (83.4%) interviewed would reduce the frequency with which they 
drove if they were prescribed a “medicine which has the pictogram concerning driving on the 
packaging”.   
Overall conclusions: The health professionals (pharmacists) that attended the training 
courses showed six months later a trend towards a more positive reported behaviour and 
actual knowledge regarding medicines and driving, while there is no (clear) change in 
attitudes/awareness on medicines and driving.  
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Spain 
 
Background: In Spain from 2011 medicines that can may influence the ability to drive, must 
carry a symbol, pictogram in the package, to indicate to drivers carefully read the package 
insert for extra precautions if they drive a vehicle (Royal Decree 1345/2007 of 11 October). 
The present study refers to the development, and consequent evaluation, of a training course 
that was carried out with the intention of informing at Health professionals of the Spanish 
National System of health (Physician and nurses) and pharmacist, about the influence of 
medicines on driving fitness, the categorization system and implementation of the pictogram 
on the packaging of certain medicines in Spain. The materials used during the training course 
were developed within DRUID WP7 (task 7.4) and aim to assist at health professional with 
more background information to be provided to pastients while prescribing and dispensing 
medicines that are known to influence driving fitness. 
 
Objective: 
 
Study 1: health professionals: physicians, pharmacists and nursing staff 
 
i) To assess health professionals’ attitudes/awareness, reported behaviour and actual 
knowledge on the topic of medicines and driving (pre-training, pre-questionnaire)). 
ii) To assess possible changes in these dimensions six months later, after the training activities 
(post-training, post-questionnaire). 
Study 2: patient questionnaire 
i) To find out whether the users of medicines know that some medicines can negatively affect 
their fitness to drive, and to evaluate the influence that the pictogram on medicines and driving 
that is printed on the packaging of the medicine could have on the patient’s attitude to driving. 
Methods:  
Study 1: health professionals: physicians, pharmacists and nursing staff 
This study was conduced in Spain, in Valladolid. To give a training course on medicines and 
driving in three groups of health professionals: Physicians and nurses working at primary 
health care centres, as well as community pharmacists. The study was carried out in 10 
primary care health centres in the Province of Valladolid and among the pharmacists working 
within the area of influence of these 10 primary care health centres. 
Health professionals were divided into three groups:  
a) Intervention group: Computer science (information through a computer science tool) 
b) Information Group: Printed (information through printed documents).  
c) Control group: Group that does not receive specific information on medicinal drugs and 
driving. 
The training was evaluated by means of a pre-questionnaire completed before the training.. 
and post questionnaire completed 6 months after training started. 
 
Study 2: patient questionnaire 
The target population is made up of “health service users” into contact with the National 
Health Service through Primary Care, Hospital-Specialized Attention or as consumers in 
pharmacies. Throughout the current text, they shall be referred to as “patients”. The sample 
size was established at 300 people in each of the three spheres of study (a total of 900 
people). Finally, 1,385 valid interviews were carried out. 
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The questionnaire used for this study, which can be seen in Annex IV, have been analyzed as 
was agreed by the partners of task 7.4.  
Results:  
Study 1: health professionals: physicians, pharmacists and nursing staff 
Pre-questionnaire: 141 physicians, 127 community pharmacists, and 139 nurses were 
invited to participate in this DRUID study, finally 72 physicians, 75 community pharmacist, and 
36 nurses health professionals responded to the study (44.9% response rate) (Table 123). 
Referred to a lack of training on medicines and driving, in both university studies and after 
finishing their university degree. They showed a high positive attitude/awareness regarding 
medicines and driving, but reported a low reported behaviour, and show a very low 
knowledge regarding medicines and driving. They consider medicines and driving in the daily 
practice to be a relevant issue (score 7.4 on 10). 
Pre-Post questionnaire comparison: For the comparative analysis between the answers 
obtained in both questionnaires, we therefore had 38 questionnaires: 22 corresponding to the 
information group and only 6 to the intervention group (Table 156).The study shows a 
“positive” change in the reported behaviour and in the actual knowledge of health 
professionals after the training course on medicines and driving. After the training course, 
pharmacists, but not physicians, give higher scores to the importance given in their daily 
practice to medicines and driving. 
Study 2: patient questionnaire 
1,385 patients responded to interview-questionnaire, the interview-questionnaire was 
conducted only once, when the patient visited a health service or a pharmacy. The majority of 
patients knew that some medicines can influence fitness to drive, and most patients (83.4%) 
interviewed would reduce the frequency with which they drove if they were prescribed a 
“medicine which has the pictogram concerning driving on the packaging”.   
Overall conclusions:  
Study 1: health professionals: physicians, pharmacists and nursing staff 
The health professionals (physicians and pharmacists) that attended the training courses 
showed six months later a trend towards a more positive reported behaviour and actual 
knowledge regarding medicines and driving. 
After the training course has been a significant change in the whole sample and particularly 
among physicians, leading to an increase in line with the will to take into account the effects 
of drugs on driving skills when they prescribe/dispense medicines. However, health 
professionals would only be willing to change the prescription for another drug with less effect 
on driving, when the patient was a professional driver or take other drugs that act on the CNS 
Across the sample and particularly among physicians, there has being a significant shift in 
favour of asking patients about their driving exposure when choosing/dispensing a medicine, 
and  for a systematic record of the patient’s traffic participation and the advice offered a 
patient when and how he/she can consider driving a car when using a driving impairing 
medicine. Also increasingly the willingness for provide a patient with written information 
materials when prescribing/dispensing a driving impairing medicine. This significant changes 
point to an increase in the effort health professionals make both to inform the patient about 
medicines and driving and to inform him/herself about the patient’s involvement in driving and 
to leave a record of these aspects in the patient’s medical history.   
For both the whole sample as well as for physicians and pharmacists separately, a significant 
positive change can be observed in the evolution in knowledge concerning the effects of 
some medicines on driving. As for as,  the importance given in their daily practice to 
medicines and driving by health professionals. 
Study 2: patient questionnaire 
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A significant proportion of patients who have been prescribed a drug with a pictogram on the 
package would, decrease the frequency of driving, would not lead without having read the 
prospectus before. The physician is the health professional to consult when they first had to 
take a medication on driving with a pictogram on the package, followed by the pharmacist and 
nurse.  
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1 Introduction 
 
Physicians frequently prescribe medicines that may affect driving fitness. In addition, 
pharmacists dispense medicines they know that may affect their clients’ performance behind 
the wheel. Driving is a complex task, and both prescribers and dispensers know that the 
guidelines at hand should ensure that their patients receive the maximum available 
information.  
This document intends to describe the overall evaluation activities of Task 7.4.2. The 
document is divided into two sections as the prime aim of the task is twofold. The first part 
includes the overall consolidation and representation of the effort involved and the second 
part corresponds to the national reports. Consequently: 
The first section describes the evaluation activities for investigating the application of driving 
specific guidelines in prescription/dispensing of medicines (A). 
The second section of this deliverable illustrates the activities conducted in each separate 
country (Belgium, The Netherlands, Spain) (B). 
 
1.1 Evaluation aims & objectives 
 
Firstly, a major objective of WP7 was to produce protocols and guidelines on driving impairing 
effects of medicines for health care professionals who prescribe and dispense medicines. 
Secondly, the effectiveness of the application of the proposed guidelines to health care 
professionals is assessed to the extent this is feasible. It is essential to note that this is not a 
study that is carried out for many years but a small scale effort and therefore its effectiveness 
is expected to be moderate but its qualities and drawbacks are of equal importance for future 
efforts. Thirdly, the assessment focus turns, also, towards the intervention/administration 
method (e.g. Integrated vs. paper version). An in depth analysis of the primary and secondary 
objectives is presented in the second part of this deliverable, where the country specific 
investigations are illustrated. 
 
1.1.1 Evaluation team (partners) 
 
The evaluation activities are usually the last part on long research collaboration towards the 
implementation of driving-related protocols and guidelines.  
The WP7 partners involved in the evaluation activities and their roles are shown in Table 1. 
Table 1: Roles and Responsibilities of the Evaluation Team Members 
 
Table 1: Roles and Responsibilities of the Evaluation Team Members 
 
Partner Title of Role Responsibilities 
 UGent/IBSR Test& Evaluation partner National study description  
Study conduction 
Data gathering 
National report 
 UVa Test & Evaluation partner National study description  
Study conduction 
Data gathering 
National report 
RugPha 
 
Test & Evaluation partner National study description  
Study conduction 
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Data gathering 
National report 
CERTH/HIT Evaluation partner Evaluation plan  
Consolidated data report 
Overall statistical composites 
 
All partners  
 
Collaboration 
DRUID Tool’s development  
Feedback,comments, amendments  
 
According the Table above, the allocation of workload illustrates the inter-connective and 
collaborative character of the implementation and evaluation of this study.   
 
2 Background and theoretical model 
 
Research has shown that many diseases may affect driving performance. However, the 
medicines prescribed for most diseases can make us being behind the wheel just as 
dangerous. Current research focuses on the Central Nervous System impairment brought 
even by the over-the-counter medicines. The realization of the need for alterations in existing 
guidelines on the way physicians and pharmacists prescribe and dispense medicines is a 
general goal of WP7. Experts have formulated new guidelines and protocols within the 
framework of the DRUID European project.   
 
2.1 Brief literature review 
 
It is important to note that there is no magical way to improve the way health professionals 
advise their patients. According to the literature effectiveness is context related. In other 
words, the communicated meaning and its periphrastic qualities are the essential “pass” to 
successful conferment. Likewise, clarity, wording, and simplicity are key parameters to the 
conveyed messages. In line with current research, focus has been shifted towards the 
amalgamation of techniques (e.g., pedagogical, learning, training) in increasing the 
effectiveness and, therefore, probably in the long run, the impact on the target population. 
Protocols and guidelines may be regarded as tools to improve clinical practice. Optimal 
guidelines will facilitate prescribers/dispensers to provide more appropriate treatments to their 
patients.  
It was essential to provide an adequate and acceptable definition of protocols and guidelines 
so as to establish the foundation for the conceptualisation of the evaluation plan. Moreover, a 
consensual glossary enabled DRUID partners to support the chosen theoretical framework.    
According to Prior and colleagues (2008) “Guidelines are defined as systematically 
formulated documents that assist practitioners to make clinical decisions informed by best 
available evidence.” Professional guidelines provide the foundation for better and cost-
effective practice. The rising of comparability in medical practice ensures the development of 
collaboration between research findings and evidence-based medicine.  
Grimshaw and Russell (1993) investigated the effectiveness of medical guidelines in 
everyday practice and they found that for guidelines to be effective, the strategies 
implemented are crucial. They found 4 out of 59 studies to report effective implementation of 
guidelines in a vast array of clinical and preventive care environments. It is important to 
emphasise that the randomised studies that proved higher effectiveness of applied medical 
guidelines were the ones that they applied a specific educational intervention, specific patient 
information and reminders with internal development strategy. In this study extra effort was 
placed on the wording of guidelines and the information provided for both practitioners and 
patients. 
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Table 2: Classification of clinical guidelines (Grimshaw & Russell, 1993) 
  
Rousseau and colleagues (2003) conducted a practice based, longitudinal, qualitative 
interview study in five general practices in north east England in order to understand the 
factors influencing the adoption of a computerised clinical decision support system for two 
chronic diseases in general practice. 
Negative comments about the decision support system significantly outweighed the positive 
or neutral comments. Three main areas of concern among clinicians emerged: timing of the 
guideline trigger, ease of use of the system, and helpfulness of the content. Respondents did 
not feel that the system fitted well within the general practice context. Experience of “on-
demand” information sources, which were generally more positively viewed, informed the 
comments about the system. Some general practitioners suggested that nurses might find the 
guideline content more clinically useful and might be more prepared to use a computerised 
decision support system, but lack of feedback from nurses who had experienced the system 
limited the ability to assess this.  
Significant barriers exist to the use of complex clinical decision support systems for chronic 
disease by general practitioners. Key issues include the relevance and accuracy of messages 
and the flexibility to respond to other factors influencing decision making in primary care.  
An overview of existing literature is disappointing but it shows the importance of the 
development of evaluation techniques for computerised protocols and more importantly for 
their application in driving as relevant literature is scarce to non existing.   
Similar findings have been reported by Grol and Grimshaw (2003). They have suggested that 
change in behaviour is possible. They continue with emphasizing that change is possible if it 
occurs at different levels (doctor, team practice, hospital, wider environment), tailored to 
specific settings and target groups. Plans for change should be based on characteristics of 
the evidence or guideline itself and barriers and facilitators to change. Therefore, the adopted 
framework described in section 2.2 takes into account related barriers (Figure 1). In general, 
evidence shows that none of the approaches for transferring evidence to practice is superior 
to all changes in all situations. 
Grol and Wensing (2004) have proposed a multilevel approach to examining incentives and 
barriers to change based on literarure and research conduced at their research centre. They 
proposed that barriers should be examined at six levels:the innovation itself, the individual 
professional, the patient, the social context, the organisational context, and the economic 
and political context. In this study not all these different levels were taken into account due to 
the limitations in both time and resources. However, type professional (e.g. medical 
practitioner and nurses), patients, and new guidelines were taken into account. It could be 
argued that the social, organizational, political and economic levels were all part of the study 
as different countries participated. However, not investigated on individual level.  
Shiffman and colleagues carried out a review of current literature and found that 14 out of 18 
studies investigatingcomputerised guidelines’ mplementation have showed improvement in 
guidelines’ adherence because of application of strategies based on computers. The 
guidelines in most cases were integrated in the existing clinical information system. 
Before focusing on to the theoretical background that the evaluation materials’ construction 
was based on, three targets were set: a) strategies should target also patients, b) content of 
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guidelines should be coherent and clear, and last but not least, c) the study should have clear 
objectives.  
The brief literature review was conducted in order to identify the parameters and 
measurements that could be important for the deveplement of both the guidelines and the 
questionnaires that were used in the country studies. The next step was to find the theoretical 
framework that would be the base of the evaluation. The research teams were aware of the 
limitations present in empirical research and the inherent difficulty of  finding strong evidence 
when diverse study designs and populations are investigated. However, the framework 
described in the next section was based on the review performed. 
 
2.2 Adopted theoretical framework 
 
The vital long-term role of this endeavour is to embed the concept of the impairing effects of 
medicines in the daily professional practice. Albeit, the impact of the implementation is 
beyond the direct goals of this task, it could be an important one for furthering this study.  
With regards the professional groups, the change in practice routines implies change in 
beliefs and opinions, by enhancing/updating existing knowledge. Therefore, the aim is to 
achieve change in personal professional level and simultaneously evaluate the most effective 
medium to achieve this. The effectiveness of a programme is more sensitive to context 
(Davies et al., 2010). The context was not identical in all groups the guidelines were provided. 
However, as the content is critical for the effectiveness of the implemented guidelines, then a 
group of health care professionals receiving no information relevant to DRUID outcomes 
allowed content comparison. The design of the study is explained in detail in the 
methodological section of this deliverable (section 4).  
The list of intervention studies is long (230 methodological adequate studies), but there is no 
clear basis for understanding which procedures are effective in which contexts. In a nutshell, 
the conclusions drawn from the literature search do not shed light on the “how” component in 
case they were successfully implemented. The main reason why it is unclear how these 
interventions have been successful is the absence of adequate information explaining the 
processes underlying the behavioural change (Michie and Johnston, 2004). The aims, goals, 
context and timelines direct us towards the adoption of the appropriate theoretical foundation 
for this task.  
 
Extensive reviews on guidelines implementation have half-heartedly reported limited and non-
consistent effect of guidelines in changing physicians’ behaviour (Cabana et al, 1999). The 
processes and factors involved in health care professionals’ adherence to guidelines have not 
been investigated in depth and little is known with regards how it could successfully be 
succeeded.  
 
DRUID 6th Framework Programme
 
Figure 1: Barriers to health care professionals’ guidelines adherence (Cabana et al., 1999)
The diagram above provides a theoretical model incorporating the terms of knowledge, 
attitudes, and behaviour, which are the main constructs in the proposed
Annex I).  
The aforementioned barriers are pertinent to be taken into account in this attempt 
the guidelines effectiveness as they are relevant to the artefacts (i.e.,
behaviour) investigated in the constructed questionnaire discussed later on in this document. 
The model adopted was based on the evaluation review 
provides a mostly linear relationship between guidelines implementation and their 
effectiveness. In other words, we assume that a behaviour change will result from changes in 
knowledge and attitudes. As th
may arise but their affect in daily practice will be time limited. Moreover, the components and 
the sequence of the model were further clarified by providing a process enabling the model to 
sketch the procedure adop
implementation of professional guidelines to inform patients on driving impairing effects of 
prescribed/dispensed medicines). The assumption that behavioural change is the result of 
change in knowledge and attitudes should be incorporated in the current methodology, 
leading to the construction of an instrument that encompasses the components (items) that 
could measure such change. The latter is the prerequisite for measuring the effectiveness of 
implemented tools. 
The procedure is schematically presented below and is comparable to learning steps of 
behavioural change.  
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Figure 2: Diagram on the process of guidelines adherence (based on the flow chart of Davis & Taylor-
Vaisey, 1997) 
 
The adoption of guidelines is an agreement/contract between the developers and the 
physician/pharmacist to implement and use the guidelines in their practice. If the 
professionals have committed to implement the suggested guidelines, then they would diffuse 
acquired knowledge unaided to their implementation in their daily practice. Following the 
diffusion, then the actual communication of the newly acquired knowledge to their patients 
would improve their prescribing/dispensing practice by choosing medicinal drugs from lower 
DRUID categories (e.g. III to II). 
The review described targeted physicians as the implementation group. In this task, we desire 
to generalise the same model to pharmacists as dispensing of medicines is a major objective. 
The assumption added to the above model is the fact that the behavioural changing process 
is common and can be generalised to all individuals, thus to pharmacists.  
Similarly, the above mentioned factors should be taken into account during professionals 
training and data analyses.   
The atheoretical perspective adopted by most methodologically sound studies has led to 
inconclusive and mixed findings. Most studies miss the link between the effect and the 
processes taken place to lead to the effective implementation of suggested guidelines. In 
order to determine the theoretical construct that could be applied in this context DRUID 
partners aimed at deriving the theoretical framework that best explains the behavioural 
change in health care professionals and not in general. An in depth description and 
discussion of the adopted model is beyond the scope of the evaluation plan.   
Section 2.1 facilitated the identification of relevant models and allowed for the selection of the 
framework. In other words, guidelines developed within WP 7.4 was based on existing 
literature (2.1) and associated parameters and barriers identified in secion 2.2 were of 
importance for the development of the evaluation materials (i.e. questionnaires) for the 
evaluation of the implemented guidelines.  
The next section sketches out the significant parts and procedures of a simultaneously 
multifocal investigation. 
 
2.3 Evaluation logical model 
 
The creation of a logical model facilitates and it is very useful through the design and 
evaluation process as it demonstrates the components and their co-relations. The layout 
presented below corresponds to the general functionalities and timelines of the design. 
The flow diagram on page 32 describes the logical model developed to link the processes, 
partners, results and summarises the involved procedures. It is a static notional view of the 
involved elements.   
Adoption 
of 
Guidelines 
 
 
   Diffusion       Dissemination 
         Implementation 
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The interconnection of the individuals, processes, instruments and external factors shown in 
the figure is taken into consideration in the following section where the methodological 
considerations are discussed in depth. 
 
 
2.3.1 Need and target population 
 
Need 
The following questions were initially addressed when the overall design was prepared: 
- What is the purpose of the study? 
- What types of information will be gathered? 
- What is the focus of the study? 
- What methods and tools are appropriate? 
- What are the units of analysis? 
- Which sampling strategies will be employed? 
- Where will the study be conducted and how will it be phased? 
- How will ethical issues and matters of confidentiality be handled? 
An effort was made by all partners to accommodate for these needs in the most productive 
way within the project’s requested timelines. 
 
Target population 
The target populations were professionals in the primary care setting: i) physicians (Belgium, 
Spain), ii) pharmacists (Belgium, The Netherlands, Spain) and iii) nurses (Spain). 
Moreover, physicians were sub-categorised to GPs and specialists (Neurologists, 
psychiatrists). The recruitment of stratified samples was not attainable by the partners; 
therefore the initial groups of physicians and pharmacists remained as the focus of 
evaluation.  
If it was decided to implement it on specialty, then another number of users was required as 
the variables involved (i.e., type of specialization) would be incorporated to the existing 
design. 
According to the Description of Work, participants could be General Practitioners and 
specialists.  As the numbers per specialism were not known for all participating countries, it 
was not possible to stratify the sampling so as to accommodate for this sampling procedure. 
Physicians’ recruitment was not feasible to be randomised in all countries. A detailed account 
of sample sources will be provided at the national level design descriptions (Part B). 
Physicians were essential for this study as they are the first in line health care professionals 
patients contact in order to get advice regarding medical problems.   
The term pharmacists refers to community pharmacists who dispense medicines. 
Pharmacists may be able to prescribe medicines in some countries, but not in the respective 
countries involved in this deliverable, where physicians are the primary prescribrers. The 
selection process was as similar as possible to the one applied to the physicians to ensure 
the balanced conduction of the trials. 
The term nurses refers to nurses recruited from primary health care centres (Spanish study 
only). 
 
2.3.2 Objectives, inputs, activities, and outcomes 
 
It is essential to pinpoint the criticality of ensuring that information concerning driving 
impairing effects of prescribed/dispensed medicines is communicated to healthcare 
professionals and consequently to patients.  
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The primary goals of this task are clearly stated as to:  
 
 
In addition, a “pure” control group was added to evaluate the effectiveness of current 
practices with no DRUID-relevant information.  However, the latter may be hindered by socio-
occupational networking elements. Researchers are aware of the limitations imposed upon 
the professional guidelines’ communication among physicians and pharmacists and possibility 
of information leakage was taken into serious consideration and effort was made to avoid this. 
Each coutry study researchers have taken leakage possibilities into consideration and this 
issue was raisen early in the project. 
It is important to explain that health care professionas who were using the integrated ICT tool 
in their daily practices were not using the stand alone tool. The website access could enhance 
the computerised practice, but was not mixed with the administration of paper information as 
the latter is a distinct type of implementation (Spanish study). In addition, the USB stick had 
access to the internet (webpage) where DRUID information was accessible.  
A detailed description of the software packages is included in the separate country reports 
and could help evaluators to sketch a representative account of possible interactions with 
measureable variables and their impact.  
The application of different software packages could enlighten us on the most effective 
characteristics of each tool separately resulting into gathering valuable findings on the 
elements that may be necessary to be incorporated in future software package.  
Consequently, the respective companies might obtain important information for future more 
sophisticated software development.  
In addition, health care professionals were trained in order to learn how to use the DRUID ICT 
tool. The integrated software group (SoSoeMe) of physicians in Belgium did not receive any 
training. Training usually is a familiarisation phase so as to avoid the investigation of 
confounding variables within a framework. In this case, it provides the transfer of DRUID 
knowledge to health care professionals comprising the target groups. The computerised 
protocols and guidelines were implemented and evaluated in the participating countries, thus 
apart from the general design methodology; an adjusted country-wise version was 
implemented to support the feasibility and validity of the process.  
 
 
Evaluate the effectiveness of the implementation of developed 
protocols and guidelines to healthcare professionals via two 
different means: 
 
• integrated (ICT) tool (additional software integrated into the ICT 
software used by the professional in his daily practice; country 
specific development) 
• non-integrated tool of the protocols and guidelines (ICT tool 
developed within the framework of the project) 
 
 Situation: integrated implementation vs. Non-integrated version of protocols and guidelines and comparison to no-DRUID-relevant information to physicians and 
pharmacists (No information group not included here as the procedure is not so complex) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Protocols 
& 
guidelines 
WP4 
Categorisation 
 
Time 
 
Funding 
 
Partners 
 
Participants: 
Pharmacists & 
Physicians 
 
Country 
specific 
Software 
packages 
 
Identify potential 
pools 
Recruitment of 
physicians (GPs and 
specialists) 
 
 
 
Contact 
organizations and 
institutes 
 
Prepare Invitation 
letters 
 
Training of health 
care 
professionals 
according to 
D.7.4.1 
(translations of 
manual and 
questionnaires) 
Sufficient pool of 
participants even in 
50% drop outs 
INPUTS OUTPUTS 
   Activities                            Reach 
OUTCOMES 
Short                                            Medium                                  
Long-term 
Software package 
companies 
established rights 
and usage 
HIT development of 
decision support 
tool database and 
website 
Findings of 
prescription 
patterns’ and 
probable 
suggestions for 
alterations 
6 months usage 
with data logging 
Baseline 
measurements 
obtained (pre 
questionnaires) 
Participate in 
training “events” in 
groups of users 
Informed consent 
signed 
Post questionnaires 
filled in 
ASSUMPTIONS:  
The increase of knowledge, attitudinal sensitivity, observed and subjective behaviour 
by the application of the drug-induced driving related guidelines is the result of the 
effectiveness of the guidelines 
 
EXTERNAL FACTORS: 
 Impossible to control information flow and professional interactions, cultural differences, 
professional experience diversity 
 
Findings on the 
usability and 
acceptance of 
implemented 
interventions 
Findings on the 
effectiveness of 
implementing 
computerised 
guidelines 
Increase 
effectiveness by 
implementing 
driving related 
guidelines in daily 
practice 
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3 Focus of the evaluation 
 
The overall evaluation aimed to deliver the objectives and goals of Task 7.4. Hence, in order 
to evaluate the effectiveness of the implementation of the developed protocols and guidelines 
within WP7 a summative approach was adopted. The application of this technique focuses on 
the examination and analyses of findings after the finalisation of work. 
The following figure presents the necessary steps taken in order to conduct the studies and to 
accomplish their harmonisation and synchronisation throughout conduction. It is useful to 
follow an a priori structured plan to ensure that important evaluation steps have not been 
omitted. 
 
EVALUATION 
 HUMAN SUBJECTS 
PROTECTION 
 TIMELINE 
 RESPONSIBILITIES 
 BUDGET 
 
ENGAGE STAKEHOLDERS  
 
Focus 
 Describe 
program-
logic model 
 Define 
purpose 
 Determine 
use/users 
 Determine 
key 
questions 
 Select 
indicators 
 Determine 
design 
 
Collect 
data 
 
 
 Identify 
sources 
 Select 
method(s) 
 Pilot test  
 Set 
schedule 
 Determine 
sample 
 
Analyze 
& 
interpret 
 Process 
data 
 Analyze 
 Interpret 
data 
 What did 
you learn? 
 What are 
the 
limitations? 
 
Use 
 Share 
findings and 
lessons 
learned 
 Use in 
decision 
making 
 Determine 
next steps 
   Standards of evaluation: 
• Utility     • Feasibility     • Propriety     •Accuracy 
 
Figure 3: Evaluation plan steps  
 
3.1 Research specific objectives  
 
This section very briefly presents overall research questions that have been adapted later on 
to the needs of each separate country study. 
 
3.1.1 Overall 
 
The aim of the study is twofold: 
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a) Evaluate the integrated (ICT) vs. stand alone delivered guidelines and protocols (input from 
Task 7.2)  
b) Evaluate the effectiveness of risk communication to patients through leaflets (input from 
Task 7.3) by the application of the developed categorization system (input from Task 4.2)  
 
The key hypotheses of the study were: 
 
Hprofo: The application of integrated guidelines will not be effective in informing the 
professionals on prescribing medicines which may affect driving 
 
  It is tested against the following alternative: 
 
Hprof1: the application of integrated guidelines will be effective in informing the professionals 
on prescribing medicines which may affect driving. 
 
3.1.2 Country specific 
 
In this section the objectives of each study are briefly presented. 
 
Belgium 
The Belgium team focused on investigating the effects of integrated vs. non integrated 
software for delivering guidelines to physicians and pharmacists (SoSoeme and ViaNova, 
respectively). In addition, a control group was added.  
 
Netherlands 
The Dutch group performed two separate studies. A patient study investigated differences in 
patients’ knowledge before and after training (6 months). A pharmacists’ study investigated 
differences in guidelines adherence with the application of an integrated tool.  
 
Spain 
The Spanish team assessed the influence of health professional training about medicines and 
driving on i) the medicine prescription patterns to the driver patient, and ii) the information 
received by patients on the effects of prescribed medications on driving. 
The Spanish team focused on three different types of health care professionals: a) medical 
practitioners, b) pharmacists, and c) nurses. They investigated the effect of computerised 
guidelines when compared to non-computerised method of administration of guidelines and 
protocols.  
 
 
4 Methods 
 
4.1 Sample size calculations 
 
This section is divided in two parts. The first section encompasses the initial sample size 
calculations based on random sampling with no interest in correlation based on marginal error 
(5%), confidence intervals (95%) and population sizes. Typically the reported margin of error 
is about twice the standard deviation, the radius of a 95% confidence interval. As a “rule of 
thumb” an acceptable level of marginal error is between 3%-6%. The chosen one was 5%. In 
other words, if we were to conduct the same study 100 times, the results would be within ±5% 
of the first time we ran the study 95 times out of 100. It is impossible to estimate the SD and 
the exact effect size (based on mean differences) as no pilot testing has been performed in 
order to act as a base for further calculations.   
 
A sample size calculator was used on the aforementioned parameters and the minimum 
sample sizes were estimated and presented in the following table. 
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Table 3: Initial sample size calculations 
Country Pharmacists Physicians 
  
Spain 383 377   
Belgium 377 380 Neurologists:166 
Psychiatrists:312 
Neuropsychiatrists:206 
Germany 377 383   
The 
Netherlands 
339 382 
  
 
As shown above, if the population consists of just a few hundred people (i.e., specialists), it 
seems that we should need to survey almost all of them in order to achieve the desired level 
of accuracy. As the population size increases, the percentage of people needed to achieve a 
high level of accuracy decreases rapidly. In other words, to achieve the same level of 
accuracy:  
 
Larger population = Smaller percentage of people surveyed  
Smaller population = Larger percentage of people surveyed 
 
It is essential to bear in mind that for the specialists’ sample size calculations no stratification 
sampling was taken into consideration as it involves a different procedure.  
The sample size calculations are important -as we are concerned in detecting an effect (i.e. 
difference between the intervention methods) so as to ensure that if an effect deemed to be 
important exists, then there is a high chance of it being detected, i.e. that the analysis will be 
statistically significant. If the sample is too small, then even if large differences are observed, 
it would impossible to show that these are due to anything more than sampling variation.  
 
Moreover, literature on existing studies was not available so as to base for standard deviation 
estimates. Hence, calculations were based on: 
a) proposed size of effect (medium=.25) 
b) desired power=.8  
c) desired significance level=.05 
d) the hypotheses (two-sided) 
Ideally, separate calculations per variable involved (attitudes, knowledge, behaviour etc.) 
could be performed but the data at hand were quite restricting.  
Sample size calculations were performed with G*Power software (version 3.0.10). Total 
number of participants per level of independent variable was estimated at n=93.  
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Figure 4: Sample size as a function of power 
 
The experimental groups (integrated vs. stand alone) received information on exactly the 
same content. It is crucial to be cautious when selecting the users so as to avoid and obstruct 
the interaction and information “leakage” among participants. Moreover, the third group got no 
information relevant to DRUID material.   
Nonetheless, it is impossible to control the exact information they receive on a daily basis.  
It was mandatory to be as strict as possible when it comes to controlling the trials, because 
the sample size calculations were based and compromised on four assumptions: 
 
 1. The participants are randomly selected 
 2. The correlations are small (i.e., users should avoid contact) 
 3. No stratification was taken into account (specialty sub-groupings) 
 4. The participants’ numbers apply only for controlled conditions (i.e., we all 
                 apply the same methodology) 
 
The sample size calculations were not based on population characteristics (common to 
qualitative data handling methodologies) but to experimental manipulation methodology.  
Hence, the same sample sizes apply to all participating partners. 
The above decision was based on the feasibility standing of the trials and followed the initial 
uncompromised sample size calculations. In addition, it was favourable to select participants 
from various parts of the country to avoid sample bias. 
A common and affordable way to randomly choose and assign people to participate in the 
study is either in SPSS or Excel. Individual reports provide detailed account of sample sizes 
and deviations from original calculations.  
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4.2 Design 
 
The studies were randomised controlled empirical trials. Moreover, the participants were 
allocated to pre and post conditions.  
The study design can be depicted in notation form as follows: 
 
RQ1NQ2 
RQ1NIQ2 
R Q1 Q1 
 
                       Where: 
                                  R= randomly assigned participants 
                                 Q1= Pre-questionnaire 
                                 Q2= Post-questionnaire (adjusted for administration method) 
             I= Integrated guidelines and protocols 
                                 NI= Non-integrated guidelines and protocols 
 
The aforementioned notation is graphically presented in Figure 5. It is important to take into 
account the internal (randomly assign participants to groups) and external validity (sampling 
issues-representativeness and generalisability). While the study sample may be considered 
representative of the original population of interest, generalisability is not a primary goal; the 
major purpose of this study is to determine whether a specific intervention method could work 
in an accessible context. 
 
All participants were measured at baseline (pre-questionnaire) and six months after (post-
questionnaire). It was essential to take into account the possibility of drop outs during the 
study as it is quite often in longitudinal methodologies. This was a topic of discussion before 
the implementation and conduction of the country studies. Each country developed the most 
appropriate methodology to deal with potential drop outs. Their own effort to keep participants 
involved is described in detail in each individual country report and by themselves these 
efforts serve as guidelines for related research that presents both experimental and empirical 
elements.  
Participants consented and were debriefed after the completion of the study.  
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93 physicians (if anticipated response rate is 50%, then double sample size was required) 
wouldparticipate in the study and would be randomly allocated to the 3 groups representing 
the respective independent variables’ levels). Individual reports would include more detailed 
section of how each study partners handled low response rates and drop outs.  
 
However, these calculations serve the main framework of research objectives of the overall 
aims of the task with regard health care professionals and computerised medical guidelines 
and protocols adherence regarding driving impairment due to medicines 
prescribed/dispensed.  
The Dutch and Spanish team investigated, also, the effect to patients’ risk awareness. The 
effect due to DRUID guidelines may be only of indirect nature, therefore the aforementioned 
calculations do not apply. However, an in depth discussion on sample characteristics of 
patients is provided in the respective reports and the increased number of filled in 
questionnaire ensures a valid outcome.  
 
4.3 Materials 
 
The independent variable (IV) of the study was the guidelines administration method. The IV 
factor is comprised of 3 levels (groups):  
 
a) Computerised (electronic administration)- experimental group (EG1) 
b) Non-integrated administration-Comparison group (EG2) 
c) No DRUID-specific information –“Pure” Control group (PCG) 
 
The dependent variable (DV) is the effectiveness of the method of administration. 
Effectiveness is a qualitative term and it is mandatory to be specified with regards the study’s 
theoretical framework. Effectiveness of the study was identified as change in knowledge, 
attitudes/awareness, behaviour due to the application of guidelines. Furthermore, user 
No 
information 
No 
information 
 
6 months N=31 N=31 N=31 
 
Figure 5: Health care professionals (N=93 per group) 
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acceptance, usability and probable (hypothesized) impact of the computerised protocols was 
estimated.  
The instruments applied were pre- and post-questionnaires based on the items decided by 
the partners. Moreover, users were trained prior the participation according to the Training 
Manual (Del. 7.4.1). Baseline measurements (pre-questionnaire) were collected on site before 
training, to ensure transparency of data. In addition, this procedure is cost-effective and 
minimizes the possibility of wearing out the participants. However, in some cases this was not 
possible (e.g. in Belgium the respondents were selected whey sent their filled in 
questionnaires back to the study team with the exception of the ViaNova pharmacists group). 
The instrument was comprised of both close-ended questions and open-ended ones 
(comments sections were included).  
The materials used in each country study range from subjective scales to objective 
measurements. A basic questionnaire was created for the pre and post testing conditions 
(Annex I). 
The basic questionnaire was constructed in order to reflect the following clusters and reflect 
the theoretical framework adopted: 
 
 
 
This questionnaire was the basic template and then adapted to the specific needs and 
requirements of each study; however the structure of the template questionnaire was kept. 
Data deriving by the answers of items in clusters C, D, and F were included in the 
consolidated database and were analysed (section 5). The findings presented in the first part 
of the deliverable are based solely on the analysis of pre and post questionnaires for these 
three clusters for physicians and pharmacists by using only the common items in all countries.  
 
A. Background information (7 items) 
Aiming at gathering information about basic demographic, 
educational background and expertise of participating 
professional. 
B. New Technologies Literacy (6 items) 
As already discussed in the Glossary, this cluster 
contained items that would target to investigate the 
familiarity of the participant with similar tools and, 
therefore, their willingness to apply them in everyday 
medical practice. 
C. Attitudes/Awareness (6 items) 
Professional judgments on medicines and driving were 
investigated.  
D. Reported Behaviour (8 items) 
These questions reflected what the professionals actually 
do in their daily practice. 
E. Sources (4 items) 
In order to get an idea of the various sources professionals 
use in order to gather information and knowledge, this 
section was added. 
F. Actual knowledge (5 items) 
Investigate acquired knowledge on medicines’ effect in 
driving behaviour. 
G. User acceptance (pre-2 items) 
How willing are to use such a tool prior testing phase 
begins. 
H. User acceptance (post tool-8 items) 
Acceptance of the content and the functionalities of the 
tool after the testing phase ends. 
I. Future use of the tool (3 items) 
For what searches they would more likely use the tool for 
and which tool they preferred. 
 
DRUID 6th Framework Programme
 
In addition to subjective data (questionnaires), objective data (logfiles) from the USB tool 
kept in the system and sent to the test leaders
 
 
4.4 Tool developed with DRUID project
 
A special tool (USB) has been designed and developed to support the physicians and 
pharmacists of the project.  
The DRUID Tool is a Java based application. The tool is able to run on different operating 
systems due to Java use. The only requirement is the runtime environment of Java (JRE) 
which is free on the web.  
The tool is also based on MySQL. This is the databa
MySQL has been selected to support DRUID tool due to its powerful engine. This is 
open source software. Partners filled in a database with all the medicines they were
responsible for their categoris
Verweisquelle konnte nicht gefunden werden.
 
Figure 6: Transfer of medicine information from an Excel file to the 
 
In more detail, the DRUID ICT tool can be used to find information about the driving impairing 
effects of medicinal drugs. The tool consists of an easy
about driving impairing medicines. 
The  tool is constructed in the following way:
1. Main Form window: 
 
2. Substance Information window
medicine:  
• Categorization 
three possible categories (1. likely to produce minor effect on fitness to drive, 
2. likely to produce moderate effect, 3. likely to produce seve
impairing effects) 
• Advice to the patient
3. DRUID Fact Sheet window
extended information about a medicine. 
4. Alternative Medicines window
alternatives medicines 
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 (Belgium).  
 
se engine where the data is stored. 
ation with WP4 and this excel file fed the tool 
).  
tool’s database
-access database 
 
 
In this window the substance can be selected in several ways. 
: This window consists specific information about a 
All driving impairing drugs are categorized into one of the 
 
 
: The tool contains the DRUID WP4 Fact Sheets with 
 
: The tool allows physicians or pharmacists to find 
that have less driving impairing effects.  
 
 
were 
free and 
 
(Fehler! 
 
 
with information 
 
re driving 
safer 
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DRUID Fact Sheets  
• The DRUID WP4 Fact Sheet is attached to each categorized medicine.  
• The information contained in the Fact Sheet is derived from the Summary of Product 
Characteristics (SPC) and the patients information leaflet, either in the WP4 
countries, UK, Ireland or EMA.  
 
4.5 Procedure 
 
The underlying procedure was based on both within and between groups’ comparisons.  
Participants were introduced to the tools/software(s) through a training scheme. In addition, 
participants were informed about the DRUID guidelines regarding driving and medicines 
uptake. The time sequence involved a standard procedure of recruitment, briefing, and 
consent. Participants filled in the pre-questionnaire and after six months of using the DRUID 
guidelines in their practice (post-questionnaire).  
They used the software during their daily practice for either prescribing or dispensing 
medicines depending on the professional groups they belonged to. After the testing period 
ended they filled in a post questionnaire investigating the same artefacts more or less as the 
initial one in order to enhance and allow comparability and evaluate the effectiveness of the 
tool and the applied guidelines.  
Procedural differences exist and will be discussed in depth in the respective reports; however, 
the framework was not significantly violated allowing for similar up to a certain extend data 
analysis. 
 
4.6 Statistical analysis 
 
Statistical data handling depended on the sample characteristics and the inherent 
assumptions underlying them. In general, non parametric tests were performed due to either 
small sample size and/or violations of normality in data distribution. Moreover, as 
questionnaire items were answered in different type of scales (i.e. interval, ordinal, and binary 
choices) median values in some cases reflected in a more robust way data handling. In more 
detail, for within group comparisons the Kruskal Wallis test was used and for the between 
groups comparisons Mann Whitney U test was used.  
Linear regression was performed for the patient questionnaire data in the Dutch study as its 
appropriateness was ensured by the big sample size. The regression analysis is discussed in 
depth in the analysis section of the respective report.  
A step further in analysis was the creation of composite scores to facilitate between countries 
potential comparisons and present the opportunity of an overall evaluation of the effect of 
guidelines. Overall composite scores were based on commonalities’ analysis across national 
studies with clustering of questionnaire items into account.  
The α level was set at .05 and SPSS was used for analyses of data.  
 
4.7 Standards, considerations, and limitations 
 
Last, it was taken into account early in the design of that response rates and drop outs should 
be anticipated because of the empirical element and the cross-country testing for quite some 
time. It was agreed that partners would make an effort to accommodate for response rates, 
which is difficult to estimate as it is usually based on previous experience (country-wise). A 
conservative estimate was 50% and consequently doubled the required sample size. In this 
section, no country specific information is provided as the same number of participants was 
calculated for all national studies.  
For some of the partners, the evaluation process was based on existing integrated decision 
support systems. In addition, in some countries the health professionals are more acquainted 
with ICT tools and rely more on their support.  
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5 Analyses  
 
This section focuses on the analyses performed for the consolidation of the results. Each 
national report is based on the initial framework; however, deviations exist in each country 
report and in depth analyses of individual hypotheses and respective research questions are 
addressed by the national studies’ researchers. Apart from in depth specific analyses it is of 
considerable importance to investigate if and how our initial framework -that the rest of the 
bottom-down studies are spreading from- accommodates our findings. The analyses are 
based on composite scores for the main behavioural clusters included in the basic 
questionnaire and are the following: 
 
A. Attitudes 
 
Strongly disagree disagree agree Strongly agree 
1 2 3 4 
 
B. Reported Behaviour 
 
Never Seldom Sometimes Regular 
1 2 3 4 
 
C. Actual Knowledge 
 
Sum of correct number of answers 
 
Following the analysis, conclusions were drawn upon the interpretations of the findings and 
potentials for future recommendations related to guidelines development and adherence.  
 
5.1 Overall demographics 
 
In total, 230 participants (NPhysicians = 68 and NPharmacists=162) were included in the overall 
analysis (descriptive statistics) were post test data were used (i.e. demographics). In the 
overall database, 2 missed cases were excluded. The numbers represent the participants of 
post conditions in order to control for overall drop outs.  
It is important to note that the control group from the Dutch study and the nurses group from 
the Spanish study were not included in this analysis, as the first one acted as a reference 
group for the intervention and nurses were not included in the other studies. In other words, 
the overall sample comprised of the participants bearing comparable characteristics for the 
analyses performed latter in the analyses section (5.2 and 5.3, respectively). The 
demographic characteristics of these two groups are discussed in detail in the respective 
country studies section included in Part B of this deliverable.  
The following graphs presents the basic demographics recorded as background information 
for the whole group in percentages (%). 
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 Figure 7: Age distribution 
 
 Figure 8: Years of practice
 
 
 
Almost a third of participants (68%) were between 30 and 55 years, which do reflect the 
normal age groups for health professionals. The group is slightly skewed due to physicians 
who get into medical practice much older (long period of studying).  
Most participants (60%) have over 15 years of practice; hence the majority is experienced 
health professionals. 
In addition, gender distribution was the “exact opposite” for physicians and pharmacists. The 
majority of participants were female in the pharmacist (66%) group and male in the physician 
(63%) group.  
 
 
Figure 9: Gender distribution across groups  Figure 10: Education about medicines’ driving 
impairing effects in driving   
 
 
 
Significantly more participants (Yes: 60/No: 169) had no education regarding medicines and 
driving during their academic studies and their professional participation in postgraduate 
education (χ2 (1) = 51.882, p<.001).  
Additional comparisons were performed in order to examine if the differences in education 
among countries is of significance (Figure 10). Cross-tabulations did not reveal any significant 
differences among groups (p>.05). 
The following graph depicts the percentages of physicians and pharmacists in before (T0) and 
after (T1) trial period. It is evident that physicians and pharmacists as experimental groups do 
not show similar variation across countries. The Dutch study focuses entirely on pharmacists 
dispensing habits; the Belgium study certainly shows increased participation by pharmacists 
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by approximately 10%. On the other hand, the Spanish study shows a harmonized distribution 
of participants with almost 30% less participants in the later part of the study. 
 
Figure 11: Health professionals across countries for both pre and post conditions 
Overall demographics (percentages of participants within country and not within condition) are 
presented in Figure 11: Health professionals across countries for both pre and post conditions 
sketch a preference of pharmacists (60%) to test the DRUID developed guidelines. The latter 
may be the result of more pharmacists using computerised decision support systems in their 
everyday practice. Specifically, for the Belgian study, two possible explanations are that 
physicians are asked to participate in many studies and there is a possibility to be more 
selective than pharmacists who are less often asked. Moreover, in Belgium there is a change 
in pharmaceutical practice, with focus on pharmaceutical care and re-evaluation of 
pharmacist’s role, which could explain the interest of pharmacists for an area where their 
consulting role is valuable.  
 
5.2 Physicians  
 
This group consisted of physicians participating in both pre and post condition from the 
Belgian (N=50) and the Spanish study (N=18). The following graph shows percentages (%) of 
physicians for each country for pre and post trial conditions. In addition, age distribution is 
presented in (Figure 12). 
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5.2.1 Background information 
 
 
The majority of physicians had over 20 years (60%) of experience in the field of medicine. 
Age distribution appears to be equal for the three age categories between 30 and 65 years of 
age (Figure 12). 
 
 
Figure 13: Education on medicinal impairing effects on driving 
Overall, significantly more physicians in Spain had no education regarding medicines and 
driving during their academic studies and their professional participation in postgraduate 
education (χ2 (1) = 16.99, p<.001) when compared to physicians in Belgium (Figure 13).  
 
 
Figure 12: Age and years of practice distributions 
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5.2.2 Pre and post comparisons 
 
This section includes results from before and after the trial of the tool for a considerable 
period of time (6 months) for all countries. Data taken into consideration are from participants 
that filled in the pre and post questionnaires. This analysis is focusing on the effect of the 
intervention itself to the prescribing patterns of physicians and DRUID guidelines adherence. 
The interpretation of these results carries inherent limitations. First of all, although, we 
attribute them characteristics of one sample repeated measures for the shake of statistical 
testing, they are not really one sample. Therefore, the inherent differences lie within the group 
itself. On one hand, this is resolved by the combination of nonparametric tests and a large 
overall sample. On the other hand, only guidelines adherence is of investigation rather than 
the tools used themselves.  
Overall statistically significant increase in Reported Behaviour (z = -2.153, p<.031) was found 
On the contrary, no significant differences in Actual Knowledge and Attitudes were revealed 
(p>.05). For almost half the participants (45%) the amount of related knowledge remained the 
same and was not affected by the training.  
 
The significant difference reflects positive change in 43% of physicians in the frequency of 
applying the DRUID guidelines when they prescribe medicines that affect driving behaviour 
(i.e. from seldom to sometimes).  
 
More specifically, further pairwise comparisons were perfomed for the aforementioned 
significant findings. Statistical significant differences for both pre and post conditions between 
the Belgian and Spanish study regarding Reported Behaviour and Actual Knowledge were 
found. It is always borne in mind that the differences may be partially affected by differences 
in the populations they represent and not the DRUID information only. 
 
 
Figure 14: Median scores for Reported Behaviour per country study for both conditions 
It is evident from the above graph (Figure 14) that Reported Behaviour in post  condition differs 
significantly between Belgium and Spain (z=-2.127 p=.033). The difference for the pre 
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condition was not of significant values (p>.05). In the Spanish study, positive change is shown 
for the group of physicians although, they take into account less driving related guidelines 
when prescribing medicines compared to Belgium, a change after the application of DRUID 
guidelines is present. If we accept our sample as a whole, then 33% of Spanish physicians 
applied between “seldom” and “sometimes” the guidelines received; however, 30% of Belgian 
physicians showed increased frequency (i.e. from “sometimes” to “regular”).  
 
In both Belgian and Spanish studies, increase in Actual Knowledge has been shown as a 
result of training and the application of DRUID guidelines (Figure 15). Actual knowledge was 
significantly higher in Belgium when compared to Spain in both pre (z=-4.695, p<.001) and 
post (z=-3.394 p<.001) conditions. The reported sum of correct answers for the artifact of 
Actual Knowledge showed a great difference. There is a chance this difference to reflect 
differences in focus (e.g. academic curricula) and training received by professionals within 
their educational programmes (i.e. academic studies) and during their participation in post-
graduate education.  
 
 
Figure 15: Mean sum of correct answers for Actual knowledge per country for both conditions 
Before moving to the overall comparisons between Belgium and Spain on the amount of 
change in the selected clusters of behavioural items after the application of DRUID 
guidelines, it is interesting to consider the situation of the control group.  
What happened to the physicians that did not receive any type of DRUID related guidelines 
for six months (control group)? 
The only significant difference was found for the Actual Knowledge (z=-2.639 p=.008). All the 
other pre-post comparisons (i.e. Attitudes and Reported Behaviour) was not of statistical 
significance (p>.05). Almost 53% of participants in the control group showed increased 
correct answers in the post phase of the study. On the other hand, 75% of the control group 
retained the same attitude towards the effect of medicines to driving and Reported Behaviour 
scores were equally distributed across negative, positive, and ties (36%, 33%, 31%, 
respectively). 
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5.2.3 Between countries comparisons 
 
Supplementary analysis to 5.2.2 was carried out in order to pay special attention to the 
differences that may exist in the size of differences from the pre to the post condition (δ). In 
other words, differences in change controls for the inherent differences discussed in the two 
previous sections. The groups included in this analysis are the participants who received the 
DRUID related training and guidelines.  
The overall amount of change for all composite scores is small as it is evident from the values 
in (Table 4).  
 
Table 4: Overall Mean±Standard Deviation statistics for the composite score for physicians 
Change in composite 
score (δ) 
Mean±Standard 
Deviation 
Reported Behaviour  0.321±0.875 
Actual Knowledge 0.071±1.112 
Attitude  0.143±0.354 
 
 
No Significant differences were found between the Belgian and Spanish studies with regard 
change (δ) in Reported Behaviour, Attitudes, and Actual Knowledge (p>.05). The change in 
professionals’ daily practice because of the applicaton of the DRUID guidelines was not 
different between the Belgian and Spanish study. 
 
The next step was to compare the change in our overall composite scores for the physicians 
that used the DRUID guidelines and categorization to the ones that did not use it at all (i.e. 
control group). The following graph (Figure 16) depicts the mean differences but it is 
important to keep in mind that the scale that corresponds to each cluster is different not only 
in rating order but more importantly in notation. All the lines have been included for 
summarizing purposes more than comparison between them. The comparisons that are 
meaningful are between the control and the DRUID information groups.  
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Figure 16: Mean change (δ) for all composite scores for the DRUID guidelines and control groups 
 
The change in Attitudes (z=-2.234, p=.026) was significantly greater for the physicians who 
were trained with the DRUID guidelines. On the other hand, Actual Knowledge (z=-1.931, 
p=.05) showed that the increase in the control group was higher but of marginal significance. 
No statistical significant difference in amount of change was found for the Reported Behaviour 
(p>.05). As mentioned above, the interpretation of Figure 16 should be followed with caution 
as its line is measured with different unit and represents different scale as described in the 
introductory section of analyses section.  
However, the interesting and very difficult to interpret finding is that Actual Knowledge 
increased for the control group much more than it did for the DRUID information group (Figure 
16) although the difference is small. There is a possibility that participants received 
information (training based) via another educational programme and/or colleagues. However, 
these variables cannot be controlled for easily in an empirical research.  
 
5.3 Pharmacists 
 
Initially, 216 pharmacists participated in the pre condition and then the number dropped to 
162 in the post condition. The following table presents the distribution of participants across 
conditions.  
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Table 5: Number of participants per country study for pre and post conditions 
 
 
 
The higher percentage of female participants (33%) is coming from Belgium and the smaller 
percentage of male (6%) is coming from Netherlands. 
 
 
Figure 17: Gender distribution across country studies 
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5.3.1 Background information 
 
Figure 18: Distribution (%) of years of 
practice 
 
Figure 19: Distribution (%) of age categories 
 
 
Half of the pharmacists (52%) have experience in their field for more than 15 years. In the 
pharmacist group, representation from different “experience” groups exists. Similar to the 
physicians group, the higher percentage of pharmacists (73%) belongs in the age categories 
between 30 and 55 years of age.  
 
 
Figure 20: Percentage (%) of participants that received or not education about impairing effect of 
medicines in driving behaviour per country study 
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It is clearly depicted in the above figure that only in the Spanish study the percentage of 
pharmacists that received training or education about the potentially impairing effects of 
medicines in driving was slightly higher (51%) than those that did not (49%).For the rest of the 
participants less than one third of pharmacists had received any related education (29% and 
18% for the Dutch and Belgian study, respectively).  
 
5.3.2 Pre and post comparisons 
 
Overall pre and post comparisons for the selected clusters related to guidelines adherence 
were conducted and significant differences were revealed for all of them. For the comparisons 
that are related to the effect of DRUID guidelines, it is self-explanatory that only the 
participants receiving the training and, consequently, the guidelines were included in this 
analysis. Separate comparisons with the control group were conducted and discussed in a 
later section of this document.  
Attitudes and awareness were significantly more positive after the implementation of DRUID 
information (z=-5.678, p<.001).  
Significant increase in Reported Behaviour (z=-4.680, p<.001) and Actual Knowledge (z=-
4.653, p<.001) was found and it is clearly shown in the following graphs. Both composite 
scores increased by one (different unit for each composite, i.e. scale for Reported Behaviour 
and sum for Actual Knowledge). Median Reported Behaviour increased from “seldom” to 
“sometimes” and the mean sum of correct answers (Actual Knowledge) increased from 2 to 3.  
Statistically significant difference has been shown for awareness after the implementation of 
DRUID related information to 33% of participating pharmacists (positive) when compared to 
those that they showed decrease (negative). However, the vast majority of pharmacists (65%) 
in the sample did not shown any change in their existing attitudes (ties). On the contrary, 58% 
of pharmacists had a positive change in their Reported Behaviour towards incorporating 
driving related guidelines in their daily practice and 49% of participants gave more correct 
answers about professional practice after the end of the trials. Reported Behaviour positive 
change in pharmacist between pre and post trial conditions is from “seldom” to “sometimes” 
that is translated in an increase in frequency of application of DRUID guidelines and 
categorization in daily dispensing practice.  
 
 
 
 
Figure 21: Median Reported Behaviour scores 
for pre and post conditions                            
 
    
Figure 22: Mean sum of correct answers    
(Actual Knowledge) per condition 
 
In general, participants showed change in both knowledge and everyday practice. It is 
important to investigate if the change was random or due to application of DRUID guidelines.  
General comparisons between the overall DRUID information group (both intervention and 
information materials were included) and the control group which did not receive any DRUID 
related information and/or guidelines were carried out. 
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Firstly, an account of pre and post differences is presented and secondly, the investigation of 
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No statistically significant difference 
group was shown for both pre and post conditions (
On the other hand, the DRUID information 
3.691, p<.001) in the post condition
graph, participants showed approximately increase of 20% in the sum of right answers they 
gave which is easily translated into one more right item 
 
Figure 24: Mean sum of correct answers
conditions  
Figure 23: Median scores for Reported Behaviour for the DRUID information and 
control group in pre and post conditions
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δ) between the DRUID information group and the control 
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in the post questionnaire. 
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It is obvious from the above graph that the control group overall showed increased knowledge 
compared to the DRUID guidelines group. In addition, change in knowledge was also noted in 
the pure control group. Therefore, their information source was different or they knew the right 
answers the second time around. However, the size of the control group (n=49, 20%) was 
very small compared to the DRUID information group (N=144) in order to yield reliable and 
interpretable results. No statistically significant difference was found for Reported Behaviour 
and Attitudes between the control and DRUID information groups (p>.05).  
If our groups do or do not differ at baseline, then how do we know that the effect we measure 
at the end of the trials is the result of the application of DRUID guidelines? 
The second step is to isolate the amount of change (δ) for each participant. The third step is 
to compare the amount of change in Actual Knowledge and Reported Behaviour for both 
DRUID information and control groups and investigate the size of the effect and if it is of 
significant value. Non parametric tests were conducted in order to investigate the differences 
in the amount of change (Levene test significant). No statistical significant differences were 
found for the three clusters of behaviour investigated between control and DRUID information 
group for the amount of change (δ) in Attitudes, Reported Behaviour, and Actual Knowledge 
(p>.05).  
 
5.3.3 Between countries comparisons 
 
Another step in the overall analysis is to investigate the potential differences among the 
different studies.  
 
 
Figure 25: Median Reported Behaviour scores for pre and post conditions among countries 
According to the graph, differences among countries appear before and after the end of trial 
period. The differences for Reported Behaviour seem to be higher in the pre condition when 
compared to the post condition. Pharmacists from the Dutch study appear to have a similar 
Reported Behaviour after the implementation of DRUID guidelines but in Spain and Belgium 
the situation is different. Pharmacists from all country report that sometimes they tend to use 
the DRUID information (guidelines and categorization) during their daily practice after the 6 
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months of trial. Initially, they seldom used any type of guidelines for informing their patients 
about the relation between medicine uptake and driving. 
An overall Wicoxon Signed-Ranks test revealed statistical significant difference among 
groups (p<.001) and pairwise comparisons followed. Overall, the following figure presents the 
statistical results and provides the significant differences among countries. Non parametric 
between groups’ comparisons (Mann Whitney U tests) revealed statistically significant 
differences between Belgium and Spain across all cluster categories  
 
On the other hand, differences exist between The Netherlands and Spain for Reported 
behaviour and Attitudes but for Actual Knowledge is not significant (p>.05). Similarly, the 
differences between Belgium and The Netherlands are of significance except Attitudes (trend, 
though, exists). In Netherlands the pharmacists show more disagreement with the statements 
in the pre-questionnaire compared to pharmacists from the other two countries. However, as 
it will be shown in later analysis these differences disappear in the post condition. It is 
remarkable how attitudes are linearly transformed after the implementation of DRUID 
information to all country studies (Figure 25). Pharmacists show positive change towards 
increase in awareness by moving from “disagree” to “agree” in all countries (median values). 
The following tables (Table 6 and Table 7) depict the significance of differences by colour in 
order to visualise the diversity brought upon by the inherent cultural and other potential 
sources. The colours do not carry a meaning but show the combination of differences in the 
clusters of behaviour under investigation (e.g. if significant differences reported only in 
Reported Behaviour were found, they are shown with turquoise colour and if differences in 
Reported Behaviour and Actual Knowledge were found they are depicted with light blue 
colour). 
 
 
Table 6: Significant comparisons among country studies (pre conditions) 
Country study Belgian Dutch Spanish 
Belgian 
 
RB, AK RB, AK, A 
Dutch RB, AK 
 
RB 
Spanish RB, AK, A RB, A 
 
RB: Reported Behaviour 
AK: Actual Knowledge 
A: Attitudes 
Differences in all behavioural clusters were found between Belgium and Spain. A note should 
be made about potential influence of the importance of negative correlation of geographical 
distances and behavioural, social aspects and structures. Individuals that live in the same 
coutrny tend to show greater similarity in their attitudes and beliefs than people who have 
greater geographical distance. Therefore, there may be a negative correlation between 
geographical proximity and similarities in the behavioural aspects that are being examined in 
this deliverable.  
As shown below, although significant differences were found among the three countries in 
attitudes, it seems that most pharmacists have a positive attitude and increased awareness 
across all countries. It is important to check the data in order to find where the differences lie 
that is not evident in the graph. The mean rank for Belgium was 57.78 and for Spain 73.45, 
which means that Belgian participants scored their attitudes a bit lower (more negative) than 
Spanish pharmacists before their participation in the trials. In addition, Dutch pharmacists 
seem to take into consideration most driving impairing effects of medicines when they 
dispense a potentially impairing medicine. On the other hand, Belgian pharmacists seem to 
know a lot more than their colleagues from Spain and Netherlands before they were trained 
with the DRUID materials and tools.  
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Figure 26: Scores for the clusters of behaviour per each country for the pre condition 
Similar comparisons among the country studies for the three behavioural clusters were 
carried out. A significant Kruskal-Wallis rank test (χ2(2) = 149.53, p<.001) led to further 
pairwise comparisons in order to reveal where the significance lies and most importantly what 
it may mean for our samples.  
The differences between Belgium and Spain pertain after the testing period ends for all 
clusters. Spanish pharmacists’ positive change is remarkably reaching a very increased 
awareness compared to Belgian (p<.001 and p=.019, respectively) and Dutch pharmacists. 
However, only the first one reaches statistical significance as the mean ranks are 41.96 for 
Belgium and 67.29 for Spain. Additionally, Spanish pharmacists show significantly less 
incorporating in to every day dispensing of DRUID guidelines compared to Belgium and the 
Netherlands (p=.011 and p= .036, respectively). Significant differences in Actual Knowledge 
gained from the participation in the DRUID study was significant for all possible comparisons 
as shown in Figure 27. 
The findings in the post condition overall should be treated with caution due to differences in 
the sample sizes.  
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Figure 27: Scores for the clusters of behaviour per each country for the post condition 
Finally, comparisons on the amount of change (δ) from the pre to the post condition for all 
countries that implemented the DRUID guidelines were carried out to simply evaluate the 
between groups size of effect, and indirectly effectiveness. 
Overall Kruskal Wallis tests were carried out for all behavioural clusters led to pairwise 
comparisons Differences in amount of change were found in Actual Knowledge and Reported 
Behaviour and not Attitudes. The amount of change in Attitudes was not significant overall 
(p>.05).  
 
Table 7: Significant comparisons among country studies (post conditions) 
Country study Belgian Dutch Spanish 
Belgian 
 
 AK A, RB, AK 
Dutch AK 
 
A, RB, AK 
Spanish A, RB, AK A, RB, AK 
 
 
Overall, significant differences were found in the amount of change from the beginning till the 
end of the study among the country studies. These differences in changes may be the result 
of many reasons and factors but before moving to the respective inferences, comparisons 
between countries would show where the differences may be found.  
 
Further pairwise comparisons were conducted in order to investigate where the differences 
lie. Significant differences were found mostly between Belgium and Netherlands, and Spain 
and Netherlands. The amount of change may be different to Netherlands because in this 
study the within DRUID developed tool was not applied and only one tool was used for the 
evaluation. In the other two studies, they applied two different ICT tools for delivering the 
guidelines.  
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6 Discussion 
 
6.1 Background characteristics 
Most participants were experienced professionals between 30 and 55 years old in both 
professional groups. Female participants were over-represented in the pharmacists group 
(66%) and male participants (63%) were over-represented in the physicians group.   
 
6.2 Physicians  
Physicians have shown a positive change in their Reported Behaviour (43%). Therefore they 
incorporated DRUID guidelines in their daily practice regime. Although, differences for 
Attitudes/Awareness and Actual Knowledge were not different between the pre and post 
conditions, according to the adopted model, changes in these two clusters are important in 
order to find differences in Reported Behaviour. The majority of physicians who did not 
receive any DRUID related information did not change their daily practice or showed negative 
change (69%). The implementation of DRUID guidelines had a 10% increase difference in the 
positive change in Reported Behaviour in the overall physicians’ samples across the country 
studies. This difference may be a simplistic measurement of effect size with all its respective 
limitations (discussed in the Limitations section) but serves as an estimate for the effect of the 
benefit the implementation of DRUID guidelines could impose on the quality of care. This 
finding also suggests the readiness of physicians to adopt DRUID guidelines. The next step 
would be appropriately target support strategies as discussed in the implementations’ section.  
Moreover, in the Belgian study, participating physicians have shown to be taking more into 
account the DRUID guidelines while prescribing medicines when compared to the physicians 
in the Spanish study. The number of participants in the Spanish study though is much smaller 
compared to the Belgian study. The difference may lie to the smaller number; however, the 
frequency is different between the studies. As discussed in the country reports, in some 
countries specific programmes and campaigns have been implemented targeting drugged 
driving. In both the Netherlands and Belgium the decision support systems have incorporated 
relevant information. Therefore existing familiarization may have enhanced the findings for 
these countries.   
The aforementioned finding is in line with the fact that physicians in the Belgian study showed 
higher Actual Knowledge (i.e. higher sum of correct answers) about the effects of certain 
medicines and doses. Again, differences exist in both sample size and pairing of pre – post 
conditions (i.e. lower pairing of pre –post responses in the Spanish study).  
With regard to difference in change in Actual Knowledge, it could be argued that the 
difference may reflect difference in relevant training during their studies (e.g. during residency 
or seminars). This argument might be supported by the fact that in the Spanish sample 20% 
less participants had received related training during their studies compared to their Belgian 
colleagues. If physicians were included in the Netherlands study, then it would be easier to 
sketch a geographical based profile on potential for guidelines’ adherence. However, as it 
was discussed in the Dutch country report, the feasibility for such an option was limited and 
therefore dropped as physicians were less eager to participate.  
Interestingly, most physicians in the group were not educated about the potentially impairing 
effects of medicines on driving fitness. Usually, patients have limited information about side 
effects of prescriptions they follow regardless if it is temporary or for a longer period of time. 
As information mainly comes from the patient information leaflet inside the medicine box, 
usually patients rely on this information. Consequently, the information they receive from their 
doctors or pharmacists is important not only in the communication of related side effects and 
dangers but for their compliance to patient instructions and warning. The relationship 
developed between the health professional and patient has been shown to be the most 
important ingredient in the compliance of patients to advice and guidelines.  
 
Regarding physicians overall positive change was found for Reported Behaviour and not for 
Actual Knowledge and Attitudes for the comparisons before and after the usage of DRUID 
information. This finding does not fit well to the adapted framework, as changes in knowledge 
should precipitate changes in attitudes and then followed by changes in reported behaviour 
according to Cabana and colleagues (1999). Changes were found for the final link but not for 
the previous ones leading to behaviour. There may be several reasons explaining these 
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inferences. More than 45% of physicians did not report increased knowledge regarding 
medicinal impairing effects in driving behaviour. Change in attitudes is unstable and it is 
usually the result of intertwining between emotional and cognitive aspects (Eagly & Chaiken, 
1995) through compliance, identification, and internalisation (Kolman, 1938). These 
processes might require more time than the six months period that the country studies lasted.  
A question mark on this finding could be placed as the differences that we try to reveal may 
have a different basis after all. In other words, if Belgian physicians’ awareness and 
application of relevant guidelines is of an adequate level, the change towards optimal 
behaviour is much more difficult to be attained, than from moving from a non awareness to an 
“acquaintance” level of practice.   
Changes not revealed for all behaviour clusters may have happened for several reasons. On 
a practical level, it could be assumed that physicians have taken more consideration, effort, 
and time in order to inform their patients about driving and medicines, as from now on, it was 
an important “item” in the “professional daily agenda” (Reported Behaviour). But they did not 
spend more time in order to learn more about detailed accounts and more specific information 
about which dosages of which drugs are more dangerous to create a problem to patients and 
other driving related information (Actual Knoweldge). 
Physicians who practice medicine for many years tend to be more empirical than when they 
begin their practice, as they rely heavily on their experience. The latter holds true for most 
professionals regardless if their occupation relates to medicines and health or not.  
Therefore, this negative finding may be an important discovery that training should be 
rigorous and frequent in order to become cost-effective in the future.  
In addition, significant changes between Belgium and Spain were shown for Reported 
Behaviour. Both countries have shown positive change in the frequency they inform patients 
about driving and medicines’ effect. Change shows a trend towards regularity in the Belgian 
study and towards more frequent implementation in Spain. These are optimistic findings if we 
take into consideration that this study lasted only 6 months with diverse tools and diverse 
populations of both professionals and countries. 
The general application of these findings could be a next step towards implementation and 
further enriching of the tool’s content.  
As discussed in section 5.2.2 significant difference in the amount of knowledge was found for 
physicians between the countries for both the pre and post comparisons. These amounts 
reflect only the participants that received the DRUID guidelines. It may be, though, that the 
differences are inherent to the educational system or the training itself. In addition, although, 
the overall analyses was adjusted to the composite scores sums needs, some of the 
questions included for both countries differ both in number and quality. Hence, their 
differences should be dealt with caution and considerable hesitation in deriving inferences.  
The amount of right questions is small for both countries. The change may be the result of 
discussion with colleagues and/or personal search. Either way, it is a positive implication and 
affect of the training and trial experience.  
The control group did not receive any DRUID related information, did not participate in the 
training schemes, and used probably the same tools they were using till now for their medical 
practice. However, a significant increase in the amount of correct answers (p=.008) was 
found. The effect may be additive in nature, meaning that physicians may have 
searched/read/discussed with other colleagues after filling in the first questionnaire and were 
motivated to find the right answers themselves the second time they were asked to complete 
the questionnaire (post questionnaire).  
As physicians in the control group appear to try to find themselves the right answers shows 
the importance, the need, and the existing gap in training health professional about the 
consequences that prescriptions have on driving fitness as in other everyday activities.  
 
Further comparisons were carried out in order to isolate the amount of change for each 
cluster of behavioural items (i.e. Attitudes, Reported Behaviour, and Actual Knowledge). The 
amount of change was comparable for Belgium and Spanish sample of physicians who were 
trained in the DRUID guidelines and categorization of medicines.  
Similar comparisons between the DRUID information and control group showed that 
physicians who received training and used the DRUID information showed a statistically 
significant positive change in their awareness level about the potential detrimental effects of 
medicines on driving fitness and in their personal, professional medical practice. The only 
slightly “off” finding is that physicians who were regarded as the control group showed of 
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marginal significance increase in their knowledge of information. Could it be their own 
curiosity and professional motivation to search and look for correct answers to the respective 
questions and statements? Did the physicians who had all day access to the guidelines and 
categorization and a whole day of training about medicines and driving rely less on their 
knowledge and automatically adjust it to their integrated tool? 
The training had an impact in the way they think and behave, but not in what they know? The 
latter might provide a basis for furthering this research for optimal communication and 
training. Physicians receive vast amounts of information every day and if they can rely on 
tools and paperwork to remind them of what they should apply; then they may leave for a 
while the practice to remember and rely the information and tool instead. The control group 
might be mostly driven by the curiosity of finding right answers just as most of us did when 
sitting exams. Other factors could be responsible for this overall finding which does not reflect 
the individual findings. Nonetheless, it should be borne in mind that the difference revealed is 
not of great significance and the differences in sample sizes could be a “thorn” in this overall 
evaluation’s “side”.  
 
6.3 Pharmacists  
Pharmacists showed positive change in all behavioural clusters that could form barriers to 
guidelines adherence (i.e. Actual Knowledge, Attitudes/Awareness, and Reported Behaviour). 
It should be noted, though, that pharmacists use more frequently decision support systems 
when dispensing medicines, therefore this fact (e.g. easiness, less deviation from routine 
practices, familiarity) could have affected the findings and should be taken into serious 
consideration. Pair-wise country comparisons regarding the behavioural clusters (Tables 7 
and 8) decreased between the Dutch and Belgian study but increased between these two 
country studies and the Spanish study. The latter probably was affected by the decreased 
sample size in the Spanish study (i.e. drop outs).  
Pharmacists demonstrated increased readiness for the implementation of DRUID guidelines 
in their daily dispensing patterns.  
An interesting finding was that pharmacists from the Spanish study (51%) seem well-informed 
about the potentially detrimental effects of medicines on driving performance as a result of 
their education or post-training.  
The success in guidelines adherence in the study groups is a strong message for the 
feasibility of guideline implementation for both guideline developers and policy makers.  
Further research would be crucial for evaluating their effectiveness based on this and other 
empirical data. Moreover, these findings support the idea that the movement towards 
evidence-based health care could enhance the quality of health care. This is a step towards 
standardised best practice based on computerised protocols. The DRUID guidelines could 
support improvements in the information provided to both health care professionals and 
patients about the effect of medicines on driving.  
Increase in the control group in the knowledge acquired was greater than the knowledge 
acquired by the health care professionals who received the DRUID guidelines. 
The finding is mirrored into another professional group within the same cross country study, it 
seems almost certain that it carries a certain weight and significance. 
It is difficult to direct the interpretation towards the cultural or personal and idiosyncratic 
variations. The multifocal aspect of training in the DRUID information group could provide an 
overload that is more difficult to be memorized and/or pay attention to. This could be a 
valuable input for future training scheme, tools training and professional information 
distribution to health professionals. Maybe information and training should be broken down to 
information blocks and/or topics with logical time lap between them in order to allow for 
adherence on a framework level. In other words, a future training scheme could provide at 
first the categorization proposed by DRUID to professionals and then guidelines, etc. 
Then allow them to digest the information and come back to them in a second training 
scheme with guidelines and literature (e.g. monographs) on the effect of medicines to driving. 
A third step could be then to provide a practical training, after a considerable time period with 
all elements incorporated and then the tool to be presented.  
This training sequence is just a proposal for a future training programme based on the 
unexpected findings in the control groups about relevant acquired knowledge for both 
physicians and pharmacists. A very important point in this inference is the fact that 
pharmacists in the control group showed increased knowledge in the pre-condition and not 
only in the post-condition. Hence, people who participated in this group were people who 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 64 of 456 
already knew a greater than the experimental groups to start with (i.e. participants were in 
most cases randomly assigned to control groups but those who participated in the control 
group were motivated to join and showed interested in the topic and probably processed 
some more baseline knowledge than average groups to compare with). A solution is to 
investigate a simple effect size (post-pre= δ) with its own limitations at hand. The differences 
were of no significant magnitude (p>.05). Thus, it is difficult to clearly state that the 
differences found were solely the result of the implementation itself (with regard these two 
groups only).  
In addition, Belgian pharmacists seem very “knowledgeable” about the effects of medicines 
on driving fitness and the Dutch pharmacists incorporate more than their colleagues driving 
advice and recommendations when they dispense medicines affecting driving. These 
differences could reflect country variations about the focus of everyday pharmaceutical 
practice. However, these findings do not carry generalisable weight; therefore they should be 
treated with caution as it is clearly stated in the limitations section. 
 
6.4 Limitations  
Overall comparisons borne many limitations. The number of participants was different for 
each group (i.e. country). The Spanish study had an increased rate of drop outs. Participants 
have received the same guidelines but the design and procedure was adjusted to the local 
requirements for answering the respective research questions.  
Sometimes it is easier to approach certain types of health professionals than others. For 
example, general practitioners in the Netherlands seemed hesitant to participate in the study 
and this was a significant reason for the decision to include only pharmacists in the Dutch 
study.  
An important limitation for the overall analysis was the emphasis on the DRUID guidelines 
and not the tools themselves. However, the usage of different ICT tools probably had an 
impact on the guidelines adherence. The variation in the types of tools used did not allow for 
comparisons with taking the tool type into account. Hence, the inferences are made with 
certain hesitation. Although, statistical comparisons were applied, it is important to state that 
the findings do not aim to be generalized on a European and/or country level but mostly to 
present the feasibility of applying the DRUID guidelines, the probable need for such 
guidelines to be implemented and the value of furthering research on guidelines about 
drugged driving and their probable effectiveness for the health care system.  
Finally, the overall composite scores are different from the country based and included items 
common to all countries. Therefore, these composite scores were commonalities scores and 
were calculated in an attempt to exclude differences in the analysis. The process of excluding 
differences in order to keep common items has an effect in the definition of the behavioural 
clusters themselves. For example, overall Reported Behaviour calculated in this section is the 
same for all country studies but different for each individual country study (Part B). 
The reason for including these analyses was to provide a salient overview of the DRUID 
guidelines feasibility for adherence based on the Cabbana and colleagues model of barriers. 
 
Differences may have not been revealed because of the inherent robustness and resistance 
in change in those two clusters. Moreover, the questionnaires applied were not validated, 
therefore inferences are not generalisable. In addition, diversities in the designs applied could 
have influenced the findings. It is also important to take into account the variations in both the 
tools and the different country settings. Context is an important factor for bringing up 
confounders into the analysis. 
 
6.5 Implications: Considerations about development, dissemination and implementation 
of DRUID guidelines 
 
Health care costs have been rising the last decades and have been highlighted as a core 
problem that affects practitioners, managers and governmental agencies alike (Shaneyfelt et 
al., 1999). The health care system is based on a cost-benefit methodology and sometimes 
pressure is exerted to practitioners so their practices to be effective, safe, and efficient 
(Forbes and Griffiths, 2002). Clinical guidelines are viewed as one of the most promising and 
effective advances for improving the quality of health care (Grol, 2001).  
The benefits exerted by the implementation of effective guidelines have been associated with 
decreased mortality and morbidity, improved efficiency and cost containment (Cluzeau et al., 
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1994). Current literature emphasizes the importance of effective guidelines and most 
importantly viable ones that can “survive” the scrutiny of daily practice (Miller and Kearney, 
2004). It is agreed that guidelines are essential but their development, implementation and 
dissemination is unfortunately much more difficult to assess and surely is not straightforward. 
This is evident by the country studies conducted within the framework of DRUID. Attitudinal 
changes were sometimes positive but probably the most difficult to be attained. The following 
sections will focus on issues related to the implementation of DRUID guidelines and, 
consequently, for guidelines in general in the health care sector. Mostly, the focus is shifted 
towards the benefits and limitations based on the DRUID experience. These findings would 
be of value for several stakeholder groups and taken into consideration that medical 
guidelines are an international “tool” of communication among health professionals and 
between practitioners and patients, then their application significance becomes universal. 
The aim of this section is to identify and address certain issues surrounding the application of 
guidelines with regard to context, content, ICT tools’ development, and discuss 
considerations for potential target groups.  
 
6.5.1 Context 
 
It is important to note that the following parameters should be taken into account when an 
experimental research design is implemented in an empirical evidence sector such as 
decision support systems in everyday clinical practice. 
The findings direct us towards positive change in behavioural aspects that are important in 
change and guidelines adherence in everyday practice. To be more specific in transferring 
these results into a future direction, communication to specific groups could follow a path 
adapted to the group itself. Context within this deliverable is defined as the local setting of the 
application of guidelines as the studies undertaken were implemented in different EU 
countries and different professional populations.  
As guidelines are derived by empirical evidence and are theoretical constructs, they should 
be then directed to the groups they aim to be implemented. In other words, these guidelines 
have been developed with taken into account the considerable gap in existing information for 
both health care professionals and patients regarding the effect medicines may have not only 
on daily activities but, also, on driving fitness, which cannot be isolated by the rest of 
everyday activities (e.g. even commuting requires an individual to use a vehicle).  
The positive feedback sprung by the country studies and the overall comparisons have shown 
that although there were differences between the countries, change within the countries was 
attained. These differences seem to increase as geographical distances increase. It could be 
argued that there might be a positive correlation that is an amalgamation of complex factors 
that become even more complex by their interactions. For example, legislation regarding 
prescribing and dispensing medicines in a country interacts with the educational background, 
awareness about driving dangers due to medicines’ uptakes, personal and socio-cultural 
characteristics. Hence, the context should be personalized and adapted to the local needs, 
requirements and settings of each country and to each professional group. 
In order to proceed to the implementation of DRUID guidelines in a country, guidelines should 
first be compared to existing guidelines with respect medicines intake and driving. 
Therefore, the adaptation and customisation to local circumstances should be the result of a 
systematic and active comparison to existing guidelines. The latter requires the participation 
of target groups discussed later on in this section. DRUID guidelines should be able to 
accommodate for questions, specific needs, policies and resources available in the local 
health services. In conclusion, the variations within the local health setting will hinder the 
adaptation process but in the long run it may prove vital for its flexibility and, in the end, their 
usage. Health professionals show variations between countries and within, also. They will be 
able to enrich the aforementioned endeavour of adaptation with recommendation, on hand 
experience about medicinal uptake in their country/community/hospital and assist in the 
creation of priorities and considerations based on the local evidence.  
 
6.5.2 Computerised guidelines (ICT tools) 
 
As discussed above, guidelines should be based on scientific evidence and be attractive to 
the end users (Selker, 1993). Computerised clinical guidelines are increasingly developed for 
health care and aim to increase to effectiveness of the guidelines in order to influence 
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physicians’ practices. A main outcome in the undertaken study is that participants showed 
preference towards the integrated tool. The implementation of the guidelines showed 
statistically significant positive change in their reported behaviour with regard to the 
application of the guidelines to prescribing and dispensing of medicines that affect driving 
behaviour and, also, in finding safer alternatives. This finding is in line with current research 
that advocates that computers may have an important role in guidelines implementation as 
incorporation of guidelines and reminders into integrated special software packages facilitates 
both updating about the cutting edge of medical knowledge but, also, may assist and support 
evaluation, clinical decision making and provides feedback about prescription and dispensing 
patient status (Heathfield and Wyatt, 1993).  
The implementation of computerised guidelines and DRUID categorisation was highly 
accepted by both physicians and pharmacists and participants were willing to continue using 
the DRUID information. Many of them requested to have this information integrated in the 
system they already use. Therefore, the acceptability and usability of the computerised 
delivery system was well-received, described as easy to use and that it contained practical 
information.  
Participants offered ideas for future developments such as inclusion of other medicines in the 
categorization scheme and the information should be adjusted to the native language.  
Future recommendations should include specialized and elderly directed advices incorporated 
in the system and adaptation to other target groups and not only drivers (e.g. heavy 
machinery usage and senior people information). 
 
6.5.3 Target groups 
 
This section is not exhaustive by nature but indicative as other groups may emerge by the 
categories mentioned below. 
 
6.5.3.1 Physicians 
 
Adherence to medical guidelines is not a road towards strict implementation but a “guide” for 
professional improvement and it is a challenge as the tool for each physician is their 
relationship with the patient. It was anticipated that physicians will emphasize more on the 
physiological well-being of the patient and not so on the driving related guidelines developed 
within DRUID. However, the results were a positive surprise as physicians collaborated in the 
application of both the categorization system and the guidelines. Changes in reported 
behaviour were found. Physicians took the information into account. The message is strong 
for further research to be based on these findings. Attitudes are more resistant in change but 
the studies were for a short period of time to evaluate impact and training was short term 
oriented mostly on a training manual basis rather than training on enriching their awareness.  
Hence, computerised and decision support systems are on the way to improve the quality of 
health care, professionals should receive this information by their affiliated routes and 
organizations. They will be the ones that will facilitate in the improvement of these guidelines, 
as more physicians will evaluate and help to improve DRUID information. 
Physician groups and organization should be informed about the DRUID information and 
categorization in order to be able to assess the impact and the effectiveness of this 
information on a large scale. 
 
6.5.3.2 Pharmacists 
 
Positive changes were found and pharmacists reported that they were using the guidelines 
and the categorization scheme in their daily practice. Attitudes are the strong frontier for 
pharmacists as well as found in the country studies but in the overall analysis positive 
changes in all clusters were reported. The same discussion as in previous section applies to 
pharmacists. However, pharmacists are more used to applying decision support system in 
their pharmacies as it is a common practice in dispensing process throughout Europe. 
According to comments derived by the country studies, emphasis was given on the need for 
EU approval in order to incorporate it in their work. The necessity for pharmacists to have a 
support tool seems to be greater than any other health care professional group.  
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Similarly to physicians, pharmacists should be informed about the results and findings of 
these studies, through conferences, publications, and training schemes in order the 
evaluation to reflect and be further adapted to their needs.  
 
6.5.3.3 Governmental agencies/policy makers 
 
Guidelines are a common point of reference for prospective and retrospective audits of 
clinicians' or hospitals' practices: the tests, treatments, and treatment goals recommended in 
guidelines provide ready process measures (review criteria) for rating compliance with best 
care practices (AHCPR, 1995). 
DRUID guidelines have been supported by evidence in these studies that they are useful, 
well-accepted by various professional groups in three different countries of implementation.  
As evidence supports these recommendations, international and national agencies on first 
basis should be informed that issue guidelines. In addition governmental agencies, medical 
specialty societies and professional organizations should be formally informed about the 
findings of these studies either electronically and/or through an event. These DRUID 
materials (guidelines and categorisation) are supported by the references of the three studies 
included in this deliverable.  
The effort encompassed in this deliverable attempts to fill in a very important gap of 
knowledge about the impairing effects on driving fitness. Alcohol remains the “number one” 
cause of accidents. Medicines may not be the most important cause but remain a “silent” 
cause that as medicines intake increases in EU over the years (especially anxiolytics and 
antidepressants) their association with road accidents increases. Sensitization about the 
relation of accidents, diseases, medicines, health care professional should be channeled 
through policies that would consider the effectiveness of information provided into 
consideration.  
 
6.5.3.4 Developers 
 
Developers are the professional who develop decision support system as the field of medical 
engineering has spread in the medical profession. Their role is critical with regard both in 
delivering a bugs-free tool but, also, to create interfaces that are accepted by diverse 
professional groups. Within DRUID a research oriented tool was used (stand-alone) for the 
first time within the framework of DRUID project. Therefore, it was more a proof-of-concept 
structure rather than complete and ready-to-use software. However, its usability could be of 
significant value for future research in order to be optimised in order to have info-on-the-go 
without any other programme needed to be installed. Its development process model has a 
good theoretical basis which needs further work to be refined. 
The integrated tools used already exist in the market, therefore they are complete software 
packages evaluated and assessed long prior the studies undertaken. Usually commercial 
software packages have been evaluated in a series of itenary cycles of software development 
(with regard their interface usability, appearance, etc.) before entering the market. 
Software companies could be contacted in order to participate from the beginning and 
develop a specific structure just for the DRUID materials that could be integrated in various 
software packages and, also, to be available as a database on the internet. For maintenance 
of data to be used in guidelines, national and international organizations could be prepared by 
developing strategies and seeking collaboration with institutes where expertise and 
experiences with designing databases and maintaining the data sets for the DRUID 
categorization and guidelines have been presented. 
 
6.5.3.5 Other 
 
The human element remains the most important link in the chain of successful 
implementation and dissemination of DRUID information. Patients could be informed about 
the impairing effects of driving under the influence of medicines. DRUID advice to the patients 
could be made available by patient information leaflets and communicated to patients and to 
the general public by means of a general website. Within WP7 certain efforts and work has 
been done in order to create risk communication means and guidelines for several target 
groups. These target groups could, also, benefit by getting to know DRUID professional and 
patient information through various media means such as internet sites and social networking 
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6.6 Main conclusions and recommendations 
The conclusions section is divided in two parts. The first part is dedicated to the discussion of 
results derived by the analysis of composites scores for the chosen clusters for both health 
professional groups. The second part provides an overview discussion about the overall 
findings (i.e. Part B) based on the critical analysis of the country studies and in some cases in 
comparison to the Part A comparisons. 
 
6.6.1 Part A 
Before pharmacists receive the DRUID information, Belgium shows increased awareness, 
pharmacists in The Netherlands seem to have incorporated driving related guidelines in their 
daily dispensing regime (higher Reported Behaviour) and pharmacists in Spain show 
increased knowledge about medicines effect on driving fitness The post-testing findings are 
more harmonised with regard to Attitudes and Reported Behaviour across countries, but 
Belgium shows a far more increase in Actual Knowledge. 
Changes in Reported Behaviour have been reported mainly for the following reasons. 
Reported Behaviour questionnaires are straightforward, therefore easier to detect change. 
Usually, question item related to knowledge and attitudes/awareness have more associations 
with other personality characteristics, therefore it is more difficult to be studied and isolated, 
especially in a cross-country study with limited time available to extrapolate findings of certain 
magnitude. However, the findings are of importance in most cases even changes were not 
reveal in specific cases.  
Post-test comparisons unravel if differences prevail and if training and DRUID information 
were effective. The post-testing scenery changes enough, as Spanish pharmacists 
awareness increases significantly compared to their other colleagues but actual practice is 
less than their colleagues. Differences in knowledge remain the same, with Belgian 
pharmacists to be the most well-informed and Spanish pharmacists to have incorporated less 
the knowledge received during the DRUID training scheme and the trial followed.  
 
Overall the consolidated findings sometimes differ from the findings in the country reports 
because the questionnaire items included in the consolidated effort (i.e. the clusters) are not 
all of the items used in the analyses in the country reports because of questionnaire 
adaptations. Therefore the composite scores constructed within the analysis framework of a 
country is not necessarily identical to the composite scores in the consolidated effort. The 
consolidated analysis by no means replaces the in depth analysis within each national report 
It is a supplementary statistical overview under a different prism in an attempt to focus on 
potential commonalities and draw a “greater picture” to be the canvas for a future research 
study of larger scale with even more specific and personalized characteristics and criteria.  
 
6.6.2 Overall 
 
Physicians and pharmacists prefer integrated tools that are not cumbersome, could provide 
flexible options with safe alternatives. However, they believe that the categorization scheme 
offered should be applied to other medicines and many participants queried about the 
possibility of implementing the DRUID materials to their own software packages. 
 
The software developed within DRUID was a research tool customized to the needs and 
requirements of the categorization system developed within WP4 (see Annex II for 
screenshots describing a search example). It was a research tool developed and used for the 
very first time within DRUID and stand alone in nature, therefore its testing was actually its 
first iterative cycle. Participants preferred the integrated tool as it does not interfere with their 
work.  
Overall, studies showed that decision support tools are welcome and usable, DRUID 
materials was indeed a need that waited to be accommodated for and most participants 
anticipated their ultimate integration to their own software packages.  
A long term goal would be to evaluate the impact on the health care system, on various 
stakeholder groups associated with the implementation of health care professionals’ 
guidelines and compare it with other related studies’ findings. In addition, further research 
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could facilitate its adaptation and customisation for different health care professional groups 
and national settings.  
 
The importance of diffusion of guidelines in daily practice has been discussed in the 
introduction. It is difficult to incorporate evidence into different populations’ daily practice 
which would be the next step for these findings.  
Overall findings suggest that change in health professionals is possible with regard to taking 
into account impairing effects of medicines on driving fitness. Moreover, the evaluation was 
based on the importance of barriers and facilitators to be considered for this change to be 
achieved. The main outcome of all country studies is in agreement with current literature that 
in order to achieve successful implementation strategies the fact that ‘one size does not fit all’ 
should be taken into serious consideration (Grimshaw et al., 2002). The differences across 
the country studies emphasise the importance of personalized strategies for change. The 
advantages and weaknesses of adopted systems highlight the fact that there is no “golden 
rule” and probably one methodological and/or strategical approach is not superior to the 
other; hence the implementation of guidelines from evidence based research should be tailor-
made but could benefit from a generalized directory of guidelines regarding impairing effects 
of medicines on driving performance.  
 
6.6.3 Application of guidelines 
 
In conclusion, the following tables present the main outcomes of the study based on both 
overall and cross-country comparisons, and comments made by the participants. It serves as 
a basis set of recommendations for medical guidelines implementation in order to be 
communicated to interested parties across Europe. Each recommendation contains the 
statement, the aetiology (need and or gap), and the rationale (inferred finding). 
Recommendations are distinguished to: a) DRUID guidelines and tools’ oriented (e.g. ICT, 
decision support systems), b) Health care professionals (e.g. general practitioners, nurses, 
etc.), c) patient specific, and d) methodology oriented. Recommendations have been named 
according to their distinction (e.g. REC1/a means that this is a recommendation number for 
ICT tools. If not specified in the respective groups (b and c), the recommendations proposed 
to be applied regarding DRUID guidelines correspond to all health care professionals who 
participated in the country studies.  
 
DRUID guidelines and ICT tools 
 
REC1/a DRUID guidelines should be incorporated into integrated tools to maximise potential for 
successful implementation and consequently be more effective and efficient in daily 
practice 
Aetiology: Diversity of available software packages and increased flexibility of offered programmes 
in combination with rapid technological breakthroughs imposes a requirement for 
sophisticated and at the same time user-friendly decision support systems. The existing 
systems lack the specificity and categorisation schemes offered by DRUID guidelines 
Rationale: Participants showed higher preference for integrated decision support systems that do 
not require extra time and effort for updating 
 
REC2/a DRUID guidelines should be available in native languages to avoid any difficulties time 
spend because of misinterpretations 
Aetiology: Guidelines adherence is sensitive to wording, content, and context. Translation to native 
language would protect these three important elements of quality of guidelines 
Rationale: Participants preferred the guidelines to be in their own native language. Their time is 
strenuous as it is and they do not want to spend any more time because they have 
difficulties in understanding the context or translating text parts.  
 
REC3/a The DRUID categorisation system could serve as a tool to improve prescribing and 
dispensing practices both at national and European level 
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Aetiology: Health care professionals might be informed about the impairing effects of medicines on 
driving fitness but a standardised system (four levels of impairment with safe 
alternatives) would harmonise the effort 
Rationale: Participants applied the categorisation system in their daily practice and for 
communication with patients 
 
 
Health care professionals 
 
REC1/b The effective implementation of DRUID guidelines would be enhanced and maximised by 
the productive collaboration of different groups of health care professionals involved in 
prescribing/dispensing medicines with regard to patient decision making. 
 
Aetiology: There is a “missing link” between physicians and pharmacists which sometimes leads to 
difficulties which might be both time consuming and less cost-effective. 
Rationale: Researchers and participants demonstrated willingness for involved health care parties 
to be of close collaboration, especially if a uniform set of DRUID medical guidelines 
would be available. 
 
REC2/b The DRUID warning label could be applied in order to facilitate health practitioners’ and 
patients’ communication  
 
Aetiology: Labelling has been proven very helpful in order to communicate risks and side effects to 
patients. It gives a strong message with limited attention required by the dispensee.  
Rationale: Pharmacists found the DRUID warning label very clear and useful to provide information 
 
REC3/b Pharmacists should be informed about safer alternative medicines with regard to driving  
 
Aetiology: The well-being of the patient is mainly viewed by the physiological and therapeutic 
standpoint and less context driven, e.g. driving appears a secondary aspect.  
Rationale: No shifts to less impairing medicines was found for the intervention pharmacies (Dutch 
study) 
 
REC4/b DRUID guidelines should be personalised and adapted to local services idiosyncrasies, 
local strategies, cultural perspectives, and legal/political frameworks 
 
Aetiology: Medical and pharmaceutical guidelines should be harmonised and be universal on a 
general level but if they are not relevant to local medical practice and culture and not 
adopted to the needs and requirements of local health care professionals, they will 
gradually be rejected by the local health care professionals  
Rationale: Health care professionals (above 90%) had negative attitude towards the usefulness of 
the information they provided to their patients; they believed the information would not 
influence their driving behaviour (Spanish study) 
 
Patients 
 
REC1/c Patients should be trained about the impairing effects of training and the potential 
consequences (training should be adjusted to general population and probably through 
edutainment) 
 
Aetiology: Patients who are drivers –also the general public- are well-informed about the effects of 
alcohol and drugs on driving but not of medicines. The latter is the result of campaigns 
and combinations of various interventions. Thus patients should receive multifaceted 
intervention with priority given to media.  
Rationale: Patients’ knowledge and attitudes did not significantly change after training (Dutch study) 
However the probability that their attitudes and knowledge were already alleviated 
because of the conduction of a huge national campaign (2008). 
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REC2/c A straightforward grading system and description of actions to follow could be included in 
the patient leaflet (the warning label could be printed on the medicine box) similar to the 
one described for health care professionals (REC2/b) 
Aetiology: Patients do get information from the patient leaflet. This process could facilitate previous 
risk communication efforts made by the health care professional (i.e. easier recall for the 
patient and a reminder) 
Rationale: Warning labels were well-accepted by the patients and messages in the leaflet could 
facilitate patients to conform with advice and maybe seek further related information by 
their physician and/or pharmacist 
 
 
Methodology 
 
REC1/d The conduction of evidence based studies seriously benefits from face-to-face 
communication, close follow up (reminders, newsletters), and concrete set of instructions 
(i..e productive assistance)  
Aetiology: Evidence based studies are violated by diverse factors and conditions due to their 
temporal demands and the lack of experimental control, therefore certain steps should 
be standardised in order to avoid leaps and drop outs 
Rationale: Good follow up, strong communication agents, administration of manual and instruction 
have been proven useful (i.e. Belgian study; Physicians study; section 4.3)  
 
. 
REC2/d Training is essential for the success of DRUID guidelines and support throughout the 
testing phase. The latter can be translated into continuous education for natural health 
settings 
Aetiology: Current research focuses on multifaceted interventions in order to facilitate the most 
effective implementation of medical guidelines but training stills holds the heaviest weight 
of importance 
Rationale: Participants who received training regarding the DRUID related materials showed 
positive change towards the implementation of DRUID guidelines in everyday practice  
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Dear participant,  
 
This study is conducted as part of the DRUID European project (Driving under the influence of 
drugs, alcohol, and medicines).  Specifically, it focuses on the actual impact drugs may 
have on driving safety.  We are interested on your opinions on the way medicines may 
affect driving.   
 
The questionnaire consists of… pages and it comprises _____questions.   
 
It will take you approximately _ minutes to complete. 
 
Please read each question carefully and tick a box  to indicate your answer.  In most cases 
you will only have to tick one box but please read the questions carefully as sometimes 
you will need to tick more than one box.  Answer the next question unless asked 
otherwise.  Once you have finished please take a minute to check whether you have 
answered all the questions that you should have answered. 
We assure you that all your answers and statements will be handled anonymously and that 
they will be used for scientific research purposes only. 
 
If you have any queries about the questionnaire please do not hesitate to contact 
_____________on __________________. 
 
 My participation in this questionnaire survey is voluntary 
 (informed consent).                
 
Thank you for your valuable participation, 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Research supervisor (name) 
(Title and address) 
(Contact details) 
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Date:__________________________ 
 
ID (filled in by the researcher): 
 
A. BACKGROUND INFORMATION  
1. Gender 
 Male               Female 
 
2. Date of birth (DD/MM/YYYY):__________________________ 
 
3. Country: ___________ 
3a. Area:  Urban    Rural    Other 
 
4. Specialism: 
 
 GP   Neurologist     
 Psychiatrist     Community Pharmacist     
 
5. Year of graduation medical school (YYYY): ___________ 
5a. How many years are you practising as a GP/Neurologist/Psychiatrist/Pharmacist? 
(Please state in full years) _____ 
 
6. Did you get any education on medicinal effects on driving skills during your studies at 
University?            
            
     Yes    No   
 
7. If you answered “Yes” in Q6, please specify: 
-----------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------- 
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B. NEW TECHNOLOGIES LITERACY 
 
1. Do you use the internet to obtain information? 
 
 Yes   No 
 
2. Do you use the internet to obtain information on medicines affecting driving behaviour? 
 
 Yes   No 
 
 
3. Have you ever used any software package / programme to obtain information on medicinal 
drugs effect on driving behaviour?  
 
 Yes   No   
 
4. If you answered “Yes” in Q3, please specify which software packages you use: 
 
________________________________________________________________________ 
 
5. Do you use any medical/clinical software package / programme? 
 
 Yes   No   
 
6. If you answered “Yes” in Q5, please specify which software packages you use: 
 
 
 
1. ______________________________________________________ 
2. ______________________________________________________ 
3. ______________________________________________________ 
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(PRE) Please consider your current experience for completing this questionnaire. 
(POST) Please consider your experience the last 6 months for completing this questionnaire. 
 
 
C. ATTITUDES / AWARENESS  
 
Please evaluate the following statements: 
 
1. I am willing to take into account the effects of medicines on driving skills when 
prescribing/dispensing medicines. 
 
 strongly disagree   disagree   agree   strongly agree 
 
2. Would you consider this (Q1) of more concern if your patient is:   
 
- a professional driver?         
     Yes   No   
- driving frequently?          
     Yes   No 
- driving long distances?        
     Yes   No 
- an “inexperienced” driver?         
 Yes   No 
- an “experienced” driver?        
     Yes   No 
- an elderly driver?          
     Yes   No 
- using other CNS active drugs ?  
    Yes   No   
 
3. I am willing to sacrifice some degree of efficacy by prescribing/dispensing a medicine that 
is less impairing to the driving skills.  
 
 strongly disagree    disagree    agree    strongly 
agree 
 
4. I feel being well aware of the effects of medicines on driving skills. 
 
 strongly disagree    disagree    agree    strongly 
agree 
 
5. It is important for me to be well-informed on medicinal effects on driving behaviour. 
 
 strongly disagree    disagree    agree    strongly 
agree 
 
6. I feel that the information I provide to patients will influence their driving behaviour. 
 
 strongly disagree    disagree    agree    strongly 
agree 
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D. REPORTED BEHAVIOUR 
 
Please reflect on the following statements according to your daily practice routines. 
 
1. I ask a patient about his/her driving exposure when choosing/dispensing a medicine.  
 
 always      regularly      sometimes      seldom      never 
 
2. I inform a patient about driving related risks when prescribing/dispensing a medicine.  
 
 always      regularly      sometimes      seldom      never 
 
3. I provide a patient with written information materials when prescribing/dispensing a driving 
impairing medicine. 
 
 always      regularly      sometimes      seldom      never 
 
4. I keep systematic records when I prescribe/dispense a driving impairing medicine. 
 
 always      regularly      sometimes      seldom      never 
 
5. I keep systematic records when I advise a patient when and how he/she can consider 
driving a car when using a driving impairing medicine. 
 
 always      regularly      sometimes      seldom      never 
 
6. I keep a record of the patient’s traffic participation (e.g. how often he/she drives to work). 
 
 always      regularly      sometimes      seldom      never 
 
7. I discuss medicinal drug consumption and driving related responsibility issues with the 
patient. 
 
 always      regularly      sometimes      seldom      never 
 
8. How frequently do you usually provide detailed information when prescribing a medicine 
with impairing effects on driving performance? 
 
 always      regularly      sometimes      seldom      never 
 
 
E. SOURCES  
 
1. I have easy access to data and information about a medicine’s effect on driving skills.    
     
 
 Yes    No   
 
2. Please report your sources: 
 
Professional websites   
Newsletters    
Organisations    
Journals    
Other    
 
Please specify: 
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-----------------------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------------------- 
 
3. Did you get any postgraduate education on medicinal effects on driving skills? 
 
    Yes    No   
 
4. If you answered “Yes” in Q3, please specify: 
-----------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------- 
 
 
F. ACTUAL KNOWLEDGE 
 
Please reflect on the following statements according to your daily practice routines. 
For each statement tick the one which best fits your professional opinion. 
 
1. How much do you agree or disagree with the following statements? 
 
Statements Totally  
Disagree 
 
Disagree 
 
Disagree  
Nor Agree 
 
Totally  
Agree 
 
Don’t  
know 
 
Temazepam (up to 20 mg) is severely impairing  
driving 8 hours after intake  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diazepam (regardless dose) is severely  
Impairing within the first 2 months of treatment  
 
 
 
 
 
 
 
 
 
 
Codeine (up to 20 mg) is mostly safe for drivers 
 
 
 
 
 
 
 
 
 
 
Fexofenadine (normal dose) is severely impairing 
driving  
 
 
 
 
 
 
 
 
 
 
Amitriptyline at the start of treatment is as impairing   
driving as after 4 weeks of treatment 
 
 
 
 
 
 
 
 
 
 
Paroxetine (up to 20 mg/day) is safe for drivers 
 
 
 
 
 
 
 
 
 
 
 
 
2. Physicians/pharmacists are obliged to inform the patients about the possible side effects 
of his/her medications on driving abilities. 
 
 True   False 
 
3. If a physician informs the Driving Licensing Authority (DLA) that his/her patient is using a 
driving impairment medication, in order to give the DLA the possibility to perform a 
check-up, you believe this is: 
 
 Mandatory practice  Good practice  No obligation  Do not know 
 
4. A patient can be punished with criminal sanctions if he causes a traffic accident while 
using a medicine with impairing properties whereas the health care provider has 
advised him not to drive. 
 
 True   False 
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G. USER ACCEPTANCE (PRE) 
 
1. If we propose to you a tool (e.g. website, cd-rom) that allows you to find information on 
medicinal drugs and driving, will you be willing to use it for prescribing/dispensing 
medicines? 
 
 Yes   No   Maybe 
 
2. If you answered “No” or “Maybe” to Q1, what are the main reasons for your reluctance to use 
them?  
-----------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------- 
 
 
H. USER ACCEPTANCE - CONTENT (POST) 
 
1. Did you use the guidelines in order to support your communication to patients? 
 
 Yes    No   
 
2. If you answered “Yes” in Q1, how often did you use the guidelines? 
  
 always      regularly      sometimes      seldom      never 
 
3. if you answered “seldom” or “never” to Q2, what are the main reasons for your reluctance 
to use them? 
 
-----------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------- 
 
4. The guidelines for prescribing/dispensing medicines that may affect driving 
performance were: 
 
 
Yes, very much Quite a lot Neutral Not so much No, not at all 
helpful      
useful      
sufficient      
 
5. Did you use the fact sheets as background information in order to inform patients on 
medicinal drugs and driving? 
 
 Yes    No   
 
6. If you answered “Yes” in Q5, how often did you use the fact sheets? 
  
 always      regularly      sometimes      seldom      never 
 
7. The fact sheets for prescribing/dispensing medicines that may affect driving performance 
were: 
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Yes, very much Quite a lot Not so much No, not at all 
helpful     
useful     
sufficient     
 
8. Did you think it was a problem that the facts sheets were provided in the English 
language? 
 Yes    No   
 
9. Did you use the pictogram system in order to inform patients on medicinal drugs and 
driving? 
 
 Yes    No   
 
10. If you answered “Yes” in Q5, how often did you use the fact sheets? 
  
 always      regularly      sometimes      seldom      never 
 
11. The pictogram system for prescribing/dispensing medicines that may affect driving 
performance was: 
 
 
Yes, very much Quite a lot Not so much No, Not at all 
helpful     
useful     
sufficient     
 
 
12. Do you think that there should be any additional information that is currently 
missing? 
 
 Yes    No 
 
 
13. If you answered “Yes” in Q9, please specify: 
-----------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------- 
 
 
I. USER ACCEPTANCE & USABILITY –TOOL (POST) 
   
Please reflect on how much the following statements represent your personal opinion. Check 
one of the fields accordingly.  
 
1. I was able to find the information I asked for with no difficulty. 
 
 strongly disagree    disagree    agree    strongly agree 
 
2. I thought the tool was cumbersome.  
 
 strongly disagree    disagree    agree    strongly 
agree 
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3. This tool would fit well in my working routines. 
 
 strongly disagree    disagree    agree    strongly 
agree 
 
 4. If you answered “strongly disagree” or “disagree” in Q3, please explain: 
 ----------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------- 
 
5. Text and icons are easy to perceive. 
 
 strongly disagree    disagree    agree    strongly 
agree 
 
 
6. If you  answered “strongly disagree” or “disagree” in Q5, please explain:  
-----------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------- 
 
7. Do you think that the tool should have additional options on the screen or are there any 
controls that are currently missing? 
 
    Yes    No 
 
8. If you answered “Yes” in Q7, please specify:  
-----------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------- 
 
 
J. FUTURE USE OF THE TOOL (POST) 
 
1. Would you be willing to use this tool in the future? 
 
 Yes   No   Maybe 
 
2. If you answered “No” or “Maybe” in Q1, please explain: 
-----------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------- 
 
3. What would you use the tool for mostly? (Please specify):  
-----------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------- 
 
General comments  
(Please provide any further comments you may have) 
 
----------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------------------
-------------------------------------------------------------------------------- 
 
Thank you for your participation! 
Please, provide your email address, in case you want to be informed about the general 
findings of this study 
DRUID 6th Framework Programme
 
Annex II: DRUID tool snapshots
Example: Searching for a drug
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Selecting ibuprofen
Select the substance out of the list with 
all names starting with the typed 
characters. 
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1 Introduction 
 
 
1.1 Background 
 
Belgium has a compulsory system of health insurance with a very broad benefits package 
that covers almost the entire population. Social security contributions and subsidies from the 
federal government are the main funding sources. The compulsory health insurance is 
managed by the The National Institute for Health and Disability Insurance (NIHDI) which gives 
a prospective budget to the sickness funds to finance the health care costs of their members. 
Delivery of health care in Belgium is mainly private. Most physicians, whether GPs or 
specialists, are paid on a fee-for-service basis. The patient pays the set fee for the 
consultation directly to the physician, and patients are then directly reimbursed by their 
sickness funds. 
In 2008, more than one quarter (27.6%) of the population reported having at least one long-
term illness, disorder or disabling condition. From 2004 to 2008 there was an observed 
increase in the prevalence of chronic diseases. The growing (elderly) population in Belgium 
results in a higher medication consumption and more frequently consultations with GP’s and 
other health care professionals, which has a direct influence on the social health costs. 1 
 
In 2009, 131 databases containing different types of health-related information were found in 
Belgium.2 The actors involved in collecting these data, as well as obligations to provide 
information, vary from one database to another. In 2007, internet or other electronic data 
exchange networks were used by 73.5% of the Belgian physicians (General Practisioners 
(GP’s) to obtain results from laboratories, compared to 39.8% in the European population 
(EU27), and by 13% of GP’s to exchange medical data (EU27:10.3%) or administrative data 
(EU27: 9.7%). In Belgium, every GP who uses approved software to manage the electronic 
medical files of his/her patients may ask to obtain an allowance paid by the NIHDI the 
following year. The number of GP’s receiving an allowance increases every year. The rate is 
higher in the Flemish region. 
 
The first step to decrease deaths on the roads attributable to medicines is by providing GP’s 
and pharmacists with accurate and clear guidelines with advice and information on medicines 
that are prone to affect driving. Secondly, introducing a uniform categorisation system, such 
as proposed within DRUID project, in the physicians and pharmacists’ computer software is a 
clear and practical approach to dispense the least impairing medicines within the same 
therapeutical class to patients. Additionally such a grading system is a valid alternative to 
improve patient care, during daily practice. Considering that GP’s in Belgium make use of 
computer software in their daily practice, including information about medicines that influence 
driving ability is a valuable way of giving advice to the health care provider for consulting their 
patients. 
 
Another step in decreasing deaths on the road attributable to medicines is a legal step. The 
Belgian law not only states that a patient can be punished with criminal sanctions if he/she 
causes a traffic accident while using a medicine with impairing properties but also that GP’s 
are obliged to inform the patients about the possible side effects of his/her medications on 
driving abilities. If not, the physician can be held partially responsible when their 
patient causes a traffic accident.  
 
1.2 Aims and objectives 
 
The object of the study was to measure the effectiveness of physicians’ training on the 
guidelines developed in DRUID WP7 for prescribing medicines with an influence on driving 
abilities, as well as the use and user acceptance of the DRUID developed prescribing support 
                                            
1
 and 2 Federaal Kenniscentrum voor de Gezonheidszorg (2010) Het Belgische 
gezondheidsysteem in 2010. KCE report138A. 
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tools in which the DRUID WP4 medicinal risk classification system was integrated. The 
effectiveness was measured through the actual use rates of the integrated and stand-alone 
ICT support tool and in a questionnaire survey (compared to baseline measurement), after 6 
months as a change in attitudes/awareness, knowledge and (reported) behaviour due to the 
implementation of the training. 
 
1.3 Evaluation team  
The study was organised, conducted and evaluated in close collaboration between Ghent 
University (UGent) and the Belgian Road Safety Institute (IBSR).  
2 Methods 
 
2.1 Research specific objectives 
 
The following research questions and hypotheses were formulated:  
- Do physicians’ attitudes and awareness about medicines and driving 
change/improve after the training and intervention?  
- Do physicians reported behaviour about medicines and driving change/improve 
after the training and intervention?  
- Do physicians actual knowledge about medicines and driving improve after the 
training and intervention?  
- Are physicians willing to accept and use the ICT prescribing (integrated/stand-
alone) and paper support tools? 
- Are pre-post questionnaire (socio-cognitive) changes and user acceptance rates 
higher in the integrated software group as compared to in the stand-alone (USB 
tool) support tool group?  
- Are pre-post questionnaire (socio-cognitive) changes in the intervention groups 
(integrated/stand-alone) higher as compared to the control group?  
- What is the use rate (prescribing data) of the ICT prescribing support tools 
(integrated/stand-alone)?  
- Are there differences in the incidence of prescribed category I, II or III medicines 
in the ICT tools (integrated/stand-alone) use rates? 
2.2 Study design 
 
The study has a pre- and post-design and includes 2 intervention groups (training + 
implementation support tool) and one control group:  
- Integrated software group, in this report further referred to as SoSoeMe group: a 
group of physicians from the total group using the SoSoeme electronic medical 
record management software in their daily practice. The DRUID WP4 and WP7 
information was integrated into the SoSoeMe software.  
 
- Stand-alone software group, in this report further referred to as USB group: a group 
of physicians from the total group of physicians in East Flanders, who declared to be 
willing to participate in the study, in the intervention group. The DRUID WP4 and 
WP7 information was delivered through an USB stick to be installed on the 
physician’s computer, together with a compendium including the same information 
 
- Control group, a group of physicians from  East Flanders, who indicated to be willing 
to participate in the study, either chosen to be in the control group or referred to the 
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control group by the research team. This group did not receive the DRUID 
information. 
 
Comparison of the intervention groups allows evaluating the difference in impact and use of 
the DRUID WP4 and WP7 information according to the type of support tool.  
Comparison with the no-intervention control group allows evaluating the impact of the DRUID 
information on prescribing behaviour and self-reported measures, controlled for effects 
outside the study scope. 
Pre- and post-conditions are accounted for by a pre-questionnaire before the training and 
intervention phase of 6 months (for the control group: 6 months without intervention), after 
which the post-questionnaire was completed.  
Pre-post comparisons within each group allow evaluating the impact of the DRUID WP4 and 
WP7 intervention.  
The study design can be roughly depicted as follows:  
Table 8: Activities that were performed by each group of physicians during the study period 
 Group 
 
SoSoeMe group USB group Control group  
Pre-training  Pre-questionnaire Pre-questionnaire  Pre-questionnaire 
Sept 2010   TRAINING _ 
Post-intervention 
(6 months after the 
training) 
Post-questionnaire 
Software use data  
Post-questionnaire 
Tool use data  
Post-questionnaire 
 
 
The study was approved by the Ethics committee, Faculty of Medicine and Health Sciences, 
Ghent University, Belgium on March 5, 2010 (B67020108021). 
All data (questionnaires, integrated and stand-alone software) were extracted anonymously. 
No patient information was collected. The privacy of the patient was guaranteed throughout 
the whole study.  
The physicians were free to refuse participation in the study. Moreover, every respondent 
could terminate his cooperation/participation at any time. All participants were asked to sign 
an informed consent form. The USB group had to sign a second informed consent provided 
by Health Base because Health Base information (GIT) was integrated in the USB tool. 
Participation to the study was on a voluntary basis. The physicians received a small monetary 
compensation for their participation. 
2.3 Materials 
 
2.3.1 Intervention/support tools 
 
• A training manual 
A training manual including the relevant DRUID WP4 and WP7 information for physicians was 
developed in DRUID Task 7.4.1 (D7.4.1). This manual was slightly adjusted to the specific 
Belgian scope. It was used as guidance when training the physicians in the USB group and 
handed out to them. The training manual was also handed out to the participants in the 
SoSoeMe group. 
The training manual addressed the general background and structure of the DRUID project 
and more specifically of the physician study. The DRUID WP7 prescribing guidelines were 
explained and possible information documents for patients were overviewed. The manual 
furthermore familiarised the physicians with the DRUID WP4 proposed categorisation system 
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for medicinal effects on driving, as well as with the group-specific support tools that include 
the relevant information.  
• SoSoeMe integrated software 
In cooperation with SoSoeMe BVBA, a new function was introduced in the electronic medical 
record management SoSoeMe. The program was regularly updated. 
When prescribing medicines that influence the driving abilities, the SoSoeMe information 
system offers support in the following ways:  
- Automatically generated warning under the form of an icon. An icon appears to 
warn the physician if he or she wants to prescribe a category 1, 2 or 3 medicine.  
- Written information about the medicine, with practical recommendations/advice 
concerning driving and medicines (i.e. Fact sheet and Patient letter)  
- Registration of the number of clicks made on the icon, fact sheet and/or patient letter 
. 
• USB stand-alone tool 
For the stand-alone group, an USB tool was developed in DRUID by CERTH-HIT and 
amended to match the Belgian situation (see general part A). This tool contains comparable 
information as the SoSoeMe software: information for the physicians in the format of a Fact 
sheet (WP4) and information for the patient (GIT: patient information letters, provided by 
Health Base), but clearly differs from SoSoeMe as physicians have to look up the medicinal 
risk guidelines and information separately by themselves (no automatic pop-up and no link 
with the patient). Each physician was asked to install (themselves) the tool on their computer.  
For the Belgian study the USB-tool described in the general part of this deliverable, was 
amended for following reasons: 
1. Patient information letters had to be included 
2. Stichting Health Base (SHB)3 provided the information for the patient letters. Because 
of copyrights, Health Base texts could not be put directly on the USB-stick. 
Permission to put the information on a secured website was granted by means of an 
IP contract (UGent Tech Transfer number A09/TT/0567) 
 
The following adjustments were made: 
1. An extra button was made to link to the patient information letters 
2. The information (Fact sheets and patient information letters) was put online. Links 
were made to PDF-files on an UGent website (http://www.druid.ugent.be/) instead of 
PDF-files in a directory on the C-drive of the computer. 
 
• Paper tool: Compendium 
For the USB group of physicians a compendium was also made. The compendium contained 
the fact sheets of the N-medicines developed within DRUID. The physicians were made 
familiar with this compendium as well as with the USB tool during the training sessions. 
Besides the use of the tool, the physicians were able to use the compendium to look up 
information on certain N01-N07 medicines. 
2.3.2 Evaluation tools 
 
Evaluation data were collected via questionnaires and through data extraction from the 
SoSoeMe software and USB tool use rates and characteristics.  
                                            
3
 SHB maintains a database with information on all medicinal drugs in the Netherlands and 
Belgium intended for patients and caregivers  
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• Pre- and post-questionnaire  
The evaluation questionnaire, developed within DRUID (D7.4.1), including a pre- and a similar 
post-part, was translated into Dutch. The translation may have generated some minor 
changes as compared to the original version. Furthermore, some small changes were made 
purposely to adapt better to the Belgian situation or for ethical reasons.  
In the pre-questionnaire, the following questions were adapted or removed from the original 
version: 
- Background information: For ethical reasons the date of birth was changed into age 
categories; practice area (rural/urban) was changed into number of inhabitants; the 
question about specialism was deleted  
- New technologies familiarity: A question about how often the physician uses the 
Internet to obtain information was added. 
- Sources: the option ‘organisation’ in ‘please report your sources’ was split up into 
traffic safety organisation and professional organisation. 
- Actual knowledge: since temazepam is not on the Belgian market, answers on the 
statement regarding this medicine were not considered; the question about informing 
the Driving Licensing Authority was left out, because it was not applicable in Belgium. 
- User acceptance: the question which type of instrument the participant would prefer 
(website, integrated in software, non-integrated tool, manual...) was added. 
 
The same adjustments as were made in the post-questionnaire, and additionally:  
- User acceptance - content: in questions 5-7 the term ‘fact sheets’ was replaced by 
‘patient letters’; question 8 ‘Was it a problem that the fact sheets were provided in 
English’ was not applicable because the information was provided in Dutch by 
Stichting Health Base. 
Furthermore, two extra questions were formulated in the post-questionnaire: 
- Do you think that the use of the guidelines has influenced your way of 
prescribing medicines? 
- Do you think that the use of the guidelines has influenced your choice of 
medication? 
- Do you think that the use of the guidelines has influenced your way of 
communicating the information to the patients?  
 
Both the pre- and post-questionnaire derive information on: personal and practice related 
background variables, familiarity with new (ICT) technologies, current sources on medicines 
and driving risks, attitudes and awareness, reported behaviour and actual knowledge related 
to prescribing medicines with potential effect on driving abilities, and user acceptance of daily 
practice support tools linking to driving. While identical for these areas of interest, the post-
questionnaire additionally includes in-depth questions regarding user acceptance and 
usability of the tool(s) being used during the intervention phase. (See annex). 
The three study groups filled-out the pre-questionnaire at baseline (before the 
training/intervention phase of 6 months): all groups filled the pre questionnaire out at home 
and sent it by post to the research team. The three groups filled-out the post-questionnaire 
after 6 months (intervention phase): all groups filled it out at home and sent it back by post to 
the research team.  
All questionnaire data were integrated into an SPSS file. 
• Software data extraction  
The data from the integrated software SoSoeMe were automatically and anonymously 
extracted by SoSoeMe and provided to the research team. The data were delivered in several 
log files. All the data from these log files were integrated in an Excel file.  
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The USB group on the other hand received a step-by-step instruction plan on how to extract 
the data from the USB tool to the format of a log file and to mail the log file to the research 
team. Physicians who installed the USB tool on several computers in the practice where 
asked to send the log file(s) from all the different computers. The data were transferred into 
Excel by the research team. The USB tool data extraction included no personal identification 
(anonymous extraction). 
Relevant SoSoeMe extracted data included: physician number, date of the search by the 
physician, ATC code and the DRUID category of the medicine searched for, use of fact sheet 
and patient letter. 
Only limited data/information could be obtained from the USB tool. Relevant USB extracted 
data included: date and hour of the search by the physician and (part of) the 
substance/medicines’ names they were searching for in the program.  
 
2.4 Study procedure 
 
2.4.1 Participant recruitment 
 
About three-hundred-thirty (330) physicians use the SoSoeMe software. In collaboration with 
SoSoeMe, the participation of these physicians was asked. An email with in annex a 
document with extra information about the DRUID-project and the study was sent to all the 
physicians using SoSoeMe. The interested physicians received a package with a 
questionnaire, the informed consent forms, an introductory letter and an envelope. Fifteen 
physicians received the training/information and filled in the questionnaire for the basic 
measurement. 
For the USB group, a letter was sent to all general practitioners in East Flanders (n = 
approximately 1600). The physicians received an introductory letter, an invitation to follow a 
training session, a questionnaire, an informed consent form and a return envelope by post. It 
was asked not to reply if they were SoSoeMe users. The aim was to include the first 40 
physicians who sent back their questionnaire. Only 23 physicians signed up to participate in 
the USB group. 
Besides the choice to follow a training session (USB group) the physicians had also the 
option to participate in the control group of the study. Sixty-three physicians were willing to 
participate in the control group. A confirmation letter of participation was only sent to 53 
physicians (as mentioned in part A, the sample size calculations determined that only 31 
respondents were required to be included in each group). 
After sending in their questionnaire, the selected physicians (USB and control group) received 
a second letter that informed them that they were selected to follow a training session (for the 
USB group) or that they would receive a second questionnaire in 6 months (for the control 
group).  
Table 9 indicates the flow of the study sample size: from initial participant recruitment to full 
study participation.  
Table 9: Sample size 
Respondents SoSoeMe USB Tool Control Group 
Total population 330* +/- 1,600 +/- 1,600 
Pre questionnaire 15 23 53**+1*** 
Training sessions  17  
Post questionnaire 13 10 35 
Full participants**** 7 10 35 
*around 90% of the users updated their system and did use the DRUID-application to inform their patients 
**62 physicians were interested to participate only 53 were selected 
*** one physician shifted from the USB group to the control group 
**** physicians who completed 2 questionnaires and sent in their log file(s). 
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2.4.2 Flow charts  
 
The following flow charts depict the study procedure, from participant recruitment over study 
steps and follow-up actions to study finalisation.  
The DRUID-functions, integrated in the SoSoeMe software were presented at training 
sessions organised by SoSoeMe. The first training was attended by the UGent research 
team. No extra training sessions were organised by the UGent team. For the USB group 2 
training sessions were organised in Ghent. The physicians who could not attend the first 
training session were kindly invited for the second training session. Of the 22 registered 
physicians 10 were not able to attend a training evening. One respondent contacted the 
research team asking to send him all information needed to self-install the program. The other 
9 respondents were asked by mail or letter whether they were still interested to participate in 
the DRUID study. If so a researcher would personally install the software and give information 
on the subject. Three physicians responded and could be included in the USB group. One 
respondent who attended a training session motivated his colleague to participate. Two 
physicians who attended a training session were excluded afterwards because of not 
installing the tool or incompatibility of the software.   
For both the Sosoeme and USB group a training manual and hand-outs of the PowerPoint 
showed during the training session, were made. Information on how to use the functions 
integrated in the SoSoeMe software and a manual on how to install and use the USB tool 
were developed. The step-by-step plan was integrated in the training manual. During the 
training sessions the physicians were informed about the DRUID project and the aim of the 
pharmacist and physician study. The legal aspects of driving under the influence in Belgium 
and the role of the physician were underlined. Furthermore, the respondents were confronted 
with practical situations and examples.  
As depicted in the flow charts underneath, several follow-up actions were set up in order to 
motivate physicians for (continued) study participation and to support them in their 
participation.  
For the SoSoeMe group, it was difficult to provide a good follow-up. The research team could 
only communicate with the SoSoeMe respondents via the providers of the software. Due to 
privacy reasons the research team did not receive a list of the physicians using SoSoeMe. 
Because of the busy schedule and agenda of the SoSoeMe company, it became very difficult 
to communicate to SoSoeMe as well as to motivate or inform the respondents about the study 
or about the available DRUID-information. 
The USB group received newsletters on a regular basis. These where a handy medium for 
establishing a communication with the participants. In total 3 newsletters were sent to 
motivate the respondents to use the program, to call in when they experienced some 
problems, or to inform them on the study. Furthermore, some practical cases were described 
or new regulations explained. Finally, the aim of the survey was underlined. The physicians 
were encouraged to report problems or practical remarks on the tool. The respondents could 
contact the research team by phone, e-mail or letter. 
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• SoSoeMe group 
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• USB and control group 
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2.5 Statistical analysis  
 
SPSS version 19 (pre- and post-questionnaire data) and Microsoft Office Excel 2003 
(extracted  SoSoeMe/USB data) were used for the data analysis. Due to sample size 
restrictions and variables’ scales robust non-parametric analyses were used (significance 
level at p≤.05; 95% confidence interval).  
• Pre-questionnaire: between-group comparisons 
For the categorical variables (background information, knowledge of new technologies, 
sources, user acceptance): descriptive crosstabs (within-group %), and Chi-square or Fisher's 
exact test to check the relationship.  
For the ordinal variables composite scores4 were calculated. For attitudes and awareness, 
and reported behaviour this was based on the median score. The knowledge variables were 
recoded into only 3 categories (don’t agree, agree and don’t know) and the composite score 
was calculated based on the sum of correct answers. Kruskal Wallis ANOVA by ranks test 
was used to check between-group differences and a Fisher's least significant difference 
(LSD) post-hoc test to locate the significant differences. 
• Within-group pre-post questionnaire change 
Pre-post significant differences were checked for attitudes and awareness, reported 
behaviour and knowledge, based on the Wilcoxon matched pairs - signed-rank test. For the 
sum composite score of knowledge paired samples t-test was used for the SoSoeMe group  
• SoSoeMe/USB data extraction 
Percentage of different click options in function of the total number of popped-up signals as a 
function of medicinal risk category and ATC group.  
3 Results 
 
3.1 Sample characteristics: SoSoeme (n=13), USB (n=12), Control (n=36) 
 
Table 10: Description of the sampled population (within-group %) 
  
Physician groups (within-group %) 
  
SoSoeMe 
N=13 
USB  
N=12 
Control  
N=36 Total  
Gender Male  76.9 66.7 72.2 72.1 
  Female 23.1 33.3 27.8 27.9 
Age* <30 years 15.4 16.7 0 6.6 
  30-45 years 53.8 41.7 25 34.4 
  46-55 years 7.7 16.7 30.6 23 
  56-65 years 23.1 25 41.7 34.4 
 >75years 0 0 2.8 1.6 
Inhabitants area practice >10000 76.9 66.7 65.7 68.3 
  <10000 23.1 33.3 34.3 31.7 
Year of graduation from 
medical school  50ies 0 0 3.2 1.9 
  70ies 18.2 25 32.3 27.8 
  80ies 9.1 16.7 35.5 25.9 
                                            
4
 A composite score combines different scores within a same category; it can be a mean, median or 
sum of the individual scores to provide one ‘overall’ category score.  
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  90ies 45.5 25 22.6 27.8 
  
2000-2009 
2010 
27.3 
0 
25 
8.3 
6.5 
0 
14.8 
1.9 
Years practising as 
physician*  <5 year 23.1 16.7 0 8.2 
  5-10 year 15.4 16.7 8.3 11.5 
  11-15 year 7.7 8.3 11.1 9.8 
  16-20 year 30.8 16.7 8.3 14.8 
  >20 year 23.1 41.7 72.2 55.7 
Education on medicinal 
effects on driving skills 
during studies at University 
no 69.2 50 50 54.1 
yes 30.8 50 50 45.9 
* Pearson Chi-square p≤.05 , Fisher’s Exact test p≤.05  
 
The majority of the participating physicians was male (72%), without difference between the 
groups (slightly less males in de USB group).  
The control group did seem to be generally older (41.7% or the biggest group in age 
category 56-65) than the two other groups (biggest group in age category 30-45), especially 
compared to SoSoeMe participants (53.8% between 30-45). The control group even included 
one physician over the age of 75. None of the physicians in the control group were younger 
than 30. 
The practicing years of the participants differed accordingly: in the control group 
significantly more physicians (up to 72%) were already practicing for over 20 years 
(especially compared to SoSoeMe participants with less practicing years).  
Around 70% of all physicians, in all groups, had a practice in an area with more than 10,000 
inhabitants (more urban).  
Half of the physicians in the USB and control group mentioned to have had no education on 
medicinal effects on driving skills during their studies, while in the SoSoeMe group this was 
even 70%. Those who did receive training/education mentioned that some information on this 
topic was integrated in a course like “pharmacology”.  
3.2 Drop-outs 
 
There were no significant differences between participants and drop-outs in the 
SoSoeMe, USB and Control group with regard to gender, age, number of inhabitants in 
the practice area, number of years from graduation or with regard to ICT familiarity. 
In the SoSoeMe group 2 female physicians dropped out. The full participation rate was 
86.7% (n=13) of the initial group.  
In the USB group 4 physicians (2 females and 2 males) in the age group 30 to 55 dropped 
out of the study. The full participation rate was 75% (n=12).  
Nineteen (19) physicians dropped out of the Control group (13 males, 6 females), from 
different age categories. The full participation rate was 65.5% (n=36) from the initial group.  
3.3 Pre-questionnaire 
 
The three groups were similar with regard to most pre-questionnaire parts (information 
sources for medicinal driving risk, pre-level attitudes and awareness, knowledge, willingness 
to use a prescribing support tool that takes driving risks into account). Two significant 
differences were found though with regard to reported behaviour and knowledge: the 
SoSoeMe group at baseline indicated that they provided less detailed information 
when prescribing as compared to the USB and Control group. On the knowledge 
question on Amitriptyline the participants from the control group gave significantly 
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fewer correct answers. In the following tables the questions were a significant pre post 
change was found were put in bold. 
3.3.1 ICT familiarity 
 
Table 11: ICT familiarity (within-group %) 
    Physician groups (within-group %)   Total  
    SoSoeMe 
N=13 
USB  
N=12 
Control  
N=35 
Do you use the 
Internet to 
obtain 
information? 
no 
yes 
7.7 
92.3 
0 
100 
8.6 
91.4 
6.7 
93.3 
Do you use the 
Internet to 
obtain 
information on 
medicines 
affecting driving 
behaviour? 
no 
yes 
75 
25 
75 
25 
71.4 
28.6 
72.9 
27.1 
If you answered 
"Yes" how often 
do you do this? 
daily  
every week 
less than weekly 
other 
25 
0 
50 
25 
0 
0 
66.7 
33.3 
10 
30 
40 
20 
11.8 
17.6 
47.1 
23.5 
Have you ever 
used any 
software 
package / 
programme to 
obtain 
information on 
medicinal drugs 
effect on driving 
behaviour?  
No 
 
yes 
83.3 
16.7 
83.3 
16.7 
80 
20 
81.4 
18.6 
Do you use any 
medical/clinical 
software 
package / 
programme in 
your daily 
practice? 
no 
yes 
1. 0 
2. 100 
3. 16.7 
4. 83.3 
5. 25.7 
6. 74.3 
7. 18.3 
8. 81.7 
 
The general ICT familiarity is fairly high in the whole sample when it concerns general 
Internet use and daily practice software use. More than 90% of all participants in all 
groups use the Internet to obtain general information, but only about 25% use Internet to 
obtain specific information on medicines affecting driving behaviour. About 80% of all 
physicians have never used any software package to obtain information on medicinal effects 
on driving behaviour. Besides all SoSoeMe participants, 83% of the USB and 74% of the 
Control group participants use a medical software package in their daily practice. Different 
kinds of programs were mentioned (e.g. Medidoc, Presribe, e-compendium...). 
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3.3.2 Sources for medicinal driving risk information 
 
Table 12: Access to information (within-group %) 
  
  
Physician groups (within-group %)  Total group  
  
  
SoSoeMe 
N=13 
USB  
N=12 
Control  
N=36 
I have easy access to data and 
information about a medicine's 
effect on driving skills.   
no 61.5 50.0 41.7 47.5 
yes 38.5 50.0 58.3 52.5 
Did you get any postgraduate 
education on medicinal effects 
on driving skills? 
no 100 100 94.4 96.7 
yes 0 0 5.6 3.3 
 
Only about half of the physicians in the whole sample (52.5%) – down to just 38% in de 
SoSoeMe group, indicated to have easy access to data and information on the topic 
‘medicines and driving’. Almost no physicians had any postgraduate education on medicinal 
effects on driving skills. 
 
Table 13: Source type (within-group %) 
Source type:  Physician groups (within-group %)  
 Total group    SoSoeMe 
N=13 
USB  
N=12 
Control  
N=36 
Professional websites  38.5 50 41.7 42.6 
Newsletters  15.4 33.3 27.8 26.2 
Organisations in road safety 0 0 8.3 4.9 
Scientific journals 23.1 16.7 36.1 29.5 
 
When “medicines and driving” related sources were indicated, the most used source of 
information for the three groups seems to be professional websites (42.6%), followed by 
scientific journals and newsletters. The package insert is furthermore mentioned as potential 
information source.  
3.3.3 Attitudes and awareness 
 
Table 14: Attitudes and awareness (within-group %) 
    Physician groups (within-group )  Total 
group  SoSoeMe 
N=13 
USB  
N=12 
Control  
N=36 
I am willing to take 
into account the 
effects of medicines 
on driving skills when 
prescribing 
medicines 
strongly disagree 0 0 2.8 1.6 
disagree 0 0 0 0 
agree 61.5 33.3 27.8 36.1 
strongly agree 38.5 66.7 69.4 62.3 
I am willing to 
sacrifice some 
degree of efficacy by 
prescribing a 
medicine that is less 
impairing to the 
driving skills. 
strongly disagree 0 0 5.6 3.3 
disagree 15.4 16.7 5.6 9.8 
agree 69.2 66.7 66.7 67.2 
strongly agree 15.4 16.7 22.2 19.7 
I feel being well strongly disagree 0 8.3 2.8 3.3 
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aware of the effects 
of medicines on 
driving skills. 
disagree 46.2 50 44.4 45.9 
agree 53.8 41.7 50.0 49.2 
strongly agree 0 0 2.8 1.6 
It is important for me 
to be well-informed 
on medicinal effects 
on driving behaviour  
strongly disagree 0 0 0 0 
disagree 0 0 0 0 
agree 61.5 50 52.8 54.1 
strongly agree 38.5 50 47.2 45.9 
I feel that the 
information I provide 
to patients will 
influence their driving 
behaviour. 
strongly disagree 0 8.3 0 1.6 
disagree 15.4 25 30.6 26.2 
agree 84.6 58.3 69.4 70.5 
strongly agree 0 8.3 0 1.6 
Composite Score  
Attitudes and 
awareness (median) 
strongly disagree (1) 0 0 0 0 
disagree (2) 0 8.3 0 1.6 
agree (3) 100 75 83.3 85.2 
strongly agree (4) 0 16.7 16.7 13.1 
* Kruskal Wallis ANOVA by Ranks p≤.05  
About 90% of the physicians in all groups strongly agreed or agreed that they were 
willing to take into account the effects of medicines on driving skills when prescribing 
medicines. Only 10-15% of the participants disagreed or even strongly disagreed to sacrifice 
some degree of efficacy by prescribing a medicine that is less impairing to the driving skills. 
Half of the physicians, again in all groups, felt not being well aware of the effects of 
medicines on driving skills. About 55% of the participants mentioned that it is important for 
them to be well informed on medicinal effects on driving behaviour. Eighty-five% of the 
physicians in the SoSoeMe group and 70% of the participants in the USB and control group 
were convinced that the information they provide to patients will influence their driving 
behaviour. 
Table 15: Type of driver (Within-group % ) 
I am willing to take into account the 
effects of medicines on driving 
skills when prescribing when the 
patient medicines:  
Would you consider this of more 
concern if your patient is: (YES) 
Physician groups (within-group )  Total 
group  
SoSoeMe 
N=13 
USB  
N=12 
Control  
N=36 
professional driver 84.6 83.3 97.2 91.8 
driving frequently 92.3 75 83.3 83.6 
driving long distances 92.3 83.3 86.1 86.9 
inexperienced driver 61.5 66.7 74.3 70 
experienced driver 38.5 50 64.7 55.9 
elderly driver 100 75 88.9 88.5 
using other CNS active drugs 100 83.3 97.2 95.1 
 
More than 80% of all physicians were willing to take into account the effects of 
medicines on driving skills when prescribing medicines when the patient is a frequent driver, 
professional, elderly or driving long distances. All physicians were less willing to take into 
account possible effects when the patient is an experienced driver.  
3.3.4 Reported behaviour 
 
Table 16: Reported behaviour (Within-group %)  
    Physicians groups (within-group )  Total 
group  SoSoeMe 
N=13 
USB  
N=12 
Control  
N=36 
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I ask a patient about 
his/her driving exposure 
when prescribing a 
medicine (Trend: p=.099) 
never 7.7 25 8.3 11.6 
seldom 61.5 25 13.9 26.2 
sometimes 7.7 25 44.4 32.8 
regularly 23.1 25 33.3 29.5 
always 0 0 0 0 
I inform a patient about 
driving related risks when 
prescribing a medicine. 
never 0 8.3 0 1.6 
seldom 7.7 8.3 5.6 6.6 
sometimes 46.2 16.7 25.0 27.9 
regularly 46.2 33.3 55.6 49.2 
always 0 33.3 13.9 14.8 
I provide a patient with 
written information 
materials when prescribing 
a driving impairing 
medicine.  
never 84.6 50 58.3 62.3 
seldom 15.4 41.7 22.2 24.6 
sometimes 0 8.3 11.1 8.2 
regularly 0 0 5.6 3.3 
always 0 0 2.8 1.6 
I keep systematic records 
when I prescribe a driving 
impairing medicine. 
never 30.8 16.7 25.0 24.6 
seldom 30.8 33.3 25.0 27.9 
sometimes 23.1 33.3 19.4 23.0 
regularly 0 8.3 16.7 11.5 
always 15.4 8.3 13.9 13.1 
I keep systematic records 
when I advise a patient 
when and how he/she can 
consider driving a car 
when using a driving 
impairing medicine. (trend: 
p=.094) 
never 
seldom 
sometimes 
regularly 
53.8 
38.5 
7.7 
0 
25.0 
8.3 
50.0 
8.3 
45.7 
14.3 
14.3 
22.9 
43.3 
18.3 
20.0 
15.0 
always 0 8.3 2.9 3.3 
I keep a record of the 
patient's traffic participation 
(e.g. how often he/she 
drives to work).  
never 46.2 41.7 36.1 39.3 
seldom 23.1 25.0 27.8 26.2 
sometimes 23.1 25.0 22.2 23.0 
regularly 7.7 8.3 11.1 9.8 
always 0 0 2.8 1.6 
I discuss medicinal drug 
consumption and driving 
related responsibility 
issues with the patient. 
never 0 8.3 8.3 6.6 
seldom 30.8 25.0 8.3 16.4 
sometimes 53.8 16.7 36.1 36.1 
regularly 15.4 41.7 38.9 34.4 
always 0 8.3 8.3 6.6 
How frequently do you 
usually provide detailed 
information when 
prescribing a medicine 
with impairing effects on 
driving performance?* 
never 7.7 8.3 5.6 6.6 
seldom 46.2 0 19.4 21.3 
sometimes 30.8 25.0 13.9 19.7 
regularly 15.4 41.7 30.6 29.5 
always 0 25.0 30.6 23.0 
Composite Score  
Reported behaviour 
never (1) 0 8.3 11.1 8.2 
seldom (2) 53.8 25.0 16.7 26.2 
sometimes (3) 38.5 25.0 41.6 37.7 
regularly (4) 7.7 33.3 27.7 24.6 
always (5) 0 8.3 2.8 3.2 
* Kruskal Wallis ANOVA by Ranks – Pearson Chi-Square p≤.05 
Overall, the frequencies of ‘wanted’ reported behaviour are rather low at baseline level 
(composite score: 34 % answers seldom or never to the statements). Only one significant 
inter-group difference with regards to reported behaviour was found. The SoSoeMe group 
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significantly provided less detailed information when prescribing compared to the USB 
and Control group (Chi-Square 8.872; p=.012). The physicians in the USB and control group 
asked a patient more about his/her driving exposure when prescribing a medicine than the 
physicians in the SoSoeMe group (trend). Half of all physicians stated that they regularly 
inform a patient about driving related risks when prescribing a medicine. Eleven out the 13 
participants (85%) in the SoSoeMe group never provided a patient with written information 
materials when prescribing a driving impairing medicine. Only 2 physicians in the SoSoeMe 
group, 1 in the USB group and 5 in the control group always kept systematic records when 
prescribing a driving impairing medicine.  
3.3.5 Knowledge 
 
Table 17: Knowledge (Within-group %) 
    Physician groups (within-group %)  Total 
group  SoSoeMe USB  Control  
Diazepam (regardless 
dose) is severely 
Impairing within the first 
2 months of treatment 
disagree 25.0 27.3 34.5 30.8 
agree 
(correct) 33.3 36.4 31.0 32.7 
don't know 41.7 36.4 34.5 36.5 
N  
 12 11 29 52 
Codeine (up to 20 mg) 
is mostly safe for 
drivers 
disagree 91.7 58.3 71.4 72.9 
agree 
(correct) 8.3 8.3 8.6 8.5 
don't know 0 33.3 20 18.6 
N  
 12 12 35 59 
Fexofenadine (normal 
dose) is severely 
impairing driving 
disagree 
(correct) 33.3 16.7 26.5 25.9 
agree 8.3 8.3 5.9 6.9 
don't know 58.3 75 67.6 67.2 
N  
 12 12 34 58 
Amitriptyline at the 
start of treatment is 
as impairing driving 
as after 4 weeks of 
treatment * 
disagree 
(correct) 46.2 58.3 20 33.3 
agree 15.4 8.3 25.7 20 
don't know 38.5 33.3 54.3 46.7 
N  
 13 12 35 60 
Paroxetine (up to 20 
mg/day) is safe for 
drivers 
disagree 46.2 8.3 30.3 29.3 
agree 
(correct) 30.8 50 39.4 39.7 
don't know 23.1 41.7 30.3 31 
N  
 13 12 33 58 
Composite Score 
Knowledge (sum on 5 
correct answers) 
0 23.1 8.3 30.6 24.6 
1 30.8 50 30.6 34.4 
2 23.1 8.3 33.3 26.2 
3 23.1 33.3 5.6 14.8 
4 0 0 0 0 
5 0 0 0 0 
N  
 13 12 36 61 
Physicians are obliged 
to inform the patients 
about the possible side 
effects of his/her 
medications on driving 
abilities. 
false  0 8.3 8.6 6.7 
true (correct) 100 91.7 91.4 93.3 
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N  
 13 12 35 60 
A patient can be 
punished with criminal 
sanctions if he causes 
a traffic accident while 
using a medicine with 
impairing properties 
whereas the health 
care provider has 
advised him not to drive 
false  9.1 8.3 2.8 5.1 
true (correct) 90.9 91.7 97.2 94.9 
N  
 11 12 36 59 
Composite Score 
Knowledge (total sum 
on 7 correct answers) 
0 0 0 0 0 
1 0 8.3 5.6 4.9 
2 38.5 8.3 27.8 26.2 
3 23.1 41.7 30.6 31.1 
4 15.4 8.3 33.3 24.6 
5 23.1 33.3 2.8 13.1 
6 0 0 0 0 
7 0 0 0 0 
N  
 13 12 36 61 
*Pearson Chi-Square p≤.05  
 
There is one significant between-group difference at baseline level on knowledge of 
specific medicinal driving risks (question on Amitriptyline). The participants from the 
control group gave significant less correct answers than the other two groups. Eightly-
five% of the respondents had less of half of the answers correct with regard to 
individual medicine’s risk.  
In general, increased proportions of participants in all groups answer incorrectly or 
failed to give any answer with regard to specific medicines’ risks: especially for Codeine 
(wrong: almost 75%) and don’t know: 18%). Only for the question on Paroxetine most 
participants answered correctly (39%). They are generally more informed about legal 
obligations and responsibilities of physicians/pharmacists and patients. 
3.3.6 User-acceptance 
 
Table 18: User-acceptance (Within-group %) 
    Physician groups (within-group )  Total 
group  SoSoeM
e 
N=13 
USB  
N=12 
Control  
N=36 
If we propose to you a tool 
(e.g. website, CD-rom) that 
allows you to find information 
on medicinal drugs and 
driving, will you be willing to 
use it for prescribing 
medicines? 
no 0 0 0 0 
yes 84.6 91.7 77.8 82 
Maybe 15.4 8.3 22.2 18 
 
More than 91% of the USB respondents and over 80% of the SoSoeMe respondents 
stated that they are willing to use a tool to find easily information regarding medicinal 
drugs and driving.  
About 20% were less eager to start using such a tool. The most frequent reasons for their 
hesitation can be linked to fears about software user-friendliness and time pressure 
during the consultation. Several physicians mentioned that the tool should be integrated, 
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easy to use when prescribing, have no effect on computer processes (e.g. slowing down) and 
cost no extra time. 
More than 90% of the SoSoeMe group respondents and about 60% of the USB and control 
group first choice was software integrated in their own software. As second choice came out a 
website and thirdly a stand-alone software. ‘Other’ referred mostly to combinations (e.g. 
website + manual). Stand-alone software (e.g. CD-rom or USB) seems generally not to be 
preferred.  
Table 19: Preference support tool (Within-group % ) 
 Which type of support tool would 
you prefer ? 
Physician groups (within-group )  Total 
grou
p  SoSoeMe USB  Control  
First 
choice Website 7.7 16.7 17.1 15 
  
Software integrated in your own 
software 
92.3 
 
66.7 
 
57.1 
 
66.7 
 
  Stand alone software 0 8.3 0 1.7 
  Manual 0 0 14.3 10 
  Other 0 0 11.4 6.6 
N   13 12 35 60 
Secon
d 
choice Website 83.3 58.3 44.8 56.6 
  
Software integrated in your own 
software 8.3 16.7 6.9 9.4 
  Stand alone software 0 16.7 24.1 17 
  Manual 8.3 8.3 10.3 9.4 
  Other 0 0 13.7 7.6 
N  
 12 12 29 53 
Third 
choice Website 0 8.3 22.6 14.5 
  
Software integrated in your own 
software 0 16.7 6.5 7.3 
  Stand alone software 50 33.3 35.5 38.2 
  Manual 25 33.3 22.6 25.5 
  Other 25 8.3 12.8 14.5 
N   12 12 31 55 
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3.4 SoSoeme group pre-post questionnaire comparison (N=13) 
 
Only one significant positive pre-post change after the intervention phase could be 
measured on the reported behaviour of SoSoeMe participants. Overall little pre-post 
change was found on attitudinal level. On the knowledge questions the number of 
incorrect or don’t know answers in the post-questionnaire remained high overall. 
3.4.1 Attitudes and awareness 
 
Overall little pre-post questionnaire change was found on attitudinal level. No 
significant changes were measured. A trend change was found with regard to the question 
if the participants were willing to sacrifice some degree of efficacy by prescribing a 
medicine that is less impairing to the driving skills (Z= -1.667; p=.096). The participants 
in the SoSoeMe group were slightly more willing to prescribe a safer alternative after the trial 
period. Five physicians out of 13 changed their answer in positive sense. Although no 
significant change could be observed, overall the positive change was bigger than the 
negative change on 4 of the 5 questions (no change measured on one question). 
Table 20: SoSoeMe group pre-post change– Attitudes and awareness  
SoSoeMe group pre-post questionnaire (within-group %) (n=13) 
    
Pre Post Change 
I am willing to take into 
account the effects of 
medicines on driving skills 
when prescribing medicines 
Strongly disagree 0 0 0 
Disagree 0 0 0 
Agree 61.5  61.5 0 
Strongly agree 38.5 38.5 0 
I am willing to sacrifice some 
degree of efficacy by 
prescribing a medicine that 
is less impairing to the 
driving skills (trend: p=.096) 
Strongly disagree 0 0 0 
Disagree 15.4 0 -15.4 
Agree 69.2 61.5 -7.7 
Strongly agree 15.4 38.5 23.1 
I feel being well aware of the 
effects of medicines on 
driving skills.  
Strongly disagree 0 0 0 
Disagree 46.2 38.5 -7.7 
Agree 53.8 61.5 7.7 
Strongly agree 0 0 0 
It is important for me to be 
well informed on medicinal 
effects on driving behaviour. 
Strongly disagree 0 0 0 
Disagree 0 0 0 
Agree 61.5 53.8 -7.7 
Strongly agree 38.5 46.2 7.7 
I feel that the information I 
provide to patients will 
influence their driving 
behaviour. 
Strongly disagree 0 0 0 
Disagree 15.4 15.4 0 
Agree 84.6 76.9 -7.7 
Strongly agree 0 7.7 7.7 
Composite Score Attitudes 
& Awareness (median) 
Strongly disagree (1) 0 0 0 
Disagree (2) 0 0 0 
Agree (3) 100 92.3 -7.7 
Strongly agree (4)  0 7.7 7.7 
 
With regard to the question whether specific characteristics of driver-patients would make a 
difference, there was no significant change compared to the baseline. On a descriptive 
level, a quite large positive change was found regarding the experienced drivers. 23% of the 
physicians changed their answer in a positive sense, and were thus more willing to take into 
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account the effects of medicines on driving skills when their patient was an experienced 
driver.  
 
Table 21: SoSoeMe group pre-post change – Detail attitudes and awareness 
SoSoeMe group pre-post questionnaire (within-group %) (n=13) 
I am willing to take into account the effects of 
medicines on driving skills when prescribing 
medicines: (YES) Pre Post Change  
professional driver 84.6 100 15.4 
driving frequently 92.3 100 7.7 
driving long distances 92.3 100 7.7 
inexperienced driver 61.5 69.2 7.7 
experienced'driver 38.5 61.5 23 
elderly driver 100 100 0 
using other CNS active drugs 100 100 0 
 
3.4.2 Reported behaviour 
 
There wasa significant positive change after the intervention phase of the SoSoeMe 
participants on 1 of the 8 reported behaviour questions. When medication with impairing 
effects on driving was to be prescribed, significantly more physicians provided a patient with 
written information materials (Z= -2.598; p=.009). Looking at the frequencies, it is clear that 
for almost all reported behaviour questions there was a good increase of the proportions of 
physicians in the ‘regularly’ and ‘always’ questions. 
Table 22: SoSoeMe group pre-post change – Reported behaviour 
SoSoeMe group pre-post questionnaire (within-group %) (N=13) 
  
Within-
group 
% Never Seldom Sometimes Regularly Always 
I ask a patient about his/her 
driving exposure when 
prescribing a medicine.  
Pre 7.7 61.5 7.7 23.1 0 
Post 15.4 23.1 15.4 46.2 0 
Change 7.7 -38.4 7.7 23.1 0 
I inform a patient about driving 
related risks when prescribing 
a medicine.  
Pre 0 7.7 46.2 46.2 0 
Post 0 7.7 30.8 53.8 7.7 
Change 0 0 -15.4 7.6 7.7 
I provide a patient with 
written information materials 
when prescribing a driving 
impairing medicine. * 
Pre 84.6 15.4 0 0 0 
Post 38.5 23.1 38.5 0 0 
Change -46.1 7.7 38.5 0 0 
I keep systematic records 
when I prescribe a driving 
impairing medicine.  
Pre 30.8 30.8 23.1 0 15.4 
Post 15.4 30.8 7.7 23.1 23.1 
Change -15.4 0 -15.4 23.1 7.7 
I keep systematic records 
when I advise a patient when 
and how he/she can consider 
driving a car when using a 
driving impairing medicine.  
Pre 53.8 38.5 7.7 0 0 
Post 38.5 30.8 30.8 0 0 
Change -15.3 -7.7 23.1 0 0 
I keep a record of the patient's 
traffic participation (e.g. how 
often he/she drives to work).  
Pre 46.2 23.1 23.1 7.7 0 
Post 15.4 53.8 30.8 0 0 
Change -30.8 30.7 7.7 -7.7 0 
I discuss medicinal drug Pre 0 30.8 53.8 15.4 0 
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consumption and driving 
related responsibility issues 
with the patient.  
Post 0 30.8 30.8 38.5 0 
Change 0 0 -23 23.1 0 
How frequently do you usually 
provide detailed information 
when prescribing a medicine 
with impairing effects on 
driving performance?  
Pre 7.7 46.2 30.8 15.4 0 
Post 15.4 23.1 15.4 46.2 0 
Change 7.7 -23.1 -15.4 30.8 0 
Composite Score Reported 
behaviour (median)  
Pre 0 53.8 38.5 7.7 0 
Post 7.7 23.1 30.8 38.5 0 
Change 7.7 -30.7 -7.7 30.8 0 
* Wilcoxon Signed Ranks Test Ranks p≤.05 
 
 
Figure 28: SoSoeMe group pre-post change- “I provide a patient with written information materials 
when prescribing a driving impairing medicine” (Within group %) (N=13) 
3.4.3 Knowledge 
 
The number of correct answers on the knowledge questions did not increase. For the 
questions on Diazepam, Amitriptyline and Paroxetine there were mainly less “don’t know” 
answers. Several physicians changed their answer in a negative sense after the trial period 
when compared with the baseline (in 3 out of 5 questions). With regard to the question on 
Amitryptiline the biggest positive change (more correct answers) was measured. With regard 
to physician/pharmacist obligations and patient responsibilities knowledge the post-
answers were more or less identical to the pre-answers, which were already 
predominantly correct.  
Overall the number of incorrect or don’t know answers in the post-questionnaire 
remained high and for some questions even around 70% and more: Codeine (92.3%), 
Diazepam (77%), Fexofenadine (69.2%) and Paroxetine (69.2%). 
Table 23: SoSoeMe group pre-post change – Knowledge 
    SoSoeMe group (within-group )    
PRE POST 
PRE-POST 
difference 
 
N 
Diazepam (regardless 
dose) is severely impairing 
within the first 2 months of 
treatment  
disagree 25 46.2 21.2 12 
agree (correct) 33.3 23.1 -10.2  
don't know 41.7 30.8 -10.9  
Codeine (up to 20 mg) is 
mostly safe for drivers  
disagree 91.7 84.6 -7.1 12 
agree (correct) 8.3 7.7 -0.6  
Never Seldom Sometimes Regularly Always
Pre 84,6 15,4 0 0 0
Post 38,5 23,1 38,5 0 0
0
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don't know 0 7.7 7.7  
Fexofenadine (normal 
dose) is severely impairing 
driving 
disagree (correct) 33.3 30.8 -2.5 12 
agree 8.3 0 -8.3  
don't know 58.3 69.2 10.9  
Amitriptyline at the start of 
treatment is as impairing 
driving as after 4 weeks of 
treatment  
disagree (correct) 46.2 53.8 7.6 13 
agree 15.4 15.4 0  
don't know 38.5 30.8 -7.7 
 
Paroxetine (up to 20 
mg/day) is safe for drivers 
disagree 46.2 61.5 15.3 13 
agree (correct) 30.8 30.8 0  
don't know 23.1 7.7 -15.4  
Composite Score 
Knowledge medicine risks 
(sum correct answers on 
5) 
0 23.1 38.5 15.4 13 
1 30.8 7.7 -23.1  
2 23.1 30.8 7.7  
3 23.1 15.4 -7.7  
4 0 7.7 7.7  
5 0 0 0  
Physicians are obliged to 
inform the patients about 
the possible side effects of 
his/her medications on 
driving abilities. 
false  0 0 0 13 
true (correct) 100 100 0 
 
A patient can be punished 
with criminal sanctions if 
he causes a traffic 
accident while using a 
medicine with impairing 
properties whereas the 
health care provider has 
advised him not to drive 
false  9.1 7.7 -1.4 11 
true (correct) 90.9 92.3 1.4 
 
Composite Score 
Knowledge (total sum 
correct answers on 7) 
0 0 0 0 13 
1 0 38.5 38.5  
2 38.5 15.4 -23.1  
3 23.1 23.1 0  
4 15.4 15.4 0  
5 23.1 7.7 -15.4  
6 0 0 0  
7 0 0 0  
 Wilcoxon Signed Ranks Test Ranks p≥.05 
 
SoSoeMe Physicians did not give significantly more correct answers in the post-
questionnaire as compared to the pre-questionnaire. 
 
Table 24: SoSoeMe group pre-post change – Knowledge composite score 
Knowledge Composite Scores (mean sum correct answers)  
  PRE POST 
Change 
(mean) 
CS specific medicinal risks (sum on 5) - Mean (SD)*  1.46 1.46 0 
CS overall Knowledge (sum on 7) - Mean (SD)* 3.23 3.38 0.2 
* Paired samples t-test p≥0.05 
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3.5 USB group pre-post questionnaire comparison (n=12) 
 
There was no significant pre-post change on the attitude and awareness, reported 
behaviour and knowledge questions for the physicians in the USB group. However two 
trends were measured on the reported behaviour question if they provided a patient 
with written information materials and if they discussed medicinal drug consumption 
and driving related responsibility issues with the patient. 
3.5.1 Attitudes and awareness 
 
Also for this group little pre-post questionnaire change was found on attitudinal level. There 
was no significant pre-post change on the attitude and awareness questions. Although 
no significant positive pre-post change was found, on all questions the positive change 
was bigger than the negative change. Several physicians changed their answer from 
‘agree’ into ‘strongly agree’ on the question if they are willing to take into account the effect 
of medicines on driving skills when prescribing medicines, if they felt aware of the potential 
effect of medicines on driving and if they felt that the information they provided to the patient 
will have an influence on his/her driving behaviour. 
Table 25: USB group pre-post change – Attitudes and awareness  
USB group pre-post questionnaire (within-group %)  
    
Pre Post Change N 
I am willing to take into 
account the effects of 
medicines on driving 
skills when prescribing 
medicines 
Strongly disagree 0 0 0 10 
Disagree 0 0 0  
Agree 33.3 30 -3.3  
Strongly agree 66.7 70 3.3  
I am willing to sacrifice 
some degree of efficacy 
by prescribing a 
medicine that is less 
impairing to the driving 
skills. 
Strongly disagree 0 0 0 11 
Disagree 16.7 0 -16.7  
Agree 66.7 90.0 23.3  
Strongly agree 16.7 10 -6.7 
 
I feel being well aware of 
the effects of medicines 
on driving skills.  
Strongly disagree 8.3 0 -8.3 11 
Disagree 50 54.5 4.5  
Agree 41.7 36.4 -5.3  
Strongly agree 0 9.1 9.1  
It is important for me to 
be well informed on 
medicinal effects on 
driving behaviour. 
Strongly disagree 0 0 0 11 
Disagree 0 0 0  
Agree 50 45.5 -4.5  
Strongly agree 50 54.5 4.5  
I feel that the information 
I provide to patients will 
influence their driving 
behaviour. 
Strongly disagree 8.3 0 -8.3 11 
Disagree 25 18.2 -6.8  
Agree 58.3 72.7 14.4  
Strongly agree 8.3 9.1 0.8  
Composite Score 
Attitudes & Awareness 
(median) 
Strongly disagree (1) 0 0 0 11 
Disagree (2) 8.3 0 -8.3  
Agree (3) 75 81.8 6.8  
Strongly agree (4)  16.7 18.2 1.5  
Wilcoxon Signed Ranks Test Ranks p≥.05 
 
With regard to the question whether specific traffic participation relevant characteristics 
of patients would make a difference in considering effects of medicines on driving skills, no 
significant changes compared to the baseline measurement were found. However rather 
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positive pre-post changes in the within-group frequency (%) were found especially when their 
patient was an inexperienced driver, an experienced driver of using other CNS active drugs. 
 
Table 26: USB group pre-post change – Detail attitudes and awareness 
USB group pre-post questionnaire (within-group %) 
I am willing to take into account the effects of 
medicines on driving skills when prescribing 
medicines: (YES) Pre Post Change  
 
 
 
 
N 
professional driver 83.3 90 6.7 10 
driving frequently 75 100 5 10 
driving long distances 83.3 90 6.7 10 
inexperienced driver 66.7 100 33.3 10 
experienced'driver 50 66.7 16.7 9 
elderly driver 75 90 15 10 
using other CNS active drugs 83.3 100 16.7 10 
 
3.5.2 Reported behaviour 
 
No significant positive change after the training and the intervention phase of USB 
participants on the behaviour questions was found. However two trends were measured on 
the question about providing a patient with written information materials (Z=-
1.890;p=.059) and discussing medicinal drug consumption and driving related 
responsibility issues with the patient (Z=-1.667;p=.096). Several physicians changed their 
answer from ‘never’ into ‘seldom’ on the question regarding the written information materials. 
Better results were found on the question whether the physicians discussed he topic ‘drugs 
and driving’” with the patient, 7 physicians out of 13 stated to discuss this topic regularly with 
their patients. 
Table 27: USB group pre-post change – Reported behaviour 
USB group pre-post questionnaire (within-group %) (n=11) 
  
Within-
group 
% Never Seldom Sometimes Regularly Always 
I ask a patient about his/her 
driving exposure when 
prescribing a medicine.  
Pre 25 25 25 25 0 
Post 18.2 27.3 0 54.5 0 
Change -6.8 2.3 -25 29.5 0 
I inform a patient about driving 
related risks when prescribing a 
medicine.  
Pre 8.3 8.3 16.7 33.3 33.3 
Post 9.1 0 9.1 72.7 9.1 
Change 0.8 -8.3 -7.6 39.4 -24.2 
I provide a patient with written 
information materials when 
prescribing a driving impairing 
medicine (trend: p=.059) 
Pre 50 41.7 8.3 0 0 
Post 27.3 54.5 9.1 9.1 0 
Change -22.7 12.8 0.8 9.0 0 
I keep systematic records when 
I prescribe a driving impairing 
medicine.  
Pre 16.7 33.3 33.3 8.3 8.3 
Post 18.2 27.3 9.1 36.4 9.1 
Change 1.5 -6 -24.2 28.1 0.8 
I keep systematic records when 
I advise a patient when and 
how he/she can consider 
driving a car when using a 
driving impairing medicine.  
Pre 25 8.3 50 8.3 8.3 
Post 18.2 18.2 36.4 27.3 0 
Change -6.8 9.9 -13.6 19 -8.3 
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I keep a record of the patient's 
traffic participation (e.g. how 
often he/she drives to work).  
Pre 41.7 25 25 8.3 0 
Post 45.5 9.1 45.5 0 0 
Change 3.8 -15.9 20.5 -8.3 0 
I discuss medicinal drug 
consumption and driving 
related responsibility issues 
with the patient (trend: p=.096) 
Pre 8.3 25 16.7 41.7 8.3 
Post 9.1 0 18.2 63.6 9.1 
Change 0.8 -25 1.5 21.9 0.8 
How frequently do you usually 
provide detailed information 
when prescribing a medicine 
with impairing effects on driving 
performance?  
Pre 8.3 0 25 41.7 25 
Post 0 9.1 45.5 36.4 9.1 
Change -8.3 9.1 20.5 -5.3 -15.9 
Composite Score Reported 
behaviour (median)  
Pre 8.3 25 25 33.3 8.3 
Post 9.1 9.1 18.2 63.7 0 
Change 0.8 -15.9 -6.8 30.4 -8.3 
 Wilcoxon Signed Ranks Test Ranks p≥.05 
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3.5.3 Knowledge 
 
No significant positive change (more correct answers) was found on the knowledge 
questions. Negative pre post changes (less correct answers) were found on the questions on 
Amitriptyline and Paroxetine. A possible explanation for the negative change in answers could 
be that the physicians were more aware about potential risks of medicines on driving after the 
training and intervention period, and thus more careful in their estimation of potential risk of 
medicines on the driving abilities. A trend was observed on the question on Diazepam (Z=-
1.732;p=.083). About 30% of the physicians gave more correct answers after the intervention. 
On the question on the physician/pharmacists responsibilities and patient 
responsibilities knowledge the post-answers were more or less identical to the pre-
answers, which were already predominantly correct. Looking at both composite score on 
the knowledge, 5 out 11 physicians scored more correct answers compared to the baseline. 
Table 28: USB group pre-post change – Knowledge 
    USB group (within-group )  
PRE POST 
PRE-POST 
difference 
N 
Diazepam (regardless dose) 
is severely impairing within 
the first 2 months of treatment 
(trend: p=.083) 
disagree 27.3 22.2 -5.1 9 
agree (correct) 36.4 77.8 44.4  
don't know 36.4 0 -36.4  
Codeine (up to 20 mg) is 
mostly safe for drivers  
disagree 58.3 72.7 6.7 11 
agree (correct) 8.3 18.2 9.9  
don't know 33.3 9.1 -24.2  
Fexofenadine (normal dose) is 
severely impairing driving 
disagree (correct) 16.7 18.2 1.5 11 
agree 8.3 0 -8.3  
don't know 75 81.8 6.8  
Amitriptyline at the start of 
treatment is as impairing 
driving as after 4 weeks of 
treatment  
disagree (correct) 58.3 54.5 -3.8 11 
agree 8.3 27.3 19  
don't know 33.3 18.2 -15.1 
 
Paroxetine (up to 20 mg/day) 
is safe for drivers 
disagree 8.3 36.4 28.1 11 
agree (correct) 50 36.4 -13.6  
don't know 41.7 27.3 -14.4  
Composite Score Knowledge 
medicine risks (sum correct 
answers on 5) 
0 8.3 18.2 9.9 11 
1 50 9.1 -40.9  
2 8.3 45.5 37.2  
3 33.3 18.2 -15.1  
4 0 9.1 9.1  
5 0 0 0  
Physicians are obliged to 
inform the patients about the 
possible side effects of his/her 
medications on driving 
abilities. 
false  8.3 9.1 0.8 11 
true (correct) 91.7 90.9 -0.8 
 
A patient can be punished 
with criminal sanctions if he 
causes a traffic accident while 
using a medicine with 
impairing properties whereas 
the health care provider has 
advised him not to drive 
false  8.3 0 -8.3 11 
true (correct) 91.7 100 8.3 
 
Composite Score Knowledge 0 0 0 0 11 
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(total sum correct answers on 
7) 
1 8.3 0 -8.3  
2 8.3 18.2 9.9  
3 41.7 18.2 -23.5  
4 8.3 36.4 28.1  
5 33.3 18.2 -15.1  
6 0 9.1 9.1  
7 0 0 0  
Wilcoxon Signed Ranks Test Ranks p≥.05 
 
 
Table 29: USB group pre-post change – Knowledge composite score 
Knowledge Composite Scores (mean sum correct answers) 
 PRE POST 
Change 
(mean) 
CS specific medicinal risks (sum on 5) - Mean (SD)* 1.7 1.9 0.2 
CS overall Knowledge (sum on 7) - Mean (SD)* 3.5 3.8 0.3 
* Paired samples t-test p≥0.05 
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3.6 Control group pre-post questionnaire comparison (n=36) 
 
There were no significant changes on the awareness and attitude, reported behaviour 
questions for the physicians in the control group. For the knowledge question on 
Amitriptyline and both composite scores a significant positive pre-post change was 
found. 
3.6.1 Attitudes and awareness 
 
There were no significant changes on the awareness and attitude questions for the 
physicians in the control group. The largest part of the physicians (69% up to 97%) 
remained at the same agreement level as in the pre-questionnaire, which is conform the 
expected results for the control group. The participants felt less aware of the effects of 
medicines on driving skills compared to the baseline measurement.  
Table 30: Control group pre-post change – Attitudes and awareness  
Control group pre-post questionnaire (within-group %)  
    
Pre Post Change N 
I am willing to take into 
account the effects of 
medicines on driving 
skills when prescribing 
medicines 
Strongly disagree 2.8 2.8 0 36 
Disagree 0 0 0  
Agree 27.8 36.1 8.3  
Strongly agree 69.4 61.1 -8.3  
I am willing to sacrifice 
some degree of efficacy 
by prescribing a 
medicine that is less 
impairing to the driving 
skills. 
Strongly disagree 5.6 0 -5.6 35 
Disagree 5.6 8.6 3  
Agree 66.7 68.6 1.9  
Strongly agree 22.2 22.9 0.7 
 
I feel being well aware of 
the effects of medicines 
on driving skills.  
Strongly disagree 2.8 0 -2.8 36 
Disagree 44.4 58.3 13.9  
Agree 50 41.7 -8.3  
Strongly agree 2.8 0 -2.8  
It is important for me to 
be well-informed on 
medicinal effects on 
driving behaviour. 
Strongly disagree 0 0 0 36 
Disagree 0 0 0  
Agree 52.8 58.3 5.5  
Strongly agree 47.2 41.7 -5.5  
I feel that the information 
I provide to patients will 
influence their driving 
behaviour. 
Strongly disagree 0 0 0 36 
Disagree 30.6 13.9 -16.7  
Agree 69.4 86.1 16.7  
Strongly agree 0 0 0  
Composite Score 
Attitudes & Awareness 
(median) 
Strongly disagree (1) 0 0 0 36 
Disagree (2) 0 0 0  
Agree (3) 83.3 88.9 5.6  
Strongly agree (4)  16.7 11.1 -5.6  
 Wilcoxon Signed Ranks Test Ranks p≥.05 
 
Looking at the questions about the characteristics of the patient it became clear that the 
majority of the physicians stayed at the same agreement level. 
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Table 31: Control group pre-post change – Detail attitudes and awareness 
Control group pre-post questionnaire (within-group %)  
I am willing to take into account the effects of 
medicines on driving skills when prescribing 
medicines: (YES) Pre Post Change  
 
 
 
N 
professional driver 97.2 91.7 -5.5 36 
driving frequently 83.3 80.6 -2.7 36 
driving long distances 86.1 86.1 0 36 
inexperienced driver 74.3 75 0.7 35 
experienced'driver 64.7 62.9 -1.8 33 
elderly driver 88.9 88.9 0 36 
using other CNS active drugs 97.2 100 2.8 36 
 
3.6.2 Reported behaviour 
 
There were no significant changes of the reported behaviour of the physicians in the control 
group. Compared to the baseline measurement, the participants stated less to ask a patient 
about his/her driving exposure (-11.1% ‘sometimes; -5.5 % ‘regularly’). On the questions if 
they kept systematic records when advising a patient on possible effects of the medicines and 
if they kept record of the patient’s traffic participation, about respectively 40-30% of the 
physicians changed their answers in a positive sense (‘regularly –‘always’ answers). A big 
part of the participants did not change their answer compared to the pre-questionnaire 
(31%-58%). 
Table 32: Control group pre-post change – Reported behaviour 
Control group pre-post questionnaire (within-group %)  
  
Within-
group % Never Seldom Sometimes Regularly Always 
N 
I ask a patient about his/her driving 
exposure when prescribing a 
medicine.  
Pre 8.3 13.9 44.4 33.3 0 36
Post 8.3 30.6 33.3 27.8 0 
Change 0 16.7 -11.1 -5.5 0 
I inform a patient about driving related 
risks when prescribing a medicine.  
Pre 0 5.6 25 55.6 13.9 36
Post 0 5.6 22.2 69.4 2.8 
Change 0 0 -2.8 13.8 -11.1 
I provide a patient with written 
information materials when 
prescribing a driving impairing 
medicine.  
Pre 58.3 22.2 11.1 5.6 2.8 36
Post 61.1 22.2 8.6 5.6 2.8 
Change 2.8 0 -2.5 0 0 
I keep systematic records when I 
prescribe a driving impairing 
medicine.  
Pre 25 25 19.4 16.7 13.9 36
Post 19.4 25 22.2 13.9 19.4 
Change -5.6 0 2.8 -2.8 5.5 
I keep systematic records when I 
advise a patient when and how 
he/she can consider driving a car 
when using a driving impairing 
medicine.  
Pre 45.7 14.3 14.3 22.9 2.9 35
Post 22.2 36.1 25 11.1 5.6 
Change -23.5 21.8 10.7 -11.8 2.7 
I keep a record of the patient's traffic 
participation (e.g. how often he/she 
drives to work).  
Pre 36.1 27.8 22.2 11.1 2.8 36
Post 38.9 19.4 27.8 13.9 0 
Change 2.8 -8.4 5.6 2.8 -2.8 
I discuss medicinal drug consumption 
and driving related responsibility 
Pre 8.3 8.3 36.1 38.9 8.3 36
Post 0 13.9 30.6 50 5.6 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 121 of 456 
issues with the patient.  Change -8.3 5.6 -5.5 11.1 -2.7 
How frequently do you usually provide 
detailed information when prescribing 
a medicine with impairing effects on 
driving performance?  
Pre 5.6 19.4 13.9 30.6 30.6 36
Post 0 19.4 30.6 33.3 16.7 
Change -5.6 0 16.7 2.7 -13.9 
Composite Score Reported behaviour 
(median) * 
Pre 11.1 16.7 41.6 27.7 2.8 36
Post 2.8 25 38.9 30.5 2.8 
Change -8.3 8.3 -2.7 2.8 0 
 Wilcoxon Signed Ranks Test Ranks p≥.05 
 
3.6.3 Knowledge 
 
For the knowledge questions significant changes were observed for the question on 
Amitriptyline (Z= -2.530; p=.011) and the two composite scores (Z=-2.639;p=.008 & Z=-
2756;p=.006). Taking a closer look at the question on Amitripyline, 26% of the physicians 
gave more correct answers (9 physicians out of 35). The majority of the physicians (71%) 
remained at the same knowledge level (25 physicians out of 35).  
A decrease in knowledge was found when calculating the composite scores. In the pre 
questionnaire 94.5% of the physicians had a score of 2/5 questions correct (composite score 
knowledge individual medicine risks) compared to 72.2% in the post questionnaire. In the pre 
questionnaire 64% of the participants had a score of 3/7 questions correct (composite score 
knowledge total) compared to 41.7% of the participants in the post questionnaire. 
On the question on codeine and fexofenadine a positive change (more correct answers) was 
found. Only 7 physicians (of the 36) gave the correct answer on the codeine question and 12 
physicians gave the correct answer on the paroxetine question. We can conclude that the 
majority of the participants gave wrong or incorrect answers on the knowledge 
questions. No big pre-post changes were found on the questions regarding legal 
obligations and patient responsibilities. 
Table 33: Control group pre-post change – Knowledge 
    Control group (within-group )   
PRE POST 
PRE-POST 
difference 
N 
Diazepam (regardless 
dose) is severly impairing 
within the first 2 months of 
treatment  
disagree 34.5 32.4 -2.1 29 
agree (correct) 31 35.3 4.3  
don't know 34.5 32.4 -2.1  
Codeine (up to 20 mg) is 
mostly safe for drivers  
disagree 71.4 63.9 -7.5 35 
agree (correct) 8.6 19.4 10.8  
don't know 20 16.7 -3.3  
Fexofenadine (normal dose) 
is severely impairing driving 
disagree (correct) 26.5 33.3 6.8 34 
agree 5.9 13.9 8  
don't know 67.6 52.8 -14.8  
Amitriptyline at the start 
of treatment is as 
impairing driving as after 
4 weeks of treatment * 
disagree (correct) 20 41.7 21.7 35 
agree 25.7 36.1 10.4  
don't know 54.3 22.2 -32.1 
 
Paroxetine (up to 20 
mg/day) is safe for drivers 
disagree 30.3 22.2 -8.1 33 
agree (correct) 39.4 38.9 -0.5  
don't know 30.3 38.9 8.6  
Composite Score 
Knowledge medicine 
risks (sum correct 
0 30.6 19.4 -11.2 36 
1 30.6 30.6 0  
2 33.3 22.2 -11.1  
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answers on 5)* 3 5.6 22.2 16.6  
4 0 2.8 2.8  
5 0 2.8 2.8  
Physicians are obliged to 
inform the patients about 
the possible side effects of 
his/her medications on 
driving abilities. 
false  8.6 2.8 -5.8 35 
true (correct) 91.4 97.2 5.8 
 
A patient can be punished 
with criminal sanctions if he 
causes a traffic accident 
while using a medicine with 
impairing properties 
whereas the health care 
provider has advised him 
not to drive 
false  2.8 5.7 2.9 35 
true (correct) 97.2 94.3 -2.9 
 
Composite Score 
Knowledge (total sum 
correct answers on 7)* 
0 0 2.8 2.8 36 
1 5.6 0 -5.6  
2 27.8 16.7 -11.1  
3 30.6 36.1 5.5  
4 33.3 16.7 -16.6  
5 2.8 22.2 19.4  
6 0 2.8 2.8  
7 0 2.8 2.8  
* Wilcoxon Signed Ranks Test Ranks p≤.05 
 
Table 34: Control group pre-post change – Knowledge composite score 
Knowledge Composite Scores (mean sum correct answers) 
  PRE POST 
Change 
(mean) 
CS specific medicinal risks (sum on 5) - Mean (SD)*  1.14 1.67 0.53 
CS overall Knowledge (sum on 7) - Mean (SD)* 3 3.56 0.56 
* Paired samples t-test p≤0.05 
 
 
Figure 29: Significant Control group pre-post change – Knowledge Composite Scores (within group%) 
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Figure 30: Control group- pre-post change: “Amitriptyline at the start of treatment is as impairing driving 
as after 4 weeks of treatment”.  
3.7 SoSoeMe group software data  
 
Only limited data was retrieved from the SoSoeMe software. When the physician wanted to 
prescribe a N-medicine a pictogram appeared in the software to warn the physician about the 
potential risk of that medicine on driving. After clicking on the pictogram the physician had the 
option to open a fact sheet and/or a patient letter. The participants had also the possibility to 
print this fact sheet and/or patient letter. Consequently after the physician had clicked on the 
pictogram, the number of clicks to open a fact sheet and/or patient letter were registered (see 
deliverable 7.4.1). 
In total the research team received data from only 7 physicians. Between 26th of March 
2010 (first click registered) and 28th of February 2011 (last click registered) 111 clicks were 
made on the pictogram in the SoSoeMe software. The number of clicks was not equally 
divided between the 7 physicians (see table below). About 58% of the clicks were made by 
two physicians (physician 2&7). When taking a closer look to the data, it became clear that 
sometimes several physicians worked within one practice. The data from physician 2 and 
physician 7 represent the use of the software by 5 physicians (physician 2: a practice with 3 
physicians; physician 7: a practice with 2 physicians). 
Table 35: SoSoeMe software data (n= 111) 
Distribution by ‘clicks’ (within group%) Distribution by risk category (%) 
Physician 1 
Physician 2 
Physician 3 
Physician 4 
Physician 5 
Physician 6 
Physician 7 
15.3 
23.4 
2.7 
1.8 
5.4 
16.2 
35.1 
Category 1 
Category 2 
Category 3 
18.9 
35.1 
45.9 
 
Of the 111 clicks on the pictogram the physicians clicked only 11 times on the fact sheet 
button. On the other hand, the patient letter was viewed 103 times. Whether the patient 
letter was printed could not be retrieved from the data. The physicians consulted the DRUID 
information the most when prescribing Anxiolytics or Antidepressants. 
Table 36: SoSoeMe software data: Distribution by ATC code 
Distribution by ATC code (absolute numbers) Fact sheet Patient letter 
Yes No Yes No 
disagree (correct) agree don't know
Within PRE-group % 20 25,7 54,3
Within POST-group % 41,7 36,1 22,2
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N01-- Anesthetics 
N02 – Analgesics 
N03 – Anti-epileptics 
N04 - Antiparkinson 
N05A – Antipsychotics 
N05B – Anxiolytics 
N05C – Hypnotics &sedatives 
N06A – Antidepressants 
N06B – Psychostimulants 
N06C – Psycholeptics/ psychanaleptics in combination 
N06D – Antidementia medicines 
N07B – Drugs used in addictive disorders 
N07C- Antivertigo preparations 
Total 
1 
2 
1 
0 
0 
3 
1 
2 
0 
0 
0 
0 
1 
11 
0 
14 
3 
1 
4 
25 
14 
29 
0 
4 
2 
1 
3 
100 
0 
14 
4 
0 
4 
26 
15 
29 
0 
4 
2 
1 
3 
103 
1 
1 
1 
0 
0 
2 
0 
2 
0 
0 
0 
0 
1 
8 
 
3.8 SoSoeMe user-acceptance 
 
Table 37: SoSoeMe group post-questionnaire – User acceptance 
 SoSoeMe group (within-group %)  
(n=13) 
 Guidelines Fact 
sheet 
Pictogram 
Did you use … in order to 
support your communication to 
patients? 
Yes 84.6 53.8 92.3 
No 15.4 46.2 7.7 
If you answered "Yes", how 
often did you use the …? 
Always 0 0 7.7 
Regularly 16.7 12.5 53.8 
Sometimes 66.7 37.5 15.4 
Seldom 8.3 50.0 15.4 
Never 8.3 0 0 
Unknown 0 0 7.7 
The … for prescribing 
medicines that may affect 
driving performance were: 
helpful 
Yes, very 
much 
61.5 30.8 100 
Quite a lot 30.8 61.5 0 
Not so 
much 
0 0 0 
No way 0 0 0 
Unknown 7.7 7.7 0 
The … for prescribing 
medicines that may affect 
driving performance were: 
useful 
Yes, very 
much 
38.5 0 84.6 
Quite a lot 38.5 46.2 15.4 
Not so 
much 
15.4 46.2 0 
No way 0 0 0 
Unknown 7.7 7.7 0 
The … for prescribing 
medicines that may affect 
driving performance were: 
sufficient 
Yes, very 
much 
53.8 30.8 38.5 
Quite a lot 30.8 61.5 61.5 
Not so 
much 
7.7 0 0 
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No way 0 0 0 
Unknown 7.7 7.7 0 
Did you think it was a problem 
that the fact sheets were 
provided in the English 
language? 
No / 53.8 / 
Yes / 30.8 / 
Unknown / 15.4 / 
 
More than 80% used the guidelines in their communication to the patients, of which 66% 
only sometimes. Only two physicians mentioned why they did not use the guidelines: their 
patient was not a driver and time pressure. About 60% found the prescribing guidelines 
very helpful. Around 80% found the guidelines very or quite a lot useful and sufficient. 
Only 50% of the participants used the fact sheets. About half of the physicians who did 
use the fact sheets use them seldom. Despite the low use of the factsheets, the participants 
scored the facts sheets as very helpful (61.5%- yes very much), useful (46.2% -quite a lot) 
and sufficient (61.5% -quite a lot). The pictogram system was used by almost every 
SoSoeMe participant (92.3%). 61.5% of the physicians used the system regularly or always. 
Every physician found the pictograms helpful, 84.6% found them very useful and 60.5% found 
the pictograms quite sufficient. Overall it can be stated that the pictogram was found useful to 
draw attention but not sufficient. When more information was needed the guidelines were 
used. 
 
Table 38: SoSoeMe group Post questionnaire - Guidelines 
 
SoSoeMe group (within-group 
%) (n= 13) 
Do you think that the 
guidelines have changed your 
manner/way to prescribe 
medication? 
Yes, very much 
Quite a lot 
Neutral 
Not so much 
No way 
0 
61.5 
15.4 
15.4 
7.7 
Do you think that the 
guidelines have changed your 
manner/way to inform the 
patient? 
Yes, very much 
Quite a lot 
Neutral 
Not so much 
No way 
0 
76.9 
23.1 
0 
0 
Do you think that the 
guidelines have changed your 
choice of medication 
Yes, very much 
Quite a lot 
Neutral 
Not so much 
No way 
0 
53.8 
15.4 
23.1 
7.7 
 
About 60% of the SoSoeMe physicians stated that the guidelines had changed the manner 
they prescribed medication quite a lot. Even 77% of the participants think that the 
provided guidelines changed their way to inform a patient quite a lot. Only half of the 
physicians mentioned an influence of the guidelines on their choice of medication. 
Table 39: SoSoeMe group Post questionnaire - User friendliness 
 
SoSoeMe group (within-group 
%) (n=13) 
I was able to find the 
information I asked for with 
no difficulty. 
Strongly disagree 0 
Disagree 0 
Agree 69.2 
Strongly agree 30.8 
I thought the tool was Strongly disagree 30.8 
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cumbersome. Disagree 69.2 
Agree 0 
Strongly agree 0 
This tool would fit well in my 
working routines. 
Strongly disagree 0 
Disagree 0 
Agree 46.2 
Strongly agree 53.8 
Text and icons are easy to 
perceive. 
Strongly disagree 0 
Disagree 0 
Agree 46.2 
Strongly agree 53.8 
Do you think that the tool 
should have additional 
options on the screen or are 
there any controls that are 
currently missing? 
Yes 23.1 
No 76.9 
Would you be willing to use 
this tool in the future 
Yes 84.6 
No 0 
Maybe 7.7 
Unknown 7.7 
 
Every physician (strongly) agreed that they could find the information without 
difficulties, that the tool would fit well in their working routines and that the texts and 
icons were easy to perceive. Every physician disagreed with the statement that the tool was 
cumbersome. 85% of the participants was willing to use this tool in the future. The two 
physicians (15.4%) who mentioned that the tool should have additional options liked more 
thorough information on side effects or less vague advice. These are also the reasons 
why these physicians did not want to use the tool in the future. On the question for what the 
physicians would use the tool mostly, they mentioned that the tool could help them to remind 
to inform the patient about possible side effects as well as provide them with the information 
to inform/advise the patient. 
3.9 USB group software data  
 
Only limited data could be extracted from the USB tool (see the annex from Part A). Only date 
and hour on which the physician searched for a medicine (used the tool) and what the 
physician typed in (the brand name or the generic name of the medicine, ATC code, partial 
brand or generic names...) was recorded and consequently extracted by the physicians in the 
format of a log file. The research team further completed the data by including a specific ATC 
code (e.g. N05BA01), a grouped ATC code (e.g. N05B-cat3) a category (1-3) and an ATC 
name (e.g. Anxiolytics-cat3). 
The physicians that used the USB tool (N=10) made only 182 clicks in the USB program 
between the time period 8th of September 2010 and 3th of March 2011 (a bit less than 6 
months). The distribution of the number/proportion of clicks was not equally divided between 
the 10 physicians. Half of the total number of clicks was made by three physicians (see 
table below). 
The most frequent medicines searched for were Lorazepam (8.7% – cat.3), Diazepam (7.7% 
- cat. 3), Tramadol (7.1% – cat. 3), Tetrazepam (6.0%- ATC code M5) and Alprazolam 
(5.5% - cat. 3). 
A risk category could be linked to 182 clicks’. No category could be linked if:  
                                            
5
 Tetrazepam has ATC code: M03BX07, and thus not included in the USB program. The 
physician had no ‘hit’. 
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- the medicine searched for was not in the database or no N-medicine (only N-
medicines were integrated into the USB tool) (25 clicks) 
- if the physicians only searched on a grouped ATC code (11 clicks) 
- the medicine was not available in Belgium (5 clicks) 
- invalid entry in tool (e.g. physicians typed ‘test’) (3 clicks) 
 
About 70% of the physicians’ clicks searched for a medicine of category 3 in the tool. 
When leaving out the missings/unknowns, 40% of the clicks were made for a medicine of the 
ATC group N05B (Anxiolytics) and N05C (Hypnotics and sedatives). 
Table 40: USB group: Description data log files ( within-group %) (n=182) 
Distribution by 
‘clicks’ (within 
group%) 
Distribution by 
risk category 
(%) 
Distribution by ATC code 
Physician 1 
Physician 2 
Physician 3 
Physician 4 
Physician 5 
Physician 6 
Physician 7 
Physician 8 
Physician 9 
Physician 10 
5.5 
3.8 
10.4 
0.5 
7.7 
15.9 
18.1 
5.5 
17.0 
15.4 
Category 
1 
Category 
2 
Category 
3 
7.2 
24.6 
68.1 
N02 – Anesthetics 
N03 – Anti-epileptics 
N05A – Antipsychotics 
N05B – Anxiolytics 
N05C – Hypnotics &sedatives 
N06A – Antidepressants 
N06B – Psychostimulants 
N06C – Psycholeptics/ psychanaleptics 
in combination 
N07B – Drugs used in addictive 
disorders 
13.0 
5.1 
8.0 
29.7 
21.0 
18.1 
0 
0.7 
 
4.3 
 
3.10 USB group- User acceptance 
 
When a physician opens the program on the USB tool he/she can type in the generic name or 
ATC code of the medicine he/she wants to prescribe. The physician had the option to search 
in a list of ATC codes or ATC names. After pushing the search button a window appeared 
where the physician had the option to choose from a lists of medicines matching his/her 
search. Next a ‘medication information window’ opened with the DRUID pictogram as well as 
the options to open a fact sheet, patient letter or an alternative medicine (see annex in Part 
A). 
Table 41: USB group post questionnaire – User acceptance 
 USB group (within-group %) (n=11) 
 Guidelines Fact 
sheet 
Pictogram 
Did you use … in order to 
support your communication to 
patients? 
Yes 90.9 81.8 36.4 
No 9.1 18.2 54.5 
If you answered "Yes", how 
often did you use the …? 
Always 0 0 0 
Regularly 18.2 11.1 22.2 
Sometimes 54.5 55.6 11.1 
Seldom 18.2 33.3 22.2 
Never 0 0 11.1 
Unknown 9.1 0 33.3 
The … for prescribing 
medicines that may affect 
driving performance were: 
helpful 
Yes, very 
much 
90.9 63.6 27.3 
Quite a lot 9.1 18.2 36.4 
Not so 
much 
0 0 27.3 
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No way 0 0 0 
Unknown 0 18.2 9.1 
The … for prescribing 
medicines that may affect 
driving performance were: 
useful 
Yes, very 
much 
36.4 18.2 27.3 
Quite a lot 18.2 45.5 27.3 
Not so 
much 
27.3 9.1 36.4 
No way 0 0 0 
Unknown 18.2 27.3 9.1 
The … for prescribing 
medicines that may affect 
driving performance were: 
sufficient 
Yes, very 
much 
9.1 36.4 27.3 
Quite a lot 72.7 54.5 27.3 
Not so 
much 
9.1 0 36.4 
No way 0 0 0 
Unknown 9.1 9.1 9.1 
 
91% of the Physicians in the USB group stated to have used the guidelines, of which 
half only sometimes used the guidelines. The physicians who mentioned not to have used the 
guidelines gave as reason the fact that the tool was: not integrated in their daily used software 
and by consequence was too time consuming. 90% found the guidelines very helpful. 82% 
used the factsheets and only 36.4 used the pictogram system. Despite the low use of 
the pictogram system half of the physicians found the pictograms (very) helpful, useful 
and sufficient. The fact sheets were even higher scored: 81% found them very much up to 
quite a lot helpful and 63% found them very much up to quite a lot useful. Every physician 
found the fact sheets (very) sufficient. 
Table 42: USB group Post questionnaire - Guidelines 
 
USB group (within-group 
%) (n=11) 
Do you think that the 
guidelines have changed your 
manner/way to prescribe 
medication? 
Yes, very much 0 
Quite a lot 36.4 
Neutral 45.5 
Not so much 18.2 
No way 0 
Do you think that the 
guidelines have changed your 
manner/way to inform the 
patient? 
Yes, very much 18.2 
Quite a lot 27.3 
Neutral 36.4 
Not so much 18.2 
No way 0 
Do you think that the 
guidelines have changed your 
choice of medication? 
Yes, very much 9.1 
Quite a lot 45.5 
Neutral 36.4 
Not so much 9.1 
No way 0 
 
Only about 35% of the physicians mentioned that the guidelines have changed their manner 
of prescribing medication. More physicians stated that the guidelines have changed their 
manner to inform the patient (45.5% quite a lot – very much) and their choice of medication 
(54.6% quite a lot – very much). 
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Table 43: USB group Post questionnaire -  User friendliness 
 
USB group (within-group %) (n=11) 
  USB stick Manual 
I was able to find the 
information I asked for 
with no difficulty. 
Strongly 
disagree 
9.1 0 
Disagree 18.2 0 
Agree 63.6 30 
Strongly agree 9.1 20 
Unknown 0 50 
I thought the USB 
stick/manual was 
cumbersome. 
Strongly 
disagree 
9.1 10 
Disagree 54.5 30 
Agree 18.2 10 
Strongly agree 18.2 0 
Unknown 0 50 
This USB-stick/manual 
would fit well in my 
working routines. 
Strongly 
disagree 
9.1 0 
Disagree 18.2 10 
Agree 63.6 30 
Strongly agree 9.1 10 
Unknown 0 50 
Text and icons are 
easy to perceive. 
Strongly 
disagree 
0 0 
Disagree 0 0 
Agree 81.8 40 
Strongly agree 18.2 10 
Unknown 0 50 
Do you think that the 
USB- stick should have 
additional options on 
the screen or are there 
any controls that are 
currently missing? 
Yes 27.3 11.1 
No 72.7 44.4 
Unknown 0 44.4 
Would you be willing to 
use this USB stick in 
the future 
Yes 63.6 50 
No 9.1 10 
Maybe 27.3 10 
Unknown 0 30 
 
About 73% of the physicians (strongly) agreed that they were able to find the information 
without difficulties and that the USB stick would fit well in their working routines. All 
participants agreed that the text and icons are easy to perceive. Four physicians stated that 
there should be two additional options to the USB tool: the categorisation of other 
medicines, the possibility to search on brand names, more safer alternatives, the 
possibility to easily print the fact sheets, a ‘match’ of information mentioned in the fact 
sheets and the Belgian situation and the possibility to integrate the tool into the daily 
used software. Only one physician mentioned why he/she was not willing to use the tool in 
the future: there was no possibility to make a connection with the daily used prescribing 
software. On the question for what they would use the USB tool the physicians answered that 
they mainly would use the information to advise the patient (e.g. showing the pictogram). 
There were quite a lot of missing data regarding the user acceptance questions on the 
manual. 5 out of 11 physicians were willing to use the manual in the future. They would 
use the tool for advising especially professional drivers, the search for brand names and to 
search to which risk category a medicine belongs. About half of the physicians agreed that 
the manual would fit in their daily practice and that the texts and icons are easily to perceive. 
Only one physician stated to miss information in the manual namely information in Dutch. 
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3.11 Control group software data and user-acceptance 
 
About 80% of the participants (29 of the 36 physicians) in the control group mentioned 
in the post questionnaire to be willing to use a tool in prescribing medicines. A small 
decrease in ‘maybe’ answers was found.  
Table 44: Control group pre-post change - User acceptance (Within-group % ) 
    Control group (Within-group %) (n=36) 
PRE POST Change  
If we propose to you a tool (e.g. 
website, CD-rom) that allows 
you to find information on 
medicinal drugs and driving, will 
you be willing to use it for 
prescribing medicines? 
 
 
no 0 2.8 2.8 
yes 77.8 80.6 2.8 
Maybe 22.2 13.9 -8.3 
Unknown 0 2.8 2.8 
 
No big changes regarding the type of support tool the physicians in the control group 
preferred was noticed. First choice was still software integrated in their own software, a 
small increase of preference (1.5%) was measured. The second choice was a website 
(increase of 2.4%). A change in third choice was found. In the pre questionnaire the third 
preference was stand-alone software (35.5%). In the post questionnaire the physicians 
preferred rather a manual (27.8%) than stand alone software (19.4%). 
Table 45: Control group pre-post change: Preference support tool (Within-group % ) 
 Which type of support tool would you 
prefer? 
Physician groups (within-group 
%) (n=36) 
PRE  POST Change  
First 
choice 
  
  
  
  
Website 17.1 19.4 2.3 
Software integrated in your own 
software 54.1 
55.6 1.5 
Stand alone software 0 0 0 
Manual 14.3 19.4 5.1 
Not filled 0 2.8 2.8 
Other 11.4 2.8 -8.6 
Secon
d 
choice 
  
  
  
Website 44.8 47.2 2.4 
Software integrated in your own 
software 6.9 
11.1 4.2 
Stand alone software 24.1 11.1 -13 
Manual 10.3 11.1 0.7 
Not filled 0 13.9 13.9 
Other 13.7 5.6 -8.1 
Third 
choice 
  
  
  
Website 22.6 19.4 -3.2 
Software integrated in your own 
software 6.5 
2.8 -3.7 
Stand alone software 35.5 19.4 -16.1 
Manual 22.6 27.8 5.2 
Not filled 0 19.4 19.4 
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Other 12.8 11.2 -1.6 
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4 Discussion 
4.1 Main study results 
 
Personal and practice related sample characteristics. From the analyses regarding 
sample characteristics it became clear that except for the characteristic ‘the years 
practicing as a physician’ the three groups (SoSoeMe; USB and Control group) did not 
differ significantly regarding personal/practice related background variables. There 
were no significant differences between participants and drop-outs in the SoSoeMe, USB and 
Control group with regard to gender, age, number of inhabitants in the practice area, number 
of years from graduation of with regard to ICT familiarity. 
Pre questionnaire. The three groups (SoSoeMe, USB and control group) were similar 
with regard to most pre-questionnaire parts. Two significant differences were found with 
regard to one knowledge question (Amitripthyline) and one reported behaviour question (on 
how frequently the physicians provided information when prescribing medicines with impairing 
effects on driving performance). It can be stated that the participants in the present study (in 
all groups) had a high ICT familiarity. Despite the high use of the Internet and use of medical 
software programs only half of the physicians stated to have easy access to data and 
information on the topic ‘medicines and driving’. Only 25% used the Internet to obtain 
information on medicines affecting driving behaviour. Overall the physicians liked being well 
informed on the topic drugged driving and the potential role they can play in providing 
information on the potential risk of medicines to the patient. Remarkably, half of the 
physicians in all groups felt not being well aware of the effects of medicines on driving 
skills. This can be (partially) due to the low access to relevant information and the fact that 
they didn’t receive it during their education. Contrary to the positive attitude, rather low 
frequencies of ‘wanted’ reported behaviour were found (composite score: 34.40 % answers 
seldom or never to the statements). The SoSoeMe group significantly provided less detailed 
information when prescribing compared to the USB and Control group. In general a low 
knowledge on the topic ‘medicines and driving’ was measured. The physicians are more 
informed about legal obligations and responsibilities of physicians/pharmacists and patients. 
Pre-post questionnaire comparison. When comparing the three groups on the pre-post 
questionnaires changes of the composite scores on attitudes & awareness, reported 
behaviour and knowledge regarding medicinal driving risk, several conclusions can be drawn 
(see table below). 
Table 46: Total group overview of pre-post changes: Composite scores 
 Composite Scores 
SoSoeMe group 
Composite Scores 
USB group 
Composite Scores 
control group 
 PRE POST Change PRE POST Change PRE POST Change 
Attitudes & awareness       
Strongly 
disagree  0 0 0 0 0 0 0 0 0 
Disagree  0 0 0 8.3 0 -8.3 0 0 0 
Agree  100 92.3 -7.7 75 81.8 6.8 83.3 88.9 5.6 
Strongly 
agree  0 7.7 7.7 16.7 18.2 1.5 16.7 11.1 -5.6 
Reported behaviour   
Never 0 7.7 7.7 8.3 9.1 0.8 11.1 2.8 -8.3 
Seldom 53.8 23.1 -30.7 25 9.1 -15.9 16.7 25 8.3 
Sometimes 38.5 30.8 -7.7 25 18.2 -6.8 41.6 38.9 -2.7 
Regularly 7.7 38.5 30.8 33.3 63.7 30.4 27.7 30.5 2.8 
Always 0 0 0 8.3 0 -8.3 2.8 2.8 0 
Knowledge medicine risk 
0 23.1 38.5 15.4 8.3 18.2 9.9 30.6 19.4 -11.2* 
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1 30.8 7.7 -23.1 50 9.1 -40.9 30.6 30.6 0 
2 23.1 30.8 7.7 8.3 45.5 37.2 33.3 22.2 -11.1* 
3 23.1 15.4 -7.7 33.3 18.2 -15.1 5.6 22.2 16.6* 
4 0 7.7 7.7 0 9.1 9.1 0 2.8 2.8* 
5 0 0 0 0 0 0 0 2.8 2.8* 
General knowledge 
0 0 0 0 0 0 0 0 2.8 2.8* 
1 0 38.5 38.5 8.3 0 -8.3 5.6 0 -5.6* 
2 38.5 15.4 -23.1 8.3 18.2 9.9 27.8 16.7 -11.1* 
3 23.1 23.1 0 41.7 18.2 -23.5 30.6 36.1 5.5* 
4 15.4 15.4 0 8.3 36.4 28.1 33.3 16.7 -16.6* 
5 23.1 7.7 -15.4 33.3 18.2 -15.1 2.8 22.2 19.4* 
6 0 0 0 0 9.1 9.1 0 2.8 2.8* 
7 0 0 0 0 0 0 0 2.8 2.8* 
 
Significant pre-post changes at composite score level were only found in the Control 
group: this group gave more wrong answers on the knowledge questions. 
Furthermore, taking a look at the number of significant pre-post changes on individual 
statements or questions, the SoSoeMe group had only 1 significant positive change 
(on a total of 20 statements/questions), the control group had also one significant 
positive change on the knowledge questions. For the USB group no significant pre-
post changes were found. 
Little pre-post questionnaire change was found on attitudinal level for the SoSoeMe, 
USB and control group. No significant pre-post change on the attitude and awareness 
questions for all three groups was found. It can be noted that for the SoSoeMe and USB 
group the overall positive change was bigger than the negative. In the control group the 
largest part of the physicians (>69%) remained at the same agreement level as in the pre-
questionnaire, which is conform the expected results for the control group. The conclusion 
can be made that the agreement level in the pre questionnaire was already high. More 
than 53% of the physicians indicated to agree or strongly agreed with the statements. When 
leaving out the question ‘I feel being well aware of the effects of medicines on driving skills’ 
the percentage even raised to 67%. Overall, the physicians included in the study had a 
positive attitude and awareness on the topic ‘medicines & driving’ but felt insecure 
about their knowledge on the potential risk of medicines on driving. This result is 
conform the remarks made by the participants during the training sessions. Several 
physicians mentioned that the motivation to participate in the study was that they wanted to 
increase their knowledge on the topic. 
Only for the SoSoeMe group a significant pre-post change was found with regard to 
the reported behaviour questions. The SoSoeMe participants provided the patient 
significantly more with written information materials after the trial period. The remark should 
be made that only the USB group had a training and not the SoSoeMe group. Due to the fact 
that the SoSoeMe group did not receive a training, smaller pre-post changes in reported 
behaviour were expected for this group. The questions on keeping systematic record of the 
patient’s traffic participation, if the patient was a driver and when prescribing a impairing 
medicine, were topics where quite a debate was raised during the training sessions of the 
USB participants. When looking at the post questionnaire answers on these questions from 
the participants of the SoSoeMe group and the USB group, the trend was found that the USB 
group stated to keep more often (more regularly) record of abovementioned information than 
the SoSoeMe users. This is a clear training effect/influence.  
Two positive pre post change trends were found for the USB group on the questions if 
the physicians provided a patient with written information materials (p=.59) and if the 
discussed medicinal drug consumption and driving related responsibility issues with the 
patient. However not significant, it can be said that a positive change in reported behaviour 
was measured after the training/ trial period. As expected, a large part of the participants in 
the control group did not change their answer on the behaviour questions in the post 
questionnaire. 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 134 of 456 
 
No significant pre-post changes were found with regard to the knowledge questions in 
the SoSoeMe group and the USB group. The physicians in the control group scored better 
(gave more correct answers) in the pre-questionnaire compared to the post questionnaire. In 
the pre questionnaire 64% of the participants had a score of 3/7 questions correct (composite 
score knowledge total) compared to 41.7% of the participants in the post questionnaire. A 
decrease in knowledge was measured after the trial period. A possible explanation could be 
that the physicians were more motivated to fill in the pre questionnaire and paid more 
attention to the questions. 
Objective data and user acceptance. Looking at the data regarding the user acceptance, 
several differences between the SoSoeMe group and USB group were found. The SoSoeMe 
group mentioned a much bigger influence of the provided prescribing support tool on their 
manner to prescribe or to inform patients than the USB group. Due to the fact that the 
information was integrated and a pop up automatically appeared on their screen, the 
physicians were ‘forced’ to pay attention to possible effects of the medicine they want to 
prescribe. It seems that such a little ‘push’ is necessary to realize a change in behaviour. 
Table 47: Summary- User acceptance 
 SoSoeMe group 
(within-group 
%) (n=11) 
USB group 
(within-group 
%) (n=36) 
Yes, very much/ Quit a lot’ answers 
  
Do you think that the guidelines have changed your 
manner/way to prescribe medication? 
61.5 36.4 
Do you think that the guidelines have changed your 
manner/way to inform the patient? 
76.9 45.5 
Do you think that the guidelines have changed your 
choice of medication? 
53.8 54.6 
USE (yes) 
  
Guidelines 84.6 90.9 
Fact sheets 53.8 81.8 
Pictograms 92.3 36.4 
 
The physicians that used the USB tool made only 182 clicks in the USB program during the 
trial period. Half of the total number of clicks was made by three physicians. The most 
frequent medicines searched for were category 3 medicines (e.g. Lorazepam, Diazepam & 
Tramadol). Most searched for ATC groups were Anxiolytics and Hypnotics and sedatives. 
Also the data from the SoSoeMe software was quite limited. In total 111 clicks where made 
on the pictogram, of which 58% was made by two physician practices. The physicians have 
a clear preference for the patient letter instead of the fact sheet. The medicines most 
searched for were also category 3 medicines. As mentioned above, the registered data out 
SoSoeMe is just the tip of the iceberg. From the software provider the remark was made that 
about 90% of their members use the information. The motivation to actually send in the data 
in the format of a query was too much of a hassle which resulted in a low response.  
 
4.2 Study limitations, challenges and solutions 
 
No link between questionnaire and software data. The study design initially took care that 
each participant had a unique DRUID identification number in order to link questionnaire data 
to tool data (SoSoeMe or USB tool). After the six months trial it became clear though that it 
was impossible to determine how many physicians exactly used the DRUID functions in the 
SoSoeMe or USB software. This was due to the fact that many of the participants work in 
practices with several physicians using the same computer, and thus using the support 
software tool.  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 135 of 456 
Sample restrictions. There was only a small number of participating physicians, especially in 
the USB and SoSoeMe group,. 
Shortened USB intervention phase. Due to some problems regarding the development of 
the USB tool the intervention period (6 months) had to be shortened in order not to delay the 
study. This may have had an influence on the measured effect of the DRUID 
information/guidelines on the questionnaire and tool use data.  
Motivated study participants. It has to be kept in mind that our population was already very 
interested in the topic medicines and driving; their participation was voluntary. All physicians 
mentioned at baseline that they already knew something about the topic but that they wanted 
to expand this knowledge. This may have led to smaller changes in reported pre-post 
measures during this study. 
Low use of the USB support tool. Due the low use of the provided prescribing support tools 
it became difficult to measure an effect on attitude & awareness, reported behaviour and 
knowledge of the physicians. However the promising results of the present study can be a 
starting point for future research. 
Besides these study limitations, several challenges had to be overcome by the research team 
during the course of the study 
Table 48: Study limitations, challenges and solutions 
Challenge  Offered solution 
An email was sent to all users by SoSoeMe to 
inform them about the study. One of the users of 
the software SoSoeme was the President of the 
General Medical Council (GMC) of East Flanders. 
By the end of March the president notified that 
all physicians had to ask permission at the GMC 
of East Flanders to participate in the study. Asking 
for an extra approval would mean that the drop 
out would be very high. 
The UGent team tried to inform and explain the 
GMC the aim of the physicians study. At the 
beginning of June we received permission to 
proceed. The study was delayed for more than 
two months 
Like explained above the research team had no 
direct communication with the SoSoeMe 
respondents. In addition, there was a difficult 
contact with the software providers due to their 
busy schedule. 
The software version had to be updated by the 
SoSoeMe users to be able to use the DRUID-
functions. That update was not performed by all 
physicians using SoSoeMe for several reasons 
(purchase of new version, no real advantages, 
happy with older version,…). Because of the lack 
of direct contact several physicians dropped out 
of the study. Some because they did not receive 
crucial information, for example the need to 
install a special program to see the DRUID 
information in their software, others because 
they simply forgot to update the software. It can 
be presumed that the lack of follow up had a 
negative influence on the non response rate. 
A lot of efforts (e.g. phone calls, emails on a 
regular base) were made to keep the 
communication going.  
 
 
The SoSoeMe company was not eager on the idea 
to organise separate training sessions. The 
The research team developed information folders 
(with a introductory letter, questionnaire, 
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physician study was introduced in the normal 
SoSoeMe training sessions. The disadvantage of 
having no specific DRUID training was that the 
possible respondents did not receive a lot of 
information about the DRUID-project or the 
physician study. It became very difficult to 
motivate the physicians to sign up to participate 
in our study  
informed consent and return envelope) for the 
physicians that were interested to participate in 
the study. SoSoeMe was encouraged to inform 
their members by email about the study. 
Before organising the training sessions for the 
USB group the research team had to wait for the 
finalisation of the USB-Tool. In the months April, 
May and June the research team experienced a 
lot of problems when installing the program on 
different computers (e.g. program was not 
found, PDF’s could not be opened, the tool did 
not run correctly on Windows Vista or on a 
Windows 64-bit). The provided USB-tool caused 
several installation but also user problems. 
Sometimes a wrong directory was linked to a 
certain medication, what caused that the 
physician did not receive the needed information. 
Due to these kinds of problems and the delay in 
finishing the USB-tool, the trial period for some 
physicians was shorter than originally foreseen (6 
months). 
The USB tool was tested on several computers by 
the research team and later modified to match 
the most current operating systems installed on 
the pharmacy computers 
It turned out that the sessions were scheduled 
too early in the evening. Some physicians did not 
make it to the training sessions 
 
SoSoeMe informed the research team about 
other training sessions organised by professional 
organisations for physicians. Still corrective 
measurements were needed to include more 
respondents. The research team personally 
installed the program for some physicians. 
Several physicians made the remark that the 
manual could be easily brought when doing 
house calls. The physicians did warn that there 
would be an underestimation of the possible 
impact of the tool/information. The physicians 
were more eager to look medication up in the 
manual than using the USB-tool. 
The research team took this remark into account 
when analysing the data from the USB support 
tool. 
Most of the participants did not know the ATC 
codes of medicines but only the brand and 
generic names. When developing a tool, search 
options should be based on the brand and 
generic name and not only on ATC codes. 
 
More information on the ATC codes of medicines 
was provided during the training sessions. 
Besides the use of the manual to search for 
corresponding ATC codes was enhanced.  
Sometimes different advices were given in the 
DRUID Fact Sheets than in the patient letters 
provided by Health Base. Several participants 
remarked that they missed concrete, detailed 
information and recommendations. Often the 
physicians found the advice too vague. 
During the training sessions attention was put on 
the fact that an advice should be tailor-made, so 
a certain flexibility should be foreseen.  
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There was difficulty to motivate the physicians to 
use the USB tool. The physicians warned the 
research team that they do not have the time to 
open several programs during consultation. 
During the training sessions the speaker and the 
research team tried to motivate the physicians by 
e.g. providing a step by step manual on how to 
install en use thee USB tool. Besides the 
possibility of making a shortcut on the computer 
desktop to easily open the USB program was 
mentioned. During the study newsletters were 
developed to keep the participants informed and 
motivated 
Several physicians had difficulties when installing 
the USB tool. 
Shortly after the training session a newsletter 
was sent to the participants in order to detect 
installation problems early in the study. Several 
physicians needed and received help with the 
installation (by phone, by email or in person). 
 
Main recommendations for future field studies with physician deal with: have good 
intermediaries or contact persons, using informative and supporting newsletters, inform and if 
necessary ask for permission of the (General) Medical Counsels in the area you want to 
perform a study. Having good contact persons help to establish a good communication with 
the respondents you want to reach. The use of newsletters turned out to be a very handy and 
useful tool in contacting the respondents directly.  
 
4.3 Overal conclusions and recommendations 
 
In conclusion it can be stated that few significant pre-post changes in attitude & awareness, 
reported behaviour and knowledge were found for any of the three groups.  
- The importance of a good follow up 
We did expect, conform with the results from the pharmacist study, to find more (significant) 
positive changes for the SoSoeMe group. A possible explanation could be the lack of contact 
between the research team and the participants. This group had no training and received no 
newsletters during the trial period. Also no follow up (e.g. when some problems raised when 
updating the software) could be foreseen. At the start of the study this group was not very 
eager to fill in questionnaires but they did want to use the information integrated in SoSoeme. 
After the trial period the conclusion could be made that about 90% of the physicians that used 
SoSoeMe had used the information on a quite regular base. Their feedback was very positive 
and all physicians wanted a continuation of the DRUID information into their daily used 
software. Therefore the lack of positive change found in attitude, behaviour and knowledge 
should be nuanced and it is very plausible that the found results are an underestimation of the 
real impact of the study. 
- A manual: a useful tool 
The lack of (significant) pre post changes in the USB group could be explained by the low 
use of the USB tool. From the data analyses of the log files it became clear that few 
physicians had used the tool, not even on a sporadic base. Some physicians warned that the 
registered searches in the usb program was an underestimation of the real impact of the 
study. Several participants mentioned that after looking up a medicine, they remember the 
advice given by the DRUID information. For the next patient they do not need to look up the 
medicine again, giving a underrepresentation of the use of the guidelines. Contrary to the low 
use of the USB tool, several physicians mentioned to have used the manual very often. Most 
physicians did prefer a manual above the software.  
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- Willingness to use a prescribing support tool 
- When looking at the user acceptance data and the objective data, the conclusion can 
be made that the physicians are willing to use a prescribing support tool when 
this tool is integrated in their daily used software, asks no extra efforts or time 
to update, is easy to use and contains practical information. The physicians 
underlined the need for more information on the topic ‘medicines and driving’. 
This information should not only be made available to physicians but also be 
integrated in the patient leaflet or on the medicine box.Suggestions with regard to 
the DRUID prescribing guidelines and the prescribing support tools: 
Following the participants’ feedback and remarks, several suggestions and recommendations 
for improvement of the DRUID prescribing guidelines and precribing support tool(s) can be 
given: 
With regard to the DRUID prescribing guidelines: 
- The physician recommend to focus on first prescriptions/ first use of a medicine 
- The respondents mentioned that the guidelines should not only focus on people that 
participate in daily traffic but also users of heavy machinery or seniors (higher risk to fall) 
- The categorisation of other and new medicines 
 
With regard to the delivery support tool(s): 
- The information should be integrated in the software and updated automatically 
- A combination of tools, ideally integrated software and a manual would be much 
appreciated 
- In case of search functions: the respondents would like to have the possibility to search 
on brand names and/or generic names and/or ATC codes 
- Safer alternatives have to be formulated if possible 
- The physicians would like to have the possibility to easily print the fact sheets or 
information for the patient. 
- The provided information in the fact sheets should ‘match’ the Belgian situation in order to 
be useful to Belgian patients.  
- The physicians underlined that the information included in the tool should be in Dutch. 
Especially patient information leaflets.  
 
- Further lessons learnt 
Further lessons learnt, remarks and recommendations should be considered in future 
physicians’ delivery support implementation plans: 
 Almost all physicians preferred to start informing and advising patients about the 
possible influence on the driving ability of certain medication at the start of therapy. 
Advising patients who already use a medicine for years to change medication is very 
difficult. Several physicians made the remark that the DRUID advice, patient letter 
and categorization are suitable for and applicable on patients who do not use 
medication on a regular base. But what to do with patients that build a tolerance for 
certain substances? 
 Most of the physicians did not know that they could be (partially) legally responsible 
when not informing a patient about possible side effects and effects on the driving 
ability. The physicians who did know about the law had already a system developed. 
After informing the patient about the effects of the prescribed medicine, the patient 
had to sign a paper acknowledging that they received information. Some physicians 
warned that signing a form of informed consent would violate the patient-doctor 
relationship. Other respondents asked if there was a standard document available to 
use in their daily practice. Besides an extra document, several physicians put a note 
in the electronic medical file of a patient when they have given certain information. 
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 The importance of therapy compliance was underlined by all physicians. Some 
physicians preferred that for example a depressed patient used his or her medication 
even if this had a possible effect on the driving ability over not using their medicines 
at all.  
 When getting to know the fact sheets and the USB-tool a lot of participants found the 
provided USB-tool useful. However it would be even more useful when the functions 
would be integrated in their daily used software. 
 Most of the respondents explained that they cannot forbid the patient to drive. The 
physicians were only willing to warn a patient. 
 All physicians were willing to prescribed an alternative if possible. According to the 
respondents an alternative is possible for some medicines but not for all. The medical 
record of the patient has also to be kept in mind when exploring the possibly to 
prescribe a safer alternative. 
 Informing the patient about the topic ‘driving and medicines’ was experienced as 
difficult. Certainly when informing older people.  
 Most of the physicians underlined that a change in knowledge and attitude of the 
physicians is possible when physicians are regularly confronted with the possible 
dangers of certain medications. The developed tools help to remind as well as 
confront the physician about the possible influences of medicines on the driving 
ability.  
 The respondents wanted to extend the target group: the target group should not only 
be people that participate in daily traffic but also users of heavy machinery or seniors 
(higher risk of falling). 
 The participants advised the research team to integrate the provided information 
and/or categorization on the patient information leaflet. Many patients use ‘old’ 
medication, medication that was once prescribed. These patients will not remember 
the information on the possible negative effects given from their physician.  
 The physicians regretted the absence of medico-pharmaceutical consultation 
structures or meetings where local physicians and pharmacists can assemble and 
discuss certain topics. The remark was made that the communication and 
collaboration between physicians and pharmacists would be easier when both health 
care workers know each other personally. It has to be noted that several attempts are 
presently made to bring pharmacists and physicians in closer collaboration. 
 After the trial period SoSoeMe let us know that out of the 330 SoSoeMe users, 
around 300 had updated their software version. Almost all of them used the 
pictogram and the fact sheets/ patient letters to inform their patients. The response of 
the users was very good, they liked the new application. This shows that an 
implementation of information about influence of medicines on driving is very warmly 
received. 
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6.4 Pre questionnaire 
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6.5 Post Questionnaire 
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1 Introduction 
 
1.1 Background 
 
Medicines that affect the fitness to drive are provided with a package information leaflet for 
the patient. The information in the package information leaflet usually does not always provide 
proper advice to the user on his/her participation in traffic. However health care professionals, 
such as physicians and pharmacists, are expected to provide this information at the time of 
prescription or dispensing of a medicine.  
 
In the past few years pharmacists play a much more central role in providing patients with 
information when delivering a medicine. Since April 2010, a new system of remuneration for 
pharmacists has come into force. The objective of this new system is to reinforce the 
intellectual role of the pharmacist and to partly disconnect the pharmacists’ remuneration from 
the drug price. Dispensing guidelines and a categorisation system, as developed by DRUID, 
integrated in their dispensing software can help the pharmacists to comply with their role and 
allow them to provide more concrete information to the patient. 
 
In the Netherlands, since October 2008, the Dutch government funded the development of 
and ICT–oriented support in dispensing practices (there is no specific ICT-oriented support for 
physicians). Based on that assignment, Health Base Foundation has developed additional 
information pertaining to the categorisation system as a support to counselling patients while 
dispensing a medicine. In Belgium one company (ESCAPO) uses the information provided by 
the Health Base Foundation as input for their dispensing support tool: ViaNova. Apart from 
the software ViaNova different other dispensing software tools/databases are available in 
Belgium (e.g., (Delphi care, Sofie (Farm@doc)), Omegasoft, Pharmawin, Aegate, Farmad 
twin, Officinall…) In contrast with the ViaNova software, specific information on the possible 
influence of a medicine on the driving abilities is not available in most of the other software 
systems. 
 
1.2 Aims and objectives   
The object of the study was to measure the effectiveness of pharmacist training on the 
dispensing guidelines for medicines with an influence on driving abilities, as well as the use 
and user acceptance of the dispensing support tools in which the medicinal risk 
classification system was integrated. The effectiveness was measured through the actual 
use rates of the integrated and stand-alone ICT support tool and in a questionnaire survey 
(compared to baseline measurement), after 6 months as a change in attitudes/awareness, 
knowledge and (reported) behaviour due to the implementation of the training. 
1.3 Evaluation team  
The study was organised, conducted and evaluated in close collaboration between Ghent 
University (UGent) and the Belgian Road Safety Institute (IBSR).   
2 Methods 
 
2.1 Research specific objectives 
The following research questions and hypotheses were formulated:  
- Do pharmacists’ attitudes and awareness about medicines and driving 
change/improve after the training and intervention?  
- Do pharmacists’ reported behaviour about medicines and driving change/improve 
after the training and intervention?  
- Do pharmacists’ actual knowledge about medicines and driving improve after the 
training and intervention?  
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- Are pharmacists willing to accept and use the ICT dispensing (integrated/stand-alone) 
and paper support tools? 
- Are pre-post questionnaire (socio-cognitive) changes and user acceptance rates 
higher in the integrated software group as compared to in the stand-alone (USB tool) 
support tool group?  
- Are pre-post questionnaire (socio-cognitive) changes in the intervention groups 
(integrated/stand-alone) higher as compared to the control group?  
- What is the use rate (dispensing data) of the ICT dispensing support tools 
(integrated/stand-alone)?  
- Are there differences in the incidence of dispensed category I, II or III medicines in 
the ICT tools (integrated/stand-alone) use rates? 
2.2 Study design 
The study has a pre- and post-design and includes 2 intervention groups (training + 
implementation support tool) and one control group:  
- Integrated software group, in this report further referred to as ViaNova group: a 
group of pharmacists using the ViaNova dispensing system in their daily practice. The 
DRUID WP4 and WP7 information was integrated into the ViaNova software.  
 
- Stand-alone software group, in this report further referred to as USB group: a group 
of pharmacists in East Flanders, , in the intervention group. The DRUID information 
was delivered through an USB stick to be installed on the pharmacists’ computer. The 
program on the USB stick had access to an internet-site were all DRUID information 
was posted. 
 
- Control group, a group of pharmacists from East Flanders, either chosen to be in the 
control group or by the research team referred to the control group. This group did not 
receive the DRUID information. 
 
Comparison of the intervention groups allows evaluating the difference in impact and use of 
the DRUID WP4 and WP7 information according to the type of support tool.  
Comparison with the no-intervention control group allows evaluating the impact of the DRUID 
information on dispensing behaviour and self-reported measures, controlled for effects 
outside the study scope. 
Pre- and post-conditions are accounted for by a pre-questionnaire before the training and 
intervention phase of 6 months (for the control group: 6 months without intervention), after 
which the post-questionnaire was asked to be filled-out.  
Pre-post comparisons within each group allow evaluating the impact of the DRUID WP4 and 
WP7 intervention.  
The study design can be roughly depicted as follows:  
Table 49: Activities that were performed bye ach Group of pharmacists during the study period. 
 Group 
 
ViaNova group USB group Control group  
Pre-training  
 Pre-questionnaire Pre-questionnaire 
April 2010 (ViaNova) 
Sept 2010 (USB) 
Pre-questionnaire + 
TRAINING TRAINING _ 
Post-intervention 
(6 months after the 
Post-questionnaire 
Software use data 
Post-questionnaire 
Tool use data 
Post-questionnaire 
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training) 
The study was approved by the Ethics committee, Faculty of Medicine and Health Sciences, 
University Ghent, Belgium on the 5th of March 2010 (B67020108020). 
All data (questionnaires, integrated and stand-alone software) were extracted anonymously. 
No patient information was collected. The privacy of the patient was guaranteed throughout 
the whole study.   
The pharmacists were free to refuse participation in the study. Moreover, every respondent 
could terminate their cooperation/participation at any time. All participants were asked to sign 
an informed consent. The USB group had to sign a second informed consent provided by 
Health Base because Health Base information (GIT) was integrated in the USB tool.  
2.3 Materials 
2.3.1 Intervention/support tools 
• Training manual 
A training manual including the relevant DRUID WP4 and WP7 information for pharmacists 
was developed in DRUID Task 7.4.1 (D7.4.1). This manual was slightly adjusted to the 
specific Belgian context. It was used as guidance when training the pharmacists in the 
ViaNova and USB group and handed out to them. 
The training manual addressed the general background and structure of the DRUID project 
and more specifically of the pharmacist study. The DRUID WP7 dispensing guidelines were 
explained and possible information documents for patients were reviewed. The manual 
furthermore familiarised the pharmacists with the DRUID WP4 proposed categorization 
system for medicinal effects on driving, as well as with the group-specific support tools that 
include the relevant information.  
• ViaNova integrated software  
Before the official start of the pharmacist study, several meetings were held with software 
company ESCAPO (provider of the pharmacy information system ViaNova) in order to make 
agreements on the activation of signals regarding the influence of medicines on driving 
abilities and how to start up the DRUID study with the integrated ViaNova group.  
It was decided that software including the relevant information could be introduced into the 
system ViaNova, with the aim of supporting the delivery of medicines and contributing to the 
education on medication with an influence on driving ability.  
More information on the ViaNova support software for dispensing potential driving-risky 
medicines can be found in D7.4.1 and D7.2.2. 
After activation of the DRUID functions by the pharmacists, ViaNova offered support in three 
manners when dispensing medicines that can influence the driving abilities: (a) Medication 
safety contains a first delivery control (e.g. a warning that driving (for a certain period) is not 
allowed). If possible, a safer alternative is proposed. (b) Medication accompaniment includes 
a first and second dispensing counselling. In the first dispensing counselling advice for safer 
driving is given. The second dispensing counselling is a continued accompaniment, where the 
pharmacist for example is requested to ask about any possible side-effects. (c) Patient 
information refers to practical and understandable information available in the ViaNova 
software that can be provided to the patient. Furthermore a warning label can be printed to 
affix on the medication box. Possible advice on this label is for example: ‘This medicine can 
influence your responsiveness’ or ‘Be careful when using alcoholic beverages’. 
Practically, when delivering medicines that influence the driving abilities, the ViaNova 
information system offers support in the following ways:  
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1. EUC signal: A ‘first delivery control signal’ appears only at the first delivery of 
medicines when: driving a car is not allowed (generally category 3) and when 
safer alternatives are available.  
2. EUB signal: the ‘first delivery accompaniment signal’ includes the 
information (concerning driving and medicines) to be told to the patient at a 
first delivery. 
3. TUB signal: the ‘second delivery accompaniment signal’: includes the 
information and possible questions for conversation with the patient at a 
second delivery.  
4. GIT: written information on the medicine, with practical 
recommendations/advices concerning driving and medicines, which can be 
printed out for the patient. 
5. Automatically generated warning: these warnings are brief messages that 
attract the attention on a possible influence of the medication on the driving 
abilities. These recommendations and warnings can be affixed on a package 
as a label. 
6. Registration of the automatic signals and how they are dealt with (which of 
these activities have been used for the patient). 
• USB stand-alone tool  
For the stand-alone group, an USB tool was developed in DRUID by CERTH-HIT and 
amended to match the Belgian situation. This tool contains comparable information as the 
ViaNova software: information for the pharmacists in the format of a Fact sheet or first 
delivery text and information for the patient (GIT: patient information letters) for the N-
medicines: N01-N07) provided by Health Base), but clearly differs from ViaNova as 
pharmacists have to look up the medicinal risk guidelines and information separately by 
themselves (no automatic pop-up and no link with the patient). Each pharmacist was asked to 
install (themselves) the tool on their computer.   
For the Belgian study the USB tool described in the general part of this deliverable, was 
amended for following reasons: 
1. Patient information letters had to be included  
2. Stichting Health Base (SHB) provided the information texts used in this study. 
Because of copyrights, Health Base texts could not be put directly on the USB-
stick. Permission to load the information on a secured website was granted by 
means of an IP contract (UGent Tech Transfer number A09/TT/0567) 
The following adjustments in the USB tool were made: 
1. An extra button was made to make the link to the patient information letters 
2. The information (Delivery accompaniments and patient information letters) was put 
online. The links leading to the information were created to pdf-files on an UGent 
website (http:/www..druid.ugent.be/) instead of PDF-files in a directory on the C-
drive of the computer. 
2.3.2  Evaluation tools  
Evaluation data were collected via questionnaires and through data extractions from the 
ViaNova software and USB tool use rates and characteristics.   
• Pre- and post-questionnaire  
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The evaluation questionnaire, developed within DRUID (D7.4.1), including a pre- and a similar 
post-part, was translated into Dutch for the Belgian pharmacist study. The translation may 
have generated some minor changes as compared to the original version. Furthermore, some 
small changes were made purposely to adapt better to the Belgian situation or for ethical 
reasons.  
With regard to the pre-questionnaire, the following questions were adapted or removed from 
the original version: 
- Background information: for ethical reasons date of birth was changed into age 
categories; practice area (rural/urban) was changed into number of inhabitants.  
- New technologies familiarity: a question about how often the pharmacist uses the 
internet to obtain information was added. 
- Sources: the option ‘organisation’ in ‘please report your sources’ was split up into 
traffic safety organisation and professional organisation. 
- Actual knowledge: since temazepam is not on the Belgian market, answers on the 
statement regarding this medicine were not considered; the question about 
informing the Driving Licensing Authority was left out because this is not applicable 
in Belgium. 
- User acceptance: the question which type of instrument the participant would prefer 
(website, integrated in software, non-integrated tool, manual...) was added. 
The same adjustments as were made in the post-questionnaire, and additionally:   
- User acceptance - content: in questions 5-7 the term ‘fact sheets’ was replaced by 
‘patient letters’; question 8 ‘Was it a problem that the fact sheets were provided in 
English’ was not applicable because the information was provided in Dutch by 
Stichting Health Base, and therefore removed.  
Furthermore, two extra questions were formulated in the post-questionnaire: 
- Do you think that the use of the guidelines has influenced your way of delivering 
medicines? 
- Do you think that the use of the guidelines has influenced your way of 
communicating the information to the patients?  
Both the pre- and post-questionnaire derive information on: personal and practice related 
background variables, familiarity with new (ICT) technologies, current sources on medicines 
and driving risks, attitudes and awareness, reported behaviour and actual knowledge related 
to dispensing medicines with potential effect on driving abilities, and user acceptance of daily 
practice support tools linking to driving. While identical for these areas of interest, the post-
questionnaire additionally includes in-depth questions regarding user acceptance and 
usability of the tool(s) being used during the intervention phase. (See annex 5). 
The three study groups filled-out the pre-questionnaire at baseline (before the 
training/intervention phase of 6 months): the ViaNova group filled it out just before the training 
session started; the USB and control group filled it out at home and sent it by mail to the 
research team. The three groups filled-out the post-questionnaire after 6 months (intervention 
phase): all groups filled it out at home and sent it back by post to the research team.  
All questionnaire data were integrated into an SPSS file. 
• ViaNova and USB data extraction   
The data from the integrated software ViaNova were automatically and anonymously 
extracted by ESCAPO and provided to the research team. The data were delivered in an 
Excel file.  
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The USB group on the other hand received a step by step instruction plan on how to extract 
the data from the USB tool in the format of a log file and to mail the log file to the research 
team. Pharmacists who installed the USB tool on several computers in the pharmacy where 
asked to send the log file(s) from all the different computers. The data were transferred into 
Excel by the research team. The USB tool data extraction included no personal identification 
(anonymous extraction). 
Relevant ViaNova extracted data included: information regarding EUC, EUB and TUB: the 
number of EUB/TUB/EUC signals, the ATC code and how the signal was handled: 
discussed/not discussed; cancelled delivery, gave GIT to patient, discussed side effects, 
ignore (signal will return) 
Relevant USB extracted data included: Only limited data/information could be obtained out 
the USB tool: date and hour of the search by the pharmacists and (part of) the 
substance/medicines they were searching for in the program.  
 
2.4 Study procedure 
 
2.4.1 Participant recruitment 
About hundred Flemish pharmacists use the ViaNova software system in their daily practice. 
In collaboration with ESCAPO, participation was asked for through an internal email. In the 
original study design it was foreseen to include 40 pharmacists, but because of the high 
enthusiasm and big response, the decision was made to include all pharmacists who wanted 
to participate. In the end, 90 pharmacists (90% of all ViaNova users) registered to follow a 
DRUID training session. After the 6 months trial it became clear that 70 pharmacists used the 
DRUID functions integrated in ViaNova on a regular base. Only those 70 pharmacists 
received a second questionnaire, 68 of them sent it back. Only the pharmacists who sent in 
the second questionnaire and the log file(s) were included in the study. After receiving the last 
questionnaire and the log file(s), a gift voucher was sent to the respondents by mail.  
With regard to the USB and control group, a letter was sent to all pharmacists of East 
Flanders (636 in total), including general study information, an invitation to follow a training 
session, the pre-questionnaire, an informed consent form and a return envelope. They were 
asked not to reply if they are ViaNova users. They were asked for their participation either in 
the USB group (select a training session date and send back the signed informed consent) or 
in the control group (fill-out and send back the pre-questionnaire and signed informed 
consent). They could thus self-select the group of participation (USB or control), although the 
letter also indicated that only the first 30 respondents would be considered for following a 
training course (USB group) or would be selected for the control group. 
The aim was to select 31 pharmacists for the USB group, but only 18 volunteered. On the 
other hand, 24 pharmacists wanted to be included in the control group; and another three who 
first registered for the USB group were added later as they were not able to attend a training 
session. 
After sending back their pre-questionnaire, the selected pharmacists in the USB and control 
group received a second letter that informed them that they were selected to follow a training 
session (USB group) or that they will receive a second questionnaire in 6 months (control 
group).  
Table 50 indicates the flow of the study sample size: from initial participant recruitment to full 
study participation.   
Table 50: Sample size 
 Pharmacist group 
Respondents ViaNova USB control 
Total population +/- 100 636 
Pre-questionnaire 84 18 24+3* 
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Training sessions 90 15  
Post-questionnaire
 
 68 12 21 
Full participants6 68 12 21 
* three absent USB group respondents in the training were switched to the control group 
2.4.2 Flow charts 
The following flow charts depict the study procedure, from participant recruitment over study 
steps and follow-up actions to study finalisation.  
For the ViaNova group of pharmacists 3 training sessions were organised in close 
collaboration with ESCAPO. The pharmacists were asked to fill in the questionnaire before 
the training session started in order to avoid invalid data/information. 
For USB group 2 training sessions were organized in Ghent. Pharmacists registered for the 
first training session who could not attend, were kindly invited for the second training session. 
For both groups a training manual and hand-outs of the Powerpoint presentation showed 
during the training session, were made. ESCAPO made a step by step plan how to activate 
and use the functions integrated in their software. Also for the USB group a manual on how to 
install and use the USB-tool was developed. During the training sessions the pharmacists 
were informed about the DRUID project and the aim of the pharmacist and physician study. 
The legal aspects of driving under the influence in Belgium and the role of pharmacists were 
underlined. Furthermore, the pharmacists were confronted with practical situations and 
examples.  
As also depicted in the flow charts, several follow-up actions were set up in order to motivate 
pharmacists for (continued) study participation and to support them in their participation.  
Newsletters were sent on a regular base to the ViaNova and USB group. The ones for the 
ViaNova group were designed in collaboration with ESCAPO, who distributed them to their 
customers. In total, 3 newsletters were sent to the all ViaNova users (see annex 1). By 
sending the newsletters to all users of ViaNova, every pharmacist was informed about the 
(progress of) the study. Several pharmacists who did not participate in the study did activate 
the DRUID functions. 
The USB group received newsletters by email from the Ghent University research team. 
Shortly after the training a first newsletter was already sent to the participants. Based on the 
reactions to this newsletter, it became clear that several pharmacists still experienced 
problems in installing the USB tool on the personal computer. Corrective supportive 
measures had to be taken, and problems could finally be solved by means of email, 
telephone calls, or personal intervention.. In total 3 newsletters were sent throughout the USB 
study (see annex 2). They mainly aimed at motivating the participants to use the tool and to 
ask for help when they experienced problems, but also at informing them on the study. 
Furthermore, some practical case studies were described or new legal regulations explained. 
Finally the aim of the survey was underlined.  
After ‘full’ participation an incentive was received. Due to the high number of participants, the 
ViaNova group received a gift voucher value of 60 euro (instead of 100 euro). The USB group 
received a gift voucher of 100 euro and the control group of 25 euro.  
Furthermore, other sensitising and dissemination actions in support of the study were set 
up. A banner was developed for the ViaNova group, which was shown on flat screens in the 
pharmacist practices using the ViaNova system (see annex 3). An interview was published in 
the magazine ‘Visie’, a paper of Christian Health Insurance and a short radio interview was 
broadcasted. The study was also presented in September 2010 on the first Belgian 
pharmaceutical care symposium (see poster in annex 4) 
                                            
6
 Full participants: intervention respondents from which the two questionnaires (pre- and post-) and software data 
extraction were received; this does not count for the control group. 
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• ViaNova group  
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• USB and control group 
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2.5 Statistical analysis  
SPSS version 19 (pre- and post-questionnaire data) and Microsoft Office Excel 2003 
(extracted ViaNova/USB data) were used for the data analysis. Due to sample size 
restrictions and variable scales robust non-parametric analyses were used (significance level 
at p≤.05; 95% confidence interval).  
• Pre-questionnaire: between-group comparisons 
For the categorical variables (background information, knowledge of new technologies, 
sources, user acceptance): descriptive crosstabs (within-group %), and Chi-square or Fisher's 
exact test to check the relationship.  
For the ordinal variables composite scores7 were calculated. For attitudes and awareness, 
and reported behaviour this was based on the median score. The knowledge variables were 
recoded into only 3 categories (don’t agree, agree and don’t know) and the composite score 
was calculated based on the sum of correct answers. Kruskal Wallis ANOVA by ranks test 
was used to check between-group differences, and a Fisher's least significant difference 
(LSD) post-hoc test to locate the significant differences. 
• Within-group pre-post questionnaire change 
Pre-post significant differences were checked for attitudes and awareness, reported 
behaviour and knowledge, based on the Wilcoxon matched pairs - signed-rank test. For the 
sum composite score of knowledge paired samples t-test was used for the ViaNova group 
(sample size restrictions in the other groups).  
• ViaNova/USB data extraction 
Percentage of different click options in function of the total number of popped-up signals (EUB 
and TUB, EUC), as a function of medicinal risk category and ATC group.  
3 Results 
 
3.1 Sample characteristics: ViaNova (n = 68), USB (n = 12), Control (n = 20) 
For the description of the study population only ‘full’ respondents were included. Full 
respondents were respondents from whom the research team received the two (pre-post) 
questionnaires. The total study population includes: 68 participants in the ViaNova group, 12 
in the USB group and 20 in the control group (total N=100). 
In Table 51 within-group distributions are shown for gender, age, inhabitants in the practice 
area, year of graduation from University, years practising as pharmacists and whether 
pharmacists had any education on medicinal effects on driving skills during their studies at 
University.  
Except for the number of inhabitants in the practice area (a measure of more rural 
versus more urban practice area) the three groups did not differ significantly regarding 
personal/practice related background variables.  
With regard to the gender distribution, 60% or more of the participants in the ViaNova and 
Control group was female, while the majority in the USB group was male (almost 60%). 45% 
of all participants had an age ranging between 30 and 45; this is the biggest portion in each 
group (42.60%-Vianova; 66.70%-USB group; 40%-Control group). Second most involved 
participant age group was 46 to 55 years. While none of the participants in the USB group 
was aged below 30 or above 55, these were smaller groups in the ViaNova and Control 
group. Taking gender into account, more than 50% of the females were aged between 30 and 
                                            
7
 A composite score combines different scores within a same category; it can be a mean, median or 
sum of the individual scores to provide one ‘overall’ category score.  
 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 179 of 456 
45, while this was more equally distributed between the age of 30 and 65 in the male 
pharmacists.  
About 70% of the pharmacists (in all groups) were practising for more than 10 years. There 
was no significant group-difference with regard to the graduation year or decade of the 
participating pharmacists. This varied between 1965 and 2009 (mean/median 1989), with 
most graduating in the 80ies (32%) and 90ies (30%). Part of the ViaNova and Control group 
graduated in the earlier years, compared to none in the USB group. Most respondents in all 
groups clearly indicated not to have had any specific education regarding possible effects of 
medicines on the driving abilities. Those who did mention education underlined that the 
information was given as ‘side information’, and that this information was often vague and 
superficial. 
Table 51: Description study participants (within-group %) 
  
Pharmacist groups (within-group %) 
  
ViaNova 
N=68 
USB  
N= 12 
Control  
n=20 Total  
Gender Male  33.8 58.3 40 38 
  Female 66.2 41.7 60 62 
Age <30 years 10.3 0 20 11 
  30-45 years 42.6 66.7 40 45 
  46-55 years 29.4 33.3 25 29 
  56-65 years 17.6 0 15 15 
Inhabitants area practice* >10000 89.2* 41.7 55 76.3 
  <10000 10.8* 58.3 45 23.7 
Year of graduation medical 
school  60ies 1.5 0 0 1 
  70ies 22.1 0 20 19 
  80ies 32.4 41.7 25 32 
  90ies 27.9 33.3 35 30 
  ≥2000 16.2 25 20 18 
Years practising as 
pharmacist <5 year 10.4 0 10 9.1 
  5-10 year 6 25 10 9.1 
  11-15 year 14.9 25 15 16.2 
  16-20 year 16.4 16.7 35 20.2 
  >20 year 52.2 33.3 30 45.5 
Education on medicinal 
effects on driving skills 
during studies at University 
no 82.1 83.3 68.4 79.6 
yes 17.9 16.7 31.6 20.4 
* Pearson Chi-Square p≤.05  
 
With regard to inhabitants in the area of the practice, ViaNova group pharmacists seemed 
to have their practice significantly more often in more populated (more urbanised) 
areas (>10,000 inhabitants) while the spreading of more or less populated locations was 
more equal in the other groups. 
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Figure 31: Inter-group difference: Inhabitants in area of practice (within-group %) (p<.000) 
 
3.2 Drop-outs  
There were no significant differences between participants and drop-outs in the USB 
and Control group with regard to personal/practice related background variables and 
ICT familiarity. With regard to the ViaNova group though, the dropped-out group 
seemed to be relatively more often younger (below 30), with less practicing years and 
more often working in a rural setting.  
In the ViaNova group 16 pharmacists dropped out (13 females, 3 males; from different age 
categories but none above 55 years). The full participation rate was 80.95% . There seem to 
be some differences between participants and drop-outs regarding age, number of inhabitants 
in the practice area and number of years from graduation. The dropped-out group had an 
increased relative number of below 30 year old participants (43.8% of drop-out group), no 
pharmacists from the oldest age groups dropped out. Connected to younger age, also the 
number of years in practice differs, with a relative high number of less than 5 working years in 
the drop-out group. Quite similar relative numbers of pharmacists in rural-urban areas 
dropped out, although taking the initial low rural area numbers into account, proportionally 
more rurally located pharmacists dropped out. There were no indications of differences with 
regard to ICT familiarity.  
In the USB group 3 female pharmacists within the age group 30 to 45 dropped out of the 
study. The full participation rate was 80%. No significant group differences between 
participants versus drop-outs were found regarding gender, age, number of inhabitants in the 
practice area, number of years from graduation of with regard to ICT familiarity.  
Five pharmacists dropped out of the Control group (3 males, 2 females), from different age 
categories but none within the 46-55 years group. The full participation rate was 80%. No 
significant differences between participants versus drop-outs were found regarding personal 
background variables or ICT familiarity.  
3.3 Pre-questionnaire: Vianova (n=68), USB (n=12), Control (n=20) 
The three groups were similar with regard to most pre-questionnaire parts (used 
sources for medicinal driving risk information, pre-level attitudes, awareness and knowledge, 
willingness to use a dispensing support tool that takes driving risks into account). Some 
differences were found though with regard to ICT familiarity (1) and reported behaviour 
(2). A small difference related to familiarity with software to find medicinal risk information 
(less in the Control group). More differences were found though with regard to pre-level 
reported behaviour: the USB and Control group less often provided written information to 
patients than the ViaNova group, and ViaNova respondents less often kept record of patients’ 
ViaNova USB group Control Group
>10000 89,2% 41,7% 55,0%
>10000 10,8% 58,3% 45,0%
0%
20%
40%
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80%
100%
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traffic participation than Control group respondents. On the level of the relevant socio-
cognitive-behavioural composite scores, the three groups were equivalent. 
3.3.1 General ICT literacy and familiarity with medicinal ICT 
 
Table 52: Medicinal ICT familiarity (within-group %) 
    
Pharmacist groups (within-group %)  Within 
total 
group 
%  
    
ViaNova 
N=68 
USB  
N=12 
Control 
N=20  
Do you use the internet 
to obtain information? 
no 3 8.3 5 4 
yes 97 91.7 95 96 
Do you use the internet 
to obtain information 
on medicines affecting 
driving behaviour? 
no 83.6 75 75 80.8 
yes 16.4 25 25 19.2 
If you answered ‘Yes’ 
how often do you do 
this? 
daily  0 0 0 0 
every week 0 0 20 5.3 
less than weekly 90.9 66.7 60 78.9 
other 9.1 33.3 20 15.8 
Have you ever used 
any software 
package / programme 
to obtain information 
on medicinal drugs 
effect on driving 
behaviour? * 
no 43.9 41.7 75* 50 
yes 56.1 58.3 25* 50 
Do you use any 
medical/clinical 
software package / 
programme in your 
daily practice? 
no 4.6 0 10 5.2 
yes 95.4 100 90 94.8 
*Pearson Chi-Square p≤.05 
In general, almost all participants had a high ICT familiarity when it concerns the general use 
of internet (96% of the total group) and the use of daily support software in their practice 
(94.8%).  
Searching medicinal driving related risks through software was indicated by about half of 
the respondents in the ViaNova and USB group, while 75% of the Control group indicated 
never to have used that (Chi² = 6.303; p=.043). Searching such risks via Internet was done 
far less frequently in all groups (more than 3/4th).  
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Figure 32: Inter-group difference: “Have you ever used any software package/programme to obtain 
information on medicinal drugs effects on driving behaviour?”.  (within-group %) 
The mentioned software packages for obtaining medicinal driving related risks, included just 
the ViaNova software (+ 1 Omegasoft) for the ViaNova group, while the other groups referred 
to national pharmaceutical organisations (BCFI, APB), scientific databases (Delphi care, Sofie 
(Farm@doc)), software tools/providers (Omegasoft, Pharmawin (Omegasoft), Aegate, 
Farmad twin, Officinall, or websites (www.geneesmiddeleninhetverkeer.nl).  
In each group the use of medical/clinical software for daily practice was well established 
(>90%). Mentioned packages/programmes were, besides mainly ViaNova in de ViaNova 
group (in order of frequency):  Delphi (care), Farmad (Twin), Corilus, pharmawin, Officinall, 
Internet / Google, BCFI, aegate, Corilus, Sofie, RIZIV, website beroepsvereniging KLAV, 
APB, Pletmedicatel Escapo, Kinget & vragen, Phenix, Sabco new.   
 
3.3.2 Sources for medicinal driving risk information  
Some questions asked the pharmacists if they had easy access to information or data about 
the possible effect of medicines on driving abilities, and if so, which type of source they 
consulted.  
More than 70% of the pharmacists in every group declared to have easy access to 
information or data. None of the pharmacists indicated to have followed any postgraduate 
education including effects of medicines on driving skills. 
Table 53: Access to information (within-group %) 
  
  
Pharmacist groups (within-group %)  Within total group % 
  
  
ViaNova 
N=68 
USB  
N=12 
Control 
N=20  
I have easy access to 
data and information 
about a medicine's 
effect on driving skills.    
no 17.9 25 30 21.2 
yes 82.1 75 70 78.8 
Did you get any 
postgraduate education 
on medicinal effects on 
driving skills? 
no 100 100 100 100 
yes 0 0 0 0 
 
The most consulted information and data sources were professional websites (45% of the 
total group), followed by scientific journals (39%). ViaNova participants (35.3%) seemed to 
consult professional websites significantly less than the USB (75%) and Control group (60%). 
Furthermore, 30% of the Control group enquired newsletters, which is much more than 
ViaNova participants (4.4%).  
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Table 54: Source type (within-group %) 
Source type crossed:  Pharmacist groups (within-group 
%)  
 Within total group 
%   ViaNova 
N=68 
USB  
N=12 
Control 
N=20  
Professional websites * 35.3* 75 60 45 
Newsletters * 4.4* 16.7 30* 11 
Organisations in road safety 0 0 0 0 
Organisations in my 
profession 14.7 16.7 30 18 
Scientific journals 32.4 58.3 50 39 
* Pearson Chi-Square p≤.05; Fisher's Exact Test p≤.05 
Other mentioned sources were: pharmacist software (e.g. ViaNova, Delphi), GIT texts, 
Informatorium Medicamentorum, Internet, BCFI, databases on professional websites, and the 
package leaflet.  
 
3.3.3 Attitudes and awareness 
There were no significant inter-group differences with regard to attitudes and 
awareness on (the relevance of considering) medicinal risks for driving. Overall, the 
participating pharmacists already generally had rather positive attitudes towards this 
topic at baseline level (composite score indicates that 91% of the whole group agrees or 
strongly agrees with the statements; looking at the individual statements more than 3/4th of 
whole sample (strongly) agreed with 4 of the 5 statements); only their feeling of being well 
aware of medicinal risk effects was more differentiated (54% (strongly) disagreeing). 99% of 
all participants even indicated that it is very important to be informed on this topic. These 
results indicate a lack of and need for information.  
Table 55: Attitudes and awareness (within-group %) 
    Pharmacist groups (within-group %)  Within 
total 
group 
% 
ViaNova 
N=68 
USB  
N=12 
Control 
N=20  
I am willing to take 
into account the 
effects of medicines 
on driving skills when 
dispensing medicines 
strongly disagree 1.5 0 0 1 
disagree 27.3 16.7 20 24.5 
agree 66.7 75 80 70.4 
strongly agree 4.5 8.3 0 4.1 
I am willing to 
sacrifice some 
degree of efficacy by 
dispensing a 
medicine that is less 
impairing to the 
driving skills. 
strongly disagree 0 0 0 0 
disagree 19.7 0 25 18.4 
agree 75.8 100 70 77.6 
strongly agree 4.5 0 5 4.1 
I feel being well 
aware of the effects 
of medicines on 
driving skills. 
strongly disagree 5.9 0 0 4 
disagree 45.6 66.7 55 50 
agree 47.1 33.3 45 45 
strongly agree 1.5 0 0 1 
It is important for me 
to be well-informed 
on medicinal effects 
on driving behaviour 
(trend) 
strongly disagree 0 0 0 0 
disagree 0 8.3 0 1 
agree 66.2 50 57.9 62.6 
strongly agree 33.8 41.7 42.1 36.4 
I feel that the strongly disagree 0 0 0 0 
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information I provide 
to patients will 
influence their driving 
behaviour. 
disagree 20.6 25 20 21 
agree 73.5 66.7 70 72 
strongly agree 5.9 8.3 10 7 
Composite Score  
Attitudes and 
awareness (median) 
strongly disagree (1) 0 0 0 0 
disagree (2) 10.3 8.3 5 9 
agree (3) 86.8 91.7 90 88 
strongly agree (4) 2.90 0 5 3 
* Kruskal Wallis ANOVA by Ranks p≤.05  
With regard to the question whether they would take medicinal driving risks more into account 
in function of the type of patient-driver, the vast majority (more than 90%) said they do in 
case a patient is using other CNS active medicines or is a professional driver; also high 
numbers of pharmacists (more than 80%) said they do when patients drive frequently or long 
distances. A further 79.4% of the total group would take it more into account for elderly 
drivers. Lower relevance was found for inexperienced (66%) and especially for experienced 
(41%) drivers. The three groups did not differ with regard to this matter.  
Table 56: Detail attitudes & awareness: Take into account possible effects of medicines on driving skills 
depending on the type of driver (within-group %) 
I am willing to take into account the 
effects of medicines on driving skills 
when dispensing medicines:  
Would you consider this of more 
concern if your patient is: (YES) 
Pharmacist groups (within-group %)  Within 
total 
group 
% 
ViaNova 
N=68 
USB  
N=12 
Control 
N=20  
Professional driver 94 91.7 95 93.9 
Driving frequently 84.6 91.7 95 87.6 
Driving long distances 89.4 91.7 90 89.8 
Inexperienced driver 63.5 66.7 75 66.3 
Experienced driver 41.3 33.3 45 41.1 
Elderly driver 80 75 80 79.4 
Using other CNS active drugs 95.5 100 90 94.9 
 
 
Figure 33: Inter-group difference: Take into account possible effects of medicines on driving skills 
depending on the type of driver (within-group %) 
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3.3.4 Reported behaviour 
Overall, the frequencies of ‘wanted’ reported behaviour were rather low at baseline 
level (composite score: 61% answers seldom or never to the statements). Most frequently 
reported behaviour dealt with informing patients about driving related risks (91% did this at 
least sometimes); on the opposite, keeping any kind of record related to driving was a very 
rare event (most say never). Asking about driving exposure, discussing responsibility issues 
and providing detailed risk information was mostly reported to take place seldom to 
sometimes. 
The groups differed significantly on two of the ‘reported behaviour’ statements (Kruskal 
Wallis; LSD). The USB and Control group indicated significantly less often than the 
ViaNova group to provide written information materials when dispensing a driving 
impairing medicine (Chi² = 11,869; p=0.003); the clear majority (>80%) in the first groups 
said they never or seldom do this, while 45% of the ViaNova group stated they at least 
sometimes did this. Furthermore, ViaNova participants indicated less often than the 
Control group that they kept record of a patient's traffic participation (Chi-Square 7,126; 
p=.028); although the vast majority in all groups indicated never to do this, a slightly larger 
proportion in the Control group (35%) indicated to do this seldom/sometimes.    
Table 57: Reported behaviour (within-group %)  
    Pharmacist groups (within-group ) Within 
total 
group 
% 
ViaNova 
N=68 
USB  
N=12 
Control 
N=20  
I ask a patient about 
his/her driving exposure 
when dispensing a 
medicine. 
never 16.2 16.7 10 15 
seldom 32.4 33.3 35 33 
sometimes 45.6 33.3 25 40 
regularly 5.9 16.7 30 12 
always 0 0 0 0 
I inform a patient about 
driving related risks when 
dispensing a medicine. 
never 0 0 0 0 
seldom 7.4 8.3 15 9 
sometimes 38.2 33.3 45 39 
regularly 47.1 58.3 35 46 
always 7.4 0 5 6 
I provide a patient with 
written information 
materials when 
dispensing a driving 
impairing medicine. * 
never 19.1 33.3 60 29 
seldom 35.3 50 20 34 
sometimes 27.9 16.7 15 24 
regularly 17.6 0 5 13 
always 0 0 0 0 
I keep systematic records 
when I dispense a driving 
impairing medicine. 
never 65.2 50 70 64.3 
seldom 18.2 25 20 19.4 
sometimes 7.6 25 5 9.2 
regularly 6.1 0 0 4.1 
always 3 0 5 3.1 
I keep systematic records 
when I advise a patient 
when and how he/she can 
consider driving a car when 
using a driving impairing 
medicine. 
never 70.6 41.7 65 66 
seldom 16.2 50 20 21 
sometimes 8.8 8.3 10 9 
regular 4.4 0 0 3 
always 0 0 5 1 
I keep a record of the 
patient's traffic 
participation (e.g. how 
often he/she drives to 
never 89.7 83.3 65 84 
seldom 10.3 8.3 30 14 
sometimes 0 8.3 5 2 
regularly 0 0 0 0 
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work). * always 0 0 0 0 
I discuss medicinal drug 
consumption and driving 
related responsibility issues 
with the patient. 
never 13.2 0 10 11 
seldom 32.4 50 45 37 
sometimes 35.3 50 25 35 
regularly 19.1 0 20 17 
always 0 0 0 0 
How frequently do you 
usually provide detailed 
information when 
dispensing a medicine with 
impairing effects on driving 
performance? 
never 5.9 0 10 6 
seldom 30.9 16.7 35 30 
sometimes 41.2 58.3 30 41 
regularly 20.6 25 15 20 
always 1.5 0 10 3 
Composite Score  
Reported behaviour 
(median) 
never (1) 13.2 8.3 20 14 
seldom (2) 48.5 41.6 45 47  
sometimes (3) 32.4 50 25 33 
regularly (4) 5.9 0 10 6 
always (5) 0 0 0 0 
* Kruskal Wallis ANOVA by Ranks p≤.05  
 
Figure 34: Inter-group difference: “I provide a patient with written information materials when dispensing 
a driving impairing medicine” (within-group %) 
 
Figure 35: Inter-group difference: “I keep a record of the patient's traffic participation” (within-group %) 
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3.3.5 Knowledge 
There were no significant between-group differences at baseline level on knowledge of 
specific medicinal driving risks, and neither to related legal aspects and 
responsibilities. The biggest respondent portion (75%) did not reach half of the total correct 
answers sum score with regard to individual medicine’s risk.  
In general, increased proportions of participants in all groups answered incorrectly or 
failed to give any answer with regard to specific medicines’ risks: especially for 
Diazepam (wrong: almost 50%, and don’t know: 1/3rd), Codeine (43% wrong – except for the 
Control group where most were correct), and Amitriptyline (most don’t know). Only for the 
question on Fexofenadine most participants answered correctly, as well as – to a lesser 
extent – on Paroxetine.  
They were generally more informed about legal obligations and responsibilities of 
physicians/pharmacists and patients. 
Table 58: Knowledge (within-group %) 
    Pharmacist groups (within-group %) Within 
total 
group 
% 
ViaNova 
N=68 
USB  
N=12 
Control 
N=20  
Diazepam (regardless 
of dose) is severely 
Impairing within the first 
2 months of treatment 
disagree 46.3 41.7 65 49.5 
agree (correct) 16.4 33.3 10 17.2 
don't know 37.3 25 25 33.3 
Codeine (up to 20 mg) 
is mostly safe for 
drivers 
disagree 44.1 50 35 43 
agree (correct) 33.8 25 60 38 
don't know 22.1 25 5 19 
Fexofenadine (normal 
dose) is severely 
impairing driving 
disagree 
(correct) 64.6 60 60 63.2 
agree 10.80 0 10 9.5 
don't know 24.6 40 30 27.4 
Amitriptyline at the start 
of treatment is as 
impairing driving as 
after 4 weeks of 
treatment 
disagree 
(correct) 34.3 25 35 33.3 
agree 22.4 33.3 25 24.2 
don't know 43.3 41.7 40 42.4 
Paroxetine (up to 20 
mg/day) is safe for 
drivers 
disagree 26.5 16.7 20 24 
agree (correct) 38.2 50 45 41 
don't know 35.3 33.3 35 35 
Composite Score - 
knowledge medicine 
risks (sum correct 
answers on 5) 
0 10.3 8.3 5 9 
1 25 33.3 15 24 
2 41.2 33.3 50 42 
3 17.6 16.7 25 19 
4 5.9 8.3 5 6 
5 0 0 0 0 
Pharmacists are 
obliged to inform the 
patients about the 
possible side effects of 
his/her medications on 
driving abilities. 
false  23.9 8.3 10 19.2 
true (correct) 76.1 91.7 90 80.8 
A patient can be false  27.7 25 25 26.8 
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punished with criminal 
sanctions if he causes 
a traffic accident while 
using a medicine with 
impairing properties 
whereas the health 
care provider has 
advised him not to drive true (correct) 72.3 75 75 73.2 
Composite Score – 
general knowledge 
(sum correct answers 
on 7) 
0 4.4 0 0 3 
1 8.8 8.3 0 7 
2 13.2 16.7 10 13 
3 22.1 16.7 25 22 
4 35.3 41.7 45 38 
5 11.8 8.3 20 13 
6 4.4 8.3 0 4 
7 0 0 0 0 
* Kruskal Wallis ANOVA by Ranks p≤.05  
3.3.6 User-acceptance 
 
Table 59: User-acceptance (within-group %) 
    Pharmacist groups (within-group %)  Within 
total 
group 
% 
ViaNova 
N=68 
USB  
N=12 
Control 
N=20  
If we propose to you a tool (e.g. 
website, cd-rom) that allows you 
to find information on medicinal 
drugs and driving, will you be 
willing to use it for dispensing 
medicines? 
no 0 0 5  1  
yes 94.1 75  70  87  
Maybe 5.9 25  25  12  
 
More than 90% of the ViaNova respondents and over 70% of the respondents from the 
USB and Control group stated that they were willing to use a tool to easily find 
information regarding medicinal drugs and driving.  
About 25% were less eager to start using such a tool. The most frequent reasons for their 
hesitation can be linked to fears about software user-friendliness. Several pharmacists 
mentioned that the tool should be integrated, easy to use when dispensing, have no effect on 
computer processes (e.g. slowing down) and cost no extra time. 
The respondents were asked about their preferred support tool. The possible options were 
website, integrated software, stand-alone software or other. More than 90% of the ViaNova 
and USB group respondents and 70% of the control group first choice was software 
integrated in their own software. As main second choice came out a website, and thirdly, 
a manual. ‘Other’ tools referred mostly to combinations (primarily: integrated software + 
manual or website, but also e.g. website + manual). Stand-alone software (e.g. cd-rom or 
USB) seemed generally not to be a preferred tool.   
Table 60: Preference support tool (within-group %) 
 Which type of support tool would 
you prefer ? 
Pharmacist groups (within-group 
%)  
Withi
n 
total 
grou
p % 
ViaNov
a 
N=68 
USB  
N=12 
Control 
N=20  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 189 of 456 
First 
choice Website 0 0 5  1  
  
Software integrated in your own 
software 94.1 91.7 70  89  
  Stand alone software 0 0 0 0 
  Manual 1.5 8.3 5  3  
  Other 4.4 0 20  7  
Second 
choice Website 48.5 58.3 55  51  
  
Software integrated in your own 
software 1.5 0 5  2  
  Stand alone software 8.8 16.7 15  11  
  Manual 16.2 8.3 20  16  
  Not filled 5.9 8.3 5  6  
  Other 19.2 8.3 0 14  
Third 
choice Website 16.2 25  15  17  
  
Software integrated in your own 
software 0 0 5  1  
  Stand alone software 29.4 25  30  29  
  Manual 38.2 33.3 15  33  
  Not filled 2.9 0 0 2 
  Other 13.2 16.7 35  18  
 
3.4 ViaNova group pre-post questionnaire comparison  
There were several significant positive pre-post changes after the training/intervention 
phase of ViaNova participants: mainly on reported behaviour (7 of the 8 statements), 
then on knowledge related to detailed medicine risk (2 of the 7 questions) and on the 
one statement measuring awareness of medicinal effects on driving. The behaviour 
and knowledge composite scores increased significantly in the post-measurement.  
3.4.1 Attitudes and awareness  
Overall, little pre-post questionnaire change was found on attitudinal level: for all statements 
the majority remained at the same agreement level as in the pre-questionnaire (Composite 
score indicates a status-quo for 76.12% of respondents). In case of changes though, the 
positive change was bigger than the negative change on 4 of the 5 statements; with regard to 
the willingness to take into account medicinal risk effects when dispensing the proportion of 
strongly agreeing doubled, but the disagreeing part also increased. The fact that less striking 
changes were found here is also related to the already rather high pre-level agreement (most 
already agreed with the statements before the intervention).  
There was only one significant positive pre-post change after the training/intervention 
phase of ViaNova participants, namely on ‘I feel being well aware of the effects of 
medicines on driving skills’ (Z= -1.980; p=.048): 25.4% of the pharmacists changed their 
answer in the positive sense, although 63% remained at the initial agreement level. 8.1% of 
the pharmacists additionally agreed or strongly agreed to feel aware in the post-
questionnaire; but, overall, a quite high percentage (43.3%) still disagreed.  
While the portion of positively ‘agreeing’ ViaNova pharmacists was clearly highest for 
most attitudinal statements, this still remained less obvious for their feeling of 
awareness and their willingness to take medicinal driving risks into account when 
dispensing.   
Table 61: ViaNova group pre-post questionnaire comparison – attitudes and awareness  
ViaNova group pre-post questionnaire (within-group %)  
    
Pre Post Change N 
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I am willing to take into account the 
effects of medicines on driving 
skills when dispensing medicines 
Strongly disagree 1.5 0  -1.5 
 
65 
Disagree 27.3 32.8 5.5  
Agree 66.7 58.2 -8.5  
Strongly agree 4.5 9  4.5  
I am willing to sacrifice some 
degree of efficacy by dispensing a 
medicine that is less impairing to 
the driving skills. 
Strongly disagree 0 1.5 1.5 66 
Disagree 19.7 11.8 -7.9  
Agree 75.8 80.9 5.1  
Strongly agree 4.5 5.9 1.4  
I feel being well aware of the 
effects of medicines on driving 
skills. * 
Strongly disagree 5.9 0  -5.9 67 
Disagree 45.6 43.3 -2.3  
Agree 47.1 52.2 5.1  
Strongly agree 1.5 4.5 3   
It is important for me to be well-
informed on medicinal effects on 
driving behaviour. 
Strongly disagree 0 1 5 1.5 68 
Disagree 0 0  0   
Agree 66.2 57.4 -8.8  
Strongly agree 33.8 41.2 7.4  
I feel that the information I provide 
to patients will influence their 
driving behaviour. 
Strongly disagree 0 0  0  67 
Disagree 20.6 11.9 -8.7  
Agree 73.5 77.6 4.1  
Strongly agree 5.9 10.4 4.5  
Composite Score attitudes & 
awareness (median) 
Strongly disagree (1) 0 0  0  68 
Disagree (2) 10.3 11.8 1.5  
Agree (3) 86.8 83.9 -2.9  
Strongly agree (4)  2.9 4.4 1.5  
* Wilcoxon Signed Ranks Test p≤.05 
 
 
Figure 36: ViaNova group pre-post change – Composite Score attitudes & awareness (median) (within-
group %) 
With regard to the question whether specific characteristics of driver-patients would make 
a difference, the Wilcoxon test showed no significant changes (most status-quo answers) as 
compared to the baseline measurement that indicated already a rather high general concern 
for most groups. For the groups that initially were of a bit less concern in the pre-
questionnaire (inexperienced and mainly experienced driver), there was an increase in 
concern up to almost 5%. the concern for elderly drivers also slightly increased.  
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Table 62: ViaNova group pre-post change –Detail attitudes & awareness: Take into account possible 
effects of medicines on driving skills depending on the type of driver (within-group %) 
ViaNova group pre-post questionnaire (within-group %) 
I am willing to take into account the effects of 
medicines on driving skills when dispensing 
medicines: (YES) Pre Post Change  
professional driver 94.0 92.6 -1.4 
driving frequently 84.6 85.3 0.7 
driving long distances 89.4 88.2 -1.2 
inexperienced driver 63.5 67.2 3.7 
experienced driver 41.3 45.5 4.2 
elderly driver 80.0 83.8 3.8 
using other CNS active drugs 95.5 91.2 -4.3 
 
3.4.2 Reported behaviour  
There was a significant positive change after the training and intervention phase of 
ViaNova participants on 7 of the 8 reported behaviour questions and on the behaviour 
composite score (Z=-6.143; p<.001). When medication with impairing effects on driving was 
to be dispensed, significantly more pharmacists reported in the post-questionnaire to ask 
patients about their patients’ driving experience (Z= -5,207; p<.001), to inform patients about 
the driving related risks (Z= -5.443; p<.001) and to discuss the medication consumption and 
driving related responsibilities (Z=-5.231; p<.001). After the intervention more pharmacists 
also indicated to provide more frequently detailed information on impairing effects of 
medication (Z= -5.733; p<.001), and to keep records when dispensing such medicines (Z= -
4.611; p<.001), when giving advice to patients (Z= -5.198, p<.001), and about patients’ traffic 
participation (Z= -3.589; p<.001).  
Looking at the frequencies, it is clear that for all reported (wished) behaviour questions 
there was a good increase of the proportion of pharmacists in the ‘sometimes’, 
‘regular’ and ‘always’ answers.   
 
Table 63: ViaNova group pre-post change – reported behaviour 
ViaNova group pre-post questionnaire (within-group %)  
  
Within-
group 
% Never Seldom Sometimes Regularly Always 
N  
I ask a patient about 
his/her driving 
exposure when 
dispensing a medicine. 
* 
Pre 13.1 32.1 46.4 7.1 1.2 68 
Post 4.4 11.8 39.7 39.7 4.4  
Change -8.7 -20.3 -6.7 32.6 3.2 
 
I inform a patient about 
driving related risks 
when dispensing a 
medicine. * 
Pre 0 6 33.3 47.6 13.1 68 
Post 0 0 4.4 69.1 26.5  
Change 0 -6 -28.9 21.5 13.4 
 
I provide a patient with 
written information 
materials when 
dispensing a driving 
impairing medicine.  
Pre 19.1 35.3 27.9 17.6 0 68 
Post 16.2 32.4 38.2 11.8 1.5  
Change -2.9 -2.9 10.3 -5.8 1.5 
 
I keep systematic 
records when I 
dispense a driving 
impairing medicine. * 
Pre 60.7 19 6 7.1 4.8 68 
Post 23.5 23.5 11.8 8.8 30.9  
Change -37.2 4.5 5.8 1.7 26.1 
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I keep systematic 
records when I advise a 
patient when and how 
he/she can consider 
driving a car when 
using a driving 
impairing medicine. * 
Pre 64.3 14.3 13.1 6 2.4 67 
Post 25 17.6 26.5 11.8 17.6  
Change -39.3 3.3 13.4 5.8 15.2 
 
I keep a record of the 
patient's traffic 
participation (e.g. how 
often he/she drives to 
work). * 
Pre 89.3 9.5 1.2 0 0 68 
Post 66.2 20.6 8.8 2.9 1.5  
Change -23.1 11.1 7.6 2.9 1.5 
 
I discuss medicinal 
drug consumption and 
driving related 
responsibility issues 
with the patient. * 
Pre 10.7 28.6 33.3 25 2.4 67 
Post 1.5 13.2 29.4 41.2 13.2  
Change -9.2 -15.4 -3.9 16.2 10.8 
 
How frequently do you 
usually provide 
detailed information 
when dispensing a 
medicine with 
impairing effects on 
driving performance? * 
Pre 4.8 25 44 20.2 6 68 
Post 0 5.9 25 50 19.1  
Change -4.8 -19.1 -19 29.8 13.1 
 
Composite Score 
Reported behaviour 
(median) * 
Pre 13.2 48.5 32.4 5.9 0 68 
Post 1.5 10.3 48.5 32.3 7.3  
Change -11.7 -38.2 16.1 26.4 7.3  
* Wilcoxon Signed Ranks Test p≤.05 
 
 
Figure 37: ViaNova group pre-post change – Composite score reported behaviour (median) (within-
group %) 
 
The proportion informing patients regularly or always about risks increased up to almost the 
maximum (95.6%). Furthermore, most group majority shifts were made from pre-level ‘seldom 
to sometimes’ answers to post-level ‘sometimes to regular’ level (asking about driving 
exposure, discussing responsibilities, frequency of detailed informing).  
With regard to record keeping when dispensing risky medicines or when giving driving related 
advise, this seemed to be clearly more often done – up to even 30.9% saying they always do 
– but also still quite large portions indicated never or seldom to do this.  
Although there was a change in the positive sense, still 86.8% of the pharmacists indicated 
never or seldom to note patients’ traffic participation information.  
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Figure 38: ViaNova group pre-post change –“ I ask a patient about his/her driving exposure when 
dispensing a medicine” (within-group %) 
 
 
Figure 39: ViaNova group pre-post change – “I inform a patient about driving related risks when 
dispensing a medicine” (within-group %) 
 
 
Figure 40: ViaNova group pre-post change – “I keep systematic records when I dispense a driving 
impairing medicine” (within-group %) 
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Figure 41: ViaNova group pre-post change – “I keep systematic records when I advise a patient when 
and how he/she can consider driving a car when using a driving impairing medicine” (within-group %) 
 
 
Figure 42: ViaNova group pre-post change – “I keep a record of the patient's traffic participation (e.g. 
how often he/she drives to work)” (within-group %)  
 
 
Figure 43: ViaNova group pre-post change –“ I discuss medicinal drug consumption and driving related 
responsibility issues with the patient” (within-group %) 
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Figure 44: ViaNova group pre-post change – “How frequently do you usually provide detailed 
information when delivering a medicine with impairing effects on driving performance” (within-group %) 
3.4.3 Knowledge 
 
Significant positive changes (more correct answers) were found on two knowledge 
questions related to risk of individual medicines, and on the composite scores (on 5 – 
focussing on individual medicinal risks – and on 7 – total score – ): Diazepam (Z= -2.200; p= 
.028) and Amitriptyline (Z= -2.744; p= .006). For both questions there were mainly fewer 
‘don’t know’ answers; this shift was actually also the case in all medicinal risk related 
questions. For the question on Diazepam though, still more than half of the pharmacists 
answered incorrectly in the post-questionnaire. With regard to the question on Amitryptiline 
almost 60% was correct afterwards.  
There was also a trend pre-post positive change for the question on Codeine (Z= -1.859; 
p=.063): 33.8% of the ViaNova pharmacists gave more correct answers after the intervention, 
coming up to 50% of the group being correct.   
Although the pre-post change direction was mainly as expected, except for the Paroxetine 
question (more incorrect post-answers), the number of incorrect or don’t know answers in 
the post-questionnaire remained overall quite high and for some questions even more 
than the majority: Paroxetine (70%), Diazepam (67%), Codeine (50%), Amitriptyline (40%) 
and Fexofenadine (34%). 
 
Table 64: ViaNova group pre-post change – Knowledge 
    Pharmacist groups (within-group )   
PRE POST 
PRE-POST 
difference 
N  
Diazepam (regardless 
of dose) is severely 
impairing within the 
first 2 months of 
treatment * 
disagree 46.3 52.2 5.9 66 
agree (correct) 16.4 32.8 16.4  
don't know 37.3 14.9 -22.4 
 
Codeine (up to 20 mg) is 
mostly safe for drivers 
(trend) 
disagree 44.1 35.3 -8.8 68 
agree (correct) 33.8 50  16.2  
don't know 22.1 14.7 -7.4  
Fexofenadine (normal 
dose) is severely 
impairing driving 
disagree (correct) 64.6 66.2 1.6 68 
agree 10.8 10.3 -0.5  
don't know 24.6 23.5 -1.1  
Amitriptyline at the disagree (correct) 34.3 59.7 25.4 66 
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start of treatment is as 
impairing driving as 
after 4 weeks of 
treatment * 
agree 22.4 28.4 6   
don't know 43.3 11.9 -31.4 
 
Paroxetine (up to 20 
mg/day) is safe for 
drivers 
disagree 26.5 41.8 15.3 67 
agree (correct) 38.2 29.9 -8.30  
don't know 35.3 28.4 -6.9  
Composite Score - 
knowledge medicine 
risks (correct answers 
on 5) * 
0 10.3 10.3 0 67 
1 25  20.6 -4.4  
2 41.2 17.6 -23.6  
3 17.6 27.9 10.3  
4 5.9 20.6 14.7  
5 0 2.9 2.9  
Pharmacists are obliged 
to inform the patients 
about the possible side 
effects of his/her 
medications on driving 
abilities. 
false  23.9 23.5 -0.4 67 
true (correct) 76.1 76.5 0.4 
 
A patient can be 
punished with criminal 
sanctions if he causes a 
traffic accident while 
using a medicine with 
impairing properties 
whereas the health care 
provider has advised 
him not to drive 
false  27.7 15.6 -12.1 61 
true (correct) 72.3 84.40 12.1 
 
Composite Score – 
general knowledge 
(correct answers on 7) 
* 
0 4.4 0 -4.4 66 
1 8.8 4.4 -4.4  
2 13.2 13.2 0  
3 22.1 23.5 1.4  
4 35.3 20.6 -14.7  
5 11.8 23.5 11.7  
6 4.4 11.8 7.4  
7 0 2.9 2.9  
* Wilcoxon Signed Ranks Testp≤.05 
 
ViaNova pharmacists gave significantly more correct answers in the post-questionnaire as 
compared to the pre-questionnaire: with regard to specific medicines’ risk level (t= -2.600; 
p=.011) (Z= -2.511; p=.012) as well as overall, including judicial obligations and 
responsibilities (t= -2.934; p= .005) (Z= -2.763; p= .006). With regard to 
physician/pharmacist obligations and patient responsibilities knowledge the post-
answers were more or less identical to the pre-answers, which were already 
predominantly correct.   
 
Table 65: ViaNova group pre-post  change – Knowledge composite score 
Knowledge Composite Scores (mean sum correct answers) 
  PRE POST 
Change 
(mean) 
CS specific medicinal risks (sum on 5) - Mean (SD)*  1.84 (1.031) 2.37 (1.37) 0.53 
CS overall Knowledge (sum on 7) - Mean (SD)* 3.28 (1.434) 3.93 (1.469) 0.65 
* Paired samples t-test p≤0.05 
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Figure 45: ViaNova group pre-post change – Knowledge Composite Scores (within-group %) 
 
 
 
Figure 46: ViaNova group pre-post change – Composite Score individual medicine risks knowledge 
(median) (within-group %) 
 
 
Figure 47: ViaNova group pre-post change – Composite score: Total knowledge (median) (within-group 
%). 
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3.5 USB group pre-post questionnaire comparison (N12) 
There were two significant positive pre-post changes after the training/intervention 
phase of the USB participants: on one statement regarding reported behaviour (‘I 
discuss medicinal drug consumption and driving related responsibility issues with the 
patient’) and on one of the knowledge questions related to the risk of individual 
medicines (Amitriptyline question). There were no significant positive changes in the 
attitude and awareness questions.  
3.5.1 Attitudes and awareness 
There were no significant changes after the training and intervention phase of the USB 
group participants in the attitude and awareness questions.  
The most pre-post positive effect was measured for the question ‘I feel being well aware of 
the effects of medicines on driving skills’: 25% changed their answer in the positive sense, 
however still 50% still disagreed with this statement, making this the only statement where a 
high number of USB group pharmacists disagreed on. Except for the awareness statement, 
all attitudinal statements were generally positively self-assessed by the clear majority.   
The biggest part of the pharmacists (66% up to 91%) remained at the same level for all 
questions regarding attitudes and awareness. Generally there was little difference in the pre- 
versus post-condition on the level of awareness and attitude (Composite Score: 91.7% no 
change).  
Table 66: USB group pre-post change – attitudes and awareness  
USB group pre-post questionnaire (within-group %) (n=12) 
    
Pre Post Change 
I am willing to take into account 
the effects of medicines on driving 
skills when dispensing medicines 
Strongly disagree 0 0 0 
Disagree 16.7 8.3 -8.4 
Agree 75 91.7 16.7 
Strongly agree 8.3 0 -8.3 
I am willing to sacrifice some 
degree of efficacy by dispensing a 
medicine that is less impairing to 
the driving skills. 
Strongly disagree 0 0 0 
Disagree 0 0 0 
Agree 100 91.7 -8.3 
Strongly agree 0 8.3 8.3 
I feel being well aware of the 
effects of medicines on driving 
skills.  
Strongly disagree 0 0 0 
Disagree 66.7 50 -16.7 
Agree 33.3 50 16.7 
Strongly agree 0 0 0 
It is important for me to be well-
informed on medicinal effects on 
driving behaviour. 
Strongly disagree 0 0 0 
Disagree 8.3 0 -8.3 
Agree 50 50 0 
Strongly agree 41.7 50 8.3 
I feel that the information I provide 
to patients will influence their 
driving behaviour. 
Strongly disagree 0 0 0 
Disagree 25 16.7 -8.3 
Agree 66.7 75 8.3 
Strongly agree 8.3 8.3 0 
Composite Score attitudes & 
awareness (median) 
Strongly disagree (1) 0 0 0 
Disagree (2) 8.3 0 -8.3 
Agree (3) 91.7 100 8.3 
Strongly agree (4)  0 0 0 
 
With regard to the question whether specific traffic participation relevant characteristics of 
patients would make a difference in considering effects of medicines on driving skills, no 
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significant changes compared to the baseline measurement were found. The rather negative 
pre-post changes in the within-group frequency (%) the table below should not be interpreted 
as less concern for specific driver-patient characteristics, but rather should be seen against 
the scope of the general question whether they would be willing to take medicinal effects on 
driving into account when dispensing, which increased (from 75%) up to 91.3% of the total 
USB group agreeing with this (so regardless of the type of patient).  
Table 67: USB group pre-post change – Detail attitudes & awareness: Take into account possible 
effects of medicines on driving skills depending on the type of driver (within-group %) 
USB group pre-post questionnaire (within-group %) (n=12) 
I am willing to take into account the effects of medicines 
on driving skills when dispensing medicines: (YES) Pre Post Change  
professional driver 91.7 91.7 0 
driving frequently 91.7 75 -16.7 
driving long distances 91.7 90.9 -0.8 
inexperienced driver 66.7 58.3 -8.4 
experienced'driver 33.3 36.4 3.1 
elderly driver 75 66.7 -8.3 
using other CNS active drugs 100 83.3 -16.7 
 
3.5.2 Reported behaviour 
One significant positive change after the training and the intervention phase of the USB 
group participants was found within the reported behaviour questions: 50% of the 
pharmacists changed their answer in a positive sense on the question whether they discuss 
medicinal drug consumption and driving related responsibility issues with the patient 
(Z= -2.333; p=.02). This is now stated to be done at least sometimes (50%) to regularly 
(25%), while at pre-level this was 50-50% seldom-sometimes.  
Table 68: USB pre-post change – Reported behaviour 
USB group pre-post questionnaire (within-group %) (n=12) 
  
Within-
group 
% Never Seldom Sometimes Regularly Always 
I ask a patient about his/her 
driving exposure when 
dispensing a medicine. 
Pre 16.7 33.3 33.3 16.7 0 
Post 0 25 50 25 0 
Change -16.7 -8.3 16.7 8.3 0 
I inform a patient about driving 
related risks when dispensing 
a medicine.  
Pre 0 8.3 33.3 58.3 0 
Post 0 16.7 8.3 75 0 
Change 0 8.4 -25 16.7 0 
I provide a patient with written 
information materials when 
dispensing a driving impairing 
medicine.  
Pre 33.3 50 16.7 0 0 
Post 33.3 41.7 16.7 8.3 0 
Change 0 -8.3 0 8.3 0 
I keep systematic records 
when I dispense a driving 
impairing medicine.  
Pre 50 25 25 0 0 
Post 58.3 33.3 8.3 0 0 
Change 8.3 8.3 -16.7 0 0 
I keep systematic records 
when I advise a patient when 
and how he/she can consider 
driving a car when using a 
driving impairing medicine.  
Pre 41.7 50 8.3 0 0 
Post 41.7 41.7 16.7 0 0 
Change 0 -8.3 8.4 0 0 
I keep a record of the patient's 
traffic participation (e.g. how 
often he/she drives to work).  
Pre 83.3 8.3 8.3 0 0 
Post 83.3 16.7 0 0 0 
Change 0 8.4 -8.3 0 0 
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I discuss medicinal drug 
consumption and driving 
related responsibility issues 
with the patient. * 
Pre 0 50 50 0 0 
Post 0 16.7 58.3 25 0 
Change 0 -33.3 8.3 25 0 
How frequently do you usually 
provide detailed information 
when dispensing a medicine 
with impairing effects on 
driving performance?  
Pre 0 16.7 58.3 25 0 
Post 0 25 50 25 0 
Change 0 8.3 -8.3 0 0 
Composite Score Reported 
behaviour (median)  
Pre 8.3 41.6 50 0 0 
Post 0 33.4 50 16.7 0 
Change -8.3 -8.2 0 16.7 0 
* Wilcoxon Signed Ranks Test p≤.05 
 
 
Figure 48: USB group pre-post change – “I discuss medicinal drug consumption and driving related 
responsibility issues with the patient” (within-group %) 
Looking at the overall composite score the frequencies indicate a clear pre-post increase of 
pharmacists in the USB group towards more regularly (wanted) reported behaviour; 
nevertheless the biggest portion remained at the ‘sometimes’ level, followed by 
‘seldom’ answer categories.  
Clearly more often reported (from ‘seldom’ to ‘regularly’) behaviour statements were related to 
asking a patient about his/her driving exposure, informing a patient about driving related risks, 
discussing driving related responsibility issues, and frequency of providing detailed 
information. Rather seldom to never were the reports on providing written information 
materials and the (systematic) record keeping. 
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Figure 49: USB group pre-post change – Composite score Reported behaviour (median) (within group 
%) 
3.5.3 Knowledge  
One significant positive change (more correct answers) was found on the knowledge 
questions related to risk of individual medicines: Amitriptyline (Z=-2.00; p=.046). On this 
question there were fewer ‘don’t know’ answers (-25%) and an increase of 33% answering 
correctly. Almost 60% (compared to 25%) answered correctly in the post-questionnaire.  
Just on a descriptive level, some negative pre-post changes (less correct answers) were 
found: on the Diazepam and Paroxetine risk questions. Although this is not a significant 
change anyway, a possible explanation could be that the pharmacists were more aware about 
potential risks of medicines on driving after the training and intervention period, and thus more 
careful in their estimation of potential risk of medicines on the driving abilities. However, one 
of the most frequently searched for substance in the provided USB tool was Diazepam (see 
part on log file data), so more correct answers for this substance was expected though. 
There was also another unexpected trend pre-post change for the question with regard to the 
health care obligations to inform patients on medicinal driving risks (Z=-1.732; p=.083): about 
25% of the USB group participants gave more wrong answers after the intervention. On the 
other hand, an extra 16% of the pharmacist gave a correct answer regarding patient 
responsibilities after the intervention period.  
Table 69: USB group pre-post change – Knowledge 
    Pharmacist groups (within-group %)   
Pre Post Change  
N  
Diazepam 
(regardless dose) is 
severely impairing 
within the first 2 
months of treatment  
disagree 41.7 33.3 -8.4 12 
agree (correct) 33.3 16.7 -16.6  
don't know 25  50 25 
 
Codeine (up to 20 
mg) is mostly safe 
for drivers 
disagree 50  50  0 12 
agree (correct) 25  33.3 8  
don't know 25  16.7 -8.3  
Fexofenadine 
(normal dose) is 
severely impairing 
driving 
disagree (correct) 60  72.7 12.7 9 
agree 0 0 0  
don't know 40  27.3 -12.7  
Amitriptyline at 
the start of 
disagree (correct) 25  58.3 33.3 12 
agree 33.3 25 -8.3  
Never Seldom Sometimes Regular Always
Within PRE-group % 8,3 41,6 50 0 0
Within POST-group % 16,7 16,7 33,3 16,7 16,7
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treatment is as 
impairing driving 
as after 4 weeks of 
treatment * don't know 41.7 16.7 -25 
 
Paroxetine (up to 20 
mg/day) is safe for 
drivers 
disagree 16.7 41.7 25 12 
agree (correct) 50  25  -25  
don't know 33.3 33.3 0  
Composite Score 
Knowledge 
individual medicine 
risks (sum correct 
answers on 5) 
0 8.3 0 -8.3 12 
1 33.3 33.3 0  
2 33.3 33.3 0  
3 16.7 33.3 16.6  
4 8.3 0 -8.3  
5 0 0 0  
Pharmacists are 
obliged to inform 
the patients about 
the possible side-
effects of his/her 
medications on 
driving abilities. 
(trend P=.083) 
false  8.3 33.3 25 12 
true (correct) 91.7 66.7 -25 
 
A patient can be 
punished with 
criminal sanctions if 
he causes a traffic 
accident while using 
a medicine with 
impairing properties 
whereas the health 
care provider has 
advised him not to 
drive 
false  25  8.3 -16.7 12 
true (correct) 75  91.7 16.7 
 
Composite Score 
Knowledge (total 
sum correct 
answers on 7) 
0 0 0 0 12 
1 8.3 0 -8.3  
2 16.7 16.7 0  
3 16.7 33.3 16.6  
4 41.7 25 -16.7  
5 8.3 25.0 16.7  
6 8.3 0 -8.3  
7 0 0 0  
* Wilcoxon Signed Ranks Test p≤.05 
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Figure 50: USB group pre-post change – “Amitriptyline at the start of treatment is as impairing driving 
as after 4 weeks of treatment” (within-group %) 
 
Looking at the composite score on the knowledge questions related to risk of individual 
medicines, 66.6% of the pharmacists did not answer half of the questions correctly (score 1 or 
2 on 5); 99.9% scored maximum 3 on 5. The overall composite score (sum on 7) shows that 
only 50% of the participants gave a correct answer on at least 4 of the 7 questions. 
 
Figure 51: USB group pre-post change – Composite score on individual medicine risks knowledge 
(median) (within-group %) 
 
3.6 Control group pre-post questionnaire comparison (N 20) 
There were no significant pre-post changes on the awareness and attitudes, reported 
behaviour or knowledge questions for the pharmacists in the control group.  
3.6.1 Attitudes and awareness 
There were no significant changes on the awareness and attitudes questions for the 
pharmacists in the control group. The largest part of the pharmacists (65% up to 90%) 
remained at the same agreement level as in the pre-questionnaire, which is conform the 
expected results for the control group. Looking at the frequencies, the participants especially 
kept feeling less aware of the effects of medicines on driving skills; furthermore, still about a 
third answered less positively with regard to willingness to take into account the effects of 
medicines on driving skills or scarifying some degree of efficacy by dispensing a medicine 
that is less impairing. 
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Table 70: Control group pre-post change - Attitudes and awareness 
Control group pre-post questionnaire (within-group %)  
    
Pre Post Change N  
I am willing to take into account the 
effects of medicines on driving 
skills when dispensing medicines 
Strongly disagree 0 0 0 20 
Disagree 20 30 10  
Agree 80 65 -15  
Strongly agree 0 5 5  
I am willing to sacrifice some 
degree of efficacy by dispensing a 
medicine that is less impairing to 
the driving skills. 
Strongly disagree 0 5 5 20 
Disagree 25 25 0  
Agree 70 60 -10  
Strongly agree 5 10 5  
I feel being well aware of the 
effects of medicines on driving 
skills.  
Strongly disagree 0 0 0 20 
Disagree 55 65 10  
Agree 45 35 -10  
Strongly agree 0 0 0  
It is important for me to be well-
informed on medicinal effects on 
driving behaviour. 
Strongly disagree 0 0 0 19 
Disagree 0 0 0  
Agree 57.9 60 2.1  
Strongly agree 42.1 40 -2.1  
I feel that the information I provide 
to patients will influence their 
driving behaviour. 
Strongly disagree 0 0 0 20 
Disagree 20 15 -5  
Agree 70 85 15  
Strongly agree 10 0 -10  
Composite Score attitudes & 
awareness (median) 
Strongly disagree (1) 0 0 0 20 
Disagree (2) 5 15 10  
Agree (3) 90 85 -5  
Strongly agree (4)  5 0 -5  
* Wilcoxon Signed Ranks Test p≤.05 
With regard to the questions about the characteristics of the patient a small increase in 
willingness to take medicinal driving risks into account was observed in case of a patient 
being a professional driver, driving frequently or driving long distances (see table below). The 
vast majority of the pharmacists stayed at the same agreement level regarding all types of 
patient-drivers (generally at a high to very high willingness level, except for experienced 
drivers, only 44.4%). 
Table 71: Control group pre-post change – Detail attitudes & awareness: Take into account possible 
effects of medicines on driving skills depending on the type of driver (within-group %) 
Control group pre-post questionnaire (within-group %) (n=20) 
I am willing to take into account the effects of medicines 
on driving skills when dispensing medicines: (YES) Pre Post Change  
professional driver 95 100 5 
driving frequently 95 100 5 
driving long distances 90 95 5 
inexperienced driver 75 63.2 -11.8 
experienced'driver 45 44.4 -0.6 
elderly driver 80 72.2 -7.8 
using other CNS active drugs 90 89.50 -0.5 
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Looking at the composite score on attitudes and awareness, it is clear that no big pre-post 
changes in answers of the participants in the control group was measured (see figure below). 
 
3.6.2 Reported behaviour 
There were no significant changes of the reported behaviour of the pharmacists in the 
control group.  For the question ‘I inform a patient about driving related risks when 
dispensing a medicine’ a positive pre-post trend was observed though (Wilcoxon Z=-
1.941; p=.052). 40% of the pharmacists (8 of the 20 participants) changed their answer in the 
positive sense. In total, 20% of the pharmacists additionally answered to inform patients 
regularly or always (up to 60% in total now) about driving related risks when dispensing 
medicines compared to the pre-questionnaire (see Table 71). The positive change in answers 
could be (partially) explained by the fact that the pharmacists in the control group were 
inclined to give ‘social acceptable answers’ or gained some awareness for this topic by just 
being included in the study. 
 
Table 72: Control group pre-post change – Reported behaviour 
Control group pre-post questionnaire (within-group %) (n=20) 
  
Within-
group 
% Never Seldom Sometimes Regular Always 
I ask a patient about his/her 
driving exposure when 
dispensing a medicine.  
Pre 10 35 25 30 0 
Post 10 25 40 20 5 
Change 0 -10 15 -10 5 
I inform a patient about driving 
related risks when dispensing a 
medicine. (trend p=.052) 
Pre 0 15 45 35 5 
Post 0 10 30 45 15 
Change 0 -5 -15 10 10 
I provide a patient with written 
information materials when 
dispensing a driving impairing 
medicine.  
Pre 60 20 15 5 0 
Post 40 35 20 5 0 
Change -20 15 5 0 0 
I keep systematic records when 
I dispense a driving impairing 
medicine.  
Pre 70 20 5 0 5 
Post 75 15 0 5 5 
Change 5 -5 -5 5 0 
I keep systematic records when 
I advise a patient when and how 
he/she can consider driving a 
car when using a driving 
impairing medicine.  
Pre 65 20 10 0 5 
Post 55 35 0 10 0 
Change -10 15 -10 10 -5 
I keep a record of the patient's 
traffic participation (e.g. how 
often he/she drives to work).  
Pre 65 30 5 0 0 
Post 75 20 5 0 0 
Change -10 10 0 0 0 
I discuss medicinal drug 
consumption and driving related 
responsibility issues with the 
patient.  
Pre 10 45 25 20 0 
Post 5 40 15 40 0 
Change -5 -5 -10 20 0 
How frequently do you usually 
provide detailed information 
when dispensing a medicine 
with impairing effects on driving 
performance?  
Pre 10 35 30 15 10 
Post 0 35 30 25 10 
Change -10 0 0 10 0 
Composite Score Reported Pre 20 45 25 10 0 
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behaviour (median)  Post 15 50 25 10 0 
Change -5 5 0 0 0 
* Wilcoxon Signed Ranks Test p≤.05 
 
 
Figure 52: Control group pre-post change –“ I inform a patient about driving related risks when 
dispensing a medicine” (trend) 
Considering the composite score an almost equal number of pharmacists changed their 
answer in a positive or negative sense or did not change their answer (about 30). 
3.6.3  Knowledge 
Also for the knowledge questions no significant changes were observed.  
On the questions regarding Diazepam and Paroxetine additionally 25% of the pharmacists in 
the control group answered correctly compared to the pre-questionnaire. For the Diazepam 
question even a positive pre-post trend was measured (Z=-1.890; p=.059). Overall the 
number of incorrect or don’t know questions are quite high. With regard to the questions 
on physician/pharmacists obligations and patient responsibilities, no big change was noticed.  
Table 73: Control group pre-post change – Knowledge questions 
    Pharmacist groups (within-group %) (n=19) 
Pre Post Change 
Diazepam 
(regardless of dose) 
is severely impairing 
within the first 2 
months of treatment  
(trend p=.059) 
disagree 65  38.9 -26.1 
agree (correct) 10  38.9 28.9 
don't know 25  22.2 -2.8 
Codeine (up to 20 
mg) is mostly safe 
for drivers 
disagree 35  36.8 1.8 
agree (correct) 60  52.6 -7.4 
don't know 5  10.5 5.5 
Fexofenadine 
(normal dose) is 
severely impairing 
driving 
disagree (correct) 60  68.4 8.4 
agree 10  5.3 -4.7 
don't know 30  26.3 -3.7 
Amitriptyline at the 
start of treatment is 
as impairing driving 
as after 4 weeks of 
treatment  
disagree (correct) 35  47.4 12.4 
agree 25  21.1 -3.9 
don't know 40  31.6 -8.4 
Paroxetine (up to 20 
mg/day) is safe for 
disagree 20  21.1 1.1 
agree (correct) 45  68.4 23.4 
Seldom Sometimes Regular Always
Within PRE-group  15 45 35 5
Within POST-group 10 30 45 15
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drivers don't know 35  10.5 -24.5 
Composite Score 
Knowledge 
individual medicine 
risks (sum correct 
answers on 5) 
0 5  10.5 5.5 
1 15  10.5 -4.5 
2 50  15.8 -34.2 
3 25  31.6 6.6 
4 5  21.1 16.1 
5 0 10.5 10.5 
Pharmacists are 
obliged to inform the 
patients about the 
possible side effects 
of his/her 
medications on 
driving abilities. 
false  10  10.5 0.5 
true (correct) 90  89.5 -0.5 
A patient can be 
punished with 
criminal sanctions if 
he causes a traffic 
accident while using 
a medicine with 
impairing properties 
whereas the health 
care provider has 
advised him not to 
drive 
false  25  21.1 -3.9 
true (correct) 75  78.9 3.9 
Composite Score 
Knowledge (total 
sum correct answers 
on 7) 
0 0 0 0 
1 0 0 0 
2 10  15.8 5.8 
3 25  15.8 -9.2 
4 45  10.5 -34.5 
5 20  31.6 11.6 
6 0 21.1 21.1 
7 0 5.3 5.3 
* Wilcoxon Signed Ranks Test p≤.05 
 
 
3.7 ViaNova software extraction and user acceptance  
Like explained above the information on medicines and driving was integrated in ViaNova. 
When an impairing substance is dispensed, ViaNova gave a warning sign in the form of a 
First dispensing Control signal (EUC) when the pharmacists wanted to deliver a medicine 
category 3 (not exclusively; sometimes category 2) or when a safer alternative existed. When 
going further in dispensing the impairing substance a first and second delivery 
accompaniment signal appeared. The first delivery accompaniment signal (EUB signal) 
included the information (concerning driving and medicines) to be told to the patient at a first 
delivery. The second delivery accompaniment signal (TUB signal) included the information 
and possible questions for conversation with the patient at a second delivery. Besides that, 
the pharmacists had the possibility to print out written information on the medicine for the 
patient (GIT). Finally a pictogram was integrated in the pop-up of the GIT in ViaNova. 
3.7.1 EUB Signals 
When the EUB signal appeared the pharmacist had several options to go further in 
dispensing a medicine: ‘continue’ (the signal will appear again later on); ‘wrong’ EUB signal, 
‘GIT’ information for the patient’, ‘discussed’, ‘side-effects discussed’, ‘not discussed’ or 
‘cancellation’ of delivery. In table 26 the registered EUB signals and the opted clicks are 
divided by medicinal risk category.  
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In general, in about 89% of the popped-up EUB signals the option ‘side-effects 
discussed’ was clicked, and this for all risk categories of medicines (1 to 3). There were 
no clear differences in click options used as a basis of the medicinal risk categories, except 
for a small effect regarding the provision of the GIT (patient information leaflet): a GIT was 
less given in case of risk category 1 (0.3%), as compared to risk category 2 (3.9%) or 3 
(3.5%); and also a small effect regarding cancellation of the (medicine) delivery: more often 
for risk category 1 (1.2%). 
Table 74: ViaNova group - EUB signals divided by risk category 
EUB signals divided by risk category  
 
Risk category 
1 
11.223 (12.8%) 
Risk 
category 2 
40.644 
(46.5%) 
Risk category 3 
35.522 (40.6%) 
Total 
87.389 (100%) 
Continue 858 (7.6%) 3,135 (7.7%) 2,713 (7.5%) 6,706 (7.6%) 
GIT for patient 398 (0.3%) 1,589 (3.9%) 1,240 (3.5%) 3,227 (3.6%) 
Wrong EUB signal 0 0 0 0 
EUB discussed 9,883 (88.1%) 
35,655 
(87.7%) 31,278 (88.1%) 76,816 (87.9%) 
EUB/side-effects 
discussed 10,007 (89.3%) 
36,327 
(89.4%) 31,699 (89.2%) 78,033 (89.2%) 
EUB not 
discussed 0 0 0 0 
Cancel delivery 143 (1.2%) 310 (0.8%) 295 (0.8%) 747 (0.8%) 
60.5% of the EUB pop-ups considered 6 ATC categories: N02 Analgesics cat3 (17.9%), 
N05C Hypnotics and sedatives cat3 (11.2%), N05B Anxiolytics cat3 (10.5%), N02 Analgesics 
cat2 (7.3%), R05 Cough and cold preparations cat2 (6.9%), and N06A Antidepressants cat1 
(6.8%).   
Looking at the proportions of ‘discussed’ clicks as a basis of the ATC type, there were no 
clear differences for the relevant N02-N07, R01, R05-06 and S categories: on average in 90% 
(SD 3.3) of the cases (EUB pop-up), the pharmacists clicked the ‘discussed’ option (either 
specifically side-effects or in general), with a min/max of 85.8/100%.     
3.7.2 TUB 
In general, in about 99% of the popped-up TUB signals the option ‘discussed’ was 
clicked, and this counted for the three risk categories of medicines (1 to 3). There were 
no clear differences in the distribution of the different click options as a basis of the medicinal 
risk categories. The only options that were clicked after a TUB signal were either ‘discussed 
(in general or specifically side-effects)’ and ‘GIT’.    
Table 75: ViaNova group - TUB signals divided by risk category 
TUB signals divided by risk category 
 
Risk 
category 1 
4747 (12.8%) 
Risk 
category 2 
14293 
(38.6%) 
Risk category 
3 
17610 (47.6%) 
Risk 
category 2/3  
351 (0.9%)  
Total 
37001 
(100%) 
Continue 0 0 0 0 0 
GIT for 
patient 93 (1.6%) 272 (1.9%) 307 (1.7%) 6 (1.7%) 678 (1.8%) 
Wrong 
TUB 
signal 0 0 0 0 0 
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TUB 
discussed 4721 (99.5%) 
14071 
(98.4%) 17399 (98.8%) 345 (98.3%) 
36536 
(98.7%) 
TUB/side-
effects 
discussed 997 (21.0%) 2751 (19.2%) 3311 (18.8%) 74 (21.1%) 
7133 
(19.3%) 
TUB not 
discussed 0 0 0 0 0 
Cancel 
delivery 0 0 0 0 0 
 
3.7.3 EUC 
The majority of the EUC signals were for medicines of risk category 3, which was expected. 
About 96% of the EUC signals (risk category 2 or 3) where discussed with the patient. 
A small minority cancelled the delivery (about 0.5%). No big differences were noticed in the 
way the EUC signal was handled between risk category 2 and risk category 3 medicines. 
Table 76: ViaNova group - EUC signals divided by risk category 
EUC signals divided by risk category 
 
Risk category 2 
25602 (38.2%) 
Risk category 3 
41447 (61.8%) 
Total 
67049 (100%) 
Continue 762 (3%) 1475 (3.6%) 2237 (3.3%) 
EUC discussed 24703 (96.5%) 39688 (95.8%) 64391 (96%) 
Cancel delivery 137 (0.5%) 284 (0.7%) 421 (0.6%) 
 
3.7.4 ViaNova group: user-acceptance 
 
Table 77: ViaNova group post-questionnaire – User acceptance 
  ViaNova group (within-group %)  
(n=68) 
  Guidelines Fact 
sheet 
Pictogram 
Did you use … in order to 
support your communication 
to patients? 
Yes 95.60 10.30 22.10 
No 4.40 88.20 76.50 
If you answered ‘Yes’, how 
often did you use the …? 
Always 15.70 0 14.30 
Regularly 69.20 28.60 50  
Sometimes 12.30 57.10 28.60 
Seldom 3.10 14.30 0 
Never 0 0 7.10 
The … for dispensing 
medicines that may affect 
driving performance were: 
helpful 
Yes, very 
much 
66.20 2.90 16.20 
Quite a lot 26.50 19.10 14.70 
Not so much 1.50 10.30 5.90 
No way 0 0 1.50 
Unknown 5.90 67.60 61.80 
The … for dispensing 
medicines that may affect 
driving performance were: 
Yes, very 
much 
48.50 4.40 16.20 
Quite a lot 41.20 14.70 17.60 
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useful Not so much 5.90 16.20 4.40 
No way 0 0 1.50 
Unknown 4.40 64.70 60.30 
The …  for dispensing 
medicines that may affect 
driving performance were: 
sufficient 
Yes, very 
much 
44.10 5.90 13.20 
Quite a lot 41.2 14.70 19.10 
Not so much 1.50 11.80 4.40 
No way 0 0 1.50 
Unknown 13.20 67.70 61.80 
 
95% of the ViaNova pharmacists indicate to have used the guidelines in their 
communication to the patients, of which 84% at least regularly. Those pharmacists who did 
not use the guidelines mentioned that they did not always find the time to use them in their 
communication to the patient. About 98% of the ViaNova participants found the 
dispensing guidelines helpful and also the clear majority (>80%) found them useful and 
sufficient.  
The fact sheets and pictogram were used much less. Only 10% of the participants 
indicated to have used the fact sheets. The pictogram was used a little bit more often (22%). 
Of the ones that have used the pictogram, almost 65% indicated to have done so at least 
regularly. The pictogram system was also rated higher (‘yes very much’) than the fact sheets 
on helpfulness (16.2%), usefulness (16.2%) and sufficiency (13.2%). 
 
Table 78: ViaNova group post-questionnaire: Guidelines 
  
ViaNova group (within-group %) 
(n=68)  
Do you think that the 
guidelines have changed 
your manner/way to dispense 
medication? 
Yes, very much 5.90 
Quite a lot 47.10 
Neutral 32.40 
Not so much 8.80 
No way 1.50 
Unknown 4.40 
Do you think that the 
guidelines have changed 
your manner/way to inform 
the patient? 
Yes, very much 14.70 
Quite a lot 45.60 
Neutral 26.50 
Not so much 8.80 
No way 0 
Unknown 4.40 
 
More than half of the ViaNova pharmacists stated that the guidelines have changed the 
manner they dispensed medication. 60% of the participants think that the provided 
guidelines changed quite a lot up to very much their way to inform a patient. 
Table 79: ViaNova group post-questionnaire: ViaNova software User friendliness 
  
ViaNova group 
(within-group %) 
(n=68) 
I was able to find the information I asked for 
with no difficulty. 
Strongly disagree 0 
Disagree 0 
Agree 67.7 
Strongly agree 21.5 
Unknown 10.8 
I thought the tool was cumbersome. Strongly disagree 27.2 
Disagree 58.5 
Agree 1.5 
Strongly agree 0 
Unknown 12.3 
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This tool would fit well in my working routines. Strongly disagree 0 
Disagree 0 
Agree 61.5 
Strongly agree 26.2 
Unknown 12.3 
Text and icons are easy to perceive. Strongly disagree 0 
Disagree 0 
Agree 68.8 
Strongly agree 18.8 
Unknown 12.5 
Do you think that the tool should have 
additional options on the screen or are there 
any controls that are currently missing? 
Yes 7.7 
No 80 
Unknown 12.3 
Would you be willing to use this tool in the 
future 
Yes 80 
No 1.5 
Maybe 1.5 
Unknown 16.9 
About 90% of the pharmacists (strongly) agreed that they could find the information 
without difficulties, that the tool would fit well in their working routines (87.7%) and 
that the texts and icons were easy to perceive (87.6%).  Five of the 68 pharmacists 
mentioned that the tool should have additional options like more thorough information on side-
effects or less vague advice. 80% of the ViaNova pharmacists want to use the tool in the 
future. 
 
3.8 USB - log files and user acceptance 
 
3.8.1 USB- Log files 
Only limited data could be extracted from the USB tool. Only ‘date’ and ‘hour’ on which the 
pharmacists searched for a medicine (used the tool) and what the pharmacists typed in (the 
brand name or the generic name of the medicine, ATC code, partial brand or generic 
names...) were recorded and consequently extracted by the pharmacists in the format of a log 
file. The research team further completed the data by including a specific ATC code (e.g. 
N05BA01), a grouped ATC code (e.g. N05B-cat3), a category (1-3) and an ATC name (e.g. 
Anxiolytics-cat3). 
The pharmacists that used the USB tool (N=12) made in total 527 searches (clicks) in the 
USB program between the time period 10th of September 2010 and 3th of March 2011 (a bit 
less than 6 months). The distribution of the amount/proportion of searches was not equally 
divided between the 12 pharmacists: only two pharmacists were responsible for about 
40% of the clicks (see table 32). Taken all data together, only 1 click/search was made every 
four days (527 clicks on 180 days * N12). 
The five medicines most frequently searched for were all of risk category 3: 
Tetrazepam (8%), Diazepam (6.2%), Lorazepam (6.2%), Alprazolam (5.1%) and Zolpidem 
(4.4%). 
A risk category could be linked to 400 ‘clicks’. No category could be linked if:  
- the medicine searched for was not in the database (only N-medicines were integrated 
into the USB tool) (102 searches) 
- the medicine was not available in Belgium (11 searches) 
- invalid entry in tool (e.g. pharmacists typed ‘test’) (7 searches) 
- the letters entered in the tool were too short to identify a medicine (3 searches) 
- if the pharmacist only searched on a grouped ATC code (2 searches) 
- a typing error occurred (1 searches) 
- entry of brand name with different ATC codes (1 searches) 
 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 212 of 456 
Several pharmacists made typing errors when searching and using the USB tool (4.4%). The 
research team tried to link a category if possible (only for 1 case of the 23 no category could 
be matched to the medicine that was searched for). About 70% of the pharmacists’ 
searches concerned a category 3 medicine. Sixty of the clicks of the 527 searches were 
made for an anxiolytics or aHypnotic/sedative. 
Table 80: USB group - Description data log files (within-group %) (n=400) 
Distribution by ‘clicks’  Distribution by risk category  
 Pharmacist 1 19.0  Category 1 9.8 
 Pharmacist 2 9.9  Category 2 17.0 
 Pharmacist 3 5.1  Category 3 73.2 
 Pharmacist 4 3.6 Distribution by ATC group 
 Pharmacist 5 3.0  N02 – Anesthetics 2.3 
 Pharmacist 6 11.2  N03 – Anti-epileptics 2.3 
 Pharmacist 7 8.6  N05A – Antipsychotics 4.8 
 Pharmacist 8 4.4  N05B – Anxiolytics 41.4 
 Pharmacist 9 22.0  N05C – Hypnotics 
&sedatives  
21.2 
 Pharmacist 10 9.0  N06A – Antidepressants  26.0 
 Pharmacist 11 3.8  N06B – Psychostimulants  1.0 
 Pharmacist 12 0.8  N06C – Psycholeptics/ 
psychanaleptics in 
combination 
0.3 
   N07B – Drugs used in 
addictive disorders 
0.8 
 
Figure 53: USB tool search distribution by medicinal risk category 
 
3.8.2 USB group: user acceptance 
 
Table 81: USB  group post-questionnaire – User acceptance 
  USB group (within-group %) 
(n=12) 
  Guidelines Fact 
sheet 
Pictogram 
Did you use … in order to 
support your communication 
to patients? 
Yes 91.7 33.3 41.7 
No 8.3 66.7 58.3 
If you answered ‘Yes’, how Always 8.3 40  20 
10%
17%
73%
category 1
category 2
category 3
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often did you use the …? Regularly 16.7 20  20 
Sometimes 25  0 40  
Seldom 50  40  20  
Never 0 0 0  
The … for dispensing 
medicines that may affect 
driving performance were: 
helpful 
Yes, very 
much 
50  33.3 50  
Quite a lot 41.7 33.3 16.7 
Not so 
much 
8.3 16.7 16.7 
No way 0 0 0 
Unknown 0 16.7 16.7 
The … for dispensing 
medicines that may affect 
driving performance were: 
useful 
Yes, very 
much 
33.3 25  41.7 
Quite a lot 50  16.7 25  
Not so 
much 
16.7 33.3 8.3 
No way 0 0 0 
Unknown 0 25  25  
The …  for dispensing 
medicines that may affect 
driving performance were: 
sufficient 
Yes, very 
much 
41.7 25  33.3 
Quite a lot 33.3 25  16.7 
Not so 
much 
16.7 25  25  
No way 8.3 0 0 
Unknown 0 25  25  
91% of the pharmacists in the USB group stated to have used the guidelines (but rather 
seldom). The pharmacists who mentioned not to have used them gave as reason the fact 
that the tool is: ‘too time consuming, not easy to use and contained too vague information’. 
They stated that they would have used the tool more often if it would have been 
integrated in their daily used software. The provided guidelines are considered helpful, 
useful and sufficient by a clear majority; the fact sheets were considered helpful but less 
useful and sufficient; while the pictogram was considered helpful and useful (>50%) but 
slightly less sufficient.  
Table 82: USB group post-questionnaire: Guidelines 
  
USB group 
(within-group %) 
(n=12) 
Do you think that the guidelines have changed 
your manner/way to dispense medication? 
Yes, very much 
Quite a lot 
Neutral 
Not so much 
No way 
16.7 
33.3 
33.3 
16.7 
0 
Do you think that the guidelines have changed 
your manner/way to inform the patient? 
Yes, very much 
Quite a lot 
Neutral 
Not so much 
No way 
8.3 
66.7 
8.3 
16.7 
0 
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Half of the pharmacists indicate that the guidelines have changed their manner of dispensing 
medication (other half is neutral or negative). More than 70% thinks that the guidelines 
have changed their way of informing the patient. 
Table 83: USB group post-questionnaire: USB tool User friendliness 
USB tool User friendliness USB group (within-group %) 
(n=12) 
I was able to find the information I asked for with 
no difficulty. 
Strongly disagree 
Disagree 
Agree 
Strongly agree 
8.3 
16.7 
58.3 
16.7 
I thought the USB stick was cumbersome. Strongly disagree 
Disagree 
Agree 
Strongly agree 
16.7 
25.0 
33.3 
25.0 
This USB-stick would fit well in my working 
routines. 
Strongly disagree 
Disagree 
Agree 
Strongly agree 
25.0 
25.0 
41.7 
8.3 
Text and icons are easy to perceive. Strongly disagree 
Disagree 
Agree 
Strongly agree 
0.0 
8.3 
83.3 
8.3 
Do you think that the USB- stick should have 
additional options on the screen or are there any 
controls that are currently missing? 
Yes 
No 
16.7 
83.3 
Would you be willing to use this USB stick in the 
future 
Yes 
No 
Maybe 
Unknown 
50.0 
25.0 
8.3 
16.7 
The feelings of user-friendliness of the USB tool are rather mixed. The USB group was 
only clear on the fact that text and icons are easy to perceive (>90%) and to a lesser extent 
that the information was easily found (74%). On the other hand, the proportions were rather 
mixed (50-50%) on the statements that the tool is cumbersome or would fit well in the working 
routines, as well as on the question if they would use the tool in the future.  
The main reason for doubts about the tool fitting well in their daily routine was that it could not 
be integrated into their pharmacy software. Only one pharmacist found the text and icons not 
easy to perceive. Two pharmacists stated that there should be two additional options to the 
USB tool: the possibility to search on brand names and the possibility to integrate the 
tool into the daily used software. Four of the 12 pharmacists were explicitly not willing to 
use the USB tool in the future because there was no integration into their software and using 
the tool took too much time. On the question in which circumstances they would use the USB 
tool pharmacists answered that they would focus on first prescriptions. 
3.8.3 Control group – User acceptance 
Seventy percent of the participants in the control group still mentioned in the post-
questionnaire to be willing to use a support tool in dispensing potentially risky medicines for 
driving (no change compared to pre-questionnaire). A small increase in ‘maybe’ (from ‘no’) 
answers was found. 
Table 84: Control group pre-post change - User acceptance (Within-group %) 
    Control group (within-group %) (n=20) 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 215 of 456 
Pre Post Change  
If we propose to you a tool (e.g. 
website, cd-rom) that allows you 
to find information on medicinal 
drugs and driving, will you be 
willing to use it for dispensing 
medicines? 
 
 
no 5  0 -5  
yes 70  70  0 
Maybe 25  30  5  
There were no big changes regarding the type of support tool they preferred.  
4 Discussion 
 
4.1 Main study results  
Personal and practice related sample characteristics. From the analyses regarding 
sample characteristics it became clear that except for the number of inhabitants in the 
practice area (a measure of more rural versus more urban practice area) the three groups 
(ViaNova, USB and Control group) did not differ significantly regarding personal or practice 
related background variables. Furthermore there were no significant differences between 
participants and drop-outs in the USB and Control group with regard to personal/practice 
related background variables and ICT familiarity. The ViaNova dropped-out group seemed 
to be relatively more often younger (below 30), with less practicing years and more 
often working in a rural setting.  
Pre-questionnaire. The three groups were quite similar with regard to pre-level ICT 
familiarity, attitudes, awareness, reported behaviour and knowledge. Some differences 
were found though with regard to ICT familiarity (1) and reported behaviour (2). A small 
difference related to familiarity with software to find medicinal risk information (less in the 
Control group). More differences were found though with regard to pre-level reported 
behaviour: the USB and Control group provided at base level already less often written 
information to patients compared to the ViaNova group, and ViaNova participants less often 
kept record of patients’ traffic participation than Control group respondents.  It can be stated 
that the participants in the present study (in all groups) had a high general ICT familiarity 
and indicated a high access to information (on the potential effect of medicines on driving). 
Despite the high access to information the participants did report a lack and need for 
information, and there seemed to be a low knowledge on medicinal driving risk 
specifics. The pharmacists had positive attitudes towards the importance of being well 
informed on the topic medicinal driving risks and on the potential role they can play in 
providing information on the potential risk of medicines to the patient. Contrary to the positive 
attitudes, low frequencies of reported behaviour that considers medicinal driving risks’ 
were found prior to the training/intervention in all groups (61% answered ‘seldom’ to ‘never’ 
on the statements). With regard to user acceptance of possible dispensing support tools, 
more than 90% of the ViaNova respondents and over 70% of the respondents from the 
USB and Control group stated that they would be willing to use a dispensing support 
tool to easily find information regarding medicinal drugs and driving. The most frequent 
reasons for any hesitation though was linked to fears about software user-friendliness (it 
should be integrated, easy to use, no effect on other computer processes and time-efficient). 
The clear first choice tool was software integrated in the proper software, second choice 
was a website, and third a manual; stand-alone software (like cd-rom or USB stick) seemed 
generally not to be preferred.   
Pre-post questionnaire comparison. When comparing the three groups on the pre-post 
questionnaire changes of the composite scores on attitudes & awareness, reported behaviour 
and knowledge regarding medicinal driving risk, several conclusions can be drawn (see Table 
85). 
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Table 85: Total group overview of pre-post changes: Composite scores 
 Composite scores 
ViaNova group 
Composite scores  
USB group 
Composite scores 
Control group 
 Pre Post Change Pre Post Change Pre Post Change 
Attitudes & awareness 
Strongly 
disagree  0 0 0 0 0 0 0 0 0 
Disagree  10.3 11.8 1.5 8.3 0 -8.3 5 15 10 
Agree  86.8 83.9 -2.9 91.7 100 8.3 90 85 -5 
Strongly agree  2.9 4.4 1.5 0 0 0 5 0 -5 
Reported behaviour 
Never 13.2 1.5 -11.7* 8.3 0 -8.3 20 15 -5 
Seldom 48.5 10.3 -38.2* 41.6 33.4 -8.2 45 50 5 
Sometimes 32.4 48.5 16.1* 50 50 0 25 25 0 
Regular 5.9 32.3 26.4* 0 16.7 16.7 10 10 0 
Always 0 7.3 7.3* 0 0 0 0 0 0 
Knowledge specific medicinal risks (sum on 5) 
0 10.3 10.3 0* 8.3 0 -8.3 5 10.5 5.5 
1 25 20.6 -4.4* 33.3 33.3 0 15 10.5 -4.5 
2 41.2 17.6 -23.6* 33.3 33.3 0 50 15.8 -34.2 
3 17.6 27.9 10.3* 16.7 33.3 16.6 25 31.6 6.6 
4 5.9 20.6 14.7* 8.3 0 -8.3 5 21.1 16.1 
5 0 2.9 2.9* 0 0 0 0 10.5 10.5 
Knowledge general (sum on 7) 
0 4.4 0 -4.4* 0 0 0 0 0 0 
1 8.8 4.4 -4.4* 8.3 0 -8.3 0 0 0 
2 13.2 13.2 0* 16.7 16.7 0 10 15.8 5.8 
3 22.1 23.5 1.4* 16.7 33.3 16.6 25 15.8 -9.2 
4 35.3 20.6 -14.7* 41.7 25 -16.7 45 10.5 -34.5 
5 11.8 23.5 11.7* 8.3 25.0 16.7 20 31.6 11.6 
6 4.4 11.8 7.4* 8.3 0 -8.3 0 21.1 21.1 
7 0 2.9 2.9* 0 0 0 0 5.3 5.3 
Significant pre-post changes at composite score level were only found in the ViaNova 
group: this group significantly increased in reported medicinal risk considering 
behaviour and in medicinal risk specific knowledge level. Furthermore, the ViaNova 
group had in total 10 significant positive changes (on a total of 20 
statements/questions), compared to just 2 in the USB group and none in the Control 
group as expected.  
Table 86: Total group overview of number of significant pre-post questionnaire changes: individual 
statements/questions  
Number of significant pre-post changes  
    
Pharmacist group 
  
Total 
statements / questions 
ViaNova 
N=68 
USB 
N=12 
Control 
N=20 
Attitudes & awareness 5 1 0 0 
Reported behaviour 8 7 1 0 
Knowledge  7 2 1 0 
 
Little pre-post questionnaire change are generally found on pharmacists’ attitudinal 
and awareness level. The majority of the pharmacists in all groups remained at the same 
agreement level as in the pre-questionnaire. Only one significant positive pre-post change 
was measured in the ViaNova group (‘I feel being well-aware of the effects of medicines on 
driving skills: 25% of the pharmacists changed their answer in the positive sense). No 
significant positive changes were found for the USB and Control group (see Table 86).  
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Very good results are found on the pre-post reported behaviour comparison of the 
integrated software group. A significant positive change after the training and intervention 
phase of ViaNova participants was found on 7 of the 8 reported behaviour questions. The 
proportion of pharmacists informing patients regularly or always about risks increased up to 
almost the maximum. Only one significant positive change was found within the USB group: 
the participants discussed medicinal drug consumption and driving related responsibility 
issues with the patient more often. For the Control group no change could be recorded. A 
big positive change in reported behaviour was found for the ViaNova group: 33.7% changed 
their answer in the better sense (regularly and always), followed by the USB group: 16.7%. 
No change was registered for the control group, conform the expected results.  
 
Rather limited pre-post change was generally found on knowledge of individual 
medicinal risks on driving; this knowledge remained generally at a low level. The best 
results were found in the ViaNova group: significant increase in mean sum score in the post-
questionnaire (from 1.84 on 5 (SD 1.031) to 2.37 on 5 (SD 1.37)) and 28% changed towards 
a sum score of at least 3 on 5. The number of incorrect and don’t know answers in the post-
questionnaire remained overall quite high though and for some questions even more than the 
majority. Besides the significant change in the composite score, a significant positive change 
was found on two knowledge questions related to risk of individual medicines: question on 
Diazepam – but still more than half of the pharmacists answered incorrectly – and 
Amitriptyline – 60% correct –). Only one significant positive change was found in the USB 
group (question on Amitriptyline). Still about half of the pharmacists answered incorrectly or 
did not know the answer in the post-questionnaire. No significant changes were found on the 
knowledge questions in the Control group. In general, the remark can be made that the 
correctness of some answers on the knowledge questions is arbitrary. Especially the question 
on Diazepam can evoke some discussion. Some studies did show that no severely impairing 
impact of Diazepam after just one month could be measured (the ‘correct’ answer in the 
questionnaire was that Diazepam was still heavily impairing after two months). Interpretation 
of the knowledge results needs thus to be done with caution due to questionnaire limitations 
(arbitrary answers, ‘mismatch’ of information in the provided study material (general 
information) and in the questions (referring to details like time periods, dosage). In addition, 
the questionnaire was developed within WP7 and has not been used before for similar 
research (i.e. not validated). The basic knowledge on legal physicians/pharmacists 
obligations and patient responsibilities is generally good, already at baseline. 
Therefore, little pre-post changes are found on this aspect 
ViaNova software data and user acceptance. The software extracted data of the ViaNova 
participants indicate that in about 89% of the popped-up EUB signals the option ‘side-
effects discussed’ was clicked, and this for the three risk categories of medicines. There 
were no clear differences in the number of clicks on ‘discussed’ in function of the ATC group. 
Also the option of printing patient information (GIT) was used on a regular basis. One 
difference in dispensing the GIT to the patient was noted: a GIT was less given to a patient 
when dispensing a risk category 1 (0.3%) medicine as compared to a risk category 2 (3.9%) 
or 3 medicine (3.5%). Similar results were found for the TUB and EUC signals. This high use 
of the DRUID functions integrated in their pharmacy software suggests a positive attitude of 
the ViaNova pharmacists. When interpreting this high percentage the reader should keep in 
mind though that the pharmacist was more or less obliged to click on ‘EUB discussed’ or 
‘gave GIT to patient’ or ‘side effects discussed’ to go further with dispensing a medicine (so to 
leave the EUB signal). If the pharmacists chose ‘continue’ the EUB signal would appear again 
in a later phase of dispensing.  
In correspondence to the observed behavioural data, the rates of user acceptance of 
the guidelines and of the integrated software user friendliness are high. The majority 
found the dispensing guidelines helpful, useful and sufficient. On the other hand, there was a 
very low use of the fact sheets and the pictogram system (10-20%). A remark regarding the 
pictograms should be made: several pharmacists did not understand this question very well, 
and pointed out that they did not know where to find these pictograms and/or if they used 
them in the software. Also the term ‘fact sheet’ was not well understood by the participants. 
This low use of the of the fact sheets and pictogram can be explained by the fact that no 
specific attention was paid to this information during the training sessions. The pictogram is 
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rather small and can be easily ‘looked over’. Furthermore the term ‘fact sheet’ was not used in 
ViaNova, there is a big possibility that most pharmacists did read the text/fact sheet but did 
not mentioned this in the questionnaire. The user acceptance responses for these two 
sources thus need to be interpreted with care, as probably the terms were not clear 
(confusing) for the respondents. Looking at the ViaNova extracted data, the conclusion can 
be made that the fact sheets and pictograms were consulted on a regular base.  
More than half of the ViaNova pharmacists stated that the guidelines have changed the 
manner they dispensed medication, and 60% of the participants think that the provided 
guidelines changed quite a lot up to very much their way to inform a patient. Up to 90% of the 
pharmacists (strongly) agreed that they could find the information without difficulties and that 
the tool would fit well in their working routines. Also the texts and icons were easy to perceive. 
Some pharmacists mentioned that the tool should have additional options like more 
thorough information on side-effects or less vague advice. 80% of the participants 
express their willingness to use the tool in the future.  
USB tool data and user acceptance. When analysing the USB tool extracted data the 
conclusion was made that most of the pharmacists seldom used the provided program. 
Furthermore, most searches were made on the day of the installation of the tool and some 
days after the participants received an email to send in their log files. The most frequent 
medicines searched for were category 3 medicines (e.g. Tetrazepam, Diazepam and 
Lorazepam). 1/4th of the clicks could not be linked to a risk category due to typing errors or 
invalid entry of substances in the tool. When looking at the answers to the questions of user 
acceptance some explanation of the low use of the USB tool could be found. The pharmacists 
mentioned that the USB tool was too time consuming, not easy to use and contained too 
vague information. They stated that they would have used the tool more often if it was 
integrated in their daily used software. Besides the integration in their daily used 
software, the pharmacists also recommend the possibility to search on brand names. 
Pharmacists who were willing to use (an adapted/optimised) USB tool, would only use it in 
cases of first prescription.  
 
4.2 Study limitations, challenges and solutions  
No link between questionnaire and software data. The study design initially took care that 
each participant had a unique DRUID identification number in order to link questionnaire data 
to tool data (ViaNova or USB tool). After the six months trial it became clear though that it was 
impossible to determine how many pharmacists exactly used the DRUID functions in the 
ViaNova or USB software. This was due to the fact that many of the participants work in 
pharmacies with several pharmacists using the same computer, and thus using the support 
software tool.  
Shortened USB intervention phase. Due to some problems regarding the development of 
the USB tool the intervention period (6 months) had to be shortened in order not to delay the 
study. This may have had an influence on the measured effect of the DRUID 
information/guidelines on the questionnaire and tool use data.   
Motivated study participants. It has to be kept in mind that our population was already very 
interested in the topic medicines and driving; their participation was based on own 
willingness. All pharmacists mentioned at baseline that they already knew something about 
the topic but that they wanted to expand this knowledge. This may have led to smaller 
changes in reported pre-post measures during this study. 
Sample restrictions. There was only a small number of participating pharmacists, especially 
in the USB and Control group. 
Age of study participants. 66% of the study population was older than 46 years. A possible 
influence of the older population is noted regarding ICT knowledge. Younger pharmacists 
found it less hard to install the USB tool. It is not unlikely that the older pharmacists were less 
inclined to use the USB tool when experiencing problems in installation or use, which resulted 
in a low amount of data that could be collected. 
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Besides these study limitations, several challenges had to be overcome by the research team 
during the course of the study:  
Table 87: Study limitations, challenges and solutions 
Challenge Offered solution 
There was difficulty to motivate the 
pharmacists to activate the functions in the 
integrated software ViaNova and to keep 
using them properly. 
During the training session the speaker and 
ESCAPO (ViaNova provider) tried to motivate 
the pharmacists by e.g. providing a step-by-
step manual on how to use and activate the 
DRUID functions. During the study 
newsletters were produced to keep the 
participants informed and motivated. 
For the non-integrated group of pharmacists 
it became very difficult to plan the training 
sessions. It turned out that the sessions were 
scheduled too early in the evening. Secondly 
it had to be taken into account that the 
courses did not overlap with other courses 
organised by professional organisations for 
pharmacists. 
Several pharmacists were consulted on the 
closing hours of the pharmacies in East 
Flanders. ESCAPO provided the research 
team with information regarding other training 
sessions organised by professional 
organisations for pharmacists. 
During the training sessions it became clear 
that the ICT knowledge of the participating 
pharmacist was rather low with regard to 
installing a new program on their computer 
(USB tool).  
Several pharmacists needed and obtained 
help with the installation (by phone, by email 
or in person). Shortly after the training 
session a newsletter was sent to the 
respondents in order to detect installation 
problems early in the study. 
Besides the delay of the USB tool the 
research team also experienced a lot of other 
problems regarding the USB-program, for 
example sometimes files were not correctly 
uploaded in the program, the tool did not run 
on windows Vista or on a Windows 64-bit, 
etc. Due to these kinds of problems and the 
delay in finishing the USB-tool, the trial 
period for some pharmacists was shorter 
than originally foreseen (6 months). 
The USB tool was tested on several 
computers by the research team and later 
modified to match the most current operating 
systems installed on the pharmacy 
computers. 
Several pharmacists were worried about the 
compatibility between their own software and 
the USB tool. Some pharmacists refused to 
install the tool unless the research team 
could guarantee that no problems would 
appear. 
 
After contacting several software companies, 
the message could be sent to all partners that 
the tool could be installed without any 
problems or risk of incompatibility.  
 
Most of the respondents made clear that 
more than one computer is used in a 
pharmacy.  
The respondents were motivated to install the 
USB tool / program on every computer 
present at the pharmacy. After the six months 
trial it was underlined to send back all log 
file(s) from all computers where the program 
was installed on.  
Almost every pharmacist present at the 
training sessions preferred a tool integrated 
into their daily used software. According to 
the pharmacists, having several programs 
open on the computer when helping patients 
is a waste of time. The new DRUID-functions 
or information should be integrated in the 
software used in daily practice.  
During the training session the study design 
and the importance of a non-integrated 
software (USB) group was explained. The 
possibility of making a shortcut on the 
computer desktop to easily open the USB 
program was mentioned.  
Most of the pharmacists did not know the 
ATC codes of medicines (only generic and 
brand names). The question whether it was 
More information on the ATC codes of 
medicines was provided during the training 
session. 
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also possible to integrate brand names was 
often mentioned. This should be kept in mind 
when developing new programs/software. 
In the end, the aim of including 31 
pharmacists in the non-integrated group 
could not be fulfilled. Few pharmacists were 
willing to follow a training session and use a 
new tool/program. 
After every training session, absent 
pharmacists were invited by letter to the next 
training session. In this way several 
pharmacists could be motivated to follow a 
training session anyway. 
Several pharmacists warned that the therapy 
compliance can be threatened when one 
informs the patients about the negative 
influence of certain medication on the driving 
ability. The respondents were not willing to 
give the DRUID information to patients who 
already used a medicine for years. 
During the training sessions it was explained 
to focus on first prescriptions. 
 
The pharmacists mentioned during the 
training sessions that there is a difficult 
collaboration between pharmacists and 
physicians. Almost none of the participants 
was prepared to make a phone call to a 
physician when a safer alternative should be 
proposed to the patient. All participants, 
especially more experienced pharmacists 
had some negative experiences in trying to 
realise a cooperation with the physicians in 
their region.  
The research team published information 
about the DRUID project and the 
physician/pharmacist study on the internal 
website of the physician of the region 
‘Tongeren’, where a training session was 
held. 
 
 
Main recommendations for future field studies with pharmacists deal with: having good 
intermediaries or contact persons, using informative and supporting newsletters for 
participants. During the study it became clear that having intermediaries or contact persons 
(e.g. contact persons within ESCAPO) has a very positive influence on the response rate, 
follow-up and outcome of the study. These contact persons help establish a good 
communication with the respondents as well as motivate them to participate actively in the 
study. The use of newsletters turned out to be a very handy and useful tool in contacting the 
respondents directly. It became furthermore clear that the subpopulation of pharmacists is 
overly asked to participate in studies. The DRUID study was carefully planned by ESCAPO in 
order to avoid overlap between several studies, which would have a negative influence on the 
participation rate. 
 
Table 88. Problems encountered 
Problems encountered 
 Difficult to motivate pharmacists (certainly the non-integrated group) 
 Difficult to plan a training session (hours) 
 ICT knowledge low (difficulties installing USB-Tool) 
 Difficult to finalise the USB-tool, delay study 
 Clear preference for integrated information in the daily used software 
 Compatibility software and usb-tool 
 (almost) No knowledge of the ATC codes  
 Installation of usb-tool on several computers: no control on who and how many 
pharmacists used the tool 
 Low number of respondents in the non integrated software group (USB) 
 Therapy compliance threatened  
 Difficult collaboration between pharmacists and physicians: There is a lack of 
structures or organisations where physicians and pharmacists can collaborate. 
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4.3 Overall conclusion and recommendations 
 
- Most positive outcome with integrated software 
As could be expected, most and highest self-reported topic-favorable (medicinal effects on 
driving) changes were found in the integrated ViaNova software group, as compared to far 
less in the stand-alone USB group and none in the Control group. Most positive changes 
were found on specific reported behaviour, on which the pharmacists were trained. Almost no 
change on attitudinal level for none of the three groups was observed, which can be related to 
an already rather a priori good attitude towards the topic medicinal driving risks of the 
participating pharmacists. One could say that the pharmacists who participated in this study 
firmly underline the importance of being well informed and aware of the possible risks of 
medicines on driving. In other words their positive attitude was a motivation to take part in the 
present study. Although the training and 6 months trial increased some awareness for risks of 
medicines for driving (also related to fine-tuned knowledge about specific medicines’ risks), 
more effort still seems to be required in order to further help pharmacists increase their 
awareness and knowledge.   
The DRUID dispensing guidelines were overall very well accepted and liked. What stands out 
most strikingly from all results is the importance of having a support system integrated in the 
daily dispensing software in order to be effectively used.  
- Lack of information on the topic ‘medicines and driving’ 
Almost every pharmacist involved in present study (all groups) underlined the importance of 
being informed on the potential risk of medicines on driving. Yet, the participants reported a 
lack of information on this topic. The majority is willing to use a tool in their daily practice, as 
long as it is integrated into their daily software, updated automatically, easy to use, focus on 
first deliveries, cost- and time-efficient, contain concrete & detailed information and if possible 
safer alternatives. 
- Suggestions with regard to the DRUID dispensing guidelines and the delivery support 
tools: 
Following the participants’ feedback and remarks, several suggestions and recommendations 
for improvement of the DRUID dispensing guidelines and dispensing support tool(s) can be 
given. 
With regard to the DRUID dispensing guidelines:  
 Guidelines have to be uniform 
 The provided information has to be detailed 
 Safer alternatives have to be formulated if possible 
 The proposed DRUID categorisation should be recognised and approved on 
European level 
 New medicines have to be classified  
 The pharmacists recommend focusing only on the first prescriptions. Patients who 
already use certain medication for several years will not agree to use another (safer) 
medication then the one they are used to. 
 
With regard to the dispensing support tool(s):  
 The information integrated in the software should be updated automatically 
 Besides the information integrated in the software, a manual or instructions folder has 
to be available to facilitate the information transition on other pharmacists or assistant 
pharmacists in the pharmacy 
 A combination of tools, ideally integrated software + a manual or a website, would be 
much appreciated 
 In case of a search function: the respondents would like to have the possibility to 
search on brand and generic name of a medicine; after typing two letters several 
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suggestions of medication have to appear (several pharmacists misspelled the 
brand/generic name which did not gave a match in the tool)  
 All the information of the USB tool has to be integrated in the daily used software. 
When this information is available it should be made compatible with all existing 
software packages used by the pharmacists in the region/country 
 
- Further lessons learnt 
The following should be considered in future pharmacists’ dispensing support implementation 
plans:  
 
 Besides the need for safer alternatives there is a need for concrete and detailed 
advice in the package leaflet or on the medicine box.  
 Most of the pharmacists mentioned that they cannot forbid patients to drive or to use 
heavy machinery when using medication that can cause impaired driving. They can 
only underline the danger of driving under the influence of the prescribed medication. 
 The pharmacists noted that informing family members, who come and collect the 
prescribed medication, can be difficult. A lot of information is lost when the 
communication was not directly with the patient. 
 Some pharmacists were worried about the fact if the pharmacy assistants were not 
enough trained to give advice about the influence of medication on the driving 
abilities. 
 Due to the difficult cooperation between physicians and pharmacists it is 
recommended, according to the participants, to inform all physicians in the 
region/province about the study. Raising the awareness of the physicians will 
augment the chance to realize a real change in behaviour of the pharmacists.  
 The pharmacists recognise that they have an important role in advising the patient. 
Certainly because of the fact that a lot of patients go to different physicians to receive 
prescriptions for several types of medication. The pharmacist can advise the patient 
not to combine certain medicines or to not drive for X hours. For this, the pharmacists 
want to point out the importance of good safer alternatives.  
 Pharmacists mentioned that patients were grateful for the advice and warnings. The 
communication with the patient turned out to be easier than expected.  
 Every patient understands that driving under the influence of alcohol is very 
dangerous. In practice, it is useful to compare the influence of certain medication with 
the influence of alcohol. Using such a comparison makes the communication with the 
patients and the information transmission smoother and more apprehensible.   
 The participating pharmacists were surprised by the number of patients who don’t 
participate in daily traffic.  
 Several pharmacists did not know that a classification of medicines was yet available. 
 Most of the pharmacists made clear that not enough attention is paid to the topic 
‘driving under the influence of medicines’. 
 Several participants expressed their worries on being (partially) legally responsible 
when a patient has a traffic accident. 
 A lot of delivery software programs are currently being used by pharmacists. Until 
today no classification of medications is included in the software. The DRUID 
classification and the accompanying pictogram is a benefit according the 
respondents. These pictograms should not only be integrated in the software but also 
put on the medicine boxes and patient information leaflet. A proposal of the 
participants was to build in a function in their software that makes it possible to print 
stickers with the pictogram. 
 During the training sessions the participants underlined the importance of a training 
manual or hand-outs. In most pharmacies several pharmacists/assistants/students 
are employed. In order to inform all co-workers a manual should be available. 
 Several pharmacists made the remark that sometimes a pop-up in the software 
warned for an influence on the driving ability while the medication was prescribed to 
infants and little children (e.g. Toplexil). Some pharmacists proposed to link an age 
category to the medicine. 
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6 Annex 
 
6.1 Annex 1: Newsletters ViaNova 
 
6.1.1 Newsletter ViaNova - April 2010 
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6.1.2 Newsletter ViaNova - June 2010 
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6.1.3 Newsletter ViaNova - October 2010 
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6.2 Annex 2: Newsletters- Non integrated software group (USB-tool) 
6.2.1 Newsletter USB– October 2010 
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6.2.2 Newsletter USB- January 2011 
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6.2.3 Newsletter USB - February 2011 
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Annex 3: Banner shown on flat screens – pharmacists ViaNova 
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Annex 4: First Belgian pharmaceutical care symposium – Poster (18/9/2010) 
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Annex 5: Questionnaires 
Baseline questionnaire 
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Second Questionnaire  
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Annex 6. Pre-post change: Wilcoxon tables  
ViaNova Group 
 
Table 89: ViaNova group pre-post change – attitudes and awareness  
  
Pre-post questionnaire change 
(within-group %) 
Negative 
change 
Positive 
change 
No 
change 
 
Total N 
I am willing to take into account the effects 
of medicines on driving skills when 
dispensing medicines  21.54 18.46 60 
 
65 
I am willing to sacrifice some degree of 
efficacy by dispensing a medicine that is 
less impairing to the driving skills.   7.58 15.15 77.27 
 
 
66 
I feel being well aware of the effects of 
medicines on driving skills. *  11.94 25.37 62.69 
 
67 
It is important for me to be well-informed 
on medicinal effects on driving behaviour.  14.71 20.59 64.71 68 
I feel that the information I provide to 
patients will influence their driving 
behaviour. 14.93 26.87 58.21 
 
67 
Composite Score Attitudes & Awareness 
(median)  13.43 11.94 76.12 68 
* Wilcoxon Signed Ranks Test p≤0.05 
 
Table 90: ViaNova group pre-post change – Detail attitudes and awareness 
  
Pre-post questionnaire change (within-group %) 
Would you consider this of more 
concern if your patient is:  
Negative 
change 
Positive 
change No change 
a professional driver 5.97 4.48 89.55 
driving frequently 9.23 12.31 78.46 
driving long distances 7.58 6.06 86.36 
an 'inexperienced driver 17.74 19.35 62.90 
an experienced driver 19.67 24.59 55.74 
an elderly driver 7.69 12.31 80  
using other CNS active drugs 7.58 3.03 89.39 
 
Table 91: ViaNova group pre-post questionnaire comparison – Reported behaviour 
  
Pre-post questionnaire change (within-group %) 
  
Negative 
change 
Positive 
change 
No 
change Total N  
I ask a patient about his/her driving 
exposure when dispensing a 
medicine.*  5.88 60.29 33.82 68 
I inform a patient about driving 
related risks when dispensing a 
medicine.*  4.41 60.29 35.29 68 
I provide a patient with written 
information materials when dispensing a 
driving impairing medicine.  29.41 35.29 35.29 68 
I keep systematic records when I 
dispense a driving impairing 
medicine.*   7.69 61.54 30.77 65 
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I keep systematic records when I 
advise a patient when and how 
he/she can consider driving a car 
when using a driving impairing 
medicine.*  5.97 61.19 32.84 67 
I keep a record of the patient's traffic 
participation (e.g. how often he/she 
drives to work).*  5.88 32.35 61.76 68 
I discuss medicinal drug 
consumption and driving related 
responsibility issues with the 
patient.*  5.97 62.69 31.34 67 
How frequently do you usually 
provide detailed information when 
prescribing a medicine with impairing 
effects on driving performance?*   4.41 69.12 26.47 68 
Composite Score Reported behaviour 
(median)*  7.35 77.94 14.71 68 
* Wilcoxon Signed Ranks Test p≤.05 
 
Table 92: ViaNova group pre-post change – Knowledge questions 
ViaNova pre-post questionnaire change (within-group %)    
  Negative change Positive change No change Total N  
Diazepam (regardless of dose) is 
severely impairing within the first 2 
months of treatment * 10.61 27.27 62.12 66 
Codeine (up to 20 mg) is mostly safe for 
drivers (trend) 17.65 33.82 48.53 68 
Fexofenadine (normal dose) is severely 
impairing driving 23.08 24.62 52.31 65 
Amitriptyline at the start of treatment 
is as impairing driving as after 4 
weeks of treatment * 13.64 37.88 48.48 66 
Paroxetine (up to 20 mg/day) is safe for 
drivers 19.40 10.45 70.15 67 
Composite score – knowledge 
medicine risk (correct answers on 5)* 25 52.94 22.06 68 
Physicians/pharmacists are obliged to 
inform the patients about the possible 
side effects of his/her medications on 
driving abilities.  10.45 11.94 77.61  67 
A patient can be punished with criminal 
sanctions if he causes a traffic accident 
while using a medicine with impairing 
properties whereas the health care 
provider has advised him not to drive.   6.56 14.75 78.69 61 
Composite score – general knowledge 
(correct answers on 7)* 26.47 50 23.52 68 
* Wilcoxon Signed Ranks Test p≤.05 
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USB group 
 
Table 93: USB group pre-post change – attitudes and awareness (within-group %) 
  
Pre-post questionnaire change 
Negative 
change 
Positive 
change 
No 
change 
 
Total 
N 
I am willing to take into account the effects of 
medicines on driving skills when dispensing 
medicines  16.67 16.67 66.67 12 
I am willing to sacrifice some degree of efficacy by 
dispensing a medicine that is less impairing to the 
driving skills.   0 8.33 91.67 12 
I feel being well aware of the effects of medicines on 
driving skills.  8.33 25  66.67 12 
It is important for me to be well-informed on medicinal 
effects on driving behaviour.  0 8.33 91.67 12 
I feel that the information I provide to patients will 
influence their driving behaviour. 8.33 16.67 75 12 
Composite Score (median)  0 8.33 91.67 12 
 
Table 94: USB pre-post change – Detail attitudes and awareness  
  
Pre-post questionnaire change (within-group %) 
Would you consider this of more 
concern if your patient is:  
Negative 
change 
Positive 
change No change 
a professional driver 0 0 100  
driving frequently 16.67 0 83.33 
driving long distances 9.09 0 90.90 
an 'inexperienced driver’ 25  16.67 58.33 
an experienced'driver’ 9.09 9.09 81.82 
an elderly driver 8.33 0 91.67 
using other CNS active drugs 16.67 0 83.33 
 
Table 95: USB group pre-post change – Reported behaviour 
  
Pre-post questionnaire change 
  
Negative 
change 
Positive 
change 
No 
change Total N  
I ask a patient about his/her driving exposure when 
dispensing a medicine. 16.67 41.67 41.67 12 
I inform a patient about driving related risks when 
dispensing a medicine. 8.33 25  66.67 12 
I provide a patient with written information materials 
when dispensing a driving impairing medicine.  16.67 25  58.33 12 
I keep systematic records when I dispense a driving 
impairing medicine. 33.33 16.67 50  12 
I keep systematic records when I advise a patient 
when and how he/she can consider driving a car 
when using a driving impairing medicine. 8.33 16.67 75  12 
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I keep a record of the patient's traffic participation 
(e.g. how often he/she drives to work). 16.67 8.33 75  12 
I discuss medicinal drug consumption and driving 
related responsibility issues with the patient.*  0 50  50  12 
How frequently do you usually provide detailed 
information when prescribing a medicine with 
impairing effects on driving performance? 16.67 8.33 75  12 
Composite Score Reported behaviour (median) 25  58.33 16.67 12 
* Wilcoxon Signed Ranks Test p≤.05 
Table 96: USB group pre-post change – Knowledge questions 
  
Pre-post questionnaire change (N -> within-group%)   
  Negative 
change 
Positive 
change 
No change Total N  
Diazepam (regardless dose) is 
severly impairing within the first 2 
months of treatment  
25  8.33 66.67 12 
Codeine (up to 20 mg) is mostly 
safe for drivers 16.67 25 58.33 12 
Fexofenadine (normal dose) is 
severely impairing driving 0 22.22 77.78 9 
Amitriptyline at the start of 
treatment is as impairing driving 
as after 4 weeks of treatment * 
0 33.33 66.67 12 
Paroxetine (up to 20 mg/day) is 
safe for drivers 41.67 16.67 41.67 12 
Composite score Knowledge on 
selected medicines’ risk (sum 
correct on 5) 50.0 50.0 0 12 
Physicians/pharmacists are 
obliged to inform the patients about 
the possible side effects of his/her 
medications on driving abilities. 
(trend) (Z= -1,732 ; p .083) 
25  0 75   12  
A patient can be punished with 
criminal sanctions if he causes a 
traffic accident while using a 
medicine with impairing properties 
whereas the health care provider 
has advised him not to drive. 
8.33 25 66.67 12 
Composite score Knowledge (total 
sum correct on 7) 50.0 41.7 8.3 12 
* Wilcoxon Signed Ranks Test p≤.05   
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Control group 
 
Table 97: Control group pre-post change – Attitudes and awareness 
  
Pre-post questionnaire change 
Negative 
change 
Positive 
change 
No 
change 
 
Total 
N 
I am willing to take into account the effects of 
medicines on driving skills when dispensing medicines  20  15  65  20 
I am willing to sacrifice some degree of efficacy by 
dispensing a medicine that is less impairing to the 
driving skills.   15  15  70  20 
I feel being well aware of the effects of medicines on 
driving skills.  10  0.0 90  20 
It is important for me to be well-informed on medicinal 
effects on driving behaviour.  15.79 15.79 68.42 19 
I feel that the information I provide to patients will 
influence their driving behaviour. 10  5  85  20 
Composite Score (median)  20  5  75  20 
 
Table 98: Control pre-post change – Detail attitudes and awareness  
  
Pre-post questionnaire change (within-group ) 
Would you consider this of more 
concern if your patient is:  
Negative 
change 
Positive 
change No change 
a professional driver 0 0 100  
driving frequently 0 0 100  
driving long distances 0 5  95  
an 'inexperienced driver’ 21.05 10.53 68.42 
an experienced'driver’ 11.11 11.11 77.78 
an elderly driver 5.56 0 94.44 
using other CNS active drugs 5.26 5.26 89.47 
 
Table 99: Control group pre-post change – Reported behaviour 
  
Pre-post questionnaire change 
  
Negative 
change 
Positive 
change 
No 
change Total N  
I ask a patient about his/her driving exposure when 
dispensing a medicine. 20  30  50  20 
I inform a patient about driving related risks when 
dispensing a medicine. (trend) 10  40  50  20 
I provide a patient with written information materials 
when prescribing/dispensing a driving impairing 
medicine.  15  25  60  20 
I keep systematic records when I prescribe/dispense 
a driving impairing medicine. 10  10  80  20 
I keep systematic records when I advise a patient 
when and how he/she can consider driving a car 
when using a driving impairing medicine. 10  15  75  20 
I keep a record of the patient's traffic participation 
(e.g. how often he/she drives to work). 20  15  65  20 
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I discuss medicinal drug consumption and driving 
related responsibility issues with the patient. 15  35  50  20 
How frequently do you usually provide detailed 
information when prescribing a medicine with 
impairing effects on driving performance? 25  35  40  20 
Composite Score (median) 30  35  35  20 
* Wilcoxon Signed Ranks Test p≤.05 
 
Table 100: Control group pre-post change – Knowledge questions 
  
Pre-post questionnaire change (N -> within-group%)   
  Negative 
change 
Positive 
change 
No change Total N  
Diazepam (regardless dose) is 
severely impairing within the first 2 
months of treatment (trend) 
5.56 33.33 61.11 18 
Codeine (up to 20 mg) is mostly 
safe for drivers 21.05 10.53 68.42 19 
Fexofenadine (normal dose) is 
severely impairing driving 5.26 15.79 78.95 19 
Amitriptyline at the start of 
treatment is as impairing driving as 
after 4 weeks of treatment  
10.53 26.32 63.16 19 
Paroxetine (up to 20 mg/day) is 
safe for drivers 15.79 36.84 47.37 19 
Composite score Knowledge on 
selected medicines’ risk (sum 
correct on 5) 
21.1 52.6 26.3 19 
Physicians/pharmacists are 
obliged to inform the patients about 
the possible side effects of his/her 
medications on driving abilities.  
10.53 10.53 78.95 19 
A patient can be punished with 
criminal sanctions if he causes a 
traffic accident while using a 
medicine with impairing properties 
whereas the health care provider 
has advised him not to drive.  
0 5.26 94.74 19 
Composite score Knowledge (total 
sum correct on 7) 26.3 52.6 21.1 19 
* Wilcoxon Signed Ranks Test p≤0.05
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Abbreviation  Full Description 
 
ATC   Anatomical Therapeutic Chemical (ATC) classification 
 
CMPM  Commentaren Medicatiebewaking Pharmacom Medicom 
(Commentary Medication Surveillance Pharmacom 
Medicom) 
 
CNS   Central Nervous System 
 
D- …   Deliverable 
 
DIM   Driving impairing medicines 
 
DGV  Instituut voor Verantwoord Medicijngebruik (The Dutch 
Institute for Rational Use of Medicines) 
 
DRUID  Driving Under the Influence of Drugs, Alcohol and 
Medicines 
 
EU    European Union 
EUB  Eerste Uitgifte Begeleiding (First-time dispensing 
counselling)  
EUC   Eerste Uitgifte Controle (First-time dispensing check) 
 
FTO  Farmacotherapeutisch Overleg (Pharmacotherapeutic 
review group) 
 
GP   General Practitioner 
 
GIT  Geneesmiddel Informatie Tekst (personalised medicines 
information leaflet)  
 
HCP   Healthcare Providers 
 
ICT   Information and Communication Technology 
 
 
LESA  Landelijke Eerstelijns Samenwerkings Afspraak (National 
primary care agreement) 
 
N05B    ATC code for anxiolytic medicines 
 
N05C    ATC code for hypnotic medicines 
 
N06A    ATC code for antidepressant medicines 
 
RUGPha
   
University of Groningen, Pharmacy 
 
OTC   Over-the-counter (self-medication without prescription) 
 
TUB  Tweede Uitgifte Begeleiding (Second-time dispensing 
counselling)  
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1 Introduction 
 
The intake of medicinal drugs, especially psychoactive medications such as sedatives, 
anxiolytics, hypnotics, antidepressants, either by themselves or in association with alcohol 
or other psychotropic substances, may lead to a decreased fitness to drive safely [1] [2] [3]. 
For that reason, psychoactive medicines are normally associated with an increase risk of 
traffic accident [3] [4]. Therefore, it is crucial to provide patients with clear information 
which should allow them to make their own judgments and decisions whether it is safe or 
not to drive their car. 
In the Netherlands, awareness about the influence of medicines on driving fitness has 
increased over the past years and several information materials were developed and are 
currently available for health care providers (HCPs).  
In October 2008, a Dutch public campaign entitled “Rij veilig met medicijnen” (drive safely 
with your medicines) was launched and aimed to advise drivers who take driving impairing 
medicines (DIM) to contact their general practitioner (GP), specialist or pharmacist for 
more information. Therefore, in May 2008, the Dutch Ministries of Transport and of Health, 
the Dutch traffic safety organizations, and the national associations of GPs and 
pharmacists developed and made available information materials to better prepare 
healthcare providers (HCPs) for the public campaigns. The information materials consisted 
of a brochure called “Geneesmiddelen in het verkeer” (medicines in traffic) that was 
developed by the Dutch Institute for Rational Use of Medicine (Instituut voor Verantwoord 
Medicijngebruik, DGV), a website (www.geneesmiddeleninhetverkeer.nl) and the new 
“Landelijke Eerstelijns Samenwerkings Afspraak (LESA) “Geneesmiddelen en 
Verkeersveiligheid” (medication and traffic safety), which is a national primary-care 
agreement between physicians and pharmacists concerning medicines and driving. These 
information materials were evaluated by means of a questionnaire that was sent to GPs 
and pharmacists, at the start of the public campaign in October 2008 [5] and two years 
after, in 2010 [6]. In 2008, 177 (out of 750) GPs and 163 (out of 500) pharmacists 
participated in the survey [5]. In 2010, the response rate was slightly lower, with 155 (out of 
750) GPs and 144 (out of 500) pharmacists [6]. Despite having a good knowledge on the 
risks of driving while taking DIM,  83% of the GPs and 90.5% of the pharmacists felt better 
prepared to inform their patients after receiving the information materials, in 2008 [5]. Two 
years later, the percentage dropped and only 55% of GPs and 85% of pharmacists felt 
being better prepared than before [6]. From the comparison between the two questionnaire 
surveys, it was concluded that GPs and pharmacists were well informed about the possible 
risks of DIM but not always this knowledge is transferred to patients [6]. However, HPCs 
believe that patients are now better informed and more aware of the influence of medicines 
on driving fitness [6]. The Dutch campaign has increased awareness about DIM, in 
particular among pharmacists and the materials developed in 2008 are still being used [6]. 
The various computer systems existing in the Netherlands and that HCPs use in their daily 
practice include the information that was mention above. However, not all HCPs are active 
with their computer system when it comes to information about medicines and driving. 
Besides the information materials that HCP have at their disposal to inform patients, it is 
common practice to label medicines that are known to impair driving fitness with a yellow 
warning sticker on the medicines’ box at dispensing. This warning sticker refers to the 
potential impairing effects of the medicine on one’s reaction time (which may include 
driving a car or operating machinery, for example) and that special attention should be paid 
to combined use with alcohol. 
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One of the goals of the European Union Project – DRUID (driving under the influence of 
drugs, alcohol and medicines)8 – is the implementation and evaluation of new 
technologies, such as computerized protocols and ICT (information and communication 
technology) tools referring to information about medicines and driving (Task 7.4). Such 
tools can be used in HCPs’ daily practice, for selecting (while prescribing or dispensing) 
the least impairing medicine within a therapeutic class and to provide patient information 
that will meet patient’s needs. In order to accomplish this specific aim, an ICT tool was 
developed. The DRUID ICT tool encompasses fact sheets of medicines that were 
categorized within the DRUID framework for the categorization and labeling of medicines. 
According to the level of impairment on the fitness to drive, a medicine can be classified as 
category 1 when there is a minor impairment, as category 2 when the impairment is 
moderate and, lastly, as category 3 when the impairment is severe. Medicines with no 
impairment have no category. A visual aid (pictogram) was developed as well and was 
also part of the tool (more information can be found in the DRUID deliverable 7.3.2 [7]). 
However, In the Netherlands, since October 2008 when the public campaign was 
launched, the Dutch government funded the development of information materials, 
websites and ICT–oriented support in dispensing practices (no specific ICT-oriented 
support for physicians), as mentioned above. Based on that assignment Health Base 
Foundation (supplier of the Pharmacom® system that is being used by 50% of all 
community pharmacies in the Netherlands) has developed additional information pertaining 
to the categorisation system as a support to counselling patients while dispensing a 
medicine. For that reason, in the Netherlands, the DRUID tool was not used. Instead, the 
Pharmacom® system was adapted based on DRUID materials.  
The present study refers to the development, and consequent evaluation, of a training 
session that was carried out with the intention of informing Dutch pharmacists, who are not 
actively using their Pharmacom® computer system, about the influence of medicines on 
driving fitness. By attending the training, pharmacists should be able to understand the use 
of the categorization system for medicines that might impair driving performance; to know 
the recommendations on dispensing information of medicines that might influence driving 
skills, as these are described in the dispensing guidelines; and to have insight in their 
policy with regard to medicines that might impair driving performance. A change in 
dispensing patterns is also expected. By calculating the incidence of driving impairing 
medicines dispensed before and after pharmacists’ training (intervention), it is our 
expectation to see a decrease in the delivery of medicines that have higher categories and, 
reversely, an increase in the dispensing of medicines with lower categories. Outcomes at 
the patient level are also expected and it is estimated that patients who take for the first 
time a DIM were provided with more detailed information about the influence of medicines 
on driving fitness.  
                                            
8
 www.druid-project.eu  
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1.1 Objectives 
 
The following objectives have been formulated: 
1. To determine the effectiveness of pharmacists’ training activities related with 
dispensing driving impairing medication as well as the use of ICT tools. The 
effectiveness will be measured in a questionnaire survey (compared to baseline 
measurement), after 6 months as a change in knowledge, attitudes/awareness and 
(reported) behaviour due to the implementation of the training..  
2. To determine the effect of the pharmacists intervention at the patient level by 
investigating a change in knowledge, attitudes/awareness and (reported) behavior by 
comparing responses before and after the study period, by requesting patients to 
complete questionnaires sent by pharmacists belonging to the intervention and 
control groups.. 
3. To determine, at the patient level, the decrease in dispensing of moderately and 
severely impairing medicines to patients by a shift to more safer alternatives within 
the same therapeutic class of medicines, after interventions by the pharmacists.  
 
1.1.1 Research Questions (RQs) 
For practical reasons, and due to the fact that results at different levels are to be expected, 
from now on, and whenever needed, the information will be divided in 3 groups referring to 
the pharmacists outcomes, patients outcomes and dispensing data outcomes.  
1. Pharmacist outcomes  
• Did pharmacists’ awareness about medicines and driving changed after the 
training?  
• Did pharmacists’ reported behaviour about medicines and driving change after the 
training?  
• Did pharmacists’ actual knowledge about medicines and driving improve after the 
training?  
• What is the overall opinion of the training and information materials provided 
during intervention period? 
• Are pharmacists willing to accept and use ICT tools? 
2. Patient outcomes 
• Are there differences in patients’ knowledge before and after the training 
(measurement T0 and T1, 6 months after the training)? 
• Does the pharmacy group (intervention or control) influence patients’ knowledge? 
• What is the role of healthcare providers (HCPs) in informing patients about the 
influence of medicines on driving fitness? 
 
• Does the information provided to patients differ within pharmacy group and 
between measurements?  
 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 270 of 456 
• Will the information that patients receive from HCPs change their frequency of 
driving? 
 
3. Dispensing data 
 
• Is there any significant difference in the proportion of dispensed category I, II or III 
medicines (anxiolytics, ATC code: N05B; hypnotics, ATC code: N05C; and 
antidepressants, ATC code: N06A) to new users, before and an intervention (DRUID 
training course). 
 
• Does the pharmacy group (intervention and control) influence the dispensing of 
different categories of medicines?  
 
 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 271 of 456 
2 Methods 
 
2.1 Study Design 
The DRUID study was conducted in the Netherlands and consisted of the training of 
community pharmacists who do not actively use the Pharmacom® system for the first-time 
dispensing counselling (EUB) and the second-time dispensing counselling (TUB), with 
respect to anxiolytic (ATC code: N05B), hypnotic (ATC code: N05C), and antidepressant 
(ATC code: N06A) medicines, known to impair driving fitness. 
The training was evaluated by means of a questionnaire that was presented to 
pharmacists before and 6 months after the training had been carried out (Annexes 1 and 2, 
respectively). The information that was provided to pharmacists regarding the information 
about the influence of medicines in driving fitness, which should be provided to patients 
while dispensing DIM, was evaluated as well at the patient level. This was done by means 
of a patient questionnaire (Annex 3), sent to patients visiting the participating pharmacies, 
before and 6 months after the training. The activities that were performed by pharmacists 
assigned to each group are described in Table 101. 
It is important to stress that general practitioners, main prescribers, were contacted to 
participate in the study as well. However, no interest was shown and, therefore, this group 
was not included.  
 
Table 101: Activities that were performed by each group of pharmacists during the study 
period.  
 Group 
 
Intervention Control 
T0 
Before the 
training 
Pharmacists’ 
questionnaire 
Patients’ questionnaire 
Dispensing data 
_ 
Patients’ 
questionnaire 
Dispensing data 
Oct/Nov 09 TRAINING _ 
T1 
6-months after the 
training 
Pharmacists’ 
questionnaire 
Patients’ questionnaire 
Dispensing data 
_ 
Patients’ 
questionnaire 
Dispensing data 
 
2.2 Recruitment of Participants 
 
2.2.1 Pharmacists 
A total of 1031 invitation letters were sent out to all pharmacists using the pharmacy 
information system called Pharmacom® in their daily practice (Annex 4). The letter 
contained a small questionnaire about the frequency of the use of EUB/TUB tools of the 
Pharmacom® system, with respect to medicines that are known to impair driving fitness. 
A total of 277 pharmacists (26.9% response rate) responded to the invitation and agreed to 
participate in this DRUID study. Pharmacists who did not use the EUB/TUB system for 
anxiolytic (ATC code: N05B), hypnotic (ATC code: N05C), and antidepressant (ATC code: 
N06A) medicines were selected to participate in the study and were randomly and equally 
distributed in 2 groups: the intervention (n=50) and the control (n=50) groups.  
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Drop-outs were verified and the final number of participants was as follows: 49 in the 
intervention group and 42 in the control group, which means a total of 91 pharmacists 
enrolled in the study. Figure 54 represents those numbers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.2.2 Patients 
 
Patients were selected by the pharmacist, if they were advised to take, any anxiolytic (ATC 
code: N05B), hypnotic (ATC code: N05C), or antidepressant (ATC code: N06A) 
medicine(s) for the first time, at both times (T0 and T1), 
 
Every pharmacist was asked to include a maximum of 35 patients who met the inclusion 
criteria mention above. A patient information letter (Annex 5), a questionnaire, and 
stamped addressed return envelope were posted to the eligible patients. 
 
Table 102 illustrates the number of patients included in each group, at both time 
measurements (T0 and T1). Regarding the baseline measurement (T0) it is not possible to 
calculate the actual response rate as there was no information on the actual number of 
patients that received the questionnaire. However, this situation was corrected for the 
follow-up measurement (T1), allowing to retrieve the actual response rate: in the second 
measurement, a total of 2968 questionnaires were sent to patients.  
 
Table 102: Total number of patients included in each group, stratified by time of the 
measurement.  
Measurement Group Response 
Rate (%) Intervention Control Total 
T0 244 177 421 13.2 (A) 
1031 pharmacies 
277 respondents 
Non-active pharmacies 
with EUB/TUB 
system 
Intervention  
     Group 
    Control 
     Group   
 
N = 49 N = 42 
R.R. = 26.9% 
Figure 54: Number of participants per study group 
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T1 312 197 509 17.1 (B) 
Total 556 374 930  
(A) – Assuming that the 91 pharmacies sent out the maximum number of 
questionnaires, 35 (total of 3185 questionnaires sent out to patients). 
(B) – 509 out of 2968 questionnaires were received and analysed. 
 
 
2.3 Honoraria and Ethical Considerations 
 
Pharmacists who attended the course (only those from the intervention group) were given 
4 points, as the course was considered part of the pharmacists’ continuous training. 
Besides the points, all participants were offered 100€ (intervention group) or 50€ (control 
group) vouchers, depending on their contribution throughout the study period.  
 
The study was approved by the Medical Ethical Committee of the Universitair Medisch 
Centrum Groningen (University Medical Centre Groningen), in the Netherlands. All data 
were extracted anonymously and the privacy of the participants was guaranteed 
throughout the whole study.  
 
 
2.4 The Training (course) 
 
The course was given 5 times to groups of 10 to 15 participating pharmacists, at the 
beginning of the study and was planned to last for 5 hours. All participants were asked to 
fill in a questionnaire at the start of the course (Annex 1) and a folder with several 
information materials was given to every course attendant (below there is a description of 
the content of this folder). A description of the objectives of the course as well as a 
description of the course folder and course content follows below. To follow-up on the 
training, three newsletters were monthly sent to pharmacists of the intervention 
group.(Annexes 6 to 8).  
 
2.4.1 
 
Main Objectives of the Course 
 
The main objectives of the course were:  
 
• To give insight in the DRUID project. 
• To motivate the participation in the study, as well as to motivate the use of the ICT-
tool.  
• To explain participants’ tasks and role during the study period.  
• To provide information on the categorization system for medicinal drugs that might 
impair driving performance. 
• To provide recommendations on dispensing information when delivering medicines 
that might influence driving skills. 
• To give insight in pharmacists own policy with respect to medicines that might 
impair driving performance. 
• To provide information materials to pharmacy technicians so that they can also 
use the ICT-tool (including informing patients). 
 
2.4.2 Course Manual 
 
At the beginning of each course participants received the course manual which consisted 
of:  
• A 'to-do-list' with the activities in the study design that pharmacists were involved 
in. 
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• Background information upon drugs and driving (what is the impact driving under 
the influence of drugs, what are the juridical consequences) 
• Detailed information on the categorization system (origin, how to use the system). 
• Technical instructions on how to use the ICT-tool. 
• Information materials to instruct and motivate pharmacy technicians and/or other 
pharmacists. The "in-pharmacy" training material provided the following 
information: 
o
 Outline of the course; 
o
 General background information about drugs and driving and the 
categorization system; 
o
 Example questions to trigger the discussion with the pharmacy team on this 
topic; 
o
 Cases to discuss with the pharmacy team; 
o
 Roll-plays to exercise with the pharmacy team the information that should be 
provided to patients when delivering a driving impairing medicine.  
• Examples of information that should be provided to patients about the influence of 
medicines on driving fitness.  
 
 
2.4.3 Course Content 
 
The course was divided in 5 sections each one of them with specific aims. A brief 
description on the content of each section follows below:  
• Introduction  
o
 DRUID questionnaire (T0 measurement for pharmacists of the intervention 
group).  
o
 Outline of the course. 
 
• Medicines and driving 
o
 Information about estimated fatalities due to driving under the influence of 
psychotropic medicines was provided. It was stressed that medicines within 
the same therapeutical class may have different levels of impairment. An 
introduction to the categorization system (hereby referring to the DRUID 
efforts) was given. 
o
 The Dutch juridical consequences on the prescription and delivery of driving 
impairing medicines were mentioned. Example of the categorization of well 
known medicines was shown.  
o
 The knowledge questions that were in the questionnaire that the 
pharmacists filled in before the actual start of the course were discussed, 
and the correct answers were provided. 
 
• Practical application 
o
 The consequences for patient information while dispensing DIM, as it is 
described in the Dutch Prescribing and Dispensing Guidelines. The available 
written materials, including warning signs, were shown and discussed. 
o
 The ICT- tool was introduced, including information on how to install and use 
it. A demonstration was displayed.  Pharmacists already using parts of the 
tool (e.g. for medicines other than driving impairing ones) will exchange their 
experiences until now. 
o
 Discussion about the use of the tool, about how the tool displays patient 
information, and about some limitations of the tool.  
 
• The DRUID intervention study 
o
 The research questions were presented. A detailed to-do-list was discussed 
so that pharmacists were completely informed of their role during the study 
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period.  
 
• The "in-pharmacy" training (how to coach the pharmacy team) 
o
 The attending pharmacists usually manage ten to fifteen employees, mainly 
pharmacy technicians and they are the ones who mostly use the ICT-tool 
and inform patients. Therefore, it was discussed, in detail, how the 
pharmacy team should be coached and how to motivate all employees.   
o
 The material for the "in-pharmacy training" included cases and some roll-
plays (as mentioned above). After making reference to these materials, the 
pharmacists had the opportunity to exercise, themselves on how to inform 
patients or on how to discuss this issue with the prescribers.  
 
• GIT (Geneesmiddel Informatie Tekst) - Personalised medicines information leaflet 
o
 With the personalized medicines information leaflet, patients receive 
complete information about their medicines, which includes information on 
the influence of the medicine on driving fitness. In this leaflet, a pictogram 
was included, as well. The pictogram (DRUID warning label), displayed 
below (Figure 55), gives information on the severity of the impairment that is 
associated with the medicine (this implies a categorization system based on 
the level of impairment of a medicine on driving fitness). The warning label, 
combined with  oral information and written warnings and instructions in the 
leaflet provides personalized information to the patient. The leaflet is printed 
and given to the patient during the first-time dispensing of a medicine. 
Additional information on the pictogram and risk communication can be 
found in DRUID deliverable 7.3.2 [7]. 
 
Figure 55: DRUID warning labels included in the GIT. Depending on the category 
of the medicine, it was added a category 1 (a), category 2 (b) or category 3 (c) 
pictogram. 
 
 
2.5 Tool Description 
 
As previously mentioned in the introductory part, the DRUID tool was not implemented in 
the Netherlands. Instead, DRUID protocols and guidelines were implemented in the 
Pharmacom® system for medication surveillance in Dutch community pharmacy practice.  
 
In case of a first prescription check (EUC) a signal informs the pharmacist that safer 
alternatives might be used, if available. If no safer alternatives can be used, the dispensing 
will follow based on the first dispensing counselling module. 
a)
b)
c)
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In case of a first dispensing counselling (EUB) to an individual patient will follow (at the 
start of treatment) specific information is shown on the computer screen. See Figure 3 as 
an example of the information that is displayed on the computer screen when flurazepam 
30mg (capsule) is dispensed, for the first time to a specific patient. By entering “Yes”(J) or 
“No” (N) after every line in this protocol responses will be logged to document the activity. 
In case of a second dispensing, the information is again displayed on the screen, primarily 
with questions to inquire about possible side effects that might have occurred). However, 
those issues that have been logged with a “N” or blank response during the first dispensing 
will be shown again.  
 
In general, the Pharmacom® system supports pharmacists in the following ways: 
 
• First-time dispensing check advises the pharmacist to look for safer 
alternatives, if existing. 
• First-time dispensing counselling after selecting the medicine that will be 
handed out to the patient. 
• Warnings that are displayed on the dispensing label as well as printouts of 
the patient information leaflet can be printed.  
• Second-time dispensing counselling to provide information to the patient 
when there is a second dispensing. 
• Documentation of counselling activities. 
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Translations of the section Eerste uitgifte begeleiding PROTOCOL 
First dispensing: Side effects: sleepiness, sedation  (F7) : J 
Driving: Do not drive while taking this medicine (cat.3) (F7) : J 
Take before the night/preferably not every day  (F7) : N 
Dosage: Before the night 1 capsule if needed   : 
Instruction for use: Might influence driving performance  : 
Do not take with alcoholic beverages    : 
 
Instructions to the pharmacy technicians: 
Explain to the patient each of the lines in the PROTOCOL and indicated “J” 
(Yes) if you did and “N” (No) if you did not. 
If you need background information please press “F7”. 
 
In case of “Driving: Do not drive while taking this medicine (cat.3)“ pressing (F7) will 
show the following background information: 
GENERAL INFORMATION 
The medicine has a severe influence on driving performance (cat 3). 
If taken daily: do not drive. 
If taken infrequently: do not drive during 3 days after intake. 
Take care in circumstances that require unaffected attention (e.g. 
operating machinery). 
Impairment by side effects, such as sedation, sleepiness, dizziness, 
blurred vision, impaired reaction time. 
Even without these side effects impaired driving performance might 
occur. 
Alcohol will potentiate impaired driving performance: do not drive! 
Figure 56: Pharmacom® EUB information that is displayed on the computer screen, when 
flurazepam 30mg capsules is dispensed for the first time to an individual patient.  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 278 of 456 
2.6 Training evaluation 
 
The evaluation of the training was performed by means of questionnaires addressed to 
pharmacists, before (Annex 1) and 6-months after (Annex 2) the training. The 
effectiveness of the training was also evaluated at the patient level, by means of a 
questionnaire addressed to patients (Annex 3), as a way of verifying whether the 
information that was given to pharmacists during the training was, indeed, provided to 
patients at the time of the dispense of medicines. Dispensing data from the participating 
pharmacists was collected as well.  
 
 
2.7 Dispensing data 
 
Pharmacists who were enrolled in the study were asked to adjust their Pharmacom® 
system in a way that was possible to retrieve 1 year of dispensing data from patients’ 
medication records concerning driver impairing medicines such as anxiolytics (ATC code: 
N05B), hypnotics (ATC code: N05C), and antidepressants (ATC code: N06A). Four 
databases were received and the data was analyzed.   
 
 
2.8 Data Analysis 
 
2.8.1  Pharmacists 
 
As for the analysis and comparisons between the time of the measurement (intervention 
group T0 and T1), the t-test for independent samples to compare means was used, as 
most of the assumptions for parametric tests were covered: the dependent variables are 
continuous, the scores were obtained using a random sample of the population and the 
observations are independent. Regarding normality of the data, it is believed that the 
statistical tests are robust enough to overcome this problem, especially when the 
population has more than 30 cases, which was always the case. At all times, homogeneity 
of variance was confirmed (the Levene's test was always not significant). 
 
In order to be able to compare means, at T0 and T1, several composite scores related to 
pharmacists’ awareness, reported behaviour, and actual knowledge were created. 
Answers between strongly disagree (0) and strongly agree (3) were used to measure 
pharmacists’ awareness. To measure pharmacists’ reported behavior, a 5-point Likert 
scale was used, ranging from never (0) to always (4). Pharmacists’ actual knowledge was 
evaluated by means of several statements related with the influence of a certain active 
substance on driving fitness. Pharmacists could totally agree or totally disagree with the 
statement. The range of answers was later on recoded into wrong (0) or right (1) answers 
(“do not know” (2) answers was also an option). 
 
For all comparisons, a p-value < 0.05 was considered statistically significant (95% 
confidence interval).  
 
For the evaluation of the tool and the materials that were provided during the course, 
descriptive analysis were conducted and presented.  
 
2.8.2 Patients 
 
Descriptive analysis was performed to give insight on participants’ gender, education level, 
frequency of driving, experience of side effects, and information about medicines (who 
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provided information to patients, when was that information shared with the patient, and 
the content of that information). 
 
To compare differences between the 2 groups of patients (at the baseline measurement, 
T0 and at the follow-up, T1), the t-test for independent samples to compare means was 
used, as most of the assumptions for parametric tests were covered. In order to be able to 
compare means, at T0 and T1, several composite scores related to patients’ knowledge 
about causes of road accidents and related to patients’ attitudes. To measure patients’ 
knowledge, a 5-point Likert scale was used, ranging from never (0) to always (4). 
Knowledge about the risk of having a road accident while driving under the influence was 
evaluated by means of several statements.  Patients could totally agree or totally disagree 
with each statement. The range of answers was later on recoded into wrong (0) or right (1) 
answers (“do not know” (2) answers was also an option) allowing to distinguish whether 
patients do acknowledge risk of having road accidents under a range of different situations 
which is also related to patients’ awareness. 
 
For all comparisons, a p-value < 0.05 was considered statistically significant (95% 
confidence interval).  
 
2.8.3 Dispensing Data 
 
Incidence data of dispensed antidepressants (ATC N06A), anxiolytics (ATC N05B) and 
hypnotics (ATC N05C) was extracted by the participating pharmacists directly from the 
Pharmacom® system covering a period from July 2008 until April 2010. Data collection 
was captured using a unique number for each individual patient as identifier, which is 
randomly assigned and for which the key to the patient personal data is only known to the 
pharmacist of the patient. Incidence data on changed prescriptions that were switched to 
less impairing medicines in each therapeutic class during the 6 months of the study were 
collected as well.  
 
Only new users of one of the selected classes of medicines (N65B, N05C and N06A) were 
considered. A new user is defined as a patient who had not used a specific medicine for a 
period of 6 months. As soon as the first prescription is detected, the upcoming records of 
the same patient having the same medicine are excluded. However, a patient can be 
repeated in the database as long as he/she is taking a different medicine for the first time 
(or for a period longer than 6 months). The extraction of the new users was conducted as it 
is described in the flowchart presented below (Figure 57).  
 
The data that was collected was used to evaluate descriptive differences in the number of 
prescriptions of the medicines belonging to the N05B, N05C and N06, before (T0) and 
after (T1) the training, in the 2 groups of pharmacists (intervention and control groups). A 
time trend analysis was performed. Note: in the dispensing data analysis, the control group 
was seen as a reference group and, therefore, it is called “reference group” in the sections 
referring to the dispensing data. Data regarding the total number of patients that are 
registered in each pharmacy was collected as well. 
 
As for the statistical analysis, the proportion per thousands of patients of new users of 
N05B, N05C and N06A medicines was calculated. Additionally, the distribution of new 
users during the study period was described (from April 2009 until April 2010). No time 
trend analysis was conducted as data from one year might not be enough to see significant 
differences. In order to verify whether or not there was a shift in the dispensing DIM into 
safer alternatives, the proportion per thousands of patients of category 1, 2 and 3 
medicines in each pharmacy group was calculated.   
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.Figure 57: Flowchart representing the criteria for inclusion of patients/prescriptions in the database 
T0 
April 09 – Oct 09 
YES 
T1 
Oct 09 – April 10 
Look back 6 months 
 
 
T0 
 
Is Patient X with 
medicine A repeated at 
T0? 
Look back 6 months 
 
Oct 08 – April 09 
Patient X with medicine A 
In which period is the 
patient? 
Patient X with 
medicine A belongs to 
T1 
 
NO 
YES 
Is Patient X with 
medicine A repeated in 
that period? 
Patient X with 
medicine A is not  
included  
 
Patient X with 
medicine A belongs 
to T0 
 
NO 
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3 Results 
 
3.1 Pharmacists 
3.1.1 Total number of participants 
 
The results shown below are referred to the following number of participants:  
 
• Pre-questionnaire (baseline measurement, T0) 
o
 Intervention group (pharmacists who attended the training). 
o
 N = 44 out of 49 
o
 Response Rate = 89.8% 
 
• Post-questionnaire (follow-up, T1) 
o
 Intervention group (in some cases, the follow-up questionnaire 
was filled in by a different pharmacist from the one who attended the 
course). 
o
 N = 44 out of 49 
o
 Response Rate = 89.8% 
 
 
3.1.2 Pharmacists’ characteristics 
 
At both measurements (T0, and T1), the percentage of females was higher than males, as 
illustrated in Figure 58, and the mean age of all participants (N=84) was 40.5 years old (s.d 
= 10.4). In average, pharmacists had 12.8 years of practice (s.d = 9.2).   
 
 
 
 
Figure 58: Pharmacists’ gender, stratified per time of the measurement (T0 and T1).  
 
Regarding new technologies literacy, 98% (n=84) of the pharmacists used internet to 
obtain general information about medicines. The percentage of pharmacists that used the 
internet to obtain information on medicines affecting driving behaviour increased after the 
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training (n=26, 59.1% baseline measurement T0 and n=27; 64.3% follow-up measurement, 
T1). Pharmacists used software packages less often than internet to obtain information on 
medicines affecting driving behaviour.  
 
3.1.3 Pharmacists’ Awareness 
 
Awareness regarding the influence of medicines on driving fitness was measured by 
means of several statements. The answers to the statements could be: 0 – strongly 
disagree, 1 – disagree, 2 – agree, and 3 – strongly agree. Table 3 shows the comparison 
between pharmacists’ awareness before and after the training (T0 and T1).  
 
The mean composite scores for awareness statements were before and after the training 
2.05 (s.d. 0.18) and 2.15 (s.d. 0.25), respectively, meaning that pharmacists agreed with 
the statements. Pharmacists’ awareness, both before and after the training, increased 
every time the patient was taking other CNS medicines (95.5% and 100%), and every time 
the patient was a professional driving (90.9% and 97.6%), drives frequently (86.4% and 
92.7%), and drives long distances (81.8% and 87.8%).  
 
Table 103: Mean scores for awareness statements at both time measurements 
(intervention group). 
 
Time of the measurement 
P-value T0 T1 
N Mean S.D N Mean S.D 
I am taking into account the effects of 
medicines on driving skills when 
dispensing medicines. 
44 2,23 0.42 41 2,37 0.49 0,167 
I am willing to sacrifice some degree of 
efficacy by dispensing a 
medicine that is less impairing to 
the driving skills. 
43 1,88 0.39 40 1,82 0.45 0,525 
I am aware of the effects of medicines 
on driving skills. 
44 1,82 0.45 42 2,26 0.44 <0,001* 
It is important for me to be well-
informed on medicinal effects on 
driving behaviour. 
44 2,5 0.51 42 2,4 0.50 0,095 
I feel that the information I provide to 
patients will influence their 
driving behaviour. 
42 1,79 0.52 42 1,95 0.44 0,116 
Answers to the statements: 0 – strongly disagree, 1 – disagree, 2 – agree, and 3 – strongly agree. 
* A p-value < 0.05 considered to be statistically significant.  
 
3.1.4 Pharmacists’ Reported Behaviour 
 
Reported behavior regarding the influence of medicines on driving fitness was measured 
by means of several statements. The answers to the statements could be: 0 – never, 1 – 
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seldom, 2 – sometimes, 3 – regularly, and 4 – always. Table 4 shows the comparison 
between pharmacists’ reported behaviour before and after the training (T0 and T1).  
 
The mean composite scores for reported behaviour statements were before and after the 
training 2.07 (s.d. 0.55) and 2.67 (s.d. 0.53), respectively, meaning that pharmacists 
behaviour towards medicines and driving was fair. 
 
Table 104: Mean scores for reported behaviour at both time measurements (intervention 
group).  
 
Time of the measurement 
P- 
value 
T0 T1 
N Mean S.D N Mean S.D 
I ask a patient about his/her driving 
exposure when dispensing a 
medicine. 
44 1.64 0.94 41 2.66 0.82 
<0,001
* 
I inform a patient about driving 
related risks when dispensing a 
medicine 
44 2.86 0.79 41 3.34 0.62 0,003* 
I provide a patient with written 
information materials when 
dispensing a driving impairing 
medicine. 
44 3.20 0.76 41 3.59 0.55 0,01* 
I keep systematic records when I 
dispense a driving impairing 
medicine (e.g. as in the EPD in 
Pharmacom). 
44 2.52 1.61 41 2.76 1.20 0,448 
I keep systematic records when I 
advise a patient when and how 
he/she can consider driving a car 
when using a driving impairing 
medicine (e.g. as in the EPD in 
Pharmacom). 
44 1.77 1.28 41 2.65 1.23 0,007* 
I keep a record of the patient’s 
traffic participation (e.g. how often 
he/she drives to work). 
44 0.25 0.72 42 0.57 0.83 0,059 
I discuss medicinal drug 
consumption and driving related 
responsibility issues with the 
patient. 
42 1.89 0.94 42 2.81 0.94 
<0,001
* 
How frequently do you usually 
provide detailed information when 
dispensing a medicine with 
impairing effects on driving 
42 2.50 0.94 42 3.14 0.78 0,001* 
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performance? 
Answers to the statements: 0 – never, 1 – seldom, 2 – sometimes, 3 – regularly, and 4 – always. 
* A p-value < 0.05 considered to be statistically significant. 
 
3.1.5. Pharmacists’ Sources of Information 
 
Pharmacists, at both measurements (T0 and T1), considered they have easy access to 
data and information about the effects of a medicine on driving skills. The preferable 
sources of information are listed in Table 105.  
 
Table 105: Preferable sources of information at both time measurements 
(intervention group).  
 
Sources of information 
Time of the measurement 
P-value T0 T1 
N % N % 
Professional websites 36 81,8 37 30,2 0,26 
Newsletters 6 13,6 2 4,9 0,17 
Organizations 15 34,1 5 12,2 0,02* 
Journals 6 13,6 4 9,8 0,58 
Other 6 13,6 2 4,9 0,17 
* A p-value < 0.05 considered to be statistically significant. 
 
 
3.1.5 Pharmacists’ Actual Knowledge 
 
Actual knowledge regarding the influence of medicines on driving fitness was measured by 
means of several statements. The answers to the statements could be: 0 – totally 
disagree, 1 – disagree, 2 – agree, 3 – totally agree, and 4 – don’t know. Table 106 
describes the statements that pharmacists were shown and which was the correct answer. 
For analysis purposes, pharmacists’ answers were afterwards recoded into right or wrong. 
The differences between the answers at both time measurements are shown in Table 107.  
 
Table 106: Statements asked to pharmacists and respective correct answers.  
Statement Correct answer 
Recoding 
0 – wrong; 1 – right;  
2 – don’t know 
Temazepam (up to 20 mg) severely impairs driving 8 
hours after intake. 
Disagree 
0 & 1 – right answer (1) 
2 & 3 – wrong answer (0) 
4 – don’t know (2) 
Diazepam (regardless the dose) severely impairs 
driving within the first 2 months of treatment. 
Agree 
0 & 1 – wrong answer (0) 
2 & 3 – right answer (1) 
4 – don’t know (2) 
Codeine (up to 20 mg) is mostly safe for drivers. Totally agree 0 & 1 – wrong answer (0) 
2 & 3 – right answer (1) 
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Table 107: Differences between the answers to the statements, at both time 
measurements (intervention group).  
 
Statement Answer 
T0 T1 
P-value 
N % N % 
Temazepam (up to 20 mg) severely 
impairs driving 8 hours after 
intake. 
Right 12 27,3 17 41,5 
0,266 Wrong 31 70,5 24 50,5 
Don't know 1 2,3 0 0 
        
Diazepam (regardless the dose) 
severely impairs driving within 
the first 2 months of treatment. 
Right 30 68,2 22 52,4 
0,215 Wrong 11 25 18 42,9 
Don't know 3 6,8 2 4,8 
        
Codeine (up to 20 mg) is mostly safe 
for drivers. 
Right 26 59,1 34 81 
0,027* Wrong 18 40,9 8 19 
Don't know 0 0 0 0 
        
Fexofenadine (normal dose) severely 
impairs driving. 
Right 32 72,7 33 80,5 
0,022* Wrong 5 11,4 8 19,5 
Don't know 7 15,9 0 0 
        
Amitriptyline has the same level of 
driving impairment at the start 
of treatment and 4 weeks after 
the start of the treatment. 
Right 26 59,1 34 82,9 
0,045* Wrong 13 29,5 6 14,6 
Don't know 5 11,4 1 2,4 
        
Paroxetine (up to 20 mg/day) is safe 
for drivers. 
Right 18 40,9 36 87,8 
<0,001* Wrong 22 50 4 9,8 
Don't know 4 9,1 1 2,4 
4 – don’t know (2) 
Fexofenadine (normal dose) severely impairs driving. Totally disagree 
0 & 1 – right answer (1) 
2 & 3 – wrong answer (0) 
4 – don’t know (2) 
Amitriptyline has the same level of driving impairment 
at the start of treatment and 4 weeks after the 
start of the treatment. 
Totally disagree 
0 & 1 – right answer (1) 
2 & 3 – wrong answer (0) 
4 – don’t know (2) 
Paroxetine (up to 20 mg/day) is safe for drivers. Totally agree 
0 & 1 – wrong answer (0) 
2 & 3 – right answer (1) 
4 – don’t know (2) 
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* A p-value < 0.05 considered to be statistically significant. 
 
For the majority of the pharmacists, a patient can be punished with criminal sanctions if 
he/she causes a traffic accident while using a medicine with impairing properties whenever 
the health care provider has advised him/her not to drive (95.4% (n=42) at baseline 
measurement and 97.6% (n=40) in the follow-up). 
Almost 75% (n=33) of the pharmacists were willing to use a tool that allows to find 
information on medicinal drugs and driving, while dispensing.  
 
3.1.6 Pharmacists’ User Acceptance of the Materials 
 
This result subsection only refers to the follow-up measurement, T1, as only pharmacists 
from the intervention group used the materials that were provided during the course 
(N=44). Bellow are shown the pharmacists’ evaluation of the materials that were given to 
them during, and after, the course.  
 
The use of the information materials that were provided during the course was limited: 
48.9% (n=21) rarely used the materials whereas only 20.9% (n=9) used the information 
materials regularly (more than 10 times for a 6-months period). However, 90.7% (n=39) 
used the materials provided to inform the pharmacy technicians working in the pharmacy. 
The collaboration between GPs and pharmacists continues not to be very visible. Almost 
90% of the pharmacists did not share the PowerPoint that was provided during the course 
with GPs. The four newsletters that were sent electronically to pharmacists were read by 
the majority of the participants (30 out of 43 pharmacists; 69.8%). Figure 59 illustrates how 
pharmacists evaluated the information materials that were developed and provided during 
the course.  
 
Figure 59: Evaluation of the course itself and of the materials that were developed. 
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3.1.7 Pharmacists’ User Acceptance of the Materials and Usability of the Tool 
(EUB-TUB module) 
 
This result subsection only refers to the follow-up measurement, T1 (N=44). Regarding the 
use of the Pharmacom® system, 97.6% of the pharmacists (41 out of 42) switched on the 
EUC module. In general, the EUB and TUB-module for N06 were more use than for N05 
medicines (95.1% EUB N05; 90.2% TUB N05; 97.6% EUB N06 and 92.7% TUB N06).   
 
The different functionalities that were incorporated in the Pharmacom® system were 
evaluated as clear, useful, complete and well organized, except for the EUC system that 
were classified as handy, clear and useful. The answers to the statements could be: 1 – 
not so much, 2 – neutral, 3 – quite a lot and 4 – very much. Table 108 shows the means of 
the evaluation of the materials by pharmacists.  
  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 288 of 456 
 
 
Table 108: Evaluation of the materials that were incorporated in the Pharmacom® system 
(mean values). 
 
 
 
Intervention group 
 
 
N Mean Std. deviation 
EU
C 
Handy 41 3,49 0,87 
Clear 41 3,49 0,87 
Useful 41 3,54 0,711 
EU
B
-
TU
B
 Clear 40 3,68 0,526 
Useful 40 3,63 0,586 
Complete 40 3,7 0,516 
Te
x
t F
7 
Clear 39 3,41 0,88 
Useful 39 3,33 0,898 
Complete 39 3,56 0,641 
Well organized 39 3,26 0,928 
CM
PM
 
Clear 40 3,1 0,841 
Useful 40 3,2 0,791 
Complete 40 3,03 0,8 
Well organized  40 3,08 0,797 
Answers to the statements: 1 – not so much, 2 – neutral,  
3 – quite a lot and 4 – very much. 
 
3.1.8 Pharmacists’ way of Informing Patients, Technicians and Physicians about 
Medicines and Driving  
 
This result subsection only refers to the follow-up measurement, T1. While dispensing 
medicines, pharmacists can make use of different sources of information to inform their 
patients, either orally or with written materials. In average, pharmacists from the 
intervention group regularly (mean score 3.69; s.d = 0.7) used the information presented in 
the EUB/TUB module to orally inform their patients about the influence of medicines on 
driving fitness. A reference to the yellow sticker (warning label affixed to medicines that 
influence driving fitness alerting to the combination with alcohol) was also regularly used 
while dispensing (mean score 3.48; s.d = 0.9), similarly to the use of the DRUID warning 
label (mean score 3.34; s.d = 0.9). Other available Dutch materials were not commonly 
used. Answers to the statements ranged from: 0 – Never, 1 – Seldom, 2 – Sometimes, 3 – 
Regularly to 4 – Always.  
 
45.2% of the pharmacists (total n=44) found the DRUID warning label very useful to 
provide information to patients. Regarding the sufficiency of information on the DRUID 
warning label, 35.7% of the pharmacists mentioned that it was quite clear and 40.5% were 
neutral. The categorization of medicines according to their level of impairment on driving 
fitness was well received by pharmacists who found the categorization clear and useful.  
 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 289 of 456 
Concerning the information that was provided during the course to inform technicians, the 
totality of the pharmacists trained their colleagues/technicians.  
 
Pharmacists did not often change a prescription to a less impairing alternative due to the 
effects on driving fitness. When that happened, it was only 1-2 times (20 out of 40 
pharmacists) and, more rarely, 3-4 times (8 out of 40 pharmacists).  
 
 
3.2 Patients 
 
3.2.1 Patients’ characteristics and participation in traffic 
 
A total of 930 respondents participated in the study. The mean age was 53.5 years-old 
(s.d. = 14.7), with a minimum of 19 years-old and a maximum of 90 years-old. Participants’ 
gender (n=927), education level (n=924), frequency of driving (n=930) and experience of 
side effects (n=880), at both time measurements and per pharmacy group, are 
represented in Figure 60. No significant differences were found neither between the 2 
times of measurement nor between groups, for all variables.  
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Figure 60: Participants’ gender (A), education level (B), frequency of driving (C), and experience of side effects (D). The percentage is stratified 
by pharmacy group (intervention and control) and time of the measurement (T0 and T1). 
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3.2.2 Patients’ knowledge about the influence of medicines on driving fitness 
 
Mean scores for causes of road accidents materials (written materials included) were 
calculated. Answers to the statements ranged from: 1 – Never, 2 – Seldom, 3 – Sometimes 
to 4 – Often. The results are displayed on Table 109, where patients from both intervention 
and control groups were included.  
 
Table 109: Mean comparison between causes of road accidents, stratified by time of 
measurement. 
 
T0  T1 
P-value 
 Statement N Mean S.D N Mean S.D 
Driving when tired 370 3.55 0.72 463 3.61 0.64 0.169 
Driving under the influence of alcohol 392 3.71 0.79 472 3.80 0.63 0.079 
To short distance to the leading car 372 3.45 0.73 455 3.47 0.69 0.594 
Speeding 370 3.42 0.75 458 3.59 0.63 0.134 
Use of medicines that might impair 
driving 
367 3.27 0.76 446 3.31 0.72 0.452 
Use of illicit drugs 354 3.49 0.84 423 3.57 0.73 0.138 
Use of a mobile phone while driving 372 3.37 0.80 457 3.39 0.73 0.759 
Answers to the statements: 1 – never, 2 – seldom, 3 – sometimes and 4 – often. 
 
Despite no significant differences were found between time measurements, a general 
improvement was observed in the follow-up measurement, in patients’ knowledge about 
causes of road accidents. Figure 61 shows the composite scores for knowledge, in each 
group stratified by time. No statistical significant differences were found. 
 
 
 
Figure 61: Composite scores for patients’ knowledge, stratified by time and pharmacy 
group (n= 731).  
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Patients’ knowledge can also be evaluated in terms of knowledge about the risk of having 
a road accident while driving under the influence of medicines. To do so, several 
statements about the risks of driving under the influence of medicines were developed. 
The answers to the statements could be: 1 – totally disagree, 2 – disagree, 3 – agree, 4 – 
totally agree, and 5 – no opinion. Table 110 describes the statements that patients were 
shown and percentage of right and wrong answers, as well as the percentage of answers 
that patients did know the correct answer. For analysis purposes, patients’ answers were 
recoded into right, wrong and don’t know. The differences between the answers at both 
time measurements are shown in Table 110.  
 
Table 110: Risk of having a road accident while driving under the influence of medicines, 
stratified by time of measurement. . 
Question about risk of driving 
under the influence of 
medicines 
T0 T1 
p-value Wrong Right 
Don't 
know 
Wrong Right 
Don't 
know 
N (%) N (%) N (%) N (%) N (%) N (%) 
The risk of having a road 
accident is smaller when you 
have just started taking a driving 
impairing medicine compared to 
long term treatment  
91 
(22.1) 
283 
(68.7) 38 (9.2) 
84 
(16.8) 
383 
(76.4) 34 (6.8) 0.032 * 
The risk of having a road 
accident may increase when you 
combine a driving impairing 
medicine and over the counter 
medicines (e.g. pain killers, 
cough remedy)  
76 
(18.5) 
266 
(64.9) 
68 
(16.6) 
109 
(21.8) 
265 
(53.0) 
126 
(25.2) 0.001 * 
The risk of having a road 
accident increases when you use 
alcohol while taking a driving 
impairing medicine  
18 
(4.4) 
388 
(94.6) 4 (1.0) 
22 
(4.4) 
475 
(94.1) 8 (1.6) 0.723 
The risk of having a road 
accident remains the same when 
you use several driving impairing 
medicines at the same time  
143 
(34.8) 
239 
(58.2) 29 (7.1) 
167 
(33.3) 
291 
(58.1) 43 (8.6) 0.667 
The risk of having a road 
accident increases with a high 
dose of a driving impairing 
34 
(8.3) 
345 
(84.1) 31 (7.6) 
43 
(8.6) 
421 
(83.9) 38 (7.6) 0.989 
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medicine  
* A p-value < 0.05 considered to be statistically significant. 
 
 
3.2.3 Information about medicines 
 
Either pharmacists or GPs (and sometimes both HCP) can inform patients about the use of 
medicines, being pharmacists the most likely source of information. Patients can either be 
spontaneously informed about the possible influence of medicines on fitness to drive or 
they might receive that information only after asking for it. The graph displayed in Figure 62 
illustrates whether patients were spontaneously informed or not, at each time 
measurement (n=911). A statistical significant difference (p-value=0.007) was found 
between the control and the intervention group, at T1, referring to the information that is 
spontaneously provided to patients.  
 
 
Figure 62: Percentage of patients who were not informed by their HCP or who were 
informed spontaneously or after request. The percentages are stratified by time and 
pharmacy group (n=911). 
 
Patients (n=607) were mainly informed about the influence of their medicines on driving 
fitness and on operating machinery and about the severity of the impairing effects, when 
compared to the influence of alcohol on driving fitness. The percentages stratified by time 
and pharmacy group can be found in Table 111. Despite the increase, in the follow-up 
measurement (T1), in the percentage of patients stating being informed by their pharmacist 
about the influence of medicines on driving fitness or on operating machinery and about 
the severity of the impairment,  no statistically significant differences were found between 
time of the measurement or between pharmacy group (intervention or control). Only 12 
patients mentioned having discussed safer alternatives with their pharmacists. In those 
situations, 6 out of the 12 pharmacies belong to the intervention group.  46.9% of the total 
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number of patients (n=930) did not remember the duration of the impairing effect that was 
communicated by the HCP responsible for providing that information. 
 
Table 111: Content of the information that was provided to patients, stratified by time of 
measurement and pharmacy group (n=607). 
 
Influence on 
driving ability 
(%) 
Influence on 
operating 
machinery (%) 
Severity of 
impairment 
(%) 
Pharmacy 
group 
T0 
T1 T0 
T1 
T0 T1 
Intervention  19.1 30.5 9.6 14.2 4.8 7.6 
Control  16.6 20.9 7.6 8.2 4.6 4.5 
 
 
 
3.2.4 Patients’ behaviour towards the influence of medicines and driving 
 
After receiving information about the possible impairing effects of the medicines, patients 
can decide whether they can stop driving their vehicles or not. Figure 63 illustrates whether 
patients (n=820) decided to change their frequency of driving or not (meaning whether 
patients changed their driving behaviour or not), stratified by time of the measurement and 
pharmacy group (intervention or control). No statistical significant differences were found. 
  
 
Figure 63: Changes in frequency of driving. The percentages presented are stratified by 
time and pharmacy group (n=820). 
 
3.2.5 Patients’ attitudes towards driving under the influence of medicines 
 
Patients’ attitudes towards the use of driving impairing medicines and the use of alcohol 
while driving was measured by means of several statements. The answers to the 
statements could be: 0 – totally disagree, 1 – disagree, 2 – agree, and 3 – totally agree. 
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Table 112 describes the statements that patients were asked at both time measurements. 
Similarly, patients’ attitudes concerning the use of driving impairing medicines and its 
consequences on traffic participation was evaluated as well. Results are shown in Table 
113. 
 
Table 112:. Patients attitudes towards the use of DIM and the use of alcohol while driving, 
stratified by time of the measurement (T0 and T1). 
 
T0  T1 
P-value 
  
N Mean S.D N Mean S.D 
When using driving impairing medicines people 
should decide for themselves whether they 
drive/ride a motorised vehicle or not. 
374 1.05 0.83 459 1.09 0.80 0.468 
Driving while using driving impairing medicines 
should be punished more severely in the 
future. 
357 2.00 0.68 437 1.91 0.74 0.073 
Driving after the consumption of alcohol should be 
prohibited. 
384 2.39 0.77 475 2.33 0.77 0.258 
The risk of driving under the influence of driving 
impairing medicines is being exaggerated. 
344 0.95 0.71 414 0.97 0.76 0.704 
The risks of driving under the influence of alcohol 
are being exaggerated. 
389 0.59 0.76 472 0.60 0.73 0.863 
Answers to the statements: 0 – totally disagree, 1 – disagree, 2 – agree, and 3 – totally agree. 
 
Table 113: Patients’ attitudes concerning the use of driving impairing medicines and its consequences 
in traffic participation, stratified by time of the measurement (T0 and T1). 
 
T0  T1 
P-value 
  
N Mean S.D N Mean S.D. 
Possible consequences of the use medication in 
traffic have never crossed my mind. 
365 0.99 0.72 460 0.91 0.68 0.137 
When I drive when using a driving impairing 
medicine I endanger my personal safety. 
359 1.98 0.724 438 1.92 0.71 0.252 
When I drive when using a driving impairing 
medicine I endanger the safety of other 
traffic participants. 
363 2.05 0.72 442 2.01 0.74 0.458 
If I know someone is using driving impairing 
medicines I will not let them drive me. 
331 1.90 0.72 409 1.79 0.77 0.063 
When I have been prescribed a driving impairing 
medicine I choose not to use my car and 
choose other types of transportation. 
347 1.90 0.76 423 1.75 0.81 0.009* 
I do not mind other traffic participants using 
driving impairing medicines. 
347 0.84 0.71 432 0.95 0.75 0.043* 
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When I have been prescribed a driving impairing 
medicine I try to use my car/vehicle as 
little as possible. 
352 2.08 0.75 451 1.97 0.79 0.060 
When other drivers participate in traffic they take 
their use of driving impairing medicines 
into account. 
226 1.10 0.71 263 1.20 0.78 0.124 
Answers to the statements: 0 – totally disagree, 1 – disagree, 2 – agree, and 3 – totally agree. 
* A p-value < 0.05 considered to be statistically significant. 
 
 
3.3 Dispensing data 
 
As mentioned in the methods section, data on the total number of patients registered in 
each pharmacy was collected as well. This information is needed to calculate the 
proportion of the new users of N05B, N05C and N06A medicines in each pharmacy group 
(intervention and reference), that can be calculated as the number of new users of one of 
the group of medicines divided by the total number of patients registered in the pharmacies 
belonging to the intervention or to the reference group. 
 
From the 91 pharmacies enrolled in this study (49 from the intervention group and 42 from 
the reference group), 14 pharmacies did not provide information on the total number of 
patients registered in their pharmacies. Of the 14 pharmacies, 11 (4 from the intervention 
and 7 from the reference groups) failed to reply to our requests after 3 e-mails and 1 phone 
call, and 3 out of the 14 pharmacies (2 from the intervention and 1 from the reference 
group) refused to provide the requested information as it was considered to be confidential. 
Therefore, the dispensing data referring to 77 pharmacies (43 from the intervention and 34 
from the reference groups) was used for the analysis.  
 
The 77 pharmacies were equally distributed among the intervention and the reference 
group, both in terms of number of patients registered but also in terms of location. Table 
114 illustrates this information.  
 
Table 114:  Pharmacies’ location, number of inhabitants and number of registered patients 
 
Pharmacy group 
Intervention  
(43 pharmacies) 
Reference 
(34 pharmacies) 
Area*  
Urban 
Intermediate 
Rural 
 
15 pharmacies 
23 pharmacies 
5 pharmacies 
 
11 pharmacies 
18 pharmacies 
5 pharmacies 
Number of inhabitants 
Total 
Mean 
 
4.078.829 
94.856 
 
2.300.344 
67.657 
Number of registered patients 
Total 
Mean 
 
397.702 
9.249 
 
311.859 
9.172 
* Urban areas include locations with 70.000 up to 750.000 inhabitants; intermediate 
areas include locations with 10.000 up to 70.000 inhabitants and rural areas include 
locations with 5.000 up to 10.000 inhabitants.  
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According to the definition of new users that was explained previously in the methods 
section, it was possible to extract a total of 23.344 new users of N05B, N05C and N06A 
medicines in the 77 pharmacies. Table 115 shows the distribution of new users stratified 
by ATC code, pharmacy group and time of measurement. The T0 (baseline measurement) 
covers the period from 01 April 2009 until 31 October 2009 and T1 (follow-up) refers to the 
6 months after the training (from 01 November 2009 until 30 April 2010).     
 
Table 115: Distribution of new users of N05B, N05C and N06A medicines in each 
pharmacy group stratified by time of measurement 
ATC code Pharmacy group 
Time of measurement 
T0 T1 
N05B Intervention 2951 3285 
Reference 2550 2993 
N05C Intervention 2118 2343 
Reference 1725 2011 
N06A Intervention 1477 1555 
Reference 1205 1471 
 
 
The proportion of new users of each of group of medicines is displayed in Table 116. In 
order to evaluate differences in the proportions that could be attributed to the training 
course, odds-ratio, and respective confidence intervals, were calculated between the 
intervention and the reference groups at T1. The results are presented in Table 116.  
 
Table 116:  Proportion per thousand patients of new users of N05B, N05C and N06A 
medicines in each pharmacy group, stratified by time of measurement 
ATC code Pharmacy group 
Time of measurement Odds-ratio 
Confidence Interval 
(95%) 
T0 T1 Lower Upper 
N05B Intervention 6,81 7,52 0,868 0,8238 0,9145 
Reference 7,34 8,66 
N05C Intervention 4,94 5,44 0,938 0,8812 0,9987 
Reference 4,90 5,80 
N06A Intervention 3,41 3,53 0,825 0,7656 0,8897 
Reference 3,50 4,27 
 
The distribution over time of new users of the selected groups of medicines is presented as 
time trend analysis in Figure 64.  
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Figure 64: Time trend analysis. The vertical line in the graphs represents the beginning of the follow-up period (starts after the training, in November 2009 and lasts for 6 months, until end of April 
2010). 
    DRAFT 1 
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Within DRUID, a categorization system was developed [8] [9] based on the level of 
impairment of a medicine on driving fitness. Table 117 shows the distribution of the 
medicines, and respective category, over a year, from 01 April 2009 until 30 April 2010, (both 
T0 and T1 included) stratified by each group.  
 
Table 117: Proportion per thousand patients of category 1, 2 and 3 medicines in each 
pharmacy group, stratified by time of measurement  
ATC code Category T0 T1 
Intervention Reference Intervention Reference 
N05B 
cat 1 0,03 0,01 0,03 0,00 
cat 2 0,18 0,14 0,21 0,20 
cat 3 6,72 7,25 7,36 8,57 
N05C 
cat 1 0,06 0,04 0,08 0,03 
cat 2 0,00 0,00 0,00 0,00 
cat 3 4,85 4,81 5,32 5,74 
N06A 
cat 1 1,13 1,18 1,05 1,49 
cat 2 1,18 1,15 1,18 1,35 
cat 3 1,21 1,24 1,39 1,56 
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4 Discussion 
 
4.1 Pharmacists 
 
Females were the majority of the participants. The mean age was approximately 40 years-old 
and, on average pharmacists had 12.8 years of practice. To obtain information on medicines 
affecting driving behaviour, pharmacists used preferably internet rather than software 
packages showing familiarity with these types of tools. 
 
Pharmacists were, in general, aware of the influence of medicines on driving fitness. .After the 
course, pharmacists’ awareness of the effects of medicines on driving fitness increased and 
became statistically (p-value<0.001) higher, especially for the awareness about the effects of 
medicines on driving fitness.  
 
Pharmacists reported, on average, some regular routines, especially when it comes to 
provide patients with written information materials while dispensing driving impairing 
medicines. Pharmacists failed, however, to keep records of patients’ participation in traffic, 
during their daily practice, both before and after the course. After the course, pharmacists’ 
routine significantly improved, and become part of their regular practice. Pharmacists did 
report having easy access to data and information about the effects of a medicine on driving 
skills and the preferable source of information was professional websites. In the 1st 
measurement, pharmacists used significantly (p-value=0.02) more organizations as source of 
information than in the 2nd measurement, maybe still due to the effect that the public 
campaign had, as most of the information was provided by national organizations. 
 
In general, pharmacists’ knowledge about the influence of certain medicines on driving fitness 
can be considered good. In the follow-up measurement, pharmacists’ knowledge significantly 
increased and, consequently, the percentage of correct answers about the influence of a 
certain active substance on driving fitness increased and the percentage of “don’t know” 
decreased. The only exception seem to deal with Diazepam (statement: “diazepam, 
regardless the dose, severely impairs driving within the first 2 months of treatment”) where the 
percentage of wrong answers was always higher. A possible explanation for this fact could be 
due to a lack of understanding of the question itself.  
 
Regarding the use of information materials that were produced, data had shown that 
pharmacists did not use the information materials very often. However, 90% of the times the 
materials developed to train pharmacy technicians were used. The cooperation with GPs was 
not considered a common practice and, therefore, materials were not frequently used to 
discuss the influence of medicines on driving fitness with GPs. The majority of the 
pharmacists welcomed and read all the newsletters that were sent to them by e-mail. The 
course and the course materials were positively evaluated by the majority of the pharmacists, 
with the exception of the materials developed for GPs, as most of the pharmacists did not use 
it during the FTO (meeting with GPs and pharmacists). This could be due to the fact that the 
topics to be discussed during these meetings are selected in advance and pharmacists did 
not know, with so much time in advance, that they would be enrolled in a course on the 
influence of medicines on driving fitness. Therefore, the topic was probably not in the agenda 
for the FTO meetings that took place during the study period. 
 
Pharmacists were willing to use a tool which allows finding information on medicinal drugs 
and driving, while dispensing. After the course, all pharmacists switched on the EUC module 
and were very active with the modules from the Pharmacom® system, in particular with the 
modules concerning N06 medicines. The materials that were integrated in the Pharmacom® 
system (EUC, EUB-TUB modules, and CMPM) were considered to be handy, clear, useful 
and complete.   
 
Pharmacists regularly used written materials such as the information on the yellow sticker and 
the GIT to inform their patients about the possible influence of medicines on driving fitness. 
The DRUID warning label was also regularly used and pharmacists’ opinion about the DRUID 
warning label was, in general, positive and considered clear and useful to provide information 
to patients. The categorization of driving impairing medicines in three categories of 
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impairment was considered clear and useful. However, according to some pharmacists, the 
DRUID warning label raised, from the patient side many questions, such as about the 
meaning of the categorization system, mainly about the real risk of taking the medicine while 
driving. According to the authors, the fact that patients have questions about the pictogram 
and about the influence of medicines on driving fitness is a good starting point for discussion 
and to have patients involved in their own decision-making process of whether they should 
stop driving or not.  
 
Changing a medicine to a less impairing alternative was rarely done by pharmacists and 
when it happen, it was only done 1-2 times. This could be due to the fact that the prescription 
of medicines is something normally done by doctors and they are the ones deciding upon 
which medicine should be prescribed to the patient. Besides, when a pharmacist suggests a 
change in the prescription, the doctor has to agree with it. If the change is not immediately 
done at the pharmacy, the patient has to go back to their doctor for a change, causing delays 
in the treatment. If GPs would be addressed the same training as the one performed with 
pharmacists, the process could be faster and unnecessary burdens to the patients could be 
avoided.  
 
4.2 Patients 
 
At both time measurements there were more females than males and the mean age was 53 
years-old with a relatively low education level. Participants experienced side-effects, such as 
sleepiness, decrease in alertness and reaction time, troubles concentrating while taking 
driving impairing medicines. Despite the presence of side effects, patients often participated 
in traffic by driving their cars very frequently.  
 
Patients acknowledge the fact that driving when tired, driving under the influence of alcohol, 
keeping short distance to the leading car, speeding, driving under the influence of medicines 
or illicit drugs, and using a mobile phone while driving can be, sometimes or often, causes of 
road accidents. The mean scores slightly increased in the follow-up measurement without any 
statistically significant differences. When it comes to knowledge about the risk of having a 
road accident while driving under the influence of medicines, it was possible to identify some 
improvements which were statistically different (p-value = 0.032), particularly with respect to 
the risk of having road accident at the start of the treatment when compared to a long term 
treatment. However, patients’ knowledge about the combination of medicines with OTC 
medicines did not seem to be clear, especially during the follow-up measurement, when the 
percentage of wrong answers significantly (p-value = 0.002) increased. One could 
hypothesize that patients do not know what over-the-counter medicines are (even if examples 
were given) or that they did not realize that a combination effect could occur. Therefore, 
pharmacists could provide some additional information on the effects of the combination of 
OTC medicines and DIM on driving fitness.   
 
Regarding main sources of information about DIM, patients referred to pharmacists as the 
main source of information. After the training (follow-up measurement) a significantly (p-value 
= 0.007) higher percentage of patients were spontaneously informed about the influence of 
medicines on their driving fitness.  The information that was provided relates with the 
influence of the medicine in driving fitness and operating machinery and about the severity of 
the impairment. No statistically significant differences were found between the two time 
measurements or between the two groups of pharmacists. Very few patients mentioned 
having discussed with their pharmacist the possibility of taking safer alternatives for the 
treatment of their disease. That could be, in a way, related with the fact that, as mentioned 
before, pharmacists rarely changed a prescription.  
In any case, though patients receive information and mentioned having experience side-
effects, they do not change their driving behaviour, by driving less frequently.  
 
Patients’ attitudes towards the use of DIM and the use of alcohol while driving did not 
significantly change between time of measurement or pharmacy group. Patients clearly 
referred that driving while using DIM should be punished more severely in the future and 
denied that the risk of driving under the influence of medicines is being exaggerated.  
Regarding attitudes towards the use of driving impairing medicines and its consequences in 
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traffic participation, patients showed more concern towards safety related to others rather 
than related to them  
 
4.3 Dispensing data 
 
Even if the number of pharmacies included in each group differed, the mean of registered 
patients in the pharmacies belonging to the intervention and the reference group was equally 
distributed in both groups (9.249 and 9.172 patients in the intervention group pharmacies and 
in the reference group, respectively). The number of new users of N05B, N05C and N06A 
medicines was always higher during the follow-up period, but the difference was never 
statistically significant. The same was valid for the proportion of new patients: the number was 
always higher in the follow-up measurement and in the reference group, however with no 
statistically significant differences.  
 
Regarding the dispensing pattern of these groups of medicines, no changes in the follow-up 
period were verified. A decrease in the number of new prescriptions was seen after the 
training. However, it is not possible to attribute this change to the training because the drop in 
the prescriptions was also seen in the reference group and, besides, during the baseline 
measurement (T0) there were also periods where the number of new users decreased. 
 
Considering the 3 categories on the different levels of impairment, it was not possible to see a 
decrease in the dispensing of higher categories medicines and a consequent increase in the 
safer alternatives. This could be easily explained by the fact that pharmacists do not prescribe 
medicines. To see and effective change, the training should have been carried out among 
prescribers (GPs or specialists).  
 
4.4 Study strengths and limitations, problems encountered and solutions 
 
The main strengths of the present study can be attributed to the outcomes at different levels 
(pharmacists, patients and dispensing data). The pre-post comparison at patient level as well 
as the dispensing data certainly added value to the study, and allow to investigate to what 
extent the pharmacists’ training was effective. The large number of participants (mainly 
patients) ensured enough statistical power.  
 
Some limitations should be considered in this study. Firstly, the main limitation deals with the 
fact that no pre-post test in the control group of pharmacists was conducted as no 
questionnaire was addressed to pharmacists belonging to the control group. This decision 
was made as the authors believed this could trigger pharmacists’ attention to the topic and, 
therefore, could bias the results, mainly at the patient level. The results, however, showed no 
differences between the patients visiting the pharmacies belonging to the intervention or 
control groups. By not having any information from the pharmacists belonging to the control 
group makes it impossible to compare the differences between both groups in the main 
outcomes (awareness, knowledge and reported behaviour).  
 
Secondly, general practitioners were not involved as participants, even if several attempts 
were made, however without any success. It would have been a challenge to investigate 
interventions at the patient level, when both GPs and pharmacists are highly involved in 
selecting the least driving impairing medicine and in providing the patient with very detailed 
information about the influence of medicines on driving fitness. Perhaps if GPs would have 
been involved, different dispensing results were to be expected as, in the Netherlands, GPs 
are the main prescribers and, therefore, responsible for the prescription of medicines, 
including those that affect driving fitness.  
 
Thirdly, the outcomes of the public campaign on the influence of medicines on driving fitness, 
launched in the Netherlands in 2008, could have positively contributed to pharmacists’ 
relatively high level of knowledge, as well as to their positive awareness towards the use of 
potentially impairing medicines while driving, at the baseline. If the campaign was not 
experienced in 2008 a more significant result of the training, expressed as observed 
behaviour, could be expected, after 6 months.  Moreover, pharmacists’ voluntary participation 
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in the study and willingness to be well informed and aware of the possible risks of medicines 
on driving may have positively biased the results obtained in the study.  
 
Lastly, it is important to mention that the participants in this study were all users of one 
specific computer system. Even if the Pharmacom® system is used by half of the pharmacies 
in the Netherlands, the sample size of the population was restricted to the users of this 
software. The participation of pharmacists who use other software systems could have 
resulted in a more heterogeneous population, as the information provided and displayed in 
other computer systems can differ and, therefore, it could, in a way, influence pharmacists’ 
knowledge. However, the authors believe that having participants using the same computer 
system is strength, as that resulted in uniformed procedures and instructions for presenting 
information to the pharmacists.  
 
Besides the study limitations discussed above, several hurdles had to be overcome 
throughout the study period. The table below lists the problems encountered and the solutions 
that were decided upon to solve these.  
 
 
Table 118: Problems encountered and solutions. 
Problem encountered Solution 
Schedule of training sessions – it 
was difficult to find dates that would 
suit the majority of the participants. 
The location for the training as, 
sometimes, an issue for the 
pharmacists.  
Several sessions, in different 
locations, were scheduled. The 
training was, at all times, given by the 
same person (Ms Hilka Wolschrijn). 
Problems with English – because 
this study is part of the European 
project DRUID, the questionnaire that 
pharmacists had to fill in right before 
the training was in English. Some 
pharmacists felt it was difficult to 
understand some of the questions.  
The person in charge of giving the 
course translated the questions that 
generate more problems. This was 
done in all training sessions to 
ensure the same level of 
understanding.  
Pharmacy assistants – in the 
Netherlands, pharmacists’ assistants 
play an important role in the 
information that is provided to 
patients while dispensing medicines. 
However, the training was aimed only 
at pharmacists.  
Information materials were created 
for pharmacists’ assistants and 
pharmacists were given instructions 
on how to train their pharmacy team. 
By doing so, it was ensured that all 
teams at all pharmacies received the 
same information.  
Collaboration with general 
practitioners – in the Netherlands, 
there is a national primary care 
agreement (LESA) that refers to the 
collaboration between pharmacists 
and GPs.  
Despite the fact that GPs were not 
included in the study, information 
materials were provided to 
pharmacists so that they could inform 
the GPs with whom they collaborate 
whenever they met. In this way, GPs 
were also up-to-date about the study 
and were aware of the influence of 
medicines on driving fitness.  
Therapy compliance – some 
pharmacists warned that therapy 
compliance could be threatened 
when patients are informed about the 
negative influence of medicines on 
driving fitness.  
During the training, practical solutions 
were provided to pharmacists on how 
they could instruct their patients to be 
more aware and to overcome the 
impairing effects of medicines on 
driving fitness at the start of the 
treatment. Suggestions like “start the 
treatment during the weekend, while 
not using their car”, or “taking most of 
the daily dose at night while patient is 
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sleeping” were mentioned.  
Data extraction – the extraction of 
dispensing data required that 
pharmacists needed to work on their 
computer system in order to send us 
the selected data sets.      
Instructions how to extract the data 
were developed with the help of the 
software developer (Pharmacom® 
system). Help-desk opportunities by 
the research team. were provided as 
well  
Motivation – throughout the study 
period, pharmacists needed to carry 
out several activities, some of them 
time consuming, such as sending out 
questionnaires to their patients. Due 
to this fact, some pharmacists did not 
put in practice some of the activities. 
To overcome this problem, frequent 
reminders were sent to the 
pharmacists, via email. References to 
the activities that needed to be 
conducted were mentioned in the 
monthly newsletters. Several 
motivational phone calls were made 
in order to give positive feedback to 
the pharmacists.  
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5 Overall conclusions and recommendations 
 
It can be concluded that Dutch pharmacists were well aware of the influence of medicines on 
driving fitness and therefore not many significant changes in awareness were found to be 
caused by the training. However, the training did have a very positive influence in 
pharmacists’ reported behavior which became much better after the training. Pharmacists’ 
knowledge was already satisfactory at the baseline but, with no doubts, the knowledge 
significantly increased after the training. Thus, we can conclude that the training positively 
changed pharmacists’ reported behavior and knowledge.  
 
The DRUID information materials integrated in the Pharmacom® system and those provided 
during the course were very well accepted by the pharmacists. The training and the 
information materials developed helped pharmacists to improve some daily routines and 
contributed greatly to improve the information provided to patients, which became more 
adequate. Pharmacists are willing to use ICT tools which include information on medicines 
and driving, just as the one used in this study, in the future. The DRUID warning label, 
introduced as part of the information materials provided to the patient in the personalized 
medicine information leaflet, raised some questions and, as a consequence, started the 
discussion between patient and pharmacist about the influence of a medicine in driving 
fitness. Ultimately, this could be a good starting point for the patient decision-making process.  
 
Patients who participated in the study had good knowledge about the influence of medicines 
on driving fitness and no changes on patients’ knowledge were found, meaning that the 
training did not have an impact on patients’ knowledge. According to patients, pharmacists 
are considered to be the main source of information about medicines and the message about 
driving under the influence of medicines was spontaneous and successfully transmitted to 
patients mainly going to pharmacies in the intervention group. Therefore, it is legitimate to 
conclude that the training had a positive impact on the spontaneity on the information given.  
Despite the knowledge acquired and the possible experience of side effects that can impair 
driving fitness, patients did not change their driving behaviour.  
 
The training did not have any impact on the delivery of safer alternatives to first time users of 
driving impairing medicines. 
 
As for recommendations, the authors believe that the collaboration between GPs and 
pharmacists is needed for appropriate prescribing and dispensing of medicines that might 
impair driving fitness. In the Netherlands, a national primary care agreement was achieved. 
However, improvements need to be implemented at the local level in order to observe more 
effectiveness of prescribing and dispensing guidelines. For example, the use of the 
categorization of medicines is not provided in all systems, although pharmacy software 
systems are more synchronized to present similar information than GP software systems, due 
to the activities performed during the campaign in 2008. 
Keeping systematic and standardized records of patients’ driving habits (for example if the 
patient is a professional driver or if the patients drives very frequently to work) could be of 
help to immediately identify the patients that are at a greater risk of being involved in a traffic 
accident and, therefore, think about less impairing alternatives, every time it is possible. 
Adding warning labels on the medicines’ box is known to enhance the recall. Therefore, this 
could help patients to remember, just by looking at the medicines’ box, that they are taking 
medicines that can potentially impair their driving fitness. The level of understanding of the 
developed pictogram was evaluated in another DRUID study (deliverable 7.3.2 [7]), 
presenting very positive and promising results.  
The development of harmonized patient information leaflets is also of great importance and 
the European focus could be even stronger by involving the European drug regulatory 
agency. Furthermore, for maintaining the sources from which the information for health care 
providers and patients will be derived, new initiatives at the European level and the level of 
the Member States will be needed involving the different stakeholders.    
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6 Summary of results, conclusions and 
recommendations 
 
Results - Pharmacists  
 
• Dutch pharmacists frequently use the internet to look for information about medicines 
in general and about medicines that affect driving fitness. The use of ICT tools is also 
frequent but, less than internet.  
• Pharmacists’ awareness regarding the influence of medicines on driving fitness was 
positive at the baseline measurement and did not statistically increase six months 
after the training except for awareness on driving skills.  
• Pharmacists’ reported behaviour in their daily routines on informing patients about the 
influence of medicines on driving fitness significantly improved after the course.  
• Pharmacists’ actual knowledge concerning the influence of certain medicines 
(codeine, fexofenadine, amitriptyline and paroxetine) on driving fitness significantly 
increased after the course. For all medicines (temazepam, diazepam, codeine, 
fexofenadine, amitriptyline and paroxetine) where a higher percentage of questions 
answered correctly was verified and, as a consequence, a decrease in the 
percentage of wrong answers. 
• The course and the information materials provided (course folder, information for 
technicians, information for GPs and newsletters) were positively evaluated by all 
pharmacists.  
• Pharmacists’ used the information materials provided to train their technicians but 
failed to use the information provided to informed the GPs during joint meetings 
(FTO).  
• The functionalities incorporated in the Pharmacom® system were evaluated as clear, 
useful, complete and well organized and pharmacists are willing to use ICT tools 
during the dispensing of medicines.  
• To help informing patients who take driving impairing medicines, pharmacists 
regularly used the yellow sticker and the DRUID warning label. Regarding the DRUID 
warning label, pharmacists found it very clear and useful to provide information to 
patients  
 
Results - Patients 
 
• Patients’  knowledge about causes of road accidents did not significantly change after 
the training. Patients’ knowledge remained stable 6 months after the training, in the 
control group, whereas the knowledge of patients in the intervention group increased, 
although not significantly. 
•  In patients’  opinion, pharmacists are the preferable source of information about 
medicines and its use. This information is often spontaneously provided to patients, 
especially after the training.  
• During a pharmacy consultation, patients were mainly informed about the influence of 
medicines on driving fitness and on operating machinery and about the severity of the 
impairment. 
• The majority of the patients decided not to change their driving frequency, despite the 
information that was provided to them by their healthcare provider. This did not 
change depending on neither the pharmacy group nor time of measurement. 
• Patients’ attitudes towards the use of driving impairing medicines while driving and 
concerning the consequences on the use of driving impairing medicines while driving 
were not influenced by the pharmacy group or the time of measurement.  
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Results - Dispensing data 
 
• The number of new users of N05B, N05C and N06A medicines was higher during the 
follow-up period than in the baseline. The differences were not statistically significant.  
•  The dispensing pattern of N05B, N05C and N06A medicines did not show any 
change that could possibly be attributed to the intervention (training). 
• No shifts to less impairing medicines were verified, especially not in the pharmacies 
belonging to the intervention group after the training.  
 
Main conclusions 
 
• The training was effective at the pharmacists’ level as pharmacists’ knowledge and 
reported behaviour increased after the training. 
• The use of information materials and ICT tools was used by pharmacists during the 
dispensing of driving impairing medicines. However, during daily practice, the training 
had no impact on the dispensing of safer alternatives of driving impairing medicines.  
• The training did not have any impact at the patient level as no statistically significant 
changes were verified in patients’ knowledge and behaviour.  
 
Recommendations 
 
• Collaborations between GPs and pharmacists regarding the prescription and 
dispensing of driving impairing medicines should be improved. 
• Establishment of a uniform categorization system of driving impairing medicines (for 
example, by implementing the DRUID categorization system). 
• Systematic use of ICT tools containing the relevant information that should be 
provided to patients at the time of dispense of driving impairing medicines. 
• Use of ICT tools to keep records of  patients’ driving habits. 
• More effective communications with patients are needed, by making use of 
pictograms or warning labels on the medicines’ box, which is known to enhance recall 
of information.  
• Development of harmonized patient information leaflets containing appropriate 
information for patients.  
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Annex 1 – Pharmacists’ questionnaire
EVALUATION 
QUESTIONNAIRE 
Pharmacists
EU Project DRUID
Driving under the influence of alcohol, drugs and 
Contract No. TREN 
Co-funded by the European Commission
 
 
 
Dear participant,  
  Deliverable D.7.4.2
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 – baseline measurement (T0) 
 
 
 
 
medicines 
 
- 05-FP6TR-SO7.61320-518404
 
 
 
 
    
 
 
 
 
-DRUID 
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This study is conducted as part of the DRUID European project (Driving under the influence of 
drugs, alcohol, and medicines).  Specifically, it focuses on the actual impact drugs may have 
on driving safety.  We are interested on your opinions on the way medicines may affect 
driving.   
The questionnaire consists of 6 pages and it comprises 38 questions.   
It will take you approximately 15 minutes to complete. 
Please read each question carefully and tick a box  to indicate your answer.  In most cases 
you will only have to tick one box but please read the questions carefully as sometimes you 
will need to tick more than one box.  Answer the next question unless asked otherwise.  Once 
you have finished please take a minute to check whether you have answered all the 
questions that you should have answered. 
We assure you that all your answers and statements will be handled anonymously and that 
they will be used for scientific research purposes only. 
 
 My participation in this questionnaire survey is voluntary (informed consent).                
 
Thank you for your valuable participation! 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
Research supervisor Prof. dr. J. J de Gier 
 
Rijksuniversiteit Groningen 
Farmacotherapie & Farmaceutische Patiëntenzorg 
 
Antonius Deusinglaan 1 
9713 AV Groningen 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 311 of 456 
A. BACKGROUND INFORMATION  
1. Gender 
 Male               Female                     
 
2. Date of birth (DD/MM/YYYY):__________________________ 
 
3. Country: ___________ 
  
3a. Area:  Urban    Rural    Other 
 
4. Year of graduation medical school (YYYY): ___________ 
4a. How many years are you practising as a Pharmacist? 
(Please state in full years) _____ 
 
5. Did you get any education on medicinal effects on driving skills during your studies at 
University?  
              
     Yes    No   
 
 
6. If you answered “Yes” in Q5, please specify: 
________________________________________________________________________________
________________________________________________________________________________
_______________________________________________________________________
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B. NEW TECHNOLOGIES LITERACY 
1. Do you use the internet to obtain information? 
 Yes   No   
 
2. Do you use the internet to obtain information on medicines affecting driving behaviour? 
 Yes   No   
 
3. Have you ever used any software package / programme to obtain information on medicinal 
drugs effect on driving behaviour?  
 Yes   No   
 
4. If you answered “Yes” in Q3, please specify which software packages you use: 
________________________________________________________________________________
________________________________________________________________________________
_____________________________________________________ 
 
5. Do you use any medical/clinical software package / programme? 
 Yes   No   
 
6. If you answered “Yes” in Q5, please specify which software packages you use: 
 
 
 
 
 
 
 
1. 
_______________________________________________
_______ 
2. 
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C. ATTITUDES / AWARENESS  
Please evaluate the following statements: 
1. I am willing to take into account the effects of medicines on driving skills when 
prescribing/dispensing medicines. 
 strongly disagree   disagree    agree    strongly agree 
 
2. Would you consider this (Q1) of more concern if your patient is:   
- a professional driver?       Yes   No   
- driving frequently?                     Yes   No 
- driving long distances?              Yes   No 
- an “inexperienced” driver?         Yes   No 
- an “experienced” driver?            Yes   No 
- an elderly driver?                    Yes   No 
- using other CNS active drugs?  Yes   No   
 
3. I am willing to sacrifice some degree of efficacy by prescribing/dispensing a 
medicine that is less impairing to the driving skills.  
 strongly disagree   disagree    agree    strongly agree 
 
4. I feel being well aware of the effects of medicines on driving skills. 
 strongly disagree   disagree    agree    strongly agree 
 
5. It is important for me to be well-informed on medicinal effects on driving 
behaviour. 
 strongly disagree   disagree    agree    strongly agree 
 
6. I feel that the information I provide to patients will influence their driving 
behaviour. 
 strongly disagree   disagree    agree    strongly agree 
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D. REPORTED BEHAVIOUR 
Please reflect on the following statements according to your daily practice routines. 
1. I ask a patient about his/her driving exposure when choosing/dispensing a medicine.  
 always   regularly   sometimes    seldom   never 
 
2. I inform a patient about driving related risks when prescribing/dispensing a medicine.  
 always   regularly   sometimes    seldom   never 
 
3. I provide a patient with written information materials when prescribing/dispensing a driving 
impairing medicine. 
 always   regularly   sometimes    seldom   never 
 
4. I keep systematic records when I prescribe/dispense a driving impairing medicine. 
 always   regularly   sometimes    seldom   never 
 
5. I keep systematic records when I advise a patient when and how he/she can consider 
driving a car when using a driving impairing medicine. 
 always   regularly   sometimes    seldom   never 
 
6. I keep a record of the patient’s traffic participation (e.g. how often he/she drives to work). 
 always   regularly   sometimes    seldom   never 
 
7. I discuss medicinal drug consumption and driving related responsibility issues with the 
patient. 
 always   regularly   sometimes    seldom   never 
8. How frequently do you usually provide detailed information when prescribing a medicine 
with impairing effects on driving performance? 
 always   regularly   sometimes    seldom   never 
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E. SOURCES  
 
1. I have easy access to data and information about a medicine’s effect on driving skills.    
     
           Yes    No   
 
2. Please report your sources: 
Professional websites       
Newsletters       
Organisations        
Journals       
Other       
Please specify: 
________________________________________________________________________________
______________________________________________________________ 
 
 
3. Did you get any postgraduate education on medicinal effects on driving skills? 
             
 Yes   No   
 
4. If you answered “Yes” in Q3, please specify: 
________________________________________________________________________________
________________________________________________________________________________
_________________________________________________________________ 
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F. ACTUAL KNOWLEDGE 
Please reflect on the following statements according to your daily practice routines. 
For each statement tick the one which best fits your professional what ?? 
 
1. How much do you agree or disagree with the following statements? 
 
Statements Totally 
Disagree 
 
Disagree
 
Agree 
 
Totally 
Agree 
 
Don’t know 
 
Temazepam (up to 20 mg) is severely impairing 
driving 8 hours after intake  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Diazepam (regardless dose) is severely  
Impairing within the first 2 months of treatment
 
 
 
 
  
 
 
 
Codeine (up to 20 mg) is mostly safe for drivers
 
 
 
 
  
 
 
 
Fexofenadine (normal dose) is severely impairing
driving  
 
 
 
 
  
 
 
 
Amitriptyline at the start of treatment is as impairing  
driving as after 4 weeks of treatment 
 
 
 
 
  
 
 
 
Paroxetine (up to 20 mg/day) is safe for drivers
 
 
 
 
  
 
 
 
 
 
2. General Practitioners/Pharmacists are obliged to inform the patients about the possible 
side effects of his/her medications on driving abilities. 
      True    False 
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3. If a General Practitioner informs the Driving Licensing Authority (DLA) that his/her patient 
is using a driving impairment medication, in order to give the DLA the possibility to perform a 
check-up, you believe this is: 
        Mandatory practice         Good practice       No obligation          Do not 
know 
 
4. A patient can be punished with criminal sanctions if he causes a traffic accident while 
using a medicine with impairing properties whereas the health care provider has advised him 
not to drive. 
               
  True      False 
 
 
G. USER ACCEPTANCE  
 
1. If we propose to you a tool (e.g. website, cd-rom) that allows you to find information on 
medicinal drugs and driving, will you be willing to use it for prescribing/dispensing 
medicines? 
 
 Yes    No     Maybe 
 
 
2. If you answered “No” or “Maybe” to Q1, what are the main reasons for your reluctance to use 
them?  
-----------------------------------------------------------------------------------------------------------------------------------------
-----------------------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------- 
General comments  
(Please provide any further comments you may have) 
 
----------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------------------
----------------------------------------------------------------------------------------------------------------------------
------------------------------------------------------------------------------------------------ 
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Thank you for your participation! 
Please, provide your email address, in case you want to be informed about the general 
findings of this study. 
 
DRUID 6th Framework Programme
 
Annex 2 – Pharmacists’ questionnaire 
 
 
EVALUATION 
QUESTIONNAIRE 
Pharmacists
EU Project DRUID
Driving under the influence of 
Contract No. TREN 
Co-funded by the European Commission
 
 
Dear participant,  
  Deliverable D.7.4.2
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– follow-up (T1) 
 
 
 
 
 
alcohol, drugs and 
medicines 
 
- 05-FP6TR-SO7.61320-518404
 
 
 
 
    
 
 
 
-DRUID 
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This study is conducted as part of the DRUID European project (Driving under the influence of 
drugs, alcohol, and medicines).  Specifically, it focuses on the actual impact drugs may have 
on driving safety.  We are interested in your opinion about the way medicines may affect 
driving and about the way your pharmacy makes use of ICT possibilities that can improve 
safe dispensing of driving impairing drugs.   
The questionnaire consists of 23 pages and it is divided in 10 sections. The first 6 sections 
are in English and they consist of general knowledge questions about the influence of 
medicines on the ability to drive. The last 4 sections of the questionnaire are in Dutch and 
they refer to specific questions about the training you followed in October/November last year 
(2009). The questionnaire should take you approximately 20 minutes to be completed.  
Please read each question carefully and tick a box  to indicate your answer.  In most cases 
you will only have to tick one box but please read the questions carefully as sometimes you 
will need to tick more than one box.  Answer the next question unless asked otherwise.  Once 
you have finished please take a minute to check whether you have answered all the 
questions that you should have answered. 
We assure you that all your answers and statements will be handled anonymously and that 
they will be used for scientific research purposes only. 
 
PLEASE TICK THE FOLLOWING BOX TO INDICATE THAT YOUR PARTICIPATION IN 
THE STUDY IS VOLUNTARY. 
 My participation in this questionnaire survey is voluntary (informed consent).                
 
Thank you for your valuable participation! 
 
 
 
 
 
 
 
 
A. BACKGROUND INFORMATION  
 
Research supervisor Prof. dr. J. J de Gier 
 
Rijksuniversiteit Groningen 
Farmacotherapie & Farmaceutische Patiëntenzorg 
 
Antonius Deusinglaan 1 
9713 AV Groningen 
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1. Gender  Male          Female             
         
2. Date of birth (DD/MM/YYYY):__________________________ 
 
3. Year of graduation from pharmacy school (YYYY): ___________ 
 
3.1. How many years are you practising as a pharmacist? __________ 
(Please state in full years)  
 
4. Did you get any education on medicinal effects on driving skills during your studies 
at University?  
 
 Yes       No   
 
4.1. If you answered “Yes” in Q5, please specify: 
_______________________________________________________________________
_______________________________________________________________________
___________________________________________________________ 
 
5. City where you are currently working: ______________________ 
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B. NEW TECHNOLOGIES LITERACY 
1. Do you use the internet to obtain information?   
 Yes   No   
 
2. Do you use the internet to obtain information on medicines affecting driving 
behaviour? 
 Yes   No   
 
3. Do you use any medical/pharmaceutical software package / programme (excluding 
Pharmacom)? 
 Yes   No   
 
3.1. If you answered “Yes” in Q3, please specify which software packages you use: 
 
 
 
 
4. Have you ever used any software package / programme (not being the Pharmacom-
system) to obtain information on medicinal drugs effects on driving behaviour?  
 Yes   No   
 
4.1. If you answered “Yes” in Q4., please specify which software packages you 
use: 
_______________________________________________________________________
_____________________________________________________ 
 
 
 
 
1. 
_______________________________________________
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C. ATTITUDES / AWARENESS  
Please evaluate the following statements: 
 
1. I am taking into account the effects of medicines on driving skills when dispensing 
medicines. 
 strongly disagree  disagree   agree   strongly agree 
1.1. If you answered agree or strongly agree, would you consider this of more 
concern if your patient is:   
- a professional driver?                Yes               No   
- driving frequently?                     Yes               No 
- driving long distances?              Yes               No 
- an “inexperienced” driver?         Yes               No 
- an “experienced” driver?            Yes               No 
- an elderly driver?               Yes              No 
- using other CNS active drugs?  Yes               No   
 
2. I am willing to sacrifice some degree of efficacy by dispensing a medicine that is less 
impairing to the driving skills. 
 strongly disagree disagree   agree   strongly agree 
 
3. I am aware of the effects of medicines on driving skills. 
 strongly disagree disagree   agree   strongly agree 
 
4. It is important for me to be well-informed on medicinal effects on driving behaviour. 
 strongly disagree disagree   agree   strongly agree 
 
5. I feel that the information I provide to patients will influence their driving behaviour. 
 strongly disagree disagree   agree   strongly agree 
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D. REPORTED BEHAVIOUR 
Please reflect on the following statements according to your daily practice routines. 
 
1. I ask a patient about his/her driving exposure when dispensing a medicine.  
 always     regularly    sometimes     seldom      never 
 
2. I inform a patient about driving related risks when dispensing a medicine.  
 always     regularly   sometimes      seldom       never 
 
3. I provide a patient with written information materials when dispensing a driving 
impairing medicine. 
 always     regularly   sometimes      seldom       never 
 
4. I keep systematic records when I dispense a driving impairing medicine (e.g. as in 
the EPD in Pharmacom). 
 always     regularly   sometimes      seldom       never 
 
5. I keep systematic records when I advise a patient when and how he/she can 
consider driving a car when using a driving impairing medicine (e.g. as in the EPD in 
Pharmacom). 
 always     regularly   sometimes      seldom       never 
 
6. I keep a record of the patient’s traffic participation (e.g. how often he/she drives to 
work). 
 always     regularly   sometimes      seldom       never 
 
7. I discuss medicinal drug consumption and driving related responsibility issues with 
the patient. 
 always     regularly   sometimes      seldom       never 
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8. How frequently do you usually provide detailed information when dispensing a 
medicine with impairing effects on driving performance? 
 always     regularly   sometimes      seldom       never 
 
 
E. SOURCES  
 
1. I have easy access to data and information about the effect of a medicine on driving 
skills.    
 
 Yes    No   
 
1.1. If yes, please report your sources: 
 
Professional websites     
 
Newsletters       
 
Organizations       
 
Journals       
 
Other       
 
Please specify: 
_____________________________________________________________
_____________________________________________________________
__ 
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F. ACTUAL KNOWLEDGE 
 
Please reflect on the following statements according to your daily practice routines. For each 
statement tick the one which best fits your professional experience. 
 
1. How much do you agree or disagree with the following statements? 
 
 
 
2. Pharmacists are obliged to inform the patients about the possible side effects of 
his/her medications on driving abilities. 
 
    True       False 
 
 
 
3. If a General Practitioner (‘huisarts’) informs the Driving Licensing Authority (‘het 
CBR’) that his/her patient is using a driving impairing medication, in order to give ‘het 
CBR’ the possibility to perform a check-up, you believe this is: 
 
Statements 
Totally 
Disagree 
Disagree 
Nor 
agree nor 
disagree 
Totally 
Agree 
Don’t 
know 
Temazepam (up to 20 mg) severely 
impairs driving 8 hours after intake. 
     
Diazepam (regardless the dose) 
severely impairs driving within the first 
2 months of treatment. 
     
Codeine (up to 20 mg) is mostly safe 
for drivers. 
     
Fexofenadine (normal dose) severely 
impairs driving. 
     
Amitriptyline has the same level of 
driving impairment at the start of 
treatment and 4  weeks  after the start 
of the treatment. 
     
Paroxetine (up to 20 mg/day) is safe 
for drivers. 
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  Mandatory (‘verplicht’) practice  
  Good practice 
  No obligation  
  Do not know 
 
4. A patient can be punished with criminal sanctions if he causes a traffic accident 
while using a medicine with impairing properties whereas the health care provider has 
advised him not to drive. 
                
  True       False 
 
 
G. USER ACCEPTANCE – COURSE (OCT/NOV ’09)  and COURSE MATERIALS 
 
The following questions will reflect your opinion about the information, as well as 
information materials, provided to you during the course: 
During the course and in the course material the following information was provided to 
you: 
- the influence medicines can have on driving ability 
- the meaning of the way the categorization system  
- guidelines on how to inform physicians and patients 
- Information about how to use the EUC (Eerste-Uitgifte-Controle) in Pharmacom 
- Information about how to use the EUB-TUB (Eerste- en Tweede- Uitgiftebegeleiding) 
in Pharmacom 
- Material to inform pharmacy technicians (‘materiaal voor werkoverleg’) 
- Powerpoint to inform physicians (sent to you by e-mail) 
 
1. Did you attend the course Rijgevaarlijke geneesmiddelen in October/November last 
year?  
 
 yes    no → go to question 2 
 
1.1 If you attended the course, what is your oppinion about it? 
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Yes, very 
much Quite a lot Neutral 
Not too 
much No, not at all 
Clear      
Useful      
Complete       
Well organized      
 
Kunt u hieronder uw keuze toelichten als u heeft gekozen voor ‘Nauwelijks mee eens’ of 
‘Absoluut niet mee eens’? 
 
__________________________________________________________________________
__________________________________________________________________________
_____________________________________________________ 
 
 
2. How often did you used the information that was provided to you during the course?  
 
 > 10 times.        9-5 times.      4-3 times.       2-1 time(s).       never 
 
2.1 Indien u informatie in de richtlijnen heeft opgezocht, wat is uw mening over 
deze richtlijnen? 
 
 
Yes, very 
much Quite a lot Neutral 
Not too 
much No, not at all 
Clear      
Useful      
Complete       
Well organized      
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Kunt u hieronder uw keuze toelichten als u heeft gekozen voor ‘Nauwelijks mee eens’ of 
‘Absoluut niet mee eens’? 
 
__________________________________________________________________________
__________________________________________________________________________
_____________________________________________________ 
 
 
2.2 Bij beantwoording met ‘2-1 keer’ of ‘nooit’ in Vraag 2, kunt u hieronder 
toelichten waarom niet vaker? 
_______________________________________________________________________
_______________________________________________________________________
___________________________________________________________ 
 
3. Did you use the materials provided to inform the pharmacy technicians working in 
your pharmacy (‘materiaal voor werkoverleg’)?  
 
 yes      no    
 
3.1. Indien u ‘Nee’ heeft geantwoord bij vraag 3: Kunt u hieronder toelichten 
waarom u het materiaal niet heeft gebruikt?  
_______________________________________________________________________
_______________________________________________________________________
____________________________________________ 
  
4. What is your opinion about the materias to inform your team (‘materiaal voor 
werkoverleg’)? 
 
Yes, very 
much Quite a lot Neutral 
Not too 
much No, not at all 
Clear      
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Useful      
Complete       
Well organized      
 
Kunt u hieronder uw keuze toelichten als u heeft gekozen voor ‘Nauwelijks mee eens’ of 
‘Absoluut niet mee eens’? 
 
__________________________________________________________________________
__________________________________________________________________________
_____________________________________________________ 
 
 
5. Did you send the powerpoint concerning the FTO to the GPs you work with 
(‘Powerpoint voor FTO’)?  
 yes    no 
 
5.1. Indien u ‘Nee’ heeft geantwoord bij vraag 5: Kunt u hieronder toelichten waarom 
u geen gebruik heeft gemaakt van de Powerpoint? 
_______________________________________________________________________
_______________________________________________________________________
____________________________________________ 
 
6. What is your opinion about the powerpoint for the FTO (Powerpoint voor FTO)? 
 
 
Yes, very 
much Quite a lot Neutral 
Not too 
much No, not at all 
Clear      
Useful      
Complete       
Well organized      
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Kunt u hieronder uw keuze toelichten als u heeft gekozen voor ‘Nauwelijks mee eens’ of 
‘Absoluut niet mee eens’? 
 
__________________________________________________________________________
__________________________________________________________________________
_____________________________________________________ 
 
 
 
7. Did you read the newsletters that were sent to you, by email, in December, January, 
February and March?  
 
 Yes, I’ve read them all              
 Yes, I’ve read a few           
 No, I did not read any of the newsletters 
 
7.1 What is your opinion about the newsletters that you receive? 
 
 
Yes, very 
much Quite a lot Neutral 
Not too 
much No, not at all 
Clear      
Useful      
Complete       
Well organized      
 
Kunt u hieronder uw keuze toelichten als u heeft gekozen voor ‘Nauwelijks mee eens’ of 
‘Absoluut niet mee eens’? 
__________________________________________________________________________
__________________________________________________________________________
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____________________________________________________ 
 
 
7.2 Bij beantwoording met “nee” in vraag 7: Kunt u hieronder aangeven waarom u 
de nieuwsbrieven niet heeft gelezen? 
 
_______________________________________________________________________
_______________________________________________________________________
___________________________________________________________ 
 
8. Do you think that the course should have any additional topics/matters? 
  
 Yes     No 
 
8.1 Bij ‘Ja’ bij vraag 8, graag hieronder toelichten: 
 
_______________________________________________________________________
_______________________________________________________________________
___________________________________________________________ 
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H. USER ACCEPTANCE & USABILITY – TOOL (EUC and EUB-TUB-module)    
In this section, your opinion regarding the information provided by the Pharmacom-
system is required 
 
1. Was the ‘Eerste Uitgifte Controle’ in the Pharmacom system switched on during 
(part of) the last half year? 
 Ja     Nee  
 
1.1 If yes, what is your opinion about the EUC-module application during the 
first delivery of a driving impairing medicine?  
 
 
Yes, very 
much Quite a lot Neutral 
Not too 
much No, not at all 
Handy 
(convenient) 
     
Clear      
Useful      
 
Kunt u hieronder uw keuze toelichten als u heeft gekozen voor ‘Nauwelijks mee eens’ of 
‘Absoluut niet mee eens’? 
 
 
__________________________________________________________________________
__________________________________________________________________________
_____________________________________________________ 
 
 
2. Did you use the ‘Eerste- en Tweede-Uitgifte Begeleidings-module’ from the 
Pharmacom system during (part of) the last half a year? 
 
 
Yes No 
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N05 (slaap- en kalmeringsmiddelen)           EUB   
TUB   
N06 (antidepressiva)                                   EUB   
TUB   
 
 
3. What is your opinion about the EUB/TUB application? 
 
 
Yes, very 
much Quite a lot Neutral 
Not too 
much No, not at all 
Handy 
(convenient) 
     
Clear      
Useful      
 
Kunt u hieronder uw keuze toelichten als u heeft gekozen voor ‘Nauwelijks mee eens’ of 
‘Absoluut niet mee eens’? 
 
__________________________________________________________________________
__________________________________________________________________________
_____________________________________________________ 
 
 
4. Do you know that the background information displayed with F7 supporst the 
EUB/TUB-texts? 
 
 Yes    No 
 
 
4.1 If yes, what is your opinion about the information regarding driving impairment in 
and behind F7 of the first delivery module (‘EUB-teksten’)?  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 335 of 456 
 
 
Yes, very 
much Quite a lot Neutral 
Not too 
much No, not at all 
Clear      
Useful      
Complete       
Well organized      
 
Kunt u hieronder uw keuze toelichten als u heeft gekozen voor ‘Nauwelijks mee eens’ of 
‘Absoluut niet mee eens’? 
 
__________________________________________________________________________
__________________________________________________________________________
____________________________________________________ 
 
 
5. In your opinion, is there anything missing in the EUB/TUB module? 
 
 Yes    No 
 
 
5.1. If you said yes, please specify.  
_______________________________________________________________________
_______________________________________________________________________
___________________________________________ 
 
6. What is your opinion about the information provided in the Chapter 
‘Verkeersdeelname’ (traffic participation) in the Commentaren Medicatiebewaking from 
Pharmacom/Medicom (CMPM) (online and/or as a book)? 
 
Yes, very 
much Quite a lot Neutral 
Not too 
much No, not at all 
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Clear      
Useful      
Complete       
Well organized      
 
Kunt u hieronder uw keuze toelichten als u heeft gekozen voor ‘Nauwelijks mee eens’ of 
‘Absoluut niet mee eens’? 
__________________________________________________________________________
__________________________________________________________________________
_____________________________________________________ 
 
 
7. We are also interested in your opinion on the book Verkeersdeelname (Traffic 
Participation) issued by the KNMP. How often did you, after completing the course in 
October / November, used the book Traffic participation KNMP?  
 > 10 times.        9-5 times.      4-3 times.       2-1 time(s).       never 
 
I. FUTURE USE OF THE TOOL (EUC and EUB-TUB-module)
 
1. Would you be willing to continue using the EUC-module, the EUB-module and the 
TUB-module in the future? (please select one option per module). 
EUC - module EUB - module TUB - module 
 yes  yes  yes 
 maybe  maybe  maybe 
 no   no   no 
 
Q1.1. If you answered “maybe”or “no”in Q1., please explain why. 
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
_______________________________________________________________________
__________________________ 
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J. IFORMATION PROVIDED TO PATIENTS, PHARMACY TEAM AND GPs 
 
1. After the course in Nov 09, to which extent did the team in your pharmacy provide 
the following material to inform patients at a first delivery of a driving impairing 
medicine (antidepressants, sedatives and tranquilizers)?  
 
Always Regularly Sometimes Seldom Never 
Reference to the 
participation in traffic section 
from the GIT 
     
 Oral information about 
drugs and driving based on 
the information coming from 
the  EBU / TUB 
     
Patients who did not appear 
at the desk were informed 
about drugs and driving by 
phone 
     
Others 
 
     
1.1. Bij Anders, kunt u hieronder toelichten op welke wijze dan? 
_______________________________________________________________________
_____________________________________________________ 
2. To what extent has your pharmacy used the following written materials to inform 
patients who take driving impairing medicines for the first time?  
 
Always Regularly Sometimes Seldom Never 
Yellow sticker (gele sticker)      
GIT (Pharmacombijsluiter)      
DRUID warning label      
VI-folder (stg UI)      
Folder from KNMP      
Folder ‘Is jouw medicijn veilig in het 
verkeer?’ from DGV       
Other ________________________      
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Bij de keuze ‘anders’, kunt u hieronder aangeven welk materiaal dat betrof? 
__________________________________________________________________________________
__________________________________________________________________________________
_____________________________________________ 
 
3. What is your opinion about the DRUID warning label  
 
Yes, very 
much Quite a lot Neutral 
Not too 
much No, not at all 
Useful to provide 
information 
     
Clear for the 
patient 
     
Gives suficient 
information      
 
Kunt u hieronder uw keuze toelichten als u heeft gekozen voor ‘Nauwelijks mee eens’ of 
‘Absoluut niet mee eens’? 
__________________________________________________________________________
__________________________________________________________________________
____________________________________________________ 
4. What is your opinion about the categorization of driving impairing drugs in three 
categories of impairment? 
 
Yes, very 
much Quite a lot Neutral 
Not too 
much No, not at all 
Clear      
Useful      
 
Kunt u hieronder uw keuze toelichten als u heeft gekozen voor ‘Nauwelijks mee eens’ of 
‘Absoluut niet mee eens’? 
__________________________________________________________________________
__________________________________________________________________________
_____________________________________________________ 
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5. After the course (Oct/Nov 09), were the technicians of your pharmacy trained about 
medicines affecting driving performance?  
 
Yes No 
By myself or by a colleague   
External training (e-learning, SBA-training)   
Other: _____________________________________________   
 
Bij de keuze ‘anders’, kunt u hieronder aangeven op welke manier het team dan is 
geïnformeerd? 
__________________________________________________________________________
________________________________________________________ 
 
6. After the course (Nov 09), were the physicians, with whom you collaborate locally, 
informed by you or any other collaborating pharmacist about medicines affecting 
driving performance? 
 Yes    No 
 
 
 
6.1. If yes, which materials were used? 
 
Yes No 
Powerpoint from DRUID   
Materials from the course that was given   
DGV FTO-module Geneesmiddelen en verkeersveiligheid (IVM)   
LESA Verkeersdeelname (Landelijke Eerstelijns 
Samenwerkingsafspraak) 
  
Others: _____________________________________________   
 
Bij de keuze ‘anders’, kunt u hieronder aangeven welk materiaal u dan heeft gebruikt?  
_________________________________________________________________________
___________________________________________________________ 
 
7. How many times, after the course, did you change a prescription to a less impairing 
alternative due to the effects on driving ability?  
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 > 10 times.        9-5 times.      4-3 times.       2-1 time(s).       never 
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Algemene opmerkingen 
 
 
Hieronder vindt u ruimte voor eventuele opmerkingen of aanvullingen: 
 
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
__________________________________________________________________________
______________________________________________________ 
 
 
 
 
AUB de enquête in de antwoordenvelop terugsturen  
aan de Rijksuniversiteit Groningen 
 
HARTELIJK DANK VOOR UW MEDEWERKING!!! 
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– baseline and follow-up measurements 
Questionnaire for patients 
 
 
 
 
 
 
 
DRUID task 7.4 
 
 
 
 
    DRAFT 1 
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Introduction to the questionnaire 
 
With the aid of this questionnaire we would like to evaluate people's opinion and 
knowledge about the use of potentially dangerous medicines in relation to 
participation in traffic. In this questionnaire you will find some questions about your 
participation in traffic, your use of medication and your knowledge about the influence 
medicines may have on your driving performance.  
 
Some of the questions may seem to not be applicable to your situation. For example 
if you are not a regular participant in traffic. Nevertheless, all the information you 
provide to us will be of great importance to our research. Therefore we kindly ask you 
to answer all questions.  
 
The majority of the questions can be answered by simply ticking the box next to the 
option of your choice. In some other questions you will be asked to write down the 
answer yourself or to specify your choice. This questionnaire is all about your opinion 
and experience. So there are no correct or wrong answers.  
 
We greatly appreciate your willingness to complete this questionnaire. After 
completing please return the questionnaire to <<NAME OF RESEARCH 
INSTITUTE>> using the stamped response envelope.  
 
If you have any questions or remarks please feel free to call <<NAME OF CONTACT 
PERSON>> at <<PHONE NUMBER (and email address (optional)) OF CONTACT 
PERSON (optional: days and hours available for this)>>.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 344 of 456 
Pharmacy 
 
Firstly we would like to ask you which pharmacy supplied you with this questionnaire (we 
will refer to this pharmacy as “your pharmacy” or “your pharmacist”  in some of our 
questions). The only purpose of this question is for us to determine the number of returned 
questionnaires per pharmacy. Privacy is guaranteed, it will not be possible to retrieve any of 
your personal information through this.  
 
<<Name>>of your pharmacy:  ...................................................................................................................  
 
Date of today:  … … - … … - … … … … (day - month - year) 
 
 
General information 
 
1. What is you gender?  male  
   female 
 
2. What is your age? ……… years 
 
3. What is your level of education? 
 Not completed primary education 
 Completed primary education 
 Lower vocational training or general education 
 Intermediate vocational training or intermediate and higher general education 
 Higher vocational training, college or university 
 
 
 
 
 
 
 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 345 of 456 
Your participation in traffic 
 
4. Please indicate how often you use the following modes of transportation as a driver. If 
you travelled by bicycle, moped, motor cycle, car, lorry, truck or van only if you were 
the driver.  
 
5 - 7 
days 
per 
week 
2 - 4 
times 
per 
week 
2 - 4 
times 
per 
month 
1 time  
per 
month 
or less never 
a. Bicycle 
     
b. Moped       
c. Motor cycle      
d. Car      
e. Bus or mini bus      
f. Lorry, truck or (mini)van      
h. Other, please specify 
…………………………………… 
     
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Medicines in traffic 
 
Questions 5 - 8 are about the use of medicines and driving performance. When you do 
not know the answer to any of these questions, please indicate so. This is also of great 
importance to this research. 
 
5. Do you know that certain medicines may have a negative effect on the ability to 
drive?  
 No → PLEASE GO TO QUESTION 7 
 Yes 
 
6. And which kind of negative effects do you think these medicines could have?  
Please take your time to think this over 
……………………………….………………………………………………………… 
……………………………….………………………………………………………… 
……………………………….……………………………………………………… 
 
7. How often do you think that the factors mentioned below are (part of) the cause of 
road accidents?  (please select one option only for every factor) 
•  
never seldom sometimes often 
don't 
know 
- Driving when tired 
     
- Driving under the influence of alcohol      
- Too short a distance to leading car      
- Speeding 
     
- Use of medicines that might impair driving      
- Use of illicit drugs 
     
- Use of a mobile phone while driving 
     
 
 
8. To which extent do you agree or disagree on the following statements?  
(please select one option per statement) 
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 totally 
agree agree disagree 
totally 
disagree 
no 
opinion 
a. The risk of having a road accident is 
smaller when you have just started 
taking a driving impairing medicine 
compared to long term treatment 
     
b. The risk of having a road accident may 
increase when you combine a driving 
impairing medicine and over the 
counter medicines (e.g. pain killers, 
cough remedy) 
     
c. The risk of having a road accident 
increases when you use alcohol while 
taking a driving impairing medicine 
     
d. The risk of having a road accident 
remains the same when you use 
several driving impairing medicines at 
the same time 
     
e. The risk of having a road accident 
increases with a high dose of a driving 
impairing medicine 
     
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Use of medicines 
9. Please fill in the table below only for your sedatives or tranquillizers or 
medicines for depression and/or for allergies? Please take into account only 
the medicines that you actually take. We kindly ask you to state the dosage you 
use, how many times a day and at which times for each medicine. Please record 
since when you have been using these medicines as well. In case you use more 
than three of these medicines please record those you have been using for the 
longest period of time.  
Please try to fill in the table as completely as you can.  
Name of medicine 
Please copy this directly 
from the label or package 
dosage per 
tablet / 
capsule? 
how many tablets/capsules do you 
take at these moments of the day? 
since 
when? 
(month/ 
year) morning afternoon evening night 
1. ...........................................
…… mg …… …… 
…… …… ... / 
…… 
2. ...........................................
…… mg …… …… 
…… ……. ... / 
…… 
3. ...........................................
…… mg …… …… 
…… …… ... / 
…… 
 
Please specify information that will clarify your statement on daily doses.  
______________________________________________________________________
______________________________________________________________________
________________________________________________________________ 
 
10. Please indicate which of the following side effects you experience or have experienced 
while using these medicines? (please select all options that apply) 
 Sleepiness or drowsiness 
 Decreased alertness 
 Problems concentrating 
 Clumsiness, problems with coordination 
 Blurred view 
 Dizziness 
 I did not experience any side effects 
 Other, please specify .............................................................................................................  
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Information about medicines 
 
Questions 11 - 15 cover the information you received about your medicines obtained last 
month in your pharmacy. 
 
11. Did you at any time receive information regarding the possible influence of one of 
your medicines on your ability to drive? (please select all options that apply) 
 No → PLEASE GO TO QUESTION 16 
 Yes, I spontaneously received information from my GP/specialist. 
 Yes, I spontaneously received information from pharmacist. 
 Yes, after I asked my GP/specialist or pharmacist for the information myself. 
 
 
12. Which medicine(s) did this concern? 
 .........................................................................................................................................................  
 .........................................................................................................................................................  
 .........................................................................................................................................................  
Please think of the one you obtained last month from your pharmacist while answering  
questions 13-18. 
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13. Who informed you about the possible influence of this medicine on your ability to 
drive? And how did you receive this information? (please select all that apply) 
 GP, specialist 
or other 
doctor 
Pharmacist 
I was not 
informed 
a. Oral information    
b. Written information (e.g. brochure)    
c. With reference to the information in the leaflet of 
the pharmacy 
   
d. With reference to the leaflet that is included in the 
medicines’ box 
   
e. With reference to the sticker on the box    
f. With reference to the text that was reported in the 
label of the pharmacy 
   
g. Other, please specify  ....................................................    
 
14. What information did you receive? (please select all the options that apply)  
 this medicine might influence your driving performance. 
 the severity of the impairment (for example compared with the effect of alcohol 
on driving). 
    the option of using alternative medicines with minor influence on driving 
performance. 
     the legal consequences of driving under the influence of my medicine. 
   how to decrease my risk of becoming involved in traffic accidents while taking my 
medicine and drive my car or moped.  
 the influence on operating machinery. 
 The influence on activities at home. 
 The influence on other activities that require attention. 
 The duration of the effect on driving performance? 
 2 hours  3 days 
 8 hours  One week 
 12 hours  Two weeks 
  16 hours  For ever 
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 24 hours  Other, please specify 
______________________ 
 2 days  I forgot 
 
 Other, please specify 
__________________________________________________ 
 
15. When was the duration of the impairing effect of your medicine discussed??? 
     at the first dispensing 
     at the second dispensing 
     I did not receive any information from my pharmacists 
     other, please specify 
__________________________________________________ 
 
Question 16 and 17 refer to information you did look for yourself. 
 
16. Did you look for any information regarding the possible influence on your driving 
performance caused by any of your medicines? 
 No → PLEASE GO TO QUESTION 18 
 Yes 
 
17. Where did you look for this information? (please select all options that apply) 
 <<I have contacted the national medicines information phone number>> 
 I have looked in a medical reference book 
 I have searched in magazines 
 I have searched the following internet pages: (please select the ones you have 
visited) 
 the medicines manufacturer’s internet page 
 an internet page about my disease or illness 
 an internet page about medicines, for example <<www.apotheek.nl>> 
 the internet page www.rijveiligmetmedicijnen.nl 
 a general internet page about one’s health 
 a health care insurance company’s internet page 
 (an)other internet address(es), please specify  ........................................................  
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 I have asked the pharmacists for extra information 
 I have asked he docter or doctre’s assistantes for extra information 
 Other, please specify .............................................................................................................  
 
• How did you apply the information you have found yourself?  
• 18. Did the information you found change your frequency of driving?  
 No, because:  
   I did not think the information was relevant to me 
   It was not feasible for me to change my frequency of driving  
   I did not notice any negative effects that influence my driving ability and 
thus frequency of driving 
   I found information stating the medicine does not have any driving 
impairing effects 
   Other, please specify……………………………………………………………….. 
 Yes, and: 
   I decided not to drive a motorised vehicle anymore 
   I decided to drive/ride a motorised vehicle less often 
   I decided to drive/ride a motorised vehicle on less parts of the day 
   I decided not to drive/ride a motorised vehicle because I also drunk 
alcohol 
   Other, please specify……………………………………………………………….. 
  
19. Did the information you found change your use of this driving impairing medicine? 
 No, because:  
 I did not think the information was relevant to me 
 there was no alternative medicine available 
 other, please specify  ................................................................................................  
 Yes, and: 
 I decided not to use the medicine 
 I decided to use my medicine less often 
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 I decided to use my medicine for a shorter time than the time that was 
planned.  
 I decided to use (most of) the medicine at night instead of during the 
day 
 I decided to only use the medicine when I did not need to be driving 
 I asked for or I was prescribed a medicine causing less impairment of the 
ability to drive 
 other, please specify  ................................................................................................  
 
• Attitude towards behaviour in traffic 
 
Questions 20 and 21 ask for your opinion regarding some statements about behaviour in 
traffic. 
 
20. To which extent do you agree or disagree on the following statements?  
(please select one option per statement only) 
 totally 
agree agree disagree 
totally 
disagree 
no 
opinion 
a. When using driving impairing 
medicines people should decide for 
themselves whether they drive/ride a 
motorised vehicle or not 
     
b. Driving while using driving impairing 
medicines should be punished more 
severely in the future 
     
c. Driving after the consumption of 
alcohol should be prohibited 
     
d. The risk of driving under the influence 
of driving impairing medicines is being 
exaggerated 
     
e. The risks of driving under the 
influence of alcohol are being 
exaggerated 
     
 
21. To which extent do you agree or disagree on the following statements?  
(please select one option per statement only) 
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 totally 
agree agree disagree 
totally 
disagree 
no 
opinion 
a. Possible consequences of the use 
medication in traffic have never 
crossed my mind 
     
b. When I drive when using a driving 
impairing medicine I endanger my 
personal safety 
     
c. When I drive when using a driving 
impairing medicine I endanger the 
safety of other traffic participants 
     
d. If I know someone is using driving 
impairing medicines I will not let them 
drive me 
     
e. When I have been prescribed a driving 
impairing medicine I choose not to use 
my car and choose other types of 
transportation 
     
f. I do not mind other traffic participants 
using driving impairing medicines 
     
g. When I have been prescribed a driving 
impairing medicine I try to use my 
car/vehicle as little as possible 
     
h. When other drivers participate in 
traffic they take their use of driving 
impairing medicines into account 
     
 
• Remarks 
 
Do you have any remarks as a result of this questionnaire? Please express them here.  
  
 ...................................................................................................................................................................  
 ...................................................................................................................................................................  
 ...................................................................................................................................................................  
 ...................................................................................................................................................................  
 ...................................................................................................................................................................  
 ...................................................................................................................................................................  
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 ...................................................................................................................................................................  
 ...................................................................................................................................................................  
 ...................................................................................................................................................................  
 
 
 
• Thank you very much for completing this questionnaire! 
 
Please send the questionnaire to <<NAME OF RESEARCH INSTITUTE>> using the enclosed 
stamped addressed envelope.  
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Annex 4 – Invitation letter for recruitment of pharmacists 
 
Betreft: Onderzoek naar interventies bij het afleveren van rijgevaarlijke 
geneesmiddelen 
 
 
Geachte Pharmacom-gebruiker,  
 
Sinds oktober 2008 is de aandacht in ons land voor het gebruik van rijgevaarlijke 
geneesmiddelen toegenomen door de start van een landelijke campagne 
“Geneesmiddelen in het verkeer”. Maar ook in Europees verband is de aandacht 
groot en wil men graag weten hoe o.a. apothekers kunnen bijdragen tot het 
terugdringen van het gebruik van rijgevaarlijke geneesmiddelen (zie www.druid-
project.eu). 
De Rijksuniversiteit Groningen is betrokken bij dit Europese project en wil graag 
i.s.m. Health Base bestuderen hoe effectief de interventies in apotheken kunnen zijn, 
waar men gebruik maakt van EU-controle en EU- en TU-begeleiding. Met deze brief 
willen wij uw medewerking vragen bij het uitvoeren van dit onderzoek.  
 
Wat bieden de onderzoekers van de Rijksuniversiteit Groningen u? 
 
• Een unieke kans om in Europees verband te laten zien hoe de Nederlandse 
apotheker FPZ bij het gebruik van rijgevaarlijke geneesmiddelen aanbiedt. 
• Een cursus (waaraan geen kosten zijn verbonden) in oktober a.s. over 
geneesmiddelen en verkeersdeelname (precieze betekenis van de 
geneesmiddelcategorieën, juridische gevolgen en wijze van implementatie 
van EUC, EUB en TUB met behulp van Pharmacom). Accreditatie zal 
worden aangevraagd. 
• Begeleiding bij het implementatie traject van EUC, EUB en TUB en de 
daarbij behorende  extracties van registraties. 
• Een kleine attentie voor u en het apotheekteam. 
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Wat vragen de onderzoekers van u? 
 
• Gebruik van EUC, EUB en TUB bij anxiolytica, hypnotica en antidepressiva 
(de EUC tabel redenen vervallen recipe zal hiervoor worden uitgebreid met 
een reden ”rijveiliger alternatief gekozen”) vanaf 1 november 2009 tot 1 mei 
2010. 
• Overzicht van de eerste verstrekkingen van genoemde geneesmiddelen in de 
periode  1 juli 2008-1 november 2009 (hiervoor wordt een speciaal extractie 
programma ontwikkeld door PharmaPartners). 
• Overzicht van de eerste verstrekkingen van genoemde geneesmiddelen in de 
periode van 1 november 2009 – 1 mei 2010 (ook hiervoor kan genoemd 
extractieprogramma worden gebruikt) 
• Overzicht van EUB- en TUB-gebruik in de periode 1 november 2009 - 1 mei 
2010 (extractieprogramma is reeds beschikbaar). 
• Verspreiding van een patiëntenenquête bij ieder EU van een geselecteerd 
aantal geneesmiddelen (anxiolytica, hypnotica en antidepressiva) gedurende 
de onderzoeksperiode van 6 maanden. 
 
Wij willen de helft van de aanmeldende collega’s via loting vragen als controle-
apotheek deel te nemen (dus zonder interventie maar met het verzoek extracties uit 
te voeren en enquêtes te verstrekken, de cursus en attentie worden natuurlijk wel 
aangeboden na afloop van de onderzoeksperiode) 
 
Wij rekenen op uw medewerking en zien uw antwoordformulier met belangstelling 
tegemoet. Laat het formulier  s.v.p. niet liggen tot na uw vakantie. Een snelle reactie 
wordt op prijs gesteld. 
 
Met dank en vriendelijke groeten, 
 
 
Jan-Kees Huyts      Han de Gier 
Health Base      Rijksuniversiteit Groningen 
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.Bijlage: Antwoordformulier 
. 
JA, ik wil deelnemen aan het onderzoek naar de interventies bij aflevering van 
rijgevaarlijke geneesmiddelen 
 
Wij maken op dit moment gebruik van de eerste-uitgifte-begeleiding   
 
O  ja   
 O  nee   
 
Indien ja, voor welke van de volgende groepen is dat het geval? 
  O antidepressiva 
  O benzodiazepines 
  O morfinomimetica 
  O anti-epileptica 
  O voor alle groepen 
 
Indien nee, bent u bereid dat in oktober 2009 onder begeleiding te gaan 
doen? 
 
  O ja  
  O nee  
      
DGV heeft in samenwerking met SBA afgelopen jaar in het land diverse cursussen 
Geneesmiddelen en Verkeersdeelname verzorgd. Zijn er apothekersassistenten in 
uw apotheek die daaraan hebben deelgenomen? 
  O nee  
  O ja  namelijk ………. assistenten (s.v.p. aantal invullen) 
 
Heeft u sinds begin 2008 in het FTO aandacht besteed aan het onderwerp 
geneesmiddelen en verkeersdeelname? 
   
 O ja, een volledig FTO is hieraan besteed 
  O ja, het is uitgebreid ter sprake gekomen tijdens een FTO 
  O nee, dit onderwerp is nog niet behandeld 
 
Werkt u samen met Medicom-artsen die veelvuldig voorschrijven via het 
Formularium? 
 
  O ja 
  O nee 
 
Wordt in uw apotheek op dit moment structureel extra schriftelijke informatie 
meegegeven bij rijgevaarlijke geneesmiddelen? 
 
  O nee, nooit 
DRUID 6th Framework Programme
 
O nee, alleen als he
patiënt ter sprake komt
 O ja, bij alle medicijnen met een gele sticker
O ja, alleen bij een of meer specifieke groepen, 
namelijk……………………….…………………………
……….………………………………….………………
……………………………………………………………
 
Uw naam:    
 
Naam apotheek: ………………………………….. 
Omvang patiëntenbestand (geschat in duizendtallen)
Adres:   …………………………………..
Plaats   …………………………………..
 
Formulier terugsturen aan de Rijksuniversiteit Groningen 
bijgevoegde antwoordenvelop
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t in het gesprek met de 
 
 
 
…………………………………. 
 
 ……………………
 
 
met behulp van 
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 Annex 5 – Patient information letter 
 
Geachte Mevrouw/Meneer,  
 
Uw apotheek doet mee aan een groot Europees onderzoek naar de invloed van 
medicijnen op verkeersongevallen. In een deelonderzoek hiervan, uitgevoerd 
door de Rijksuniversiteit Groningen, wordt bestudeerd welke informatie mensen 
ontvangen als zij 'rijgevaarlijke' geneesmiddelen gebruiken. Meer (Engelstalige) 
informatie over het Europese onderzoek kunt u vinden op de website www.druid-
project.eu. 
 
Wij hebben u deze brief toegestuurd, omdat u een of meer medicijnen gebruikt 
die de rijvaardigheid beïnvloeden. De onderzoekers zijn geïnteresseerd in uw 
mening en uw ervaringen met deze medicijnen en met de informatie die u van 
uw arts en van ons ontvangt.  
 
Het is voor ons zeer waardevol als u aan dit onderzoek deelneemt. Dat kan door 
bijgaande vragenlijst in te vullen.  
 
Omdat de onderzoekers vooral uw mening en uw ervaringen willen weten, zijn er 
geen goede of foute antwoorden. De meeste vragen kunt u eenvoudig 
beantwoorden door een vakje aan te kruisen. Er zijn ook enkele vragen waarbij u 
zelf een antwoord op moet schrijven. Het zal ongeveer vijftien minuten kosten 
om de vragenlijst in te vullen. 
 
De vragenlijst is anoniem, u hoeft uw naam dus niet in te vullen. De 
onderzoekers zullen de individuele antwoorden ook niet aan ons doorgeven.  
 
Wij danken u bij voorbaat voor uw bereidheid om deel te nemen. 
 
 
 
U kunt de vragenlijst terugsturen in de bijgaande antwoord-envelop aan de 
Rijksuniversiteit Groningen. Een postzegel is niet nodig.  
 
 
Met vriendelijke groet,  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 361 of 456 
 
 
 
 
        (handtekening van de apotheker) 
 
 
 
 
 
 
  
 
  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
   
Page 362 of 456 
 Annex 6 – Newsletter January 2010  
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Annex 7 – Newsletter February 2010 
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Annex 8 – Newsletter March/April 2010 
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1 INTRODUCTION 
 
1.1. Medicines and driving in Spain 
 
It is estimated that between 5 and 10% of traffic accidents in the European Union may be due 
to driving under the influence of some medicines (1). Some medications can produce certain 
adverse reactions, such as decreased reaction time, dizziness, drowsiness, double and 
blurred vision, decreased alertness, etc., that could impair ability to drive (2). 
 
In Spain, 16.7% of drivers are chronic users of medicines and 3.4% have two or more drugs 
daily. Most worrying is that 75% of these people who use drugs and lead, say they have not 
received an information on the effects of these medications on driving.It is also important to 
note that almost 30% of people self-medicate (unknown if medication has adverse effects on 
driving) (3) 
 
At present many European countries that are strengthening information related to the effects 
of medicines on driving in order to reduce the road accidents rate, as it is considered one of 
the areas of intervention that can contribute prevent up to 50% of traffic injury collisions (2) 
 
In Spain, regarding the consumption of medicines and driving the IV General Regulations 
Driver (BOE de 8 de junio de 2009) (4) say: “Not supported the habitual use of substances 
that compromise the ability to drive safely, or the habitual use of medicines that, individually 
or together, serious adverse effects on driving ability”. Recently in Spain (from 2011) 
medicines that can may influence the ability to drive, must carry a symbol, pictogram in the 
package, to indicate to drivers carefully read the package insert for extra precautions if they 
drive a vehicle (Royal Decree 1345/2007 of 11 October) (5). The section "Driving and using 
machines" of the leaflet for patients to contain warning about the adverse effects that may 
occur with respect to driving, so the pictogram indicates see leaflet and if necessary request  
information to doctor or pharmacist. 
 
In this sense, doctors and pharmacists often prescribe or dispense medications to patients 
who drive, In order to be able to explain all risks to the patient, physicians and pharmacists 
need to be well prepared. The present study refers to the development, and consequent 
evaluation, of a training course that was carried out with the intention of informing at Health 
professionals of the Spanish National System of health (Physician and nurses) and 
pharmacist, about the influence of medicines on driving fitness, the DRUID categorization 
system (categorization for the relevant therapeutic groups of medicines) and implementation 
of the pictogram on the packaging of certain medicines in Spain. On the other hand, it would 
also be advisable to health professionals, develop an effective strategy to communicate the 
risk related to the use of medicines and driving.  
 
It has carried out a study in patients to determine whether the users of medicines know that 
some medicines can negatively affect their fitness to drive, and to evaluate the influence that 
the pictogram on medicines and driving that is printed on the packaging of the medicine could 
have on the patient’s attitude to driving. 
 
 
In order to understand how the Spanish trial was designed and carried out, some key issues 
should be highlighted: 
 
1.2. The Spanish Health System 
 
Spain has a universal, free, public health service that covers health care for all nationals and 
residents (6). Spain’s National Health Service can be divided into two basic areas of cover: 
 
• Primary care: This is the initial and basic level of care that guarantees the global 
nature and continuity of care throughout the patient’s life. Primary care is 
administered in Primary Health Care Centres, which are the centre of reference for 
the “Basic Health Area”, which is the territory within a 30 minute radius of the 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
    
Page 372 of 456 
Primary Health Care Centre and may stretch over a single suburb or several 
suburbs; it may also cover a town or several villages (7). 
 
• Hospital and specialist care: This is the second organisational level of public health 
care services in Spain. Access to this level is gained by first visiting the primary 
health care level, i.e., the general practitioner, who will forward the patient to the 
appropriate specialist. This type of care is administered in hospitals and in 
Specialised Centres, either as outpatients or under hospital admissions (8). 
 
Included within the National Health Service is the pharmaceutical medication (Normal cost for 
the patient: 40% of the Recommended Retail Price (RRP). Reduced cost for the patient: 10% 
of the RRP in medicaments to treat some chronic illness. No cost for the patient: pensioners 
and treatments originating in professional illnesses and accidents at work). The pharmacist’s 
mission is to dispense the medicaments to the patients and carry out an individualised control 
of the use of the said medicaments (9). 
 
 
1.3. The Spanish pictogram on medicines and driving 
 
Recently (Figure 65), Spain has introduced a mandatory pictogram on medicines and driving 
(5). When developing the current trial, this issue has been addressed during the training 
courses carried out in the study, and in fact has relevant importance in the design of the 
study. For further details, please see Annex 1. 
In orden a 
 
 
 
Figure 65: Pictogram in the medicines' box regarding driving. 
 
 
 
1.4. The target population among health professional: physicians, pharmacist 
and nurses.  
 
Among the health professionals, the Spanish trial included physicians (who prescribe the 
medication), pharmacists (who dispense the medication), as well as nurses. With the recent 
implementation of electronic prescriptions, nurses have a role in following up prescribed 
medicines. Therefore, following a suggestion by the national and regional health authorities, 
this target population, nurses, was included in the study. 
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1.5. The setting for training: Regular training activities at primary care centres 
 
The current training activities in the present trial were done at primary health care centres 
following regular training activities for physicians and nurses. That is, participants were 
enrolled as currently they are involved in other training activities. However, the pharmacists 
involved in the current trial were attending also these regular training activities, while this is 
not a normal rule. 
 
1.6. Granted continuous training activities 
 
Participation at the trial was not rewarded in any specific form (money, tickets, etc).  
 
As a normal rule, the training activities were submitted for approval as a continuous training 
activity twice; first for physicians and pharmacists, and later for nurses (please see 
methodology, section 2). These were granted the status of Continuous Training by the Health 
Authorities. 
 
1.7. Training activity in cooperation with National and Regional Health 
Authorities 
 
These training activities were done in co-operation with the National (Agencia Española de 
Medicamentos y Productos Sanitarios) and Regional Health authorities (Junta de Castilla y 
León, Consejería de Sanidad, Sacyl). Furthermore, the National (Consejo General de 
Colegios Oficiales de Farmacéuticos) and Local (Colegio Oficial de Farmacéuticos de 
Valladolid) Associations of Pharmacists, as well as scientific societies (SET, SEMT), were all 
consulted. Therefore, many aspects of the design were done in accordance with their 
recommendations and following their suggestions.  
 
1.8. Intranet and software programmes for prescribing and dispensing 
 
Health professionals currently use software programmes in their daily activity for prescribing 
or dispensing medicines and patient follow up. However, for the present study, as agreed with 
the partners involved, no DRUID information was integrated in the existing intranet software 
of the public health system for prescribing, or of pharmacies for dispensing. However, as 
mentioned in deliverable 7.4.1., some information on the Spanish pictogram on medicines 
and driving does exist in some resources. For the training course a web page was developed, 
this included clear, well-structured contents to facilitate access to the largest number of 
people possible, as this could also be consulted in the future, at least part of the contents, by 
the general public. This web page has been developed in Spanish 
(http://www.uva.es/medicamentosyconduccion), but will be translated to English in the near 
future. 
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2 METHODOLOGY 
 
2.1 STUDY 1: HEALTH PROFESSIONALS: PHYSICIANS, PHARMACISTS AND 
NURSING STAFF 
 
2.1.1 Objectives  
 
Please see pages 379 and 383 of this report. 
 
i) Common objectives to the DRUID-trial (please see page 390 of this deliverable) 
• To assess health professional attitudes/awareness, reported behaviour, sources, actual 
knowledge and user’s acceptance on the topic of medicines and driving (pre-training). 
• To assess possible changes in these dimensions six months later, after the training 
activities (post-training). 
 
ii) Specific objectives for the Spanish trial 
• To assess the importance that the professionals give to the fact of offering information to 
their patients concerning medicines and driving while carrying out their daily work (at pre-
training and post-training). With this aim two questions were developed: 
*In their daily practice, during the previous 6 months, what importance has been given to the 
question of medicines and driving (from 1 to 10, 10 being the maximum)? 
*In their daily practice over the previous year, with what frequency have they come across 
cases in which the effect of medication on driving has been an important aspect at the time 
of selecting medicines? 
 
2.1.2 Target populations  
 
As earlier indicated, it was included physicians and nurses working at primary health care 
centers, as well as community pharmacists. 
 
2.1.3 Sample size 
 
Please see page 379 and 384. The sample size was initially established at 93 physicians, 93 
pharmacists and 93 nursing staff.  
 
2.1.4 Groups: Control, information and intervention group  
 
Three work groups were to be formed within these health professionals based on the means 
of administering the information (please see page 387 of this deliverable): 
 
• Control Group: Group that did not receive any information on medicines and driving. 
• Information Group: group that received information and training on medicines and 
driving through printed documents specifically designed for the trial. On occasions 
during the DRUID trial we denominated this group as a non-integrated tool. 
• Intervention Group: Group that received specific information on medicines and 
driving throught printed documents and thought a web page.  On occasions during the 
DRUID trial this group was denominated as integrated tool (ICT-tool).  As pointed out 
in the introduction section, we had no access to current software used for prescription 
and dispensing. Therefore we did no use a “real” ICT-tool in this trial.  
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2.1.5 Setting 
 
 
The study was carried out in 10 primary care health centres in the Province of Valladolid and 
among the pharmacists working within the area of influence of these 10 primary care health 
centres. Figure 66 shows the geographic distribution of the participating primary care health 
centres: Parquesol, Tordesillas, Huerta del Rey, Rondilla I and II, Circular, Pilarica, Canterac, 
Circunvalación, la Tórtola and Delicias.  
 
The distribution was done in accordance with Regional Health Authorities for both Valladolid-
west and Valladolid-east. Urban and rural centres were included. Prior to carrying out of the 
courses had a meeting with each of the coordinators of the participating health centers, they 
agreed to inform members of their medical health center on the theme of the course and 
agreed to the day the time of fulfillment.The pharmacists were invited by a mail informing him 
of the objectives, theme, date and venue of the course.Courses are carried out in each of the 
participating health centers, together pharmaceutical physicians and nurses. 
 
All physicians, nurses and pharmacist belonging to these 10 primary health care centres were 
included in the study and the training courses were carried out as part of the regular training 
activities. 
 
 
 
Figure 66:  Geographic distribution of the participating Primary Health Care Centres 
 
Finally, the sample was established as shown in Table 119 regarding health professional 
group and training group. It involved 141 physicians, 127 community pharmacist, and 139 
nurses. 
 
Table 119: Distribution of health professional by training group. 
Groups Background Included 
Control 
Physician 41 
Pharmacist 33 
Nurses 41 
Information 
Physician 56 
Pharmacist 46 
Nurses 52 
Intervention 
Physician 44 
Pharmacist 48 
Nurses 46 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
    
Page 376 of 456 
 
2.1.6 Description of training activities and material produced for the three groups: 
control, intervention and experimental 
 
• Control group 
 
This group was made up of health professionals (41 physicians and 41 nursing staff) from the 
primary health care centres of Circunvalación, la Tórtola and Delicias (Figure 66) and 33 
pharmacists in the same areas of influence.  
 
They did not receive any specific information on medicines and driving. 
 
• Information group 
 
This group was made up of health professionals (56 physicians and 52 nursing staff) from the 
primary health care centres of Parquesol, Tordesillas and Huerta del Rey (Figure 66) and 46 
pharmacists in the same areas of influence. 
 
The information group received printed material concerning the effects of medicines on 
driving and concerning the Spanish pictogram on medicines and driving printed on the 
packaging (RD: 1345/2007).  
 
  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
    
Page 377 of 456 
 
 
 Figure 67:Flowchart representing the organization of training course   
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The following specific material has been produced for the trial:  
 
o Posters about the Spanish pictogram on medicines and driving (Figure 68). They 
were distributed among participating primary health care centres and pharmacies.  
 
       
      Figure 68: Posters: English version 
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o Leaflets aimed at patients and the general public on medicines and driving 
 
Leaflets aimed at the general public, but mainly patients taking certain groups of medicines 
were developed ( 
Figure 69).  
 
- Leaflet 1: Medicines and driving  
- Leaflet 2: Sleeping pills and driving  
- Leaflet 3: Antidepressants and driving  
- Leaflet 4: Elderly people, medicines and driving  
 
Sixty thousand leaflets were printed and distributes in primary care health centres and 
pharmacies. The leaflet “Elderly people, medicines and driving” was distributed specifically by 
nursing staff (in Castile and León, the nursing staff are somewhat responsible for monitoring 
the treatment of chronic illnesses). The other three leaflets were distributed by physicians and 
pharmacists.  
  
 
   
Figure 69: Leaflets for patients 
 
o Brochure specifically aimed at health professionals 
 
This brochure, basically, provides information concerning the Spanish pictogram on 
medicines and driving and the methodology followed by the Agencia Española de 
Medicamentos y Productos Sanitarios (Spanish Agency for Medicines and Health Products) 
to assign, or not, the pictogram on driving to a medicine. The brochure gives useful advice to 
the professional who must prescribe medicines to patients who are also drivers (Figure 70).   
 
o Brochure “Medicines and driving: The prescription of medicines to patient who 
drive”  
 
The book concerns the implantation of the pictogram in Spain. It sets out the guidelines and 
protocols concerning the prescription of medicines to patients who drive and the effects of 
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medicines on psychomotor performance and traffic accidents. It introduces DRUID’s 
categorization criteria for medicines with respect to driving (Figure 70). As this was the key 
document for describing DRUID categorization system as well as describing the guidelines 
and protocols for prescribing to the driver patient, the full brochure is presented in Annex I. 
 
 
                 
Figure 70: Cover page of the brochure   Figure 71: Cover page of the brochure 
“Medicines, driving and healthcare       “Medicines and driving: The prescription of  
professionals”.      medicines to patients who drive” 
       Please see Annex 2. 
 
o Book on the “Workshop on medicines and their effect on driving: new warning 
pictogram for medicines” 
 
The book sets out a summary of the information from the workshop held in Madrid on June 8th 
2009 in the Agencia Española de Medicamentos y Productos Sanitarios (Spanish Agency for 
Medicines and Health Products), including the methodology and the criteria for the 
introduction of the Spanish pictogram on the packaging on medicines and driving. Three 
hundred copies of this short book have been printed and distributed among health 
professionals ( Figure 72). 
 
o Book “Medicines and Driving. DRUID Categorization (N Group: Nervous 
System)” 
 
This book included the DRUID categorization system for N medicines (N01 to N07). It was 
translated from English to Spanish. Furthermore to the categorization for N medicines, it 
included the specific information to be provided by health professional to the driver patient. 
Also it was included wether or not the medicine has the Spanish Pictogram (Figure 73).  
 
 
\ 
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• Intervention group 
 
This group was made up of primary health care centres professionals (44 physicians and 46 
nursing staff) from the Centres of Rondilla I y II, Pilarica y Circular (Figure 66) and 48 
pharmacists in the same areas of influence (Table 119). 
 
Besides the material aimed at the information group, a web page was developed for the 
formation of this group l, which included clear, well-structured contents to facilitate access to 
the largest number of people possible, as this could also be consulted in the future, at least 
part of the contents, by the general public. This web page has been developed in Spanish 
(http://www.uva.es/medicamentosyconduccion), but will be translated to English in the near 
future. The general structure of the web page is as follows: 
 
From the home page of “Medicines and Driving” (Figure 74), the desired language (Spanish 
or English) can be chosen and all the contents and the information accessible to the public in 
general can be accessed: 
 
− What you need to know: General introduction to medicines and driving 
− Legislation: Reference to the RD 1345/2007 of 11th October 
− Videos 
− Materials: All the materials in PDF format. 
− Links to the pages of the collaborating organisms and institutions (“click” on the logo). 
Link to documents concerning medicines and driving 
− Button to access the area reserved for health professionals (physicians, pharmacists 
and nursing staff). 
 
 
. Figure 72:    Figure 73: Cover page of the book “Medicines and  
. Cover page of the book   driving:DRUID Categorization (N Group: Nervous  
 about the workshop on medicines  “Medicines and System)”. 
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Figure 74: Home page of “Medicamentos y Conducción” 
http://www.uva.es/medicamentosyconduccion 
 
Within the area reserved for health professionals, there are also unrestricted contents, which 
can be seen by anyone, and restricted contents that need a password. The open contents 
can be seen by clicking on the buttons “Materials”, “Legislation” and “Links”, which are 
shown in Figure 75. Clicking on the “Search” button initiates access to the restricted area and 
user ID and password are asked for (Figure 76). 
 
 
Figure 75: Area reserved for health professionals 
 
 
 
Figure 76: Access to the restricted area 
 
The page has a search button which, on introducing either the active ingredient or the ATC 
code, the user can discover whether a medicine carries the pictogram concerning medicines 
and driving in Spain or not, as well as the DRUID categorization of the medicine. 
 
• The training (course) 
 
A training manual including the relevant DRUID WP4 and WP7 information for health 
professionals was developed in DRUID Task 7.4.1 (D 7.4.1). Please consult the full report for 
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further details (http://www.druid-project.eu/nn_107548/Druid/EN/deliverales-
list/downloads/Deliverable__7__4__1,templateId=raw,property=publicationFile.pdf/Deliverabl
e_7_4_1.pdf). 
 
This manual was slightly adjusted to the specific Spanish scope. It was used as guidance 
when training the health professionals. 
 
The objectives of the training course were as follows (please see page 14, D 7.4.1): 
• To understand the use of the categorization system for medicines that might impair 
driving performance; 
• To know the recommendations on dispensing information when prescribing and 
delivering medicines that might influence driving skills, as these are described in the 
prescribing and dispensing guidelines; 
• To have an insight into their own policy with regard to medicines that might impair 
driving performance; 
• To be able to make joint agreements on patient information policies and allocation of 
tasks between the GP’s practice and the community pharmacy with respect to those 
medicines that might impair driving skills (this objective is only applicable if a joint 
statement exists within the respective countries; an example of joint agreements is 
found in Appendix A4). 
 
With this aim the training courses were given to the information and intervention groups in 
several sessions lasting each one about one hour.  
 
• Questionnaire PRE and POST 
 
An adapted version was used of the EVALUATION QUESTIONNAIRE Health care workers 
(pre-post) that appears as an annex in the Deliverable 7.4.1 (http://www.druid-
project.eu/nn_107548/Druid/EN/deliverales-
list/downloads/Deliverable__7__4__1,templateId=raw,property=publicationFile.pdf/Deliverabl
e_7_4_1.pdf). Please see also page 389 of this deliverable. 
 
Notice that in the questionnaire for nurses there was a slight change in two questions in order 
to accommodate them to the fact that they follow medication treatment, but do not prescribe 
or dispense medicines.  
 
The PRE-questionnaire was completed before the training. The POST-questionnaire was 
completed 6 months after training started. The post-questionnaire was mailed together with a 
stamped envelope to facilitate its return by health professionals. 
 
Notice that several persons participated in the training courses assist the training, but they did 
not want to fill in the questionnaire. Overall, there were very frequent criticisms about the 
usefulness of the questionnaire.  
 
As agreed upon by the partners of task 7.4, annexes II and III present the pre and post 
questionnaires in their Spanish versions. 
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2.2 STUDY 2: PATIENT QUESTIONNAIRE 
 
2.2.1 Objective  
  
To find out whether the users of medicines know that some medicines can negatively affect 
their fitness to drive, and to evaluate the influence that the pictogram on medicines and 
driving that is printed on the packaging of the medicine could have on the patient’s attitude to 
driving. 
 
2.2.2 Target population  
 
The target population is made up of “health service users”. Throughout the current text, they 
shall be referred to as “patients”. However, it should be taken into account that what we really 
mean by this term is people who come into contact with the National Health Service through 
Primary Care, Hospital-Specialized Attention or as consumers in pharmacies. 
 
The “health service users“ included in the study correspond to three different health service 
levels: i) Pharmacies; ii) Primary Care; iii) Hospital-Specialized Attention. The study was 
aimed at both patients with a driving license and those without. 
 
2.2.3 Sample size 
 
The sample size was established at 300 people in each of the three spheres of study (a total 
of 900 people). Finally, 1,385 valid interviews were carried out. 
 
 
2.2.4 Setting 
 
The study was carried out in different health care environments within the Province of 
Valladolid.  
 
• The patients were interviewed in:  
• Primary Care facilities by nursing staff,  
• In pharmacies by trained survey personnel, 
• In Specialist Attention (pre-anesthesia visits in the “Hospital Clínico” in Valladolid) by 
trained survey personnel. 
 
2.2.5 Questionnaire used 
 
For this study, the socio-demographic variables (sex, age, educational level, possession of a 
driving license or not and kilometers driven per year) and 3 of the questions from the 
questionnaire created for this purpose, and which can be seen in Annex IV, have been 
analyzed as was agreed by the partners of task 7.4. The analyzed questions were: 
 
• Did you know that some medicines can influence fitness to drive? The options for 
answering are: Yes / No. 
• Supposing that you are prescribed this medicine which has the pictogram about 
driving on the packaging. With what frequency would you drive during the period in 
which you were taking the medicine? Possible answers are: “The same frequency as 
usual”, “Less frequently”, “A lot less frequently”, “I would only drive rarely”, “I would 
not drive at all”, 
• What would you do if you were prescribed this medicine with the pictogram about 
driving on the packaging? Possible answers are: “I would drive without taking any 
other precautions”, “I would not drive without first reading the package insert”, “I 
would not drive without the advice of a doctor or pharmacist”, “I would not drive until 
my doctor told me it was safe to do so”. 
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2.3 Ethical principles 
 
The study was approved by the Clinical Research Ethics Committee of the Faculty of 
Medicine at the University of Valladolid and by the Research Commission of the “Hospital 
Clínico Universitario” of Valladolid. 
 
All the health professionals and patients we
participated voluntarily and their anonymity was preserved.
 
 
2.4 Statistical analysis 
 
The data gathered from both studies have been recorded in a database of the statistical 
package PASW Statistics 18. The r
median for the quantitative variables and percentages for the categorical variables. Also, 
respectively, the T-test and the Squared Chi test have been used to analyze the results. 
Within-group pre-post questionnaire change, for ordinal variables (attitudes and awareness, 
reported behaviour, knowledge) Wilcoxon matched pairs 
of the different tests, values of P 
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re adequately informed of the nature of the study, 
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Physicians 2.8 
Pharmacists 2.8 
Nursing staff 3.8 
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-
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3 RESULTS 
 
3.1 STUDY 1: HEALTH PROFESSIONALS: PHYSICIANS, PHARMACISTS AND 
NURSING STAFF  
 
The sample was established as shown in Table 120 regarding health professional group and 
training group. It involved 141 physicians, 127 community pharmacists, and 139 nurses, of 
whom, 72 physicians, 75 pharmacists and 36 nursing staff answered the initial questionnaire.  
 
 
Table 120: Distribution of health professionals by training group and responses (PRE). 
 
Groups Profession Included Responses Questionnaire PRE 
 
Control 
Physician 41 21 
Pharmacist 33 29 
Nursing 41 7 
Information 
Physician 56 26 
Pharmacist 46 27 
Nursing 52 13 
Intervention 
Physician 44 25 
Pharmacist 48 19 
Nursing 46 16 
 
 
3.1.1 BACKGROUND INFORMATION 
 
A total of 183 health professionals, 65 men (35.5%) and 118 women (64.5%) answered the 
initial questionnaire. There are significant differences in the distribution of the health 
professionals who answered the questionnaire with respect to sex (Χ22=11.437; p<0.005); 
while, among physicians the proportion is 1:1, among the pharmacists and the nursing staff, 
the men: women ratio is 1:3 (Table 121). Within each collective, there are no significant 
differences with respect to sex among the control/information/intervention groups. No 
significant differences were observed in the distribution of the health professionals 
(physicians/pharmacists/nursing staff) who answered the questionnaire between urban and 
rural areas (Χ22=1.217; p>0.05,Table 122). 
     
Table 121: Gender distribution 
 
Male 
N (%)  
Female 
N (%) 
Total 
N (%)  Χ
2
2; p (Control/Information/ Intervention) 
Physicians 36 (50.0) 36 (50.0) 72 (100.0) 0.241; p>0.05 
Pharmacist 21 (28.0) 54 (72.0) 75 (100.0) 0.065; p>0.05 
Nursing 8 (22.2) 28 (77.8) 36 (100.0) 4.095; p>0.05 
Total 65 (35.5) 118 (64.5) 183 (100.0)  
 
Χ
2
2=11.437; p<0.005 
 
 
Table 122: Region distribution 
 
 
Physicians  
N (%)  
Pharmacist  
N (%) 
Nursing  
N (%)  
Total 
N (%) 
Χ
2
2; p  
 
 Urban 62 (86.1) 63 (84.0) 33 (91.7) 158 (86.3) 1.217; p>0.05 Region Rural 10 (13.9) 12 (16.0) 3 (8.3) 25 (13.7) 
 Total 72 (100.0) 75 (100.0) 36 (100.0) 183 (100.0)  
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The average age of the health professionals (Mean±SD) is 48.24±10.42 years. There are 
significant differences between the three collectives (F=19.272; p<0.0001), the pharmacists 
being the youngest collective (43.10±10.73 years). Similarly, there are significant differences 
in the average age of the professionals’ work experience (F=28.555; p<0.0001), the 
pharmacists being the collective with the lowest work experience (14.81±9.60 years). Within 
each collective (physicians, pharmacists and nursing staff), no significant differences were 
observed between the control/information/intervention groups, neither in the average age nor 
the work experience (Table 123). 
 
Table 123: Sampled population: Age and years practicing 
 
Age (years) Practising (years)  
N Mean±SD 
F; p 
(Control/Information/ 
Intervention) 
N Mean±SD 
F; p 
 (Control/Information/ 
Intervention) 
Physicians 63 52.14±8.39 0.353; p>0.05 70 23.26±9.55 0.041; p>0.05 
Pharmacist 72 43.10±10.73 1.424; p>0.05 70 14.81±9.60 2.460; p>0.05 
Nursing 28 52.68±7.80 1.241; p>0.05 36 28.31±8.23 0.686; p>0.05 
Total 163 48.24±10.42  176 20.93±10.68  
 
F=19.272; 
p<0.0001 
 F=28.555; 
p<0.0001  
 
 
63.4% of the health professionals referred to not having received any type of formation 
concerning the effects of medicines on driving during their university studies. There are 
significant differences (Χ22=11.736; p<0.005), the pharmacists being the group that most 
frequently referred to having received formation in this respect (51.4%). Within each 
collective, no significant differences were observed between the 
control/information/intervention groups (Table 124). 
 
Table 124: Did you get any education on medicinal effects on driving skills during your 
studies at University? 
 
Yes 
N (%)  
No 
N (%) Χ
2
2; p  
Χ
2
2; p (Control/Information/ Intervention) 
Physicians 19 (27.5) 50 (72.5) 
11.736; p<0.005 
2.254; p>0.05 
Pharmacist 37 (51.4) 35 (48.6) 0.180; p>0.05 
Nursing 8 (23.5) 26 (76.5) 5.652; p>0.05 
Total 64 (36.6) 111 (63.4)   
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3.1.2 NEW TECHNOLOGIES LITERACY 
 
The questions “Do you use the internet to obtain information on medicines affecting driving 
behaviour?” and “Have you ever used any software package/program to obtain information on 
the effects of medicines on driving behaviour?” are grouped into a single item which includes 
internet (Table 125). 
Two out of every three health professionals (63.4%) referred to not using internet or any type 
of software and/or computer programme to obtain information about the effects of medicines 
on driving. The pharmacists most frequently referred to using one or more of these means 
(59.2%), and there were significant differences (Χ22=17.405; p<0.0001). Within each 
collective, no significant differences were observed between the 
control/information/intervention groups (Table 125). 
 
Table 125: Have you ever used any software package/program to obtain information on 
medicines effect on driving behaviour? (Internet is included in the Spanish version) 
 
Yes 
N (%)  
No 
N (%) Χ
2
2; p  
Χ
2
2; p (Control/Information/ Intervention) 
Physicians 19 (26.4) 53 (73.6) 
17.405; p<0.0001 
0.402; p>0.05 
Pharmacist 42 (59.2) 29 (40.8) 0.494; p>0.05 
Nursing 11 (31.4) 24 (68.6) 0.751; p>0.05 
Total 64 (36.6) 111 (63.4)   
 
Almost all the pharmacists (98.7%) referred to using some kind of medical/clinical software 
package /program; this use id referred to less frequently by physicians (65.2%) and by 
nursing staff (58.3%). There were significant differences between the three collectives 
(Χ22=33.107; p<0.0001). No significant differences were observed among physicians or 
pharmacists in their replies to this question according to group (control, information or 
intervention), but there were significant differences among the nursing staff (Χ22=7.912; 
p<0.05,Table 126). 
 
Table 126: Do you use any medical/clinical software package /program?   
 
Yes 
N (%)  
No 
N (%) Χ
2
2; p  
Χ
2
2; p (Control/Information/ Intervention) 
Physicians 45 (65.2) 24 (34.8) 
33.107; p<0.0001 
0.917; p>0.05 
Pharmacist 74 (98.7) 1 (1.3) 2.987; p>0.05 
Nursing 21 (58.3) 15 (41.7) 7.912; p<0.05 
Total 140(77.8) 40 (22.2)   
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3.1.3 ATTITUDES/AWARENESS 
 
In order to evaluate the attitude of health professionals concerning the effects of medicaments 
on fitness to drive, a series of questionnaires were made that asked for their agreement or 
disagreement on certain questions (Tables 127-132).  
 
The great majority of health professionals stated they “agreed” or “strongly agreed” with the 
statement “I am willing to take into account the effects of medicines on driving skills when 
prescribing/dispensing medicines”, although there were significant differences (Χ26=16.493; 
p<0.05). The nursing staff showed the greatest percentage of disagreement (Table 127). 
 
Table 127: I am willing to take into account the effects of medicines on driving skills when 
prescribing/dispensing medicines. 
 (*) 4 degrees of freedom for this chi square 
 
In addition, the health professionals were asked if they would take the above question even 
more into account if the patients were in any of the groups of drivers indicated in Table 128. In 
general, a high percentage of health professionals, including physicians, pharmacists and 
nursing staff, answered that they would. The affirmative answers were over 90% in almost all 
the groups. The highest percentage was for professional drivers, while the percentage was 
lower for the group of inexperienced drivers (81.0%) and even lower than that for experienced 
drivers (68.3%). Significant differences were only observed among health professionals on 
considering drivers who were taking other drugs that affected the CNS, (Χ22=10.505; p<0.01). 
This fact would be taken into consideration more frequently by physicians (96.9%) and 
pharmacists (98.5%) than by nursing staff (83.9%). 
 
  
 Strongly disagree  
N (%)  
Disagree 
N (%) 
Agree 
N (%)  
Strongly 
agree  
N (%) 
Χ
2
6; p 
(Control/Information/ 
Intervention) 
Physicians 1 (1.4) 3 (4.2) 64 (88.9) 4 (5.6) 6.927; p>0.05 
Pharmacist 2 (2.7) 7 (9.5) 52 (70.3) 13 (17.6) 5.805; p>0.05 
Nursing 0 (0.0) 7 (20.0) 27 (77.1) 1 (2.9) 4.221; p>0.05* 
Total 3 (1.7) 17 (9.4) 143 (79.0) 18 (9.9)  
 
Χ
2
6=16.493; p<0.05  
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Table 128: Would you consider this (Q1) of more concern if your patient is: 
Q1 
 
Yes 
N (%)  
No 
N (%) Χ
2
2; p  
A professional driver? 
Physicians 68 (98.6) 1 (1.4) 
2.898; p>0.05 Pharmacist 73 (98.6) 1 (1.4) 
Nursing 29 (93.5) 2 (6.5) 
 Total 170 (97.7) 4 (9.4)  
Driving frequently? 
Physicians 66 (95.7) 3 (4.3) 
4.353; p>0.05 Pharmacist 67 (94.4) 4 (5.6) 
Nursing 28 (84.8) 5 (15.2) 
 Total 161 (93.1) 12 (6.9)  
Driving long distances? 
Physicians 62 (91.2) 6 (8.8) 
3.874; p>0.05 Pharmacist 63 (92.6) 5 (7.4) 
Nursing 24 (80.0) 6 (20.0) 
 Total 149 (89.8) 17 (10.2)  
An “inexperienced” driver? 
Physicians 51 (76.1) 16 (23.9) 
3.006; p>0.05 Pharmacist 61 (87.1) 9 (12.9) 
Nursing 24 (77.4) 7 (22.6) 
 Total 136 (81.0) 32 (19.0)  
An “experienced” driver? 
Physicians 43 (66.2) 22 (33.8) 
0.331; p>0.05 Pharmacist 46 (68.7) 21 (31.3) 
Nursing 23 (71.9) 9 (28.1) 
 Total 112 (68.3) 52 (31.7)  
An elderly driver? 
Physicians 63 (91.3) 6 (8.7) 
2.170; p>0.05 Pharmacist 65 (95.6) 3 (4.4) 
Nursing 28 (87.5) 4 (12.5) 
 Total 156 (92.3) 13 (7.7)  
Using other CNS active drugs? 
Physicians 63 (96.9) 2 (3.1) 
10.505; p<0.01 Pharmacist 66 (98.5) 1 (1.5) 
Nursing 26 (83.9) 5 (16.1) 
 Total 155 (95.1) 8 (4.9)  
 
 
Three out of every four health professionals would “agree” (70.6%) or “strongly agree” (6.2%), 
with changing the prescription/dispensation for another medicament that had less of an effect 
on fitness to drive vehicles (Table 129). Of the health professionals, 93.9% stated they 
“agreed” (74.7%) or “strongly agreed” (19.2%) with the statement “I feel I am well aware of the 
effects of medicines on driving skills” (Table 130). Almost all of them (96.2%) also agreed that 
“It is important for me to be well-informed on medicinal effects on driving behaviour” (Table 
131).  
Nevertheless, most health professionals (91.1%) are sceptical about the usefulness of 
information given to the patient: 80.1% “disagreed” and 11.0% “strongly disagreed” with the 
statement “I feel that the information I provide to patients will influence their driving behaviour” 
(Table 135). No significant differences were noted in any of these questions (Tables 132-135) 
among the different groups of health professionals (physicians, pharmacists and nursing 
staff). Within each of these groups, no significant differences were found between control, 
information or intervention groups either (p>0.05). 
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Table 129: I am willing to sacrifice some degree of efficacy by prescribing/dispensing a 
medicine that is less impairing to the driving skills 
(*) 4 degrees of freedom for this chi square 
 
Table 130: I feel being well aware of the effects of medicines on driving skills. 
 (*) 4 degrees of freedom for this chi square 
 
Table 131: It is important for me to be well-informed on medicinal effects on driving 
behaviour. 
 (*) 4 degrees of freedom for this chi square 
 
Table 132: I feel that the information I provide to patients will influence their driving behaviour. 
 
 
  
 
Strongly disagree  
N (%)  
Disagree 
N (%) 
Agree 
N (%)  
Strongly agree  
N (%) 
Χ
2
6; p 
(Control/Information/ 
Intervention) 
Physicians 0 (0.0) 14 (19.7) 51 (71.8) 6 (8.5) 5.903; p>0.05* 
Pharmacist 5 (7.0) 15 (21.1) 48 (67.6) 3 (4.2) 9.136; p>0.05 
Nursing 1 (2.9) 8 (17.1) 26 (74.3) 2 (5.7) 5.016; p>0.05 
Total 6 (3.4) 35 (19.8) 125 (70.6) 11 (6.2)  
 
Χ
2
6=6.629; p>0.05  
 
 
Strongly disagree  
N (%)  
Disagree 
N (%) 
Agree 
N (%)  
Strongly agree  
N (%) 
Χ
2
6; p 
(Control/Information/ 
Intervention) 
Physicians 1 (1.4) 3 (4.2) 57 (79.2) 11 (15.3) 12.517; p>0.05 
Pharmacist 0 (0.0) 3 (4.0) 51 (68.0) 21 (28.0) 3.264; p>0.05* 
Nursing 2 (5.7) 2 (5.7) 28 (80.0) 3 (8.6) 9.454; p>0.05 
Total 3 (1.6) 8 (4.8) 136 (74.7) 35 (19.2)  
 
Χ
2
6=11.376; p>0.05  
 
 
Strongly disagree  
N (%)  
Disagree 
N (%) 
Agree 
N (%)  
Strongly agree 
N (%) 
Χ
2
6; p 
(Control/Information/ 
Intervention) 
Physicians 1 (1.4) 3 (4.2) 54 (75.0)  14 (19.4) 7.882; p>0.05 
Pharmacist 0 (0.0) 1 (1.3) 42 (56.0) 32 (42.7) 2.840; p>0.05* 
Nursing 1 (2.9) 1 (2.9) 25 (71.4) 8 (22.9) 8.616; p>0.05 
Total 2 (1.1) 5 (2.7) 121 (66.5) 54 (29.7)  
 
Χ
2
6=12.448; p>0.05  
 
 
Strongly disagree  
N (%)  
Disagree 
N (%) 
Agree 
N (%)  
Strongly agree  
N (%) 
Χ
2
4; p 
(Control/Information/ 
Intervention) 
Physicians 9 (12.7) 56 (78.9) 6 (8.5) 0 (0.0) 3.751; p>0.05 
Pharmacist 6 (8.0) 63 (84.0) 6 (8.0) 0 (0.0) 6.281; p>0.05 
Nursing 5 (14.3) 26 (74.3) 4 (11.4) 0 (0.0) 2.017; p>0.05 
Total 20 (11.0) 145 (80.1) 16 (8.8) 0 (0.0)  
 
Χ
2
4=1.774; p>0.05  
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3.1.4 REPORTED BEHAVIOUR 
 
In order to evaluate this aspect, the health professionals were given 6 statements, in which 
they had to evaluate the frequency (always, regularly, sometimes, seldom, never) with which, 
in the course of their daily activity, they asked the patients about the frequency of their driving 
and whether they informed patients about the possible effects of the medicaments they 
prescribed/dispensed/supervised on fitness to drive. On the other hand, they were also asked 
whether they made a record in the patients’ files of the frequency with which the patients 
drove and the fact that of having informed them in the case where the medicament concerned 
negatively affected fitness to drive. In addition, they were asked whether, when 
prescribing/dispensing/supervising a medicament that could affect fitness to drive, they gave 
the patients printed information and whether they analysed, with the patient, the latter’s 
responsibility when consuming medicaments while driving. 
 
More than half the physicians (52.8%) “always” (13.9%) or “almost always” (38.9%) asked 
their patients about frequency of driving when prescribing a medicine. Only 1 out of every 3 
did so in the case of pharmacists, while scarcely 1 out of every 6 did so in the case of nursing 
staff. Significant differences were observed between physicians, pharmacists and nursing 
staff (Χ28=15.748; p<0.05). It should be pointed out that 1 in 3 health professionals “never” 
(7.7%) or “almost never” (23.2%) asked their patients about driving frequency (Table 133). 
 
Table 133: I ask a patient about his/her driving exposure when choosing/dispensing a 
medicine. 
 
 
Of the health professionals, 66.9% “regularly” (40.9%) or “always” (26.0%) inform patients 
about the possible adverse effects on fitness to drive when prescribing a medicament. Among 
physicians, 8 out of every 10 “almost always” (54.2%) or “always” (27.8%) inform patients. in 
the case of pharmacists and nursing staff, just over half “almost always” (28.4% and 40.0% 
respectively) or “always” (29.7% and 14.3% respectively) inform the patient about the 
negative effects on fitness to drive when dispensing medicaments to patients or advising 
patients on the medicaments they have to take (Table 134). 
 
Table 134: I inform a patient about driving related risks when prescribing/dispensing a 
medicine. 
 
(*) 6 degrees of freedom for this chi square 
 
Most health professionals (8 out of every 10) “never” (59.1%) or “seldom” (21.0%) provide 
printed information concerning a medicament’s possible negative effects on fitness to drive 
(Table 135). Neither is it frequent for health professionals to make a note in the patients’ files 
of the advice they might give verbally concerning the negative effects of a medicament on 
driving. Of physicians and nursing staff, 8 out of every 10, and 9 out of every 10 pharmacists 
answered “seldom” or “never” to the statement: “I keep systematic records when I advise a 
patient about when and how he/she can consider driving a car when using a medicine that 
 
 Always 
N (%)  
Regularly 
N (%) 
Sometimes 
N (%)  
Seldom 
N (%) 
 
Never 
N (%) 
Χ
2
8; p 
(Control/Information/ 
Intervention) 
Physicians 10 (13.9) 28 (38.9) 15 (20.8) 15 (28.8) 4 (5.6) 9.734; p>0.05 
Pharmacist 7 (9.5) 17 (23.0) 28 (37.8) 16 (21.6) 6 (8.1) 4.855; p>0.05 
Nursing 1 (2.9) 5 (14.3) 14 (40.0) 11 (31.4) 4 (11.4) 4.649; p>0.05 
Total 18 (9.9) 50 (27.6) 57 (31.5) 42 (23.2) 14 (7.7)  
 
Χ
2
8=15.748; p<0.05  
 
 Always 
N (%)  
Regularly 
N (%) 
Sometimes 
N (%)  
Seldom 
N (%) 
 
Never 
N (%) 
Χ
2
8; p 
(Control/Information/ 
Intervention) 
Physicians 20 (27.8) 39 (54.2) 11 (15.3) 0 (0.0) 2 (2.8) 6.966; p>0.05* 
Pharmacist 22 (29.7) 21 (28.4) 24 (32.4) 5 (6.8) 2 (2.7) 10.915; p>0.05 
Nursing 5 (14.3) 14 (40.0) 6 (17.1) 4 (11.4) 6 (17.1) 6.660; p>0.05 
Total 47 (26.0) 74 (40.9) 41 (22.7) 9 (5.0) 10 (5.5)  
 
Χ
2
8=31.189; p<0.0001  
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impairs driving”. Significant differences were, however, observed between the replies of the 
different health professionals (Χ28=37.060; p<0.0001;Table 136). 
 
Table 135: I provide a patient with written information materials when prescribing/dispensing 
a driving impairing medicine. 
 
 (*) 6 degrees of freedom for this chi square 
 
Table 136: I keep systematic records when I advise a patient when and how he/she can 
consider driving a car when using a driving impairing medicine. 
 
(*) 6 degrees of freedom for this chi square 
 
In general, health professionals “never” (59.3%) or “seldom” (24.3%) make a note of patients’ 
driving habits. Only 8.4% of physicians and 2.4% of pharmacists “always” or “regularly” do so 
(Table 140). Significant differences can be observed between the health professionals 
(Χ28=23.458; p<0.01). Neither is it usual for health professionals to analyse, with their 
patients, the latter’s responsibility when consuming medicaments that have a possibly 
negative effect on fitness to drive: Over half the health professionals “never” (22.3%) or 
“seldom” (27.4%) did so, while there were no significant differences between the three 
collectives. 
 
Table 137: I keep a record of the patient’s traffic participation (e.g. how often he/she drives to 
work). 
 
 (*) 4 degrees of freedom for this chi square 
  
 
 Always 
N (%)  
Regularly 
N (%) 
Sometimes 
N (%)  
Seldom 
N (%) 
 
Never 
N (%) 
Χ
2
8; p 
(Control/Information/ 
Intervention) 
Physicians 1 (1.4) 4 (5.6) 11 (15.3) 17 (23.6) 39 (54.2) 15.531; p<0.05 
Pharmacist 2 (2.7) 4 (5.4) 8 (10.8) 11 (14.9) 49 (66.2) 4.590; p>0.05 
Nursing 0 (0.0) 3 (8.6) 3 (8.6) 10 (28.6) 19 (54.3) 3.024; p>0.05* 
Total 3 (1.7) 11 (6.1) 22 (12.2) 38 (21.0) 107 (59.1)  
 
Χ
2
8=6.186; p>0.05  
 
 Always 
N (%)  
Regularly 
N (%) 
Sometimes 
N (%)  
Seldom 
N (%) 
 
Never 
N (%) 
Χ
2
8; p 
(Control/Information/ 
Intervention) 
Physicians 0 (0.0) 4 (5.6) 12 (16.7) 26 (36.1) 30 (41.7) 3.189; p>0.05 
Pharmacist 1 (1.4) 3 (4.3) 2 (2.9) 7 (10.1) 56 (81.2) 12.369; p>0.05 
Nursing 0 (0.0) 6 (17.1) 7 (20.0) 6 (17.1) 16 (45.7) 10.149; p>0.05* 
Total 1 (0.6) 13 (7.4) 21 (11.9) 39 (22.2) 102 (58.0)  
 
Χ
2
8=37.060; p<0.0001  
 
 Always 
N (%)  
Regularly 
N (%) 
Sometimes 
N (%)  
Seldom 
N (%) 
 
Never 
N (%) 
Χ
2
8; p 
(Control/Information/ 
Intervention) 
Physicians 2 (2.8) 4 (5.6) 11 (15.3) 25 (34.7) 30 (41.7) 12.119; p>0.05 
Pharmacist 1 (1.4) 1 (1.4) 4 (5.7) 9 (12.9) 55 (78.6) 6.327; p>0.05 
Nursing 0 (0.0) 0 (0.0) 6 (17.1) 9 (25.7) 20 (57.1) 2.205; p>0.05* 
Total 3 (1.7) 5 (2.8) 21 (11.9) 43 (24.3) 105 (59.3)  
 
Χ
2
8=23.458; p<0.01  
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Table 138: I discuss medicinal drug consumption and driving related responsibility issues with 
the patient. 
 Always 
N (%)  
Regularly 
N (%) 
Sometimes 
N (%)  
Seldom 
N (%) 
 
Never 
N (%) 
Χ
2
8; p 
(Control/Information/ 
Intervention) 
Physicians 2 (2.8) 15 (21.1) 24 (33.8) 17 (23.9) 13 (18.3) 12.661; p>0.05 
Pharmacist 9 (12.3) 4 (5.5) 22 (30.1) 20 (27.4) 18 (24.7) 8.689; p>0.05 
Nursing 1 (2.9) 4 (11.4) 9 (25.7) 12 (34.3) 9 (25.7) 8.964; p>0.05 
Total 12 (6.7) 23 (12.8) 55 (30.7) 47 (27.4) 40 (22.3)  
 
Χ
2
8=15.044; p>0.05  
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3.1.5 SOURCES 
 
Of the health professionals, 63.9% referred to having easy access to information concerning 
the effects of medicines on driving. Significant differences were observed (Χ22=29.464; 
p<0.0001): the pharmacists (86.7%) being those who most frequently referred to having easy 
access to the said information. Within each collective, no differences were observed between 
the control/information/intervention groups (Table 139). 
 
Table 139: I have easy access to data and information about a medicine’s effect on driving 
skills 
 
 
Table 140 shows the percentage of health professionals who use each of the sources of 
information concerning the effects of medication on driving. The most frequently referred to 
sources were: “Professional websites” (40.4%), “Journals” (39.9%) and “Newsletters” 
(36.6%). 
 
Table 140: Reported sources 
 
 
73.8% of the health professionals referred to having received no formation on the effects of 
medication on driving after finishing their university degrees. There were significant 
differences (Χ22=14.022; p<0.005), physicians being the collective that least frequently 
received this kind of formation (11.1%). No significant differences were observed within each 
collective between the control/information/intervention groups (Table 141). 
 
Table 141: Did you get any postgraduate education on medicinal effects on driving skills? 
 
 
If you answered “Yes”, please specify: 
The types of post-graduate formation that health professionals indicated they had received 
were: “Courses” (9.3%), “Journals and/or reading material” (3.8%), “Seminars/conferences” 
(2.7%), and “On-line formation” (0.5%). 
  
 
 
Yes 
N (%)  
No 
N (%) Χ
2
2; p  
Χ
2
2; p (Control/Information/ Intervention) 
Physicians 37 (51.4) 35 (48.6) 
29.464; p<0.0001 
0.888; p>0.05 
Pharmacist 65 (86.7) 10 (13.3) 1.767; p>0.05 
Nursing 15 (41.7) 21 (58.3) 1.512; p<0.05 
Total 117 (63.9) 66 (36.1)   
 
 
 
Professional 
websites 
N (%)  
Newsletters 
N (%) 
Organisations 
N (%)  
Journals 
N (%) 
 
Other 
N (%) 
Physicians (n=72) 21 (29.2) 19 (26.4) 4 (5.6) 25 (34.7) 3 (4.2) 
Pharmacist (n=75) 45 (60.0) 39 (52.0) 29 (38.7) 42 (56.0) 10 (13.3) 
Nursing (n=36) 8 (22.2) 9 (25.0) 3 (8.3) 6 (16.7) 3 (8.3) 
Total 74 (40.4) 67 (36.6) 36 (19.7) 73 (39.9) 16 (8.7) 
 
 
 
Yes 
N (%)  
No 
N (%) Χ
2
2; p  
Χ
2
2; p (Control/Information/ Intervention) 
Physicians 8 (11.1) 64 (88.9) 
14.022; p<0.005 
5.075; p>0.05 
Pharmacist 27 (36.0) 48 (64.0) 0.420; p>0.05 
Nursing 13 (36.1) 23 (63.9) 1.563; p>0.05 
Total 48 (26.2) 135 (73.8)   
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3.1.6 ACTUAL KNOWLEDGE 
 
The knowledge that health professionals have concerning the effects of some medicines on driving 
was analyzed. Tables 142-147 show the results for the medicines in which significant differences 
were found in answers to the question "How much do you agree or disagree with the following 
statements?” The possible answers were “Totally Disagree”, “Disagree”, “Disagree nor Agree”, 
“Totally Agree” and “Don’t Know”. 
 
Table 142: Lormetazepam (1 mg) is severely impairing driving 8 hours after intake. 
 
(*) 6 degrees of freedom for this chi square (**) 4 degrees of freedom for this chi square 
 
Table 143: Diazepam (regardless dose) is severely impairing within the first 2 months of 
treatment. 
 
 
Table 144: Codeine (up to 20 mg) is mostly safe for drivers. 
 (*) 6 degrees of freedom for this chi square 
 
Table 145: Fexofenadine (normal dose) is severely impairing driving. 
 (*) 6 degrees of freedom for this chi square 
 
  
 
 
Totally 
Disagree 
N (%)  
Disagree 
N (%) 
Disagree 
nor Agree 
N (%)  
Totally 
Agree 
N (%) 
 
Don’t Know 
N (%) 
Χ
2
8; p 
(Control/Information/ 
Intervention) 
Physicians 1 (1.4) 1 (1.4) 36 (52.2) 30 (43.5) 1 (1.4) 9.257; p>0.05 
Pharmacist 1 (1.3) 2 (2.7) 35 (47.9) 35 (47.9) 0 (0.0) 3.837; p>0.05* 
Nursing 0 (0.0) 0 (0.0) 21 (60.0) 10 (28.6) 4 (11.4) 3.228; p>0.05** 
Total 2 (1.1) 3 (1.7) 92 (52.0) 75 (42.4) 5 (2.8)  
 
Χ
2
8=16.069; p<0.05  
 
 
 
Totally 
Disagree 
N (%)  
Disagree 
N (%) 
Disagree 
nor Agree 
N (%)  
Totally 
Agree 
N (%) 
 
Don’t Know 
N (%) 
Χ
2
8; p 
(Control/Information/ 
Intervention) 
Physicians 3 (4.3) 11 (15.9) 36 (52.2) 15 (21.7) 4 (5.8) 2.570; p>0.05 
Pharmacist 2 (2.8) 24 (33.8) 25 (35.2) 18 (25.4) 2 (2.8) 8.931; p>0.05 
Nursing 1 (2.9) 2 (5.7) 18 (51.4) 7 (20.0) 7 (20.0) 9.310; p>0.05 
Total 6 (3.4) 37 (21.1) 79 (45.1) 40 (22.9) 13 (7.4)  
 
Χ
2
8=23.182; p<0.005  
 
 
Totally 
Disagree 
N (%)  
Disagree 
N (%) 
Disagree 
nor Agree 
N (%)  
Totally 
Agree 
N (%) 
 
Don’t Know 
N (%) 
Χ
2
8; p 
(Control/Information/ 
Intervention) 
Physicians 10 (14.3) 32 (45.7) 22 (31.4) 0 (0.0) 6 (8.6) 2.419; p>0.05* 
Pharmacist 12 (16.7) 31 (43.1) 22 (30.6) 5 (6.9) 2 (2.8) 6.569; p>0.05 
Nursing 6 (17.1) 13 (37.1) 9 (25.7) 2 (5.7) 5 (14.3) 10.727; p>0.05 
Total 28 (15.8) 76 (42.9) 53 (29.9) 7 (4.0) 13 (7.4)  
 
Χ
2
8=9.998; p>0.05  
 
 
 
Totally 
Disagree 
N (%)  
Disagree 
N (%) 
Disagree 
nor Agree 
N (%)  
Totally 
Agree 
N (%) 
 
Don’t Know 
N (%) 
Χ
2
8; p 
(Control/Information/ 
Intervention) 
Physicians 2 (3.0) 19 (28.4) 31 (46.3) 3 (4.5) 12 (17.9) 5.596; p>0.05 
Pharmacist 9 (12.7) 30 (42.3) 25 (35.2) 2 (2.8) 5 (7.0) 4.924; p>0.05 
Nursing 0 (0.0) 9 (26.5) 11 (32.4) 2 (5.9) 12 (35.3) 8.146; p>0.05* 
Total 11 (6.4) 58 (33.7) 67 (39.0) 7 (4.1) 29 (16.9)  
 
Χ
2
8=23.494; p<0.005  
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Table 146: Amitriptyline at the start of treatment is as impairing driving as after 4 weeks of 
treatment. 
 
(*) 6 degrees of freedom for this chi square 
Table 147: Paroxetine (up to 20 mg/day) is safe for drivers. 
 
 
The answers corresponding to the questions in ACTUAL KNOWLEDGE (Tables 142-147) 
were recoded as dichotomies, correct/not correct, except for the first of them 
(lormetazepam,Table 142) as it was different in the Spanish questionnaire. The answers of 
“Disagree nor Agree”  and “Totally agree” were considered to be “correct” in the questions 
referring to diazepam, codeine, and paroxetine; while the replies “Disagree” and “Totally 
disagree” were considered “correct” in the questions referring to fexofenadine and 
amitriptyline. The answer “don’t know” and no answer at all were also considered “not correct” 
in the recoding. As can be seen in Table 145, for the recoded answers, significant differences 
between physicians/pharmacists/nursing staff are only noted in the case of fexofenadine 
(Χ22=11.234; p<0.01). No significant differences were observed between the 
control/information/intervention groups for any of the questions, neither in the sample as a 
whole, nor in each collective of professionals separately. 
  
 
 
Totally 
Disagree 
N (%)  
Disagree 
N (%) 
Disagree 
nor Agree 
N (%)  
Totally 
Agree 
N (%) 
 
Don’t Know 
N (%) 
Χ
2
8; p 
(Control/Information/ 
Intervention) 
Physicians 0 (0.0) 5 (7.4) 41 (60.3) 14 (20.6) 8 (11.8) 5.202; p>0.05* 
Pharmacist 1 (1.4) 10 (13.9) 46 (63.9) 11 (15.3) 4 (5.6) 4.541; p>0.05 
Nursing 1 (2.9) 3 (8.6) 16 (45.7) 6 (17.1) 9 (25.7) 4.740; p>0.05 
Total 2 (1.1) 18 (10.3) 103 (58.9) 31 (17.7) 21 (12.0)  
 
Χ
2
8=13.199; p>0.05  
 
 
Totally 
Disagree 
N (%)  
Disagree 
N (%) 
Disagree 
nor Agree 
N (%)  
Totally 
Agree 
N (%) 
 
Don’t Know 
N (%) 
Χ
2
8; p 
(Control/Information/ 
Intervention) 
Physicians 4 (5.7) 33 (47.1) 23 (32.9) 4 (5.7) 6 (8.6) 2.483; p>0.05 
Pharmacist 5 (6.8) 35 (47.9) 29 (39.7) 2 (2.7) 2 (2.7) 5.894; p>0.05 
Nursing 2 (5.7) 15 (42.9) 8 (22.9) 1 (2.9) 9 (25.7) 10.028; p>0.05 
Total 11 (6.2) 83 (46.6) 60 (33.7) 7 (3.9) 17 (9.6)  
 
Χ
2
8=16.372; p<0.05  
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Table 148: How much do you agree or disagree with the following statements? 
 
 
 Correct 
N (%)  
Not 
correct 
N (%) 
Χ
2
2; p  
Diazepam (regardless dose) is 
severely impairing within the first 2 
months of treatment. 
Physicians 51 (70.8) 21 (29.2) 
3.328; p>0.05 Pharmacist 43 (57.3) 32 (42.7) 
Nursing 25 (69.4) 11 (30.6) 
 Total 119 (65.0) 64 (35.0)  
Codeine (up to 20 mg) is mostly safe 
for drivers. 
Physicians 22 (30.6) 50 (69.4) 
0.595; p>0.05 Pharmacist 27 (36.0) 48 (64.0) 
Nursing 11 (30.6) 25 (69.4) 
 Total 60 (32.8) 123 (67.2)  
Fexofenadine (normal dose) is 
severely impairing driving. 
Physicians 21 (29.2) 51 (70.8) 
11.234; p<0.01 Pharmacist 39 (52.0) 36 (48.0) 
Nursing 9 (25.0) 27 (75.0) 
 Total 69 (37.7) 114 (62.3)  
Amitriptyline at the start of 
treatment is as impairing driving as 
after 4 weeks of treatment. 
Physicians 5 (6.9) 67 (93.1) 
2.252; p>0.05 Pharmacist 11 (14.7) 64 (85.3) 
Nursing 4 (11.1) 32 (88.9) 
 Total 20 (10.9) 163 (89.1)  
Paroxetine (up to 20 mg/day) is safe 
for drivers. 
Physicians 27 (37.5) 45 (62.5) 
2.836; p>0.05 Pharmacist 31 (41.3) 44 (58.7) 
Nursing 9 (25.0) 27 (75.0) 
 Total 67 (36.6) 116 (63.4)  
 
 
3.1.7 G. USER ACEPTANCE 
 
Most health professionals would be willing to use a tool that would provide information 
concerning the effects of medication on driving (Table 149). 3.3% would not use such a tool, 
while 13.7% said “maybe”. There were no significant differences in the answers of physicians, 
pharmacists and nursing staff. The main reasons referred to were: A lack of time, no 
computer or internet connection problems in the surgery ( 
Table 150). 
   
Table 149: If we propose you a tool (e.g. website,cd-rom) that allows you to find information 
on medical drugs and driving, will you be willing to use it for prescribing/dispensing 
medicines? 
 
 
 
 
Yes 
N (%)  
No 
N (%) 
Maybe 
N (%)  Χ
2
4; p (Control/Information/ Intervention) 
Physicians 56 (78.9) 1 (1.4) 14 (19.7) 4.906; p>0.05 
Pharmacists 63 (84.0) 3 (4.0) 9 (12.0) 7.324; p>0.05 
Nursing 32 (88.9) 2 (5.6) 2 (5.6) 4.490; p>0.05 
Total 151 (83.0) 6 (3.3) 25 (13.7)  
 
Χ
2
4=5.511; p>0.05  
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Table 150: If you answered “No” or “Maybe” to Q1, what are the main reasons for your 
reluctance to use them? 
 
 
3.1.8 SPECIFIC QUESTIONS: SPANISH QUESTIONNAIRE 
 
The health professionals were asked to score (from 1 to 10 where 10 is the maximum) the 
importance they give in their daily practice to the subject of medicines and driving. The 
average score given (Mean±SD) was 7.38±2.06 points, and no significant differences were 
observed between the three collectives (F=1.481; p>0.05). Within each collective (physicians, 
pharmacists and nursing staff), there were no significant differences either between the 
control/information/intervention groups, in their average scores (Table 151). 
 
Table 151: In your daily practice, what importance do you give to the subject of medication 
and driving (from 1 to 10, where 10 is the maximum)? 
 
 
44.2% of the health professionals have “frequently” or “very frequently” had cases in which 
the effect of medicines on driving was an important aspect at the time of selecting medication. 
No significant differences were observed in the answers from physicians, pharmacists and 
nursing staff. There were no significant differences either, within each collective, between the 
control, information and intervention groups (Table 152). 
 
Table 152: Over the last year, in your daily practice, how often have you had a case in which 
the effect of medicines on driving has been an important aspect at the time of selecting 
medication? 
 
  
 
 Lack of 
time 
N (%)  
I already 
have a 
program 
N (%) 
No 
computer/c
onnection 
problems 
N (%)  
Only 
useful for 
few cases 
N (%) 
 
Other 
reason 
N (%) 
Χ
2
8; p 
(Control/Information/ 
Intervention) 
Physicians 4 (33.3) 0 (0.0) 5 (41.7) 1 (8.3) 2 (8.6) 5.340; p>0.05 
Pharmacists 2 (16.7) 6 (50.0) 0 (0.0) 3 (25.0) 1 (2.7) 7.500; p>0.05 
Nursing 1 (33.3) 0 (0.0) 1 (33.3) 0 (0.0) 1 (33.3) 3.000; p>0.05 
Total 7 (25.9) 6 (22.2) 6 (22.2) 4 (14.8) 4 (14.8)  
 
Χ
2
8=15.777; p<0.05  
 
 
 
N Mean±SD F; p (Control/Information/intervention) 
Physicians 67 7.58±1.66 0.197; p>0.05 
Pharmacists 70 7.06±2.11 0.497; p>0.05 
Nursing 32 7.66±2.61 2.681; p>0.05 
Total 169 7.38±2.06  
 
F=1.481; p>0.05  
 
 
Very 
frequently 
N (%) 
Frequently 
N (%) 
Seldom 
N (%) 
Hardly 
ever 
N (%) 
Χ
2
6; p 
(Control/Information/ 
Intervention) 
Physicians 9 (13.2) 29 (42.6) 14 (20.6) 16 (23.5) 6.497; p>0.05 
Pharmacists 11 (15.5) 19 (26.8) 17 (23.9) 24 (33.8) 12.854; p>0.05 
Nursing 3 (9.1) 5 (15.2) 10 (30.3) 15 (45.5) 4.727; p>0.05 
Total 23 (13.4) 53 (30.8) 41 (23.8) 55 (32.0)  
 
Χ
2
6=11.134; p>0.05  
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3.1.9 POST TRAINING 
 
For legal reasons, and to preserve the privacy of the interviewees, both questionnaires (“Pre” 
and “Post”) were done anonymously. The correspondence between one questionnaire and 
the other was made via the coincidence of the socio-demographic variables: “Profession”, 
“Gender”, and “Date of birth”, “Date of graduation medical/pharmacist school” and “Years 
practicing”. A total of 69 health professionals answered the “Post” questionnaire, of which the 
correspondence in the “Pre” questionnaire was only established in 38 cases. The other 31 
cases did not correspond to any cases from the initial questionnaire (Table 153). 
 
Table 153: Participants included in the study and replies obtained in the 2nd questionnaire 
 
3.1.10 ANALYSIS PRE / POST 
 
For the comparative analysis between the answers obtained in both questionnaires, we 
therefore had 38 questionnaires: 22 corresponding to the information group and only 6 to the 
intervention group (Table 153). Given the low number of replies obtained and the impossibility 
of supposing any kind of normality from the sample, a non-parametric test has been used, the 
Wilcoxon sign test, as an alternative to the “t” of Student for related samples. In what follows, 
only the results where significant Pre/Post differences were found on applying the Wilcoxon 
test are shown. 
 
3.1.11  ATTITUDES/AWARENESS (PRE / POST) 
 
Significant changes were observed between the first and second questionnaires in the degree 
of agreement with the first statement of this section: “I am willing to take into account the 
effects of medicines on driving skills when prescribing/dispensing medicines”. For both the 
whole sample and among the collective of the physicians, an increase in the degree of 
agreement with this statement was observed (Tables 154-155 and Figures 77-78). In the 
following question: “Would you consider this (previous sentence) of more concern if your 
patient is”, differences were only observed in cases where the patient was a professional 
driver (for the whole sample and among the collective of pharmacists, Tables 156-157) or 
where the patient was taking other substances which affected the CNS (Tables 158-159). 
 
Table 154: I am willing to take into account the effects of medicines on driving skills when 
prescribing/dispensing medicines. 
 
 
 
 
 
 
 Groups Profession Included Responses / post (matches) 
Responses / post  
(not matches) 
Information 
Physician 56 12 12 
Pharmacist 46 20 15 
Nursing 52   
Intervention 
Physician 44 6 4 
Pharmacist 48   
Nursing 46   
Total 292 38 31 
 
 
 
PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 18 2.94±0.24 3.00 18 3.22±0.43 3.00  -2.236; p<0.05 
Pharmacists 20 3.00±0.73 3.00 20 3.20±0.52 3.00 -1.069; p>0.05 
Total 38 2.97±0.55 3.00 38 3.21±0.47 3.00 -2.065; p<0.05 
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Table 155: I am willing to take into account the effects of medicines on driving skills when 
prescribing/dispensing medicines. Significant differences pre-post (Wilcoxon test) 
 
 
 
 
Figure 77: Significant pre-post change - I am willing to take into account the effects of 
medicines on driving skills when prescribing/dispensing medicines- % in the total sample. 
Strongly disagree Disagree Agree Strongly agree
PRE 2,6 7,9 78,9 10,5
POST 0,0 2,6 73,7 23,7
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Figure 78: Significant pre-post change - I am willing to take into account the effects of 
medicines on driving skills when prescribing/dispensing medicines- within physicians group %  
 
 
Table 156: “Would you consider this of more concern if your patient is”: a professional driver 
 
Table 157: “Would you consider this of more concern if your patient is”: a professional driver. 
Significant differences pre-post (Wilcoxon test) 
 
 
Table 158: “Would you consider this of more concern if your patient is”: using other CNS 
active drugs 
 
Strongly disagree Disagree Agree Strongly agree
PRE 0,0 5,6 94,4 0,0
POST 0,0 0,0 77,8 22,2
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PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 17 1.00±0.00 1.00 17 0.94±0.24 1.00  -1.000; p>0.05 
Pharmacists 19 1.00±0.00 1.00 20 0.80±0.41 1.00 -2.000; p<0.05 
Total 36 1.00±0.00 1.00 37 0.86±0.35 1.00 -2.236; p<0.05 
 
  
N Mean Rank Sum of Ranks  Z p  
 
Pharmacist 
Negative Ranks 4 2.5 10.00 
-2.000 <0.05 
Positive Ranks 0 0.00 0.00 
Ties 15   
 Total 19   
Total sample 
Negative Ranks 5 3.00 15.00 
-2.236 <0.05 
Positive Ranks 0 0.00 0.00 
Ties 30   
 Total 35   
 
 
 
PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 17 1.00±0.00 1.00 15 0.80±0.41 1.00  -1.732; p>0.05 
Pharmacists 18 1.00±0.00 1.00 20 0.85±0.37 1.00 -1.732p>0.05 
Total 35 1.00±0.00 1.00 35 0.83±0.38 1.00 -2.449; p<0.05 
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Table 159: “Would you consider this (Q1) of more concern if your patient is”: using other CNS 
active drugs. Significant differences pre-post (Wilcoxon test) 
 
 
Composite score. The answers obtained in each of the 5 statements in this section, which 
had 4 possible answers, had the following scores: Strongly disagree (1 point); Disagree (2 
points); Agree (3 points); Strongly agree (4 points). The points obtained were added for each 
of the 5 statements and the results for the PRE and POST questionnaires were compared 
using the Wilcoxon test. No significant differences were found for either the whole sample or 
for each collective separately (Table 160).  
 
Table 160:  Composite score “Attitudes/awareness” (points sum)  
 
3.1.12 REPORTED BEHAVIOUR (PRE / POST) 
 
As for the first questionnaire, in both the whole sample and among the physicians, a 
significant change was observed in favor of the statement: “I ask a patient about his/her 
driving exposure when choosing/dispensing a medicine” (Tables 161-162). In general, the 
percentages decreased for those who replied “never” or “seldom” and the percentages 
increased for those who replied “sometimes” and “always” (Figure 79). 
 
Table 161: I ask a patient about his/her driving exposure when choosing/dispensing a 
medicine. 
 
 
Table 162: I ask a patient about his/her driving exposure when choosing/dispensing a 
medicine. Significant differences pre-post (Wilcoxon test) 
 
 
 
PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 18 14.78±1.63 15.00 18 15.56±1.50 15.00  -1.589; p>0.05 
Pharmacists 20 15.25±1.86 15.00 20 15.45±1.76 15.00 -0.648; p>0.05 
Total 38 15.03±1.75 15.00 38 15.50±1.62 15.00 -1.372; p>0.05 
 
 
 
PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 18 1.94±1.11 2.00 18 2.50±0.99 3.00  -1.997; p<0.05 
Pharmacists 20 1.70±0.87 2.00 20 1.90±0.97 2.00 -0.884; p>0.05 
Total 38 1.82±0.98 2.00 38 2.18±1.01 2.00 -2.048; p<0.05 
 
 
 
N Mean Rank Sum of Ranks  Z p  
 
Physicians 
Negative Ranks 3 5.00 15.00 
-1.977 <0.05 
Positive Ranks 9 7.00 63.00 
Ties 6   
 Total 18   
Total sample 
Negative Ranks 7 10.57 74.00 
-2.048 <0.05 
Positive Ranks 16 12.63 202.00 
Ties 15   
 Total 38   
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Figure 79: Significant pre-post change - I ask a patient about his/her driving exposure when 
choosing/dispensing a medicine- % in the total sample. 
 
There were also significant differences between both questionnaires among the whole sample 
and among the collective of physicians in “I provide a patient with written information 
materials when prescribing/dispensing a driving impairing medicine” (Tables 163-164), “I keep 
systematic records when I advise a patient when and how he/she can consider driving a car 
when using a driving impairing medicine” (Tables 165-166) and “I keep a record of the 
patient’s traffic participation” (Tables 167-168). The percentages of the replies (for the whole 
sample) in the PRE and POST questionnaires are shown in Figures 80-82. 
 
Table 163: I provide a patient with written information materials when prescribing/dispensing 
a driving impairing medicine. 
 
Table 164: I provide a patient with written information materials when prescribing/dispensing 
a driving impairing medicine. Significant differences pre-post (Wilcoxon test) 
 
Never Seldom Sometimes Regular Always
PRE 10,5 26,3 34,2 28,9 0,0
POST 7,9 10,5 44,7 28,9 7,9
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PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 18 0.28±0.46 0.00 18 0.83±0.99 0.50  -2.308; p<0.05 
Pharmacists 20 0.85±1.82 0.00 20 1.15±1.10 1.00 -1.097; p>0.05 
Total 38 0.58±0.95 0.00 38 1.00±1.04 1.00 -2.309; p<0.05 
 
 
 
N Mean Rank Sum of Ranks  Z p  
 
Physicians 
Negative Ranks 1 4.00 4.00 
-2.308 <0.05 
Positive Ranks 8 5.13 41.00 
Ties 9   
 Total 18   
Total sample 
Negative Ranks 7 9.50 66.50 
-2.309 <0.05 
Positive Ranks 16 13.09 209.50 
Ties 15   
 Total 38   
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Figure 80: Significant pre-post change -I provide a patient with written information materials 
when prescribing/dispensing a driving impairing medicine - % in the total sample. 
 
Table  165: I keep systematic records when I advise a patient when and how he/she can 
consider driving a car when using a driving impairing medicine. 
 
 
Table 166:I keep systematic records when I advise a patient when and how he/she can 
consider driving a car when using a driving impairing medicine. Significant differences pre-
post (Wilcoxon test) 
 
Never Seldom Sometimes Regular Always
PRE 63,2 23,7 7,9 2,6 2,6
POST 39,5 31,6 21,1 5,3 2,6
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PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 18 0.44±0.62 0.00 18 1.50±1.20 1.00  -2.844; p<0.05 
Pharmacists 19 0.47±0.84 0.00 19 0.53±0.91 0.00 -0.356; p>0.05 
Total 37 0.46±0.73 0.00 37 1.00±1.16 1.00 -2.365; p<0.05 
 
 
 
N Mean Rank Sum of Ranks  Z p  
 
Physicians 
Negative Ranks 0 .00 .00 
-2.844 <0.005 
Positive Ranks 10 5.50 55.00 
Ties 8   
 Total 18   
Total sample 
Negative Ranks 3 10.67 32.00 
-2.365 <0.05 
Positive Ranks 15 9.27 139.00 
Ties 18   
 Total 36   
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Figure 81: Significant pre-post change -I keep systematic records when I advise a patient 
when and how he/she can consider driving a car when using a driving impairing medicine - % 
in the total sample. 
 
Table 167: I keep a record of the patient’s traffic participation (e.g. how often he/she drives to 
work). 
 
Table 168: I keep a record of the patient’s traffic participation (e.g. how often he/she drives to 
work). Significant differences pre-post (Wilcoxon test) 
 
Never Seldom Sometimes Regular Always
PRE 64,9 27 5,4 2,7 0,0
POST 44,7 23,7 15,8 10,5 2,6
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PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 18 0.44±0.62 0.00 18 1.22±0.94 1.00  -2.697; p<0.01 
Pharmacists 19 0.37±0.68 0.00 19 0.74±0.87 1.00 -1.897; p>0.05 
Total 37 0.41±0.64 0.00 37 0.97±0.93 1.00 -3.279; p<0.005 
 
 
 
N Mean Rank Sum of Ranks  Z p  
 
Physicians 
Negative Ranks 1 3.50 3.50 
-2.697 <0.01 
Positive Ranks 10 6.25 62.50 
Ties 7   
 Total 18   
Total sample 
Negative Ranks 2 6.50 13.00 
-3.279 <0.005 
Positive Ranks 16 9.88 158.00 
Ties 18   
 Total 36   
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Figure 82: Significant pre-post change -I keep a record of the patient’s traffic participation 
(e.g. how often he/she drives to work) - % in the total sample. 
 
The significant changes in this section point to an increase in the effort health professionals 
make both to inform the patient about medicines and driving and to inform him/herself about 
the patient’s involvement in driving and to leave a record of these aspects in the patient’s 
medical history.   
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Composite scores. The replies obtained in each of the 6 statements in this section were 
scored as follows: Never (0 points); Seldom (1 points); Sometimes (2 points); Regularly (3 
points); Always (4 points). The points obtained in each of the 6 questions were aadded and 
the results from the PRE and POST questionnaires were compared using the Wilcoxon test 
(Tables 169-170). A significant positive change on the “reported behaviour” composite score 
was observed for the whole sample and for the collective of physicians (Tables 172-173). The 
percentages according to the range of scoring (between 0 and 24 points) in the PRE and 
POST questionnaires are shown in Figure 83. 
 
Table 169: Composite score “Reported Behaviour” (points sum)  
 
Table 170: Composite score “Reported Behaviour” (points sum). Significant differences pre-
post (Wilcoxon test) 
 
 
Figure 83: Significant pre-post change questionnaire: Reported behaviour score - % in the 
total sample.  
 
 
PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 18 7.28±3.23 7.5 18 10.72±4.39 12.00  -2.848; p<0.005 
Pharmacists 20 7.40±3.90 6.00 20 8.70±3.23 8.50 -1.686; p>0.05 
Total 38 7.34±3.55 7.00 38 9.66±3.91 9.00 -3.272; p<0.005 
 
 
 
N Mean Rank Sum of Ranks  Z p  
 
Physicians 
Negative Ranks 3 5.50 16.5 
-2.848 <0.005 
Positive Ranks 14 9.75 136.5 
Ties 1   
 Total 18   
Total sample 
Negative Ranks 9 12.89 116.00 
-3.272 <0.005 
Positive Ranks 26 19.77 515.00 
Ties 3   
 Total 38   
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3.1.13 ACTUAL KNOWLEDGE (PRE / POST) 
 
The evolution in knowledge concerning the effects of some medicines on driving has been analyzed, 
using the replies obtained from the pre / post questionnaires. Tables 171--176 show the results in 
which significant differences have been found (Wilcoxon test) using the original categories of the 
variables (“Totally Disagree”, “Disagree”, “Disagree nor Agree”, “Totally Agree” and “Don’t Know”). 
 
How much do you agree or disagree with the following statements? 
 
Table 171: Codeine (up to 20 mg) is mostly safe for drivers. 
 
Table 172: Codeine (up to 20 mg) is mostly safe for drivers. Significant differences pre-post 
(Wilcoxon test) 
 
Table 173: Amitriptyline at the start of treatment is as impairing driving as after 4 weeks of 
treatment. 
 
Table 174: Amitriptyline at the start of treatment is as impairing driving as after 4 weeks of 
treatment. Significant differences pre-post (Wilcoxon test) 
  
 
 
PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 17 1.88±0.93 2.00 18 2.39±0.502 2.00  -2.066; p<0.05 
Pharmacists 18 2.11±0.76 2.00 20 2.30±0.98 2.00 -0.647; p>0.05 
Total 35 2.00±0.84 2.00 38 2.34±0.78 1.00 -1.927; p>0.05 
 
 
 
N Mean Rank Sum of Ranks  Z p  
 
Physicians 
Negative Ranks 3 6.00 18.00 
-2.066 <0.05 
Positive Ranks 10 7.30 73.00 
Ties 4   
 Total 17   
 
 
 
PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 16 2.94±1.24 3.00 18 2.22±1.22 2.00  -2.280; p<0.05 
Pharmacists 18 2.72±0.96 3.00 20 2.10±1.17 2.00 -2.648; p<0.01 
Total 34 2.82±1.09 3.00 38 2.16±1.18 2.00 -3.426; p<0.005 
 
 
 
N Mean Rank Sum of Ranks  Z p  
 
Physicians 
Negative Ranks 7 4.86 34.00 
-2.280 <0.05 
Positive Ranks 1 2.00 2.00 
Ties 8   
 Total 16   
Pharmacists 
Negative Ranks 10 6.15 61.50 
-2.648 <0.01 
Positive Ranks 1 4.50 4.50 
Ties 7   
 Total 18   
Total sample 
Negative Ranks 17 10.47 178.00 
-3.426 <0.005 
Positive Ranks 2 6.00 12.00 
Ties 15   
 Total 34   
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Table 175: Paroxetine (up to 20 mg/day) is safe for drivers. 
 
Table 176: Paroxetine (up to 20 mg/day) is safe for drivers. Significant differences pre-post 
(Wilcoxon test) 
 
Recoding the replies as right/wrong, as was done in the “pre” questionnaire, the Wilcoxon 
Signed Rank Test showed a significant positive change after the training in the replies given 
for amitriptyline, for both the whole sample and both collectives separately (physicians and 
pharmacists, Tables 177-178). 
 
Table 177: Amitriptyline at the start of treatment is as impairing driving as after 4 weeks of 
treatment - Right / Wrong- 
 
Table 178: Amitriptyline at the start of treatment is as impairing driving as after 4 weeks of 
treatment - Right / Wrong. Significant differences pre-post (Wilcoxon test) 
 
 
Composite score: Giving a score of “1” to each correct answer and adding up the points 
obtained in this section by each participant in the study, scores of between 0 and 5 are 
obtained for the PRE and POST questionnaires. These scores will be used as variables to 
evaluate knowledge evolution. For both the whole sample as well as for physicians and 
pharmacists separately, a significant positive change can be observed in the second 
 
 
PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 17 1.59±1.06 2.00 18 2.50±0.62 2.00  -2.801; p<0.01 
Pharmacists 19 2.37±0.60 2.00 20 2.15±0.93 2.00 -0.971; p>0.05 
Total 36 2.00±0.93 2.00 38 2.32±0.81 2.00 -1.642; p>0.05 
 
 
 
N Mean Rank Sum of Ranks  Z p  
 
Physicians 
Negative Ranks 1 4.50 4.50 
-2.801 <0.01 
Positive Ranks 11 6.68 73.50 
Ties 5   
 Total 17   
 
 
 
PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 18 0.00±0.00 0.00 18 0.39±0.50 0.00  -2.646; p<0.01 
Pharmacists 20 0.15±0.37 0.00 20 0.50±0.51 0.50 -2.648; p<0.01 
Total 38 0.08±0.27 0.00 38 0.48±0.50 0.00 -3.742; p<0.005 
 
 
 
N Mean Rank Sum of Ranks  Z p  
 
Physicians 
Negative Ranks 0 0.00 0.00 
-2.646 <0.01 
Positive Ranks 7 4.00 28.00 
Ties 11   
 Total 18   
Pharmacists 
Negative Ranks 0 0.00 0.00 
-2.646 <0.01 
Positive Ranks 7 4.00 28.00 
Ties 13   
 Total 20   
Total sample 
Negative Ranks 0 0.00 0.00 
-3.742 <0.0001 
Positive Ranks 14 7.50 105.00 
Ties 24   
 Total 34   
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questionnaire with respect to the first (Tables 179-180). Figure 100 shows the percentages of 
those who obtained each of the possible scores (from 0 to 5 points) in the PRE and POST 
questionnaires. 
 
Table 179: PRE-POST questionnaire knowledge composite score 
 
 
Table 180: PRE-POST questionnaire knowledge composite score. Significant differences 
pre-post (Wilcoxon test) 
 
 
Figure 84: Significant pre-post change questionnaire: knowledge composite score - % in the 
total sample.  
 
 
PRE POST  
Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 18 1.22±1.11 1.00 18 2.39±1.09 2.00  -3.250; p<0.005 
Pharmacists 20 1.80±1.06 2.00 20 2.40±1.05 2.00 -2.012; p<0.05 
Total 38 1.53±1.11 1.00 38 2.40±1.05 2.00 -3.742; p<0.0001 
 
 
 
N Mean Rank Sum of Ranks  Z p  
 
Physicians 
Negative Ranks 0 0.00 0.00 
-3.250 <0.005 
Positive Ranks 13 7.00 91.00 
Ties 5   
 Total 18   
Pharmacists 
Negative Ranks 3 7.17 21.50 
-2.012 <0.05 
Positive Ranks 11 7.59 83.50 
Ties 6   
 Total 20   
Total sample 
Negative Ranks 3 12.17 36.50 
-3.764 <0.0001 
Positive Ranks 24 14.23 341.50 
Ties 11   
 Total 38   
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3.1.14 SPECIFIC QUESTIONS: SPANISH QUESTIONNAIRE (PRE / POST) 
 
As for the importance given in their daily practice to medicines and driving by health 
professionals, a significant positive change can be seen after the training among the 
coolective of pharmacists (Wilcoxon test, Tables 181-182). 
     
Table 181: In your daily practice, what importance would you give to the subject of medicines 
and driving (on a scale of 1 to 10, where 10 is the maximum)? 
 
Table 182: In your daily practice, what importance would you give to the subject of medicines 
and driving (on a scale of 1 to 10, where 10 is the maximum)? 
 
No significant differences were found for the question “In your daily practice over the last 
year, how often have you had cases in which the effect of medicines on driving has been an 
important aspect at the time of selecting medication”. 
  
 
 
PRE  POST Z; p 
N Mean±SD Median N Mean±SD Median 
Physicians 17 7.41±1.84 8.00 17 6.24±1.99 7.00 -1.805; p>0.05 
Pharmacists 19 6.74±2.16 7.00 18 7.17±2.16 8.00 -2.489; p<0.05 
Total 36 7.06±2.01 7.50 35 6.71±1.89 7.00 -0.738; p>0.05 
 
 
 
N Mean Rank Sum of Ranks  Z p  
 
Pharmacists 
Negative Ranks 1 4.00 4.00 
-2.489 <0.05 
Positive Ranks 9 5.67 51.00 
Ties 7   
 Total 17   
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3.2 STUDY 2: PATIENT QUESTIONNAIRE (PICTOGRAM) 
 
3.2.1 BACKGROUND INFORMATION 
 
A total of 1,385 questionnaires were done, 47.7% to men (n= 660) and 52.3% to women (n= 
725). 79.3% had a driving license (n= 1098) and 20.7% did not (n= 287). There were 
significant differences between men and women (Χ2=123.63; p<0.0001). The drivers had a 
better level of education (Table 186) and there were significant differences between drivers 
and non-drivers (Χ24=100.75; p=0.0001). The average age was 50.50±15.55 years, 
differences being observed between drivers (47.27±14.72 years) and non-drivers (50.50 
±15.55 years, t=5.277; p<0.0001). The average number of kilometers driven annually (in 
thousands of kilometers/year) by the 1,041 patients who provided this data (some patients 
had a license but did not drive) was of 14.83±26.23 thousand kilometers /year (Table 183). 
 
93.9% of those interviewed (95.4% of the drivers and 88.5% of the non-drivers (Χ2=18.76; 
p<0.05), knew that some medicines can influence fitness to drive (Table 184). 
  
Table 183: Socio-demographic characteristics of the interviewed patients 
 
Table 184: Did you know that some medicines can influence fitness to drive? 
  
  
 
     
  No Conductor Conductor Total 
 
Gender  
N (%) 
Male 53 (18.5) 607 (55.3) 660 (47.7) Χ2=123.63; 
p<0.0001 Female 234 (81.5) 491 (44.7) 725 (52.3) 
 Total 287 (100.0) 1098 (100.0) 1385 (100.0)  
Educational 
level 
N (%) 
Did not finish 
primary school 38 (13.4) 49 (4.5) 87 (6.3) 
Χ
2
4=100.75; 
p<0.0001 
Finished 
primary school 144 (50.9) 334 (30.4) 478 (34.6) 
Finished 
secondary 
school 
38 (13.4) 142 (12.9) 180 (13.0) 
Completed “A” 
level (age 18) 35 (12.4) 260 (23.7) 295 (21.4) 
University 
degree/diploma 28 (9.9) 312 (28.4) 340 (24.6) 
 Total     
Edad (Mean ± SD) 55.23 ± 17.61 47.27 ± 14.72 50.50 ± 15.55 
t(1383)=5.277; 
p<0.0001 
Thousand Km/año (Mean ± SD)  14.83 ± 26.23 
 
  
 
 
 No conductor 
N (%) 
Conductor 
N (%) 
Total 
N (%) 
Χ
2; p  
Yes 254 (88.5) 1047 (95.4) 1301 (93.9) 18.76; p<0.0001 
No 33 (11.5) 51 (4.6) 84 (6.1) 
Total 287 (100.0) 1098 (100.0) 1385  
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3.2.2 ATTITUDES / AWARENESS 
 
The interviewed patients were asked the following question: “Supposing you were prescribed 
this medicine which has the pictogram concerning driving on the packaging. How frequently 
would you drive during the period in which you were taking the medicine?” The question had 
5 possible answers: the first answer would imply no change in attitude –“With the same 
frequency”- while the other four present a growing degree of change –“Less frequently”; “A lot 
less frequently”; “I would hardly drive at all” and “I would not drive at all”. As can be seen in 
Table 185, only 14.6% of those interviewed would not reduce the frequency with which they 
drove (16.1% of drivers and 8.6% of non-drivers) but differences were observed between 
both, drivers being those who were the least likely to change their attitude (Χ24=41.78; 
p<0.0001).  
 
Table 185: Supposing you were prescribed this medicine which has the pictogram concerning 
driving on the packaging. How frequently would you drive during the period in which you were 
taking the medicine? 
 
Those interviewed were asked: “What would you do if you were prescribed this medicine with 
a pictogram about driving on the packaging?” There were 5 possible answers i) I would drive 
without taking extra care; ii) I would not drive without first reading the package insert; iii) I 
would not drive without the advice of a doctor or a pharmacist and iv) I would not drive until 
my doctor indicated that it was safe to do so. 
 
Most patients would take some kind of measure when faced with this situation (Table 186): 
40.0% (43.2% of drivers and 28.0% of non-drivers) would not drive without having first read 
the package insert; 34.5% (29.8% of drivers and 52.5% of non-drivers) would not drive until 
their doctor told them it was safe to do so and 21.8% (23.1% of drivers and 17.0% of non-
drivers) would not drive without the advice of a doctor or a pharmacist. That is, only 3.7% 
(4.0% of drivers and 2.5% of non-drivers) would ignore the pictogram and drive without taking 
extra care. 
 
Table 186: What would you do if you were prescribed this medicine with a pictogram about 
driving on the packaging? 
 
It is the doctor whom most people would consult if they had to take a medicine with a 
pictogram about driving on the packaging (Table 187), followed by the pharmacist and finally 
the nursing staff. 89.5% would “probably” or “very probably” consult the doctor (75.5% of 
drivers and 82.0% of non-drivers), 76.2% would consult the pharmacist (88.0% of drivers and 
 
 
Non-driver 
N (%) 
Driver 
N (%) 
Total 
N (%) Χ
2
4; p  
With the same frequency 24 (8.6) 172 (16.1) 196 (14.6) 
41.78; p<0.0001 
Less frequently  46 (16.4) 213 (20.0) 259 (19.2) 
A lot less frequently 23 (8.2) 157 (14.7) 180 (13.4) 
I would hardly drive at all 58 (20.7) 232 (21.7) 290 (21.5) 
I would not drive at all 129 (46.1) 293 (27.5) 422 (31.3) 
Total     
 
 
 
Non-driver 
N (%) 
Driver 
N (%) 
Total 
N (%) 
Χ
2
3; p  
I would drive without taking extra care 7 (2.5) 43 (4.0) 50 (3.7) 
51.38; p=0.0001 
I would not drive without first reading 
the package insert 79 (28.0) 464 (43.2) 543 (40.0) 
I would not drive without the advice of 
a doctor or a pharmacist 48 (17.0) 248 (23.1) 296 (21.8) 
I would not drive until my doctor 
indicated that it was safe to do so 148 (52.5) 320 (29.8) 468 (34.5) 
Total     
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95.4% of non-drivers) and 47.8% would consult nursing staff (48.4% of drivers and 45.3% of 
non-drivers). 
   
Table 187: If you had to take a medicine with a pictogram about driving on the packaging, 
would you ask for advice about driving? 
  
  
 
No 
conductor 
N (%) 
Conductor 
N (%) 
Total 
N (%) 
Χ
2
4; p  
Pharmacist 
Very improbable 6 (2.2) 95 (9.1) 101 (7.6) 
24.88; p<0.0001 
Improbable 7 (2.5) 67 (6.4) 74 (5.6) 
Neither probable nor 
improbable 37 (13.3) 95 (9.1) 132 (10.0) 
Probably 127 (45.7) 438 (41.8) 565 (42.6) 
Very probably 101 (36.3) 353 (33.7) 454 (34.2) 
 
Total 278 (100.0) 1048 (100.0) 1326 (100.0) 
 
Nursing 
Very improbable 13 (4.7) 102 (9.9) 115 (8.8) 
17.04; p<0.005 
Improbable 28 (10.1) 119 (11.5) 147 (11.2) 
Neither probable nor 
improbable 111 (39.9) 313 (30.2) 424 (32.3) 
Probably 101 (36.3) 362 (35.0) 463 (35.3) 
Very probably 25 (9.0) 139 (13.4) 164 (12.5) 
 
Total 278 (100.0) 1035 (100.0) 1313 (100.0) 
 
Physician 
Very improbable 2 (0.7) 43 (4.0) 45 (3.3) 
29.40; p<0.0001 
Improbable 1 (0.4) 33 (3.1) 34 (2.5) 
Neither probable nor 
improbable 10 (3.6) 53 (5.0) 63 (4.7) 
Probably 44 (15.8) 256 (24.0) 300 (22.3) 
Very probably 222 (79.6) 683 (64.0) 905 (67.2) 
 Total 279 (100.0) 1068 (100.0) 1347 (100.0) 
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4 DISCUSSION 
 
4.1 Study 1: implementation, evaluation and new technologies of practice guidelines 
and information materials for health professionals: physicians, pharmacists and 
nursing staff 
 
4.1.1 Main study results 
 
 
• PRE-QUESTIONNAIRE 
The sociodemographic characteristics and the replies obtained in the first questionnaire (PRE) 
for the control, information and intervention groups showed a great homogeneity within each 
collective (physicians, pharmacists and nursing staff).  
 
o Training at university studies on medicines and driving, and sources of 
information on medicines and driving 
 
• Overall, the health professionals participating in the study referred to lack of training on 
medicines and driving, both in their university studies and after finishing their university degrees: 
 
o Two out of every three health professionals participating in the study referred to 
not having received any type of formation concerning the effects of medicines 
on driving during their university studies. The pharmacists (51.4%) referred to 
having received formation in this topic twice as much as the physicians 
(27.5%). 
o Seven out of every 10 of the health professionals referred to not having 
received formation on the effects of medicines on driving after finishing their 
university degrees. 
 
• On the contrary, 2 out of every 3 health professional referred to having easy access to 
information concerning the effects of medicines on driving. 
 
o New technologies literacy, and user acceptance 
 
• On average, 3 out of every 4 participants in the study referred to using some kind of 
medical/clinical software package /program (in their daily activity). Of note, almost all the 
pharmacists (98.7%) use them, and less frequently physicians (65.2%) and nursing staff 
(58.3%). 
• However, two out of every three health professionals (63.4%) referred to not using internet or 
any type of software and/or computer programme to obtain information about the effects of 
medicines on driving. Again, the pharmacists (59.2%) doubled the physicians (26.4%) in the 
percentage referring to using one or more of these means. 
• Most health professionals (83%) would be willing to use a tool that would provide information 
concerning the effects of medication on driving 
 
o Attitudes/awareness 
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In the current study the attitude/awareness of health professionals on medicines on driving was 
assessed through the agreement or disagreement on certain statements. A composite score was 
calculated based on the responses to 5 of the 6 statements.   
 
• Overall, health professionals participating in the study showed a high positive 
attitude/awareness regarding medicines and driving: 
 
o Most health professionals (88.9%, 94.5% for physicians) are “willing to take into 
account the effects of medicines on driving skills when prescribing/dispensing 
medicines”. 
o This is even more evident for those patients who are professional drivers 
(97.7%), are using CNS medicines (95.1%), those who drove frequently 
(93.1%), and are elderly drivers (92.3%). 
o Three out of every four health professionals would “agree” (70.6%) or “strongly 
agree” (6.2%), with changing the prescription/dispensation for another medicine 
that had less of an effect on fitness to drive vehicles (Table 11).  
o Furthermore, most health professionals (93.9%) referred to being well aware of 
the effects of medicines on driving skills.  
o Almost all of them (96.2%) also agreed that “It is important for me to be well-
informed on medicinal effects on driving behaviour” 
 
• However, we should underline that most health professionals (91.1%) have a negative 
attitude about the usefulness of information given to the patient regarding medicines and driving: 
they do not support the statement that the information they provide to patients will influence their 
driving behaviour. 
 
o Reported behaviour 
 
The reported behaviour of health professionals concerning medicines on driving was assessed 
through six questions-statements, and a composite score was calculated based on the 
responses to these questions.   
 
• Overall, and contrary to attitude/awareness, health professionals participating in the study 
showed a low reported behaviour regarding medicines and driving as measured by the 6 
questions used in the study. For example: 
o It is quite infrequent that health professionals ask their patients about driving 
exposure (km driven). More than half the physicians “always” (13.9%) or 
“almost always” (38.9%) asked their patients about frequency of driving when 
prescribing a medicine. Only 1 out of every 3 did so in the case of pharmacists, 
while scarcely 1 out of every 6 did so in the case of nursing staff.  
o It is even less frequent that health professionals make a note in the patient’s 
clinical record regarding driving exposure (km driven)  
o or discuss legal issues on medicines and driving with the patient.  
 
• However, 2 out of every three health professionals say that they inform (always + regularly) 
patients about the driving related risk of medicine prescribed.  
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• But, in only in 8 out of every 100 cases, do they keep a record  of when they advise a patient 
about when and how he/she can consider driving a car when using a medicine that impairs 
driving. 
 
o Actual knowledge 
 
As in previous dimensions, the reported actual knowledge of health professionals concerning 
medicines on driving was assessed through six questions-statements, and a composite score 
was calculated based on the responses to questions 2-6, because the first question was different 
from those formulated in the other participating countries.   
 
• The responses show a very low knowledge regarding medicines and driving as measured by 
the 6 questions used in the study. Another issue is whether or not the low knowledge could be 
attributed to the ambiguity of the questions (please see limitations, text below). As an example, 
to highlight that only 10.9% give the correct answer to the statement “Amitriptyline at the start of 
treatment is as impairing for driving as after 4 weeks of treatment”. 
o Relevance on medicines and driving in the daily practice 
 
• Health professionals give a high score to this issue (mean ± sd, 7.38 ± 2.06 points, on a 
maximum of 10).   
• 55.8% of physicians and 42.3% of pharmacists have “frequently” or “very frequently” had 
cases in which the effect of medicines on driving was an important aspect at the time of 
selecting medication.  
 
DRUID 6th Framework Programme  Deliverable D.7.4.2 
    
Page 419 of 456 
• PRE/POST [SIX MONTHS LATER] DIFFERENCES 
 
Below are highlighted the changes (positive or negative) observed after the training course. The 
post questionnaire was fulfilled 6 month later than the pre-questionnaire. 
 
o Attitudes/awareness 
 
• There were hardly any changes in the section attitudes/awareness among health 
professionals after the 6 months of training on medicines and driving: 
 
o There were no statistically significant changes in the composite score (pre= 
1515.03±1.75; post = 15.50±1.62, p > 0.05). 
o There was only one positive significant change for the entire sample and for the 
collective of pharmacists in the question “I am willing to take into account the 
effects of medicines on driving skills when prescribing/dispensing medicines” 
and significantly negative changes (for the entire sample and among the 
pharmacists) with respect to taking into account the fact of whether the patient 
is a professional driver and “using other CNS active drugs” (for the entire 
sample).  
 
o Reported behaviour 
 
• The study shows a “positive” change in the reported behaviour of health professionals after 
the training course on medicines and driving. 
 
o There was an increase in the composite score from 7.34±3.55 (pre) to 
9.66±3.91 (post), p < 0.005. 
o There were several significant changes in the entire sample and among the 
collective of the physicians. All such changes were positive and point to an 
increase in the effort health professionals make, both to inform the patient 
about medicines and driving and to find out about the patient’s driving habits 
and to note them down in the patient’s file. The changes were observed in the 
questions:  “I ask a patient about his/her driving exposure when 
choosing/dispensing a medicine”; “I provide a patient with written information 
materials when prescribing/dispensing a driving impairing medicine”; “I keep 
systematic records when I advise a patient when and how he/she can consider 
driving a car when using a driving impairing medicine” and “I keep a record of 
the patient’s traffic participation”.  
 
o Actual knowledge 
 
• The study shows a “positive” change in the actual knowledge of health professionals after 
the training course on medicines and driving. 
 
o There was an increase in the composite score from 1.53±1.11 (pre) to 
2.40±1.05 (post), p < 0.0001. Worthy of mention is the fact that this “positive” 
change was observed among both physicians and pharmacists. 
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o In 4 out of the 5 statements an improvement in actual knowledge was observed 
(except in the question regarding diazepam, from which the higher frequency of 
correct responses was observed in the pre-questionnaire). 
 
o Relevance on medicines and driving in the daily practice 
 
• After the training course pharmacists, but not physicians, give higher scores to the 
importance given in their daily practice to medicines and driving. 
 
 
o Drop outs 
 
Of the 407 professionals included in the study, initially 183 answered the first questionnaire. 
Given the anonymous character of the questionnaires, it is not possible to establish whether 
there are differences between those who answered the questionnaire and those who finally did 
not participate.  
 
The answers obtained for the second questionnaire (post) were few: of the 126 PRE 
questionnaires obtained from the information and intervention groups, correspondence was only 
found with the POST questionnaires in 38 cases (30.2%). However, using the replies from the 
PRE questionnaire, we were able to determine that there were no significant differences with 
respect to sociodemographic data (gender, age), mean number of years of professional 
experience or education received during or after the degree among those who answered the 
second questionnaire and the rest who did not answer. 
 
 
o Limitations of the study 
 
The following limitations must be borne in mind before taking into account the results of the 
Spanish trial. 
 
Related to the questionnaire: 
• The questionnaire used in the study was developed by the DRUID task 7.4. However, it is a 
non-validated questionnaire, and we are not sure what dimensions it is measuring in reality. 
However, as it is the first one developed in the field, there is no better option. Further studies 
are needed with this questionnaire to confirm the findings observed. 
• There is the risk that some questions-statements are inadequately given. For example, those 
that measure actual knowledge. The low figures obtained in the pre-questionnaire brought up 
the issue of whether these are well formulated or whether they are too ambiguous. 
• At least, during the Spanish trial a considerable number of health professionals started 
answering the questionnaire, but did not finish. Many stated that they did not like it (see 
methodology, study 1, section 1.8). 
 
Related to drop-out: 
• We have had a very high level of drop-outs. There are various possible reasons. Among 
them, we could highlight the fact that the questionnaires were anonymous. In many cases, we 
were not able to link pre and post-questionnaires. Questionnaires were anonymous due a 
question of ethic approval. 
 
Not really an intervention group with an integrated tool: 
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• As explained in the methodology, in the introduction to the Spanish trial, section 7, we had no 
access to current software used for prescription and dispensing. Therefore, we did not use a 
“real” integrated-tool in this trial. A web page was therefore developed.  
 
Some advantages of the study were that:  
 
• The study included nursing staff 
• Participation in the trial was not rewarded in any specific form (money, tickets, etc). 
• The current training activities were done at primary health care centres following regular 
training activities for physicians and nurses, and these were granted the status of Continuous 
Training by the Health Authorities. 
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5 OVERAL CONCLUSIONS AND RECOMMENDATIONS 
 
The number of professionals who responded to the Post-Questionnaire was small, higher in 
the group information on the intervention. In what follows, only the results where significant 
Pre/Post differences were found on applying the Wilcoxon test are shown. The questionnaire 
was sent by mail a postcard with a letter with a letter encouraging your answer. We do not 
know the reason why so few professionals responded to the post-questionnaire, it might be a 
very long time (6 months) that did reduce their interest by topic or lack of stimuli to respond. 
There were hardly any changes in the section attitudes/awareness among health 
professionals after the 6 months of training on medicines and driving: 
There was only one positive significant change for the entire sample in the question “I am 
willing to take into account the effects of medicines on driving skills when 
prescribing/dispensing medicines”. However, health professionals would only be willing to 
change the prescription for another drug with less effect on driving, when the patient was a 
professional driver or take other drugs that act on the CNS. 
Across the sample and particularly among physicians, there has being a significant shift in 
favour of asking patients about their driving exposure when choosing/dispensing a medicine, 
and  for a systematic record of the patient’s traffic participation and the advice offered a 
patient when and how he/she can consider driving a car when using a driving impairing 
medicine. Also increasingly the willingness for provide a patient with written information 
materials when prescribing/dispensing a driving impairing medicine. This significant changes 
point to an increase in the effort health professionals make both to inform the patient about 
medicines and driving and to inform him/herself about the patient’s involvement in driving and 
to leave a record of these aspects in the patient’s medical history.   
For both the whole sample as well as for physicians and pharmacists separately, a significant 
positive change can be observed in the evolution in knowledge concerning the effects of 
some medicines on driving. As for as,  the importance given in their daily practice to 
medicines and driving by health professionals. 
A large majority of patients are aware that some drugs affect driving, also a significant 
proportion of them who have been prescribed a drug with a pictogram on the package would, 
decrease the frequency of driving, would not lead without having read the prospectus before. 
The physician is the health professional to consult when they first had to take a medication on 
driving with a pictogram on the package, followed by the pharmacist and nurse. 
As for recommendations the authors believe that it is recommended that special attention will 
be paid in educating those subjects who might play an active role in traffic safety. With this 
respect, medical and pharmacy schools could develop targeted educational programs 
covering the issue of medication use and driving whereas police officers and driving 
instructors could be adequately trained on this topic in order to be able to transfer the 
message to potential patients who also participate in traffic. 
It would be important for the whole group of health professionals of Spain, conducting training 
courses (similar to the DRUID Trining course) on prescribing /dispensing and advice on 
medicines and driving. 
The categorization system could be seen as a tool to improve prescribing and dispensing 
procedures both at a national and European level, and, therefore, as a instrument to better 
inform and involve HCPs (Health Care Professionals). With this respect, it is important that 
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HCPs know the fundamentals of the categorization system, and, consequently, use it properly 
in order to fully inform their patients about the risks of driving under the influence of impairing 
medicines. Furthermore, HCPs should be able to distinguish between the four levels of 
impairment, and, therefore, if possible, choose the least impairing medication within the same 
therapeutic group. Moreover, this system should encourage HCPs to update their knowledge 
on medicines and driving in order to be prepared to answer questions that patients might 
have on this topic.  
The training in DRUID categorization system should also be used as a tool to motivate health 
care professionals to provide patients with clear information, communicate to patients the risk 
associated with driving under the influence of medicines, and start HCP-patient discussion 
leading to both safer prescriptions and the patient’s conscious decision whether to drive or not 
[1, 21].  
From the patient point of view, this classification could play an active role in helping them to 
be involved along the decision-making process, to understand the hazards of some 
medications to traffic safety, and to remind them to use caution while driving until their 
individual responses to the therapy have been well established. 
Finally, a guideline should be developed to explain the use of the categorization system to 
HCPs and to serve as a support in the decision making process. On the other hand, since the 
patient package leaflet is the most accessible source of information for patients, it would also 
be advisable to develop an effective strategy to communicate the risk related to the use of 
medicines and driving. For instances, a straightforward grading system could be included in 
the patient package leaflet and the use of pictograms (warning labels) could be printed on the 
medication box to provide clear directions for patients. 
  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
    
Page 424 of 456 
6 REFERENCES 
 
1. European Commission. White Paper European Transport Policy for 2010: time to decide. 
Luxembourg: Office for Official Publications of the European Communities, 2001. 
http://ec.europa.eu/transport/strategies/2001_white_paper_en.htm 
2. Alvarez FJ, del Río MC. Consumo de medicamentos y aptitud para la conducción de 
vehículos. En: Dirección general de Tráfico. Manual sobre aspectos relacionados con la 
capacidad de conducción de vehículos.2ª Ed. Madrid: Ediciones Doyma S.L. 2004:163-
171 
3. Alvarez FJ, del Río MC, Martín F. Pautas de consumo de medicamentos, alcohol y drogas 
en los conductores españoles. Ed: Universidad de Valladolid. Valladolid, 2003. 
4. Real Decreto 818/2009, de 8 de mayo, por el que se aprueba el Reglamento General de 
Conductores BOE de 8 de junio de 2009: 48068-48182. 
5. Real Decreto 1345/2007, de 11 de octubre, por el que se regula el procedimiento de 
autorización, registro y condiciones de dispensación de los medicamentos de uso 
humano fabricados industrialmente. BOE 267 de 07 de Noviembre de 2007 :45652 a 
45698. 
6. Ley 14/1986, de 25 de abril, General de Sanidad. BOE número 102 de 29/4/1986, pp 
15207-5224. 
7.  Ley 16/2003, de 28 de mayo, de cohesión y calidad del Sistema Nacional de Salud 
(artículo 12). BOE. 2003/05/29;(128):20573.  
8. Ministerio de Sanidad y Política Social. Organización del Sistema Sanitario de Salud. 
http://www.msps.es/organizacion/sns/docs/organizacion08.pdf. (downloaded 23 June 
2011).  
9. Ministerio de Sanidad y Consumo. Cartera de servicios comunes de prestación 
farmacéutica. 
http://www.msps.es/profesionales/CarteraDeServicios/ContenidoCS/5PrestacionFarmace
utica/PF-PrestacionFarmaceutica.htm (Consulted, 23 June 2011) 
  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
    
Page 425 of 456 
ANNEX I: Brochure “Medicines and driving: The prescription of medicines to patient 
who drive”  
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ANNEX II: Health professional questionnaire (Study 1 PRE) 
 
  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
    
Page 448 of 456 
 
  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
    
Page 449 of 456 
 
  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
    
Page 450 of 456 
 
  
DRUID 6th Framework Programme  Deliverable D.7.4.2 
    
Page 451 of 456 
ANNEX III: Health professional questionnaire (Study 1 POST)  
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ANEX IV: Patient questionnaire (Study 2) 
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